{"5e8cc1543e2089cb3429ab791a4cd23290335e08": [["Other reports regarding asymptomatic cases are only single or multicentre studies of hospitalized COVID-19 patients, or series case reports (4, 5, 8, 9) .", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["A thorough investigation on the incidence, the longitudinal clinical features and outcomes of asymptomatic patients of COVID-19 is still lacking.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["A thorough investigation", "TEST", 0, 24], ["COVID", "TEST", 119, 124]]]], "PMC7100570": [["IntroductionThe demon shrimp, Dikerogammarus haemobaphes (Eichwald 1841), is a non-native freshwater amphipod in the UK that exerts low levels of ecological damage and inter-species competition (Bovy et al., 2015).", [["Dikerogammarus haemobaphes", "ORGANISM", 30, 56], ["Eichwald 1841", "ORGANISM", 58, 71], ["UK", "GENE_OR_GENE_PRODUCT", 117, 119], ["shrimp", "SPECIES", 22, 28], ["Dikerogammarus haemobaphes", "SPECIES", 30, 56], ["demon shrimp", "SPECIES", 16, 28], ["Dikerogammarus haemobaphes (Eichwald 1841)", "SPECIES", 30, 72], ["low levels", "OBSERVATION_MODIFIER", 132, 142]]], ["The species hosts multiple mortality-inducing and behaviour-altering pathogens that have been carried alongside the invasion into the UK (Bojko et al., 2018a).", [["altering pathogens", "PROBLEM", 60, 78]]], ["Infection with the microsporidian pathogen Cucumispora ornata Bojko, Dunn, Stebbing, Ross, Kerr, Stentiford 2015 was noted to reduce activity in heavily infected hosts and was associated with mortality in both D. haemobaphes and non-target Gammarus pulex (L.), which also have the infection in wild populations (Bojko et al., 2018a).", [["infection", "DISEASE", 281, 290], ["Cucumispora ornata", "ORGANISM", 43, 61], ["D. haemobaphes", "ORGANISM", 210, 224], ["Gammarus pulex", "ORGANISM", 240, 254], ["L.)", "ORGANISM", 256, 259], ["Cucumispora ornata", "SPECIES", 43, 61], ["D. haemobaphes", "SPECIES", 210, 224], ["Gammarus pulex", "SPECIES", 240, 254], ["Cucumispora ornata", "SPECIES", 43, 61], ["D. haemobaphes", "SPECIES", 210, 224], ["Gammarus pulex", "SPECIES", 240, 254], ["Infection", "PROBLEM", 0, 9], ["heavily infected hosts", "PROBLEM", 145, 167], ["non-target Gammarus pulex", "PROBLEM", 229, 254], ["the infection", "PROBLEM", 277, 290], ["heavily", "OBSERVATION_MODIFIER", 145, 152], ["infected", "OBSERVATION", 153, 161], ["Gammarus pulex", "OBSERVATION", 240, 254], ["infection", "OBSERVATION", 281, 290]]], ["\u2018Dikerogammarus haemobaphes bi-facies-like Virus\u2019 (DhbflV), was also identified as a mortality-inducing virus at low prevalence within the D. haemobaphes population in the UK (Bojko et al., 2018a).", [["Dikerogammarus haemobaphes bi-facies-like Virus\u2019", "ORGANISM", 1, 49], ["DhbflV", "GENE_OR_GENE_PRODUCT", 51, 57], ["Dikerogammarus haemobaphes", "SPECIES", 1, 27], ["Dikerogammarus haemobaphes", "SPECIES", 1, 27], ["D. haemobaphes", "SPECIES", 139, 153], ["Dikerogammarus haemobaphes bi-facies", "PROBLEM", 1, 37], ["a mortality-inducing virus", "PROBLEM", 83, 109]]], ["Finally, a likely novel member of the Nudiviridae, \u2018Dikerogammarus haemobaphes Bacilliform Virus\u2019 (DhBV) was found to increase the activity of its host and potentially alter the rate of invasion spread (Bojko et al., 2018a).IntroductionThis species, and specifically its parasites, are now considered a high-risk invasion system that requires the development of diagnostic methods to track the invasion, associated diseases and their effects.", [["Nudiviridae", "GENE_OR_GENE_PRODUCT", 38, 49], ["\u2018", "ORGANISM", 51, 52], ["Dikerogammarus haemobaphes Bacilliform Virus\u2019", "ORGANISM", 52, 97], ["DhBV", "ORGANISM", 99, 103], ["Dikerogammarus haemobaphes Bacilliform Virus", "SPECIES", 52, 96], ["Dikerogammarus haemobaphes Bacilliform Virus", "SPECIES", 52, 96], ["DhBV", "SPECIES", 99, 103], ["the Nudiviridae", "TREATMENT", 34, 49], ["Dikerogammarus haemobaphes Bacilliform Virus", "PROBLEM", 52, 96], ["invasion spread", "PROBLEM", 186, 201], ["a high-risk invasion system", "PROBLEM", 301, 328], ["diagnostic methods", "TEST", 362, 380], ["the invasion", "PROBLEM", 390, 402], ["associated diseases", "PROBLEM", 404, 423], ["invasion", "OBSERVATION", 186, 194], ["risk", "OBSERVATION_MODIFIER", 308, 312], ["invasion", "OBSERVATION", 313, 321], ["invasion", "OBSERVATION", 394, 402]]], ["To date, mitochondrial data for this species are restricted to short ~ 600 bp sequence tags of the Cytochrome Oxidase Sub-Unit 1 gene (cox1) (Grabner et al., 2015) and partial 16S.", [["mitochondrial", "ANATOMY", 9, 22], ["mitochondrial", "CELLULAR_COMPONENT", 9, 22], ["Cytochrome Oxidase Sub-Unit 1", "GENE_OR_GENE_PRODUCT", 99, 128], ["~ 600 bp sequence tags", "DNA", 69, 91], ["Cytochrome Oxidase Sub-Unit 1 gene", "DNA", 99, 133], ["cox1", "DNA", 135, 139], ["2015", "DNA", 158, 162], ["16S", "DNA", 176, 179], ["mitochondrial data", "TEST", 9, 27], ["this species", "PROBLEM", 32, 44], ["the Cytochrome Oxidase Sub", "TREATMENT", 95, 121]]], ["Next generation sequencing platforms and bioinformatic tools provide the ability to rapidly provide data on the genomic composition of the demon shrimp and aid the development of diagnostic tools.", [["Next generation sequencing platforms", "TEST", 0, 36], ["bioinformatic tools", "TEST", 41, 60], ["the demon shrimp", "TREATMENT", 135, 151]]], ["Recent advances in the sequencing of mitochondrial genomes from amphipods has also allowed for increased phylogenetic information, with an excess of 50 mitochondrial genomes being available for Amphipoda (Romanova et al., 2016; Macher et al., 2017; Cormier et al., 2018).IntroductionHerein, the mitochondrial genome of the demon shrimp is presented.", [["mitochondrial genomes", "ANATOMY", 37, 58], ["mitochondrial", "ANATOMY", 152, 165], ["mitochondrial", "ANATOMY", 295, 308], ["mitochondrial", "CELLULAR_COMPONENT", 37, 50], ["mitochondrial", "CELLULAR_COMPONENT", 152, 165], ["mitochondrial", "CELLULAR_COMPONENT", 295, 308], ["mitochondrial genomes", "DNA", 37, 58], ["50 mitochondrial genomes", "DNA", 149, 173], ["mitochondrial genome", "DNA", 295, 315], ["shrimp", "SPECIES", 329, 335], ["mitochondrial genomes", "PROBLEM", 37, 58], ["IntroductionHerein", "TREATMENT", 271, 289], ["mitochondrial genomes", "OBSERVATION", 37, 58], ["mitochondrial genome", "OBSERVATION", 295, 315], ["demon shrimp", "OBSERVATION", 323, 335]]], ["The mitochondrial genome of this UK-based individual will act as a resource to develop additional PCR diagnostics for population genetics studies to determine the genetic diversity and likely origins of invasive populations.", [["mitochondrial", "ANATOMY", 4, 17], ["mitochondrial", "CELLULAR_COMPONENT", 4, 17], ["UK", "GENE_OR_GENE_PRODUCT", 33, 35], ["mitochondrial genome", "DNA", 4, 24], ["PCR diagnostics", "TEST", 98, 113], ["population genetics studies", "TEST", 118, 145], ["invasive populations", "PROBLEM", 203, 223], ["mitochondrial genome", "OBSERVATION", 4, 24], ["invasive", "OBSERVATION_MODIFIER", 203, 211]]], ["Furthermore, this genome provides detailed information on the evolution of Dikerogammarus sp. and can be used in tandem with disease screening data to identify the potential origins of its parasites.Specimen collection and mitochondrial genome assembly ::: Materials and methodsIn 2016, a single animal was collected by hand from Carlton Brook, UK (British National Grid [BNG] ref: SK3870004400).", [["mitochondrial", "ANATOMY", 223, 236], ["hand", "ANATOMY", 320, 324], ["Dikerogammarus sp", "ORGANISM", 75, 92], ["mitochondrial", "CELLULAR_COMPONENT", 223, 236], ["hand", "ORGANISM_SUBDIVISION", 320, 324], ["Dikerogammarus sp", "PROBLEM", 75, 92], ["disease screening data", "TEST", 125, 147], ["Specimen collection", "TEST", 199, 218], ["collection", "OBSERVATION", 208, 218], ["mitochondrial genome", "OBSERVATION", 223, 243]]], ["The urosome of this individual underwent phenol:chloroform DNA extraction after an overnight digestion with Proteinase K. This extract was prepared into a DNA library using a NEXTERA-XT library preparation method for MiSeq sequencing (Illumina; www.illumina.com) and Illumina TruSeq\u00ae DNA PCR-Free library preparation kit for HiSeq (Illumina; www.illumina.com).", [["extract", "ANATOMY", 127, 134], ["phenol", "CHEMICAL", 41, 47], ["Proteinase K", "CHEMICAL", 108, 120], ["phenol", "CHEMICAL", 41, 47], ["chloroform", "CHEMICAL", 48, 58], ["phenol", "SIMPLE_CHEMICAL", 41, 47], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["Proteinase K", "GENE_OR_GENE_PRODUCT", 108, 120], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["DNA", "CELLULAR_COMPONENT", 284, 287], ["DNA library", "DNA", 155, 166], ["chloroform DNA extraction", "TREATMENT", 48, 73], ["Proteinase K", "TREATMENT", 108, 120], ["a DNA library", "TREATMENT", 153, 166], ["a NEXTERA-XT library preparation method", "TREATMENT", 173, 212], ["MiSeq sequencing", "TEST", 217, 233], ["Illumina", "TEST", 267, 275], ["DNA PCR", "TEST", 284, 291], ["HiSeq (Illumina", "TREATMENT", 325, 340]]], ["Raw data were trimmed (Illuminatrim-TRIMMOMATIC) and then assembled using SPAdes v.3.13.0 (default settings with km: 21, 33, 55, 77, 99, 127) (Bankevich et al., 2012; Bolger et al., 2014).Specimen collection and mitochondrial genome assembly ::: Materials and methodsThis resulted in a 15,460 bp circular contig with 243.97X coverage.", [["mitochondrial", "ANATOMY", 212, 225], ["mitochondrial", "CELLULAR_COMPONENT", 212, 225], ["15,460 bp circular contig", "DNA", 286, 311], ["SPAdes", "TEST", 74, 80], ["Specimen collection", "TEST", 188, 207], ["a 15,460 bp circular contig", "TREATMENT", 284, 311], ["collection", "OBSERVATION", 197, 207], ["mitochondrial genome", "OBSERVATION", 212, 232]]], ["Trimmed reads were re-aligned to the sequence to confirm even coverage across the circular sequence.", [["circular sequence", "DNA", 82, 99], ["the sequence", "TEST", 33, 45]]], ["This sequence was submitted to MITOS (invertebrate) to provide detailed annotation of protein coding (PCG) and non-coding RNA (ncRNA) genetic regions (Bernt et al., 2013), which were further edited and confirmed using data available on NCBI.", [["MITOS", "DNA", 31, 36], ["non-coding RNA (ncRNA) genetic regions", "DNA", 111, 149], ["protein coding (PCG) and non-coding RNA (ncRNA) genetic regions", "PROBLEM", 86, 149]]], ["Individual ncRNA and PCGs were compared to available sequence data from alternative D. haemobaphes and other Amphipoda using NCBI, BLASTp and BLASTn.", [["PCGs", "CELLULAR_COMPONENT", 21, 25], ["D. haemobaphes", "ORGANISM", 84, 98], ["ncRNA", "DNA", 11, 16], ["PCGs", "DNA", 21, 25], ["NCBI, BLASTp and BLASTn", "DNA", 125, 148], ["D. haemobaphes", "SPECIES", 84, 98], ["D. haemobaphes", "SPECIES", 84, 98], ["Individual ncRNA", "TEST", 0, 16], ["available sequence data", "TEST", 43, 66]]], ["Circa (www.omgenomics.com/circa) and CLC (www.qiagenbioinformatics.com) were used to develop diagrammatic representations of the genetic data.Specimen collection and mitochondrial genome assembly ::: Materials and methodsSequence data for the D. haemobaphes mitochondrial genome can be acquired from NCBI (accession number: MK644228).Phylogenetic analyses ::: Materials and methodsThree maximum likelihood phylogenetic trees were calculated using the mitochondrial genome of D. haemobaphes.", [["mitochondrial", "ANATOMY", 166, 179], ["mitochondrial genome", "ANATOMY", 258, 278], ["mitochondrial genome", "ANATOMY", 451, 471], ["mitochondrial", "CELLULAR_COMPONENT", 166, 179], ["mitochondrial", "CELLULAR_COMPONENT", 258, 271], ["mitochondrial", "CELLULAR_COMPONENT", 451, 464], ["D. haemobaphes", "ORGANISM", 475, 489], ["D. haemobaphes mitochondrial genome", "DNA", 243, 278], ["mitochondrial genome", "DNA", 451, 471], ["D. haemobaphes", "SPECIES", 243, 257], ["D. haemobaphes", "SPECIES", 243, 257], ["D. haemobaphes", "SPECIES", 475, 489], ["the genetic data", "TEST", 125, 141], ["Specimen collection", "TEST", 142, 161], ["Sequence data", "TEST", 221, 234], ["the D. haemobaphes mitochondrial genome", "PROBLEM", 239, 278], ["Phylogenetic analyses", "TEST", 334, 355], ["collection", "OBSERVATION", 151, 161], ["mitochondrial genome", "OBSERVATION", 166, 186], ["phylogenetic trees", "OBSERVATION", 406, 424], ["mitochondrial genome", "OBSERVATION", 451, 471]]], ["The first two used the 16S (276 positions) or cox1 (614 positions) gene to compare Dikerogammarus sp. from NCBI (n = 16 sequences and 39 sequences, respectively) (evolutionary model: HKY + F+ I).", [["Dikerogammarus sp", "ORGANISM", 83, 100], ["16S", "DNA", 23, 26], ["cox1 (614 positions) gene", "DNA", 46, 71], ["NCBI (n = 16 sequences", "DNA", 107, 129], ["cox1", "TREATMENT", 46, 50], ["NCBI (n = 16 sequences and 39 sequences", "TEST", 107, 146]]], ["The final tree used individually aligned and subsequently concatenated amino acid (AA) sequences (13 genes: atp6, atp8-0, cob, cox1, cox2, cox3, nad1, nad2, nad3, nad4, nad4L, nad5, nad6) (n = 38 Amphipoda and 1 Isopoda outgroup) (evolutionary model: mtInv + F +I + G4).", [["amino acid", "CHEMICAL", 71, 81], ["amino acid", "CHEMICAL", 71, 81], ["amino acid", "AMINO_ACID", 71, 81], ["atp6", "GENE_OR_GENE_PRODUCT", 108, 112], ["atp8-0", "GENE_OR_GENE_PRODUCT", 114, 120], ["cob", "GENE_OR_GENE_PRODUCT", 122, 125], ["cox1", "GENE_OR_GENE_PRODUCT", 127, 131], ["cox2", "GENE_OR_GENE_PRODUCT", 133, 137], ["cox3", "GENE_OR_GENE_PRODUCT", 139, 143], ["nad1", "GENE_OR_GENE_PRODUCT", 145, 149], ["nad2", "GENE_OR_GENE_PRODUCT", 151, 155], ["nad3", "GENE_OR_GENE_PRODUCT", 157, 161], ["nad4", "GENE_OR_GENE_PRODUCT", 163, 167], ["nad4L", "GENE_OR_GENE_PRODUCT", 169, 174], ["nad5", "GENE_OR_GENE_PRODUCT", 176, 180], ["nad6", "GENE_OR_GENE_PRODUCT", 182, 186], ["concatenated amino acid (AA) sequences", "DNA", 58, 96], ["atp6", "DNA", 108, 112], ["atp8", "DNA", 114, 118], ["cob", "DNA", 122, 125], ["cox1", "DNA", 127, 131], ["cox2", "DNA", 133, 137], ["cox3", "DNA", 139, 143], ["nad1", "DNA", 145, 149], ["nad2", "DNA", 151, 155], ["nad3", "DNA", 157, 161], ["nad4", "DNA", 163, 167], ["nad4L", "DNA", 169, 174], ["nad5", "DNA", 176, 180], ["nad6", "DNA", 182, 186], ["mtInv", "DNA", 251, 256], ["F", "DNA", 259, 260], ["G4", "DNA", 266, 268], ["amino acid (AA) sequences", "TEST", 71, 96], ["atp6", "TEST", 108, 112], ["atp8", "TEST", 114, 118], ["cob", "TEST", 122, 125], ["cox1", "TEST", 127, 131], ["cox2", "TEST", 133, 137], ["cox3", "TEST", 139, 143], ["nad1", "TEST", 145, 149], ["nad2", "TEST", 151, 155], ["nad3", "TEST", 157, 161], ["nad4", "TEST", 163, 167], ["nad4L", "TEST", 169, 174], ["nad5", "TEST", 176, 180], ["nad6", "TEST", 182, 186], ["Amphipoda", "TEST", 196, 205], ["Isopoda outgroup", "TEST", 212, 228]]], ["In all cases the sequences were trimmed and aligned using MAFFT in Geneious v.10.0.2 (gap: 1.53, cost: 0.123) before phylogenetic analysis and model matching according to Bayesian Information Criterion (BIC).", [["MAFFT", "TEST", 58, 63], ["gap", "TEST", 86, 89], ["phylogenetic analysis", "TEST", 117, 138], ["model matching", "TREATMENT", 143, 157]]], ["IQtree was used to calculate the phylogenetic trees (Nguyen et al., 2015) and included the use of ultrafast approximated bootstraps (n = 1000) (Minh et al. 2013). \u2018+F\u2019 refers to the empirical base frequencies and counts base frequencies directly from the alignment; \u2018+I\u2019 refers to a fix the proportion of invariable sites; finally, \u2018+G4\u2019 refers to the addition of the discrete Gamma model.Phylogenetic analyses ::: Materials and methodsMultiple sources of literature were used to compare known microparasites [Nudiviridae, \u2018Candidatus Aquirickettsiella\u2019, Microsporidia (Cucumispora and Dictyocoela) and gregarines (Apicomplexa)] of each amphipod with a known mitochondrial genome to the phylogenetic information determined by this study (Madyarova et al., 2015; Bojko, 2017; Bojko et al., 2017; Bacela-Spychalska et al., 2018; Dimova et al., 2018; Ironside & Wilkinson, 2018; Bojko & Ovcharenko, 2019).Mitochondrial genome composition and similarity ::: ResultsThe mitochondrial genome of D. haemobaphes is 15,460 bp in length (coverage = 243.97%) and encodes 24 tRNA, 2 rRNA and 14 protein coding genes (including a duplication of atp8) (Table 1; Fig. 1).", [["mitochondrial", "ANATOMY", 659, 672], ["Mitochondrial", "ANATOMY", 902, 915], ["mitochondrial", "ANATOMY", 965, 978], ["mitochondrial", "CELLULAR_COMPONENT", 659, 672], ["Mitochondrial", "CELLULAR_COMPONENT", 902, 915], ["mitochondrial", "CELLULAR_COMPONENT", 965, 978], ["D. haemobaphes", "ORGANISM", 989, 1003], ["mitochondrial genome", "DNA", 659, 679], ["mitochondrial genome", "DNA", 965, 985], ["protein coding genes", "DNA", 1083, 1103], ["atp8", "DNA", 1132, 1136], ["Candidatus Aquirickettsiella\u2019", "SPECIES", 524, 553], ["D. haemobaphes", "SPECIES", 989, 1003], ["D. haemobaphes", "SPECIES", 989, 1003], ["ultrafast approximated bootstraps", "TREATMENT", 98, 131], ["the empirical base frequencies", "TEST", 178, 208], ["counts base frequencies", "TEST", 213, 236], ["Phylogenetic analyses", "TEST", 389, 410], ["known microparasites", "PROBLEM", 488, 508], ["Nudiviridae", "TREATMENT", 510, 521], ["Microsporidia", "PROBLEM", 555, 568], ["this study", "TEST", 726, 736], ["bp", "TEST", 1014, 1016], ["length", "TEST", 1020, 1026], ["coverage", "TEST", 1028, 1036], ["tRNA", "TEST", 1063, 1067], ["a duplication of atp8)", "TREATMENT", 1115, 1137], ["Gamma model", "OBSERVATION", 377, 388], ["mitochondrial genome", "OBSERVATION", 659, 679], ["genome composition", "OBSERVATION", 916, 934], ["mitochondrial genome", "OBSERVATION", 965, 985]]], ["The closest associated genome is that of Gammarus duebeni (NC017760), which shares two closely related tRNAs and six protein coding genes, primarily linked with the cytochrome complex.", [["Gammarus duebeni", "ORGANISM", 41, 57], ["NC017760", "GENE_OR_GENE_PRODUCT", 59, 67], ["cytochrome complex", "GENE_OR_GENE_PRODUCT", 165, 183], ["tRNAs", "DNA", 103, 108], ["protein coding genes", "DNA", 117, 137], ["cytochrome complex", "PROTEIN", 165, 183], ["Gammarus duebeni", "SPECIES", 41, 57], ["Gammarus duebeni", "SPECIES", 41, 57], ["six protein coding genes", "PROBLEM", 113, 137], ["the cytochrome complex", "PROBLEM", 161, 183], ["genome", "OBSERVATION", 23, 29]]], ["The cox1 and 16S (rrnL) genes of the D. haemobaphes mitochondrial genome showed closest similarity to D. haemobaphes haplotypes from Germany (Main River and North Rhine-Westphalia) (Table 1).Mitochondrial genome composition and similarity ::: ResultsStructurally, the mitochondrial genome is A+T rich with 33.8% GC content across the circular genome.", [["mitochondrial genome", "ANATOMY", 52, 72], ["Mitochondrial", "ANATOMY", 191, 204], ["mitochondrial genome", "ANATOMY", 268, 288], ["cox1", "GENE_OR_GENE_PRODUCT", 4, 8], ["16S", "GENE_OR_GENE_PRODUCT", 13, 16], ["rrnL", "GENE_OR_GENE_PRODUCT", 18, 22], ["mitochondrial", "CELLULAR_COMPONENT", 52, 65], ["Mitochondrial", "CELLULAR_COMPONENT", 191, 204], ["mitochondrial", "CELLULAR_COMPONENT", 268, 281], ["cox1 and 16S (rrnL) genes", "DNA", 4, 29], ["D. haemobaphes mitochondrial genome", "DNA", 37, 72], ["mitochondrial genome", "DNA", 268, 288], ["circular genome", "DNA", 334, 349], ["D. haemobaphes", "SPECIES", 37, 51], ["D. haemobaphes", "SPECIES", 102, 116], ["D. haemobaphes", "SPECIES", 37, 51], ["D. haemobaphes", "SPECIES", 102, 116], ["The cox1", "TEST", 0, 8], ["the D. haemobaphes mitochondrial genome", "PROBLEM", 33, 72], ["A+T rich", "TEST", 292, 300], ["genome composition", "OBSERVATION", 205, 223], ["mitochondrial genome", "OBSERVATION", 268, 288], ["circular genome", "OBSERVATION", 334, 349]]], ["The closest relatives with full mitochondrial genome availability were Gammarus duebeni Lilljeborg, 1852 (NC017760) and Eulimnogammarus cyaneus (Dybowsky, 1874) (NC033360), which show high levels of relative gene organisation along the circular mitochondrial genome but with some small reorganisation of tRNAs.", [["mitochondrial", "ANATOMY", 32, 45], ["mitochondrial genome", "ANATOMY", 245, 265], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["Eulimnogammarus cyaneus", "ORGANISM", 120, 143], ["mitochondrial", "CELLULAR_COMPONENT", 245, 258], ["circular mitochondrial genome", "DNA", 236, 265], ["tRNAs", "RNA", 304, 309], ["Gammarus duebeni", "SPECIES", 71, 87], ["Eulimnogammarus cyaneus", "SPECIES", 120, 143], ["Gammarus duebeni Lilljeborg, 1852 (NC017760)", "SPECIES", 71, 115], ["Eulimnogammarus cyaneus (Dybowsky, 1874)", "SPECIES", 120, 160], ["relative gene organisation", "PROBLEM", 199, 225], ["the circular mitochondrial genome", "PROBLEM", 232, 265], ["some small reorganisation of tRNAs", "PROBLEM", 275, 309], ["high", "OBSERVATION_MODIFIER", 184, 188], ["gene organisation", "OBSERVATION", 208, 225], ["circular", "OBSERVATION_MODIFIER", 236, 244], ["mitochondrial genome", "OBSERVATION", 245, 265], ["small", "OBSERVATION_MODIFIER", 280, 285], ["reorganisation of tRNAs", "OBSERVATION", 286, 309]]], ["The trnR and trnE are present in that order instead of trnE-trnR as seen in the genomes of G. duebeni and E. cyaneus (Fig. 2).", [["trnR", "GENE_OR_GENE_PRODUCT", 4, 8], ["trnE", "GENE_OR_GENE_PRODUCT", 13, 17], ["trnE", "GENE_OR_GENE_PRODUCT", 55, 59], ["trnR", "GENE_OR_GENE_PRODUCT", 60, 64], ["G. duebeni", "ORGANISM", 91, 101], ["E. cyaneus", "ORGANISM", 106, 116], ["trnR", "PROTEIN", 4, 8], ["trnE", "PROTEIN", 13, 17], ["trnE", "PROTEIN", 55, 59], ["trnR", "DNA", 60, 64], ["G. duebeni", "SPECIES", 91, 101], ["E. cyaneus", "SPECIES", 106, 116], ["G. duebeni", "SPECIES", 91, 101], ["E. cyaneus", "SPECIES", 106, 116], ["trnE", "TEST", 55, 59]]], ["Dikerogammarus haemobaphes also has a duplication of the trnQ.", [["Dikerogammarus haemobaphes", "ORGANISM", 0, 26], ["trnQ.", "GENE_OR_GENE_PRODUCT", 57, 62], ["Dikerogammarus haemobaphes", "SPECIES", 0, 26], ["Dikerogammarus haemobaphes", "PROBLEM", 0, 26], ["duplication", "OBSERVATION", 38, 49]]], ["A duplication of atp8, which is part of the Adenosine Tri-Phosphate synthesis pathway (genes: atp8-0 and atp8-1), is present.Phylogenetics of related species and conspecifics of the genus Dikerogammarus ::: ResultsThe 16S phylogeny, incorporating multiple Dikerogammarus sp., identifies a Dikerogammarus villosus (Sowinsky, 1894) group (bootstrap = 100), a D. haemobaphes group (bootstrap = 98), a Dikerogammarus caspius (Pallas, 1771) group and a Dikerogammarus bispinosus Martynov, 1925 group.", [["Adenosine", "CHEMICAL", 44, 53], ["Phosphate", "CHEMICAL", 58, 67], ["Adenosine", "CHEMICAL", 44, 53], ["Phosphate", "CHEMICAL", 58, 67], ["atp8", "GENE_OR_GENE_PRODUCT", 17, 21], ["Adenosine Tri-Phosphate", "GENE_OR_GENE_PRODUCT", 44, 67], ["atp8-0", "GENE_OR_GENE_PRODUCT", 94, 100], ["atp8-1", "GENE_OR_GENE_PRODUCT", 105, 111], ["Dikerogammarus sp.", "ORGANISM", 256, 274], ["Dikerogammarus villosus", "ORGANISM", 289, 312], ["Dikerogammarus caspius", "ORGANISM", 398, 420], ["atp8", "DNA", 17, 21], ["atp8", "DNA", 94, 98], ["atp8", "DNA", 105, 109], ["Dikerogammarus sp.", "SPECIES", 256, 274], ["Dikerogammarus villosus", "SPECIES", 289, 312], ["D. haemobaphes group", "SPECIES", 357, 377], ["Dikerogammarus caspius", "SPECIES", 398, 420], ["Dikerogammarus bispinosus", "SPECIES", 448, 473], ["Dikerogammarus villosus", "SPECIES", 289, 312], ["D. haemobaphes", "SPECIES", 357, 371], ["Dikerogammarus caspius", "SPECIES", 398, 420], ["Dikerogammarus bispinosus", "SPECIES", 448, 473], ["A duplication of atp8", "PROBLEM", 0, 21], ["the Adenosine Tri-Phosphate synthesis pathway", "TEST", 40, 85], ["atp8", "TEST", 94, 98], ["related species", "PROBLEM", 142, 157], ["bootstrap", "TEST", 337, 346], ["bootstrap", "TEST", 379, 388], ["duplication", "OBSERVATION", 2, 13], ["genus Dikerogammarus", "OBSERVATION", 182, 202]]], ["The D. haemobaphes 16S isolate from the UK branches alongside an isolate from Poland (Vistula River) (bootstrap = 51) (Fig. 3), but the UK isolate is genetically dissimilar by 3.27%, suggesting that although this is the closest isolate, they are not genetically identical.", [["UK", "GENE_OR_GENE_PRODUCT", 40, 42], ["UK", "GENE_OR_GENE_PRODUCT", 136, 138], ["D. haemobaphes", "SPECIES", 4, 18], ["D. haemobaphes", "SPECIES", 4, 18], ["The D. haemobaphes", "TEST", 0, 18], ["bootstrap", "TEST", 102, 111], ["branches", "ANATOMY_MODIFIER", 43, 51]]], ["Greater genetic variation is visible between the D. haemobaphes 16S gene than the D. villosus 16S data (Fig. 3).Phylogenetics of related species and conspecifics of the genus Dikerogammarus ::: ResultsThe tree based on the cox1 gene also results in two distinct clades of D. villosus and D. haemobaphes, both with high (95\u2013100) bootstrap support.", [["haemobaphes 16S", "GENE_OR_GENE_PRODUCT", 52, 67], ["cox1", "GENE_OR_GENE_PRODUCT", 223, 227], ["D. villosus", "ORGANISM", 272, 283], ["D. haemobaphes", "ORGANISM", 288, 302], ["D. haemobaphes 16S gene", "DNA", 49, 72], ["cox1 gene", "DNA", 223, 232], ["D. haemobaphes", "SPECIES", 49, 63], ["D. villosus", "SPECIES", 82, 93], ["D. villosus", "SPECIES", 272, 283], ["D. haemobaphes", "SPECIES", 288, 302], ["D. haemobaphes", "SPECIES", 49, 63], ["D. villosus", "SPECIES", 82, 93], ["D. villosus", "SPECIES", 272, 283], ["D. haemobaphes", "SPECIES", 288, 302], ["Greater genetic variation", "PROBLEM", 0, 25], ["related species", "PROBLEM", 129, 144], ["D. haemobaphes", "PROBLEM", 288, 302], ["bootstrap support", "TREATMENT", 328, 345], ["variation", "OBSERVATION_MODIFIER", 16, 25], ["genus Dikerogammarus", "OBSERVATION", 169, 189], ["tree", "ANATOMY_MODIFIER", 205, 209], ["high", "OBSERVATION_MODIFIER", 314, 318]]], ["The UK isolate of D. haemobaphes shows closest nucleotide similarity to a D. haemobaphes haplotype 1 (KY075268) sampled in Germany (sim. = 100%, cov. = 100%, e-value = 0.0).", [["nucleotide", "CHEMICAL", 47, 57], ["nucleotide", "CHEMICAL", 47, 57], ["UK", "GENE_OR_GENE_PRODUCT", 4, 6], ["D. haemobaphes", "ORGANISM", 18, 32], ["D. haemobaphes", "SPECIES", 18, 32], ["D. haemobaphes", "SPECIES", 74, 88], ["D. haemobaphes", "SPECIES", 18, 32], ["D. haemobaphes", "SPECIES", 74, 88], ["D. haemobaphes", "PROBLEM", 18, 32], ["closest nucleotide similarity", "PROBLEM", 39, 68], ["a D. haemobaphes haplotype", "TEST", 72, 98], ["sim.", "TEST", 132, 136], ["cov.", "TEST", 145, 149], ["e-value", "TEST", 158, 165]]], ["In Fig. 3 all the D. haemobaphes isolates branch together apart from one individual (AY529049), which originates from the North Caspian Sea, the species native range.Phylogenetics of related species and conspecifics of the genus Dikerogammarus ::: ResultsA concatenated phylogeny of all available mitochondrial protein sequences (n = 13 genes) from available amphipod mitochondrial genomes confirms that D. haemobaphes sits within the Gammaridae, but also identifies the species as an early branching member (bootstrap support = 100) relative to the Gammarus genus and other species from Europe and the Ponto-Caspian region (Fig. 4).", [["mitochondrial", "ANATOMY", 297, 310], ["mitochondrial genomes", "ANATOMY", 368, 389], ["mitochondrial", "CELLULAR_COMPONENT", 297, 310], ["mitochondrial", "CELLULAR_COMPONENT", 368, 381], ["D. haemobaphes", "ORGANISM", 404, 418], ["mitochondrial protein sequences", "DNA", 297, 328], ["amphipod mitochondrial genomes", "DNA", 359, 389], ["D. haemobaphes", "SPECIES", 18, 32], ["D. haemobaphes", "SPECIES", 18, 32], ["D. haemobaphes", "SPECIES", 404, 418], ["related species", "PROBLEM", 183, 198], ["mitochondrial protein sequences", "TEST", 297, 328], ["amphipod mitochondrial genomes", "TREATMENT", 359, 389], ["D. haemobaphes sits", "PROBLEM", 404, 423], ["the species", "PROBLEM", 467, 478], ["bootstrap support", "TEST", 509, 526], ["the Gammarus genus", "PROBLEM", 546, 564], ["other species", "PROBLEM", 569, 582], ["branch", "OBSERVATION_MODIFIER", 42, 48], ["genus Dikerogammarus", "OBSERVATION", 223, 243], ["Gammarus genus", "ANATOMY", 550, 564], ["Caspian", "ANATOMY", 609, 616], ["region", "ANATOMY_MODIFIER", 617, 623]]], ["Other Amphipoda show predicted branching throughout the tree, with all genera represented by multiple species (Eulimnogammarus, Gammarus, Platorchestia, Hyallela, Epimeria, Pseudoniphargus, Stygobromus, Metacrangonyx and Caprella) branching together (Fig. 4).", [["Metacrangonyx", "GENE_OR_GENE_PRODUCT", 203, 216], ["Caprella", "GENE_OR_GENE_PRODUCT", 221, 229], ["multiple species", "PROBLEM", 93, 109], ["Eulimnogammarus", "TEST", 111, 126], ["Gammarus", "TEST", 128, 136], ["Platorchestia", "TEST", 138, 151], ["Hyallela", "TEST", 153, 161], ["Epimeria", "TEST", 163, 171], ["Pseudoniphargus", "TEST", 173, 188], ["Stygobromus", "TEST", 190, 201], ["branching", "OBSERVATION_MODIFIER", 31, 40], ["tree", "ANATOMY_MODIFIER", 56, 60], ["all", "OBSERVATION_MODIFIER", 67, 70], ["genera", "OBSERVATION_MODIFIER", 71, 77], ["multiple", "OBSERVATION_MODIFIER", 93, 101], ["species", "OBSERVATION", 102, 109]]], ["The tree shows low bootstrap support close to the root (55 or 38), suggesting that further sequencing of highly derived amphipods may help to add detail to the tree and its topology, providing further detail to the tree and increase its accuracy at predicting topology.Phylogenetics of related species and conspecifics of the genus Dikerogammarus ::: ResultsUsing available literature (Madyarova et al., 2015; Bojko, 2017; Bojko et al., 2017; Bacela-Spychalska et al., 2018; Dimova et al., 2018; Ironside & Wilkinson, 2018; Bojko & Ovcharenko, 2019), the known microparasites of those amphipods from Europe and the Ponto-Caspian region are presented alongside the phylogenetics conducted by this study to identify possible points of parasite evolution and yet undetermined hosts that may harbour infection (Fig. 5).", [["root", "ANATOMY", 50, 54], ["infection", "DISEASE", 796, 805], ["low bootstrap support", "TREATMENT", 15, 36], ["related species", "PROBLEM", 286, 301], ["those amphipods", "PROBLEM", 579, 594], ["this study", "TEST", 691, 701], ["parasite evolution", "PROBLEM", 733, 751], ["harbour infection", "PROBLEM", 788, 805], ["tree", "ANATOMY_MODIFIER", 4, 8], ["low", "OBSERVATION_MODIFIER", 15, 18], ["bootstrap support", "OBSERVATION", 19, 36], ["root", "ANATOMY", 50, 54], ["genus Dikerogammarus", "OBSERVATION", 326, 346], ["parasite", "OBSERVATION", 733, 741], ["infection", "OBSERVATION", 796, 805]]], ["Bacilliform viruses (Nudiviridae), intracellular bacteria (\u2018Candidatus Aquirickettsiella\u2019), species from two genera of Microsporidia (Cucumispora and Dictyocoela) and the presence of gregarines (Apicomplexa) are presented on the tree alongside known hosts (Fig. 5).", [["intracellular", "ANATOMY", 35, 48], ["Bacilliform viruses", "ORGANISM", 0, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["gregarines", "GENE_OR_GENE_PRODUCT", 183, 193], ["Candidatus Aquirickettsiella", "SPECIES", 60, 88], ["Bacilliform viruses", "SPECIES", 0, 19], ["Bacilliform viruses", "PROBLEM", 0, 19], ["Nudiviridae", "TREATMENT", 21, 32], ["intracellular bacteria (\u2018Candidatus Aquirickettsiella\u2019", "PROBLEM", 35, 89], ["species", "PROBLEM", 92, 99], ["Microsporidia", "PROBLEM", 119, 132], ["viruses", "OBSERVATION", 12, 19]]], ["Bacilliform viruses are present in two Gammarus sp. and D. haemobaphes, which sit at the base of the Gammaridae in Fig. 4.", [["Bacilliform viruses", "ORGANISM", 0, 19], ["Gammarus sp", "ORGANISM", 39, 50], ["D. haemobaphes", "ORGANISM", 56, 70], ["Bacilliform viruses", "SPECIES", 0, 19], ["D. haemobaphes", "SPECIES", 56, 70], ["Bacilliform viruses", "PROBLEM", 0, 19], ["D. haemobaphes", "PROBLEM", 56, 70], ["viruses", "OBSERVATION", 12, 19], ["haemobaphes", "OBSERVATION", 59, 70], ["base", "ANATOMY_MODIFIER", 89, 93]]], ["These same individuals also host intracellular bacteria (Candidatus Aquirickettsiella).", [["intracellular", "ANATOMY", 33, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["host intracellular bacteria", "PROBLEM", 28, 55], ["host", "OBSERVATION_MODIFIER", 28, 32], ["intracellular bacteria", "OBSERVATION", 33, 55]]], ["Systematically identified Cucumispora sp. are restricted to two host species with mitochondrial genome data, D. haemobaphes and Gammarus roeselii (L.); however, multiple SSU sequences from Ponto-Caspian amphipod hosts place Cucumispora candidates across Fig. 5.", [["mitochondrial", "ANATOMY", 82, 95], ["Cucumispora sp", "ORGANISM", 26, 40], ["mitochondrial", "CELLULAR_COMPONENT", 82, 95], ["D. haemobaphes", "ORGANISM", 109, 123], ["Gammarus roeselii", "ORGANISM", 128, 145], ["L.)", "ORGANISM", 147, 150], ["Ponto-Caspian amphipod hosts", "ORGANISM", 189, 217], ["Cucumispora", "ORGANISM", 224, 235], ["mitochondrial genome", "DNA", 82, 102], ["multiple SSU sequences", "DNA", 161, 183], ["D. haemobaphes", "SPECIES", 109, 123], ["Gammarus roeselii", "SPECIES", 128, 145], ["D. haemobaphes", "SPECIES", 109, 123], ["Gammarus roeselii", "SPECIES", 128, 145], ["mitochondrial genome data", "TEST", 82, 107], ["multiple SSU sequences", "TEST", 161, 183], ["Caspian amphipod hosts", "TREATMENT", 195, 217], ["mitochondrial genome", "OBSERVATION", 82, 102], ["Gammarus", "ANATOMY", 128, 136]]], ["Gregarines have been observed in D. haemobaphes, all Gammarus sp. and in members of the Eulimnogammarus genus (Fig. 5).Phylogenetics of related species and conspecifics of the genus Dikerogammarus ::: ResultsTwo species, Pallaseopsis kessleri (Dyb.) and Crypturopus tuberculatus (Dyb.), do not yet have any identified microparasite groups explored herein.Tracking biological invasions associated with disease introduction ::: DiscussionBiological invasions that introduce disease tend to be understudied, with the majority focussing on the host introduction pathway and host-associated impact in novel environments (Roy et al., 2017).", [["Gregarines", "CHEMICAL", 0, 10], ["Gregarines", "GENE_OR_GENE_PRODUCT", 0, 10], ["D. haemobaphes", "ORGANISM", 33, 47], ["Gammarus sp", "ORGANISM", 53, 64], ["Eulimnogammarus genus", "ORGANISM", 88, 109], ["Pallaseopsis kessleri", "ORGANISM", 221, 242], ["Dyb.)", "ORGANISM", 244, 249], ["Crypturopus tuberculatus", "ORGANISM", 254, 278], ["D. haemobaphes", "SPECIES", 33, 47], ["Pallaseopsis kessleri", "SPECIES", 221, 242], ["Crypturopus tuberculatus", "SPECIES", 254, 278], ["D. haemobaphes", "SPECIES", 33, 47], ["Pallaseopsis kessleri", "SPECIES", 221, 242], ["Crypturopus tuberculatus", "SPECIES", 254, 278], ["related species", "PROBLEM", 136, 151], ["Two species", "PROBLEM", 208, 219], ["DiscussionBiological invasions", "PROBLEM", 426, 456], ["disease", "PROBLEM", 472, 479], ["genus Dikerogammarus", "OBSERVATION", 176, 196], ["invasions", "OBSERVATION", 375, 384], ["invasions", "OBSERVATION", 447, 456]]], ["Dikerogammarus haemobaphes is a high-risk species for the introduction of disease; therefore it is important to note that the use of molecular resources in combination with disease screening efforts may be able to define the invasion pathway of the host and its parasites.", [["Dikerogammarus haemobaphes", "ORGANISM", 0, 26], ["Dikerogammarus haemobaphes", "SPECIES", 0, 26], ["Dikerogammarus haemobaphes", "SPECIES", 0, 26], ["Dikerogammarus haemobaphes", "PROBLEM", 0, 26], ["a high-risk species", "PROBLEM", 30, 49], ["disease", "PROBLEM", 74, 81], ["molecular resources", "TREATMENT", 133, 152], ["disease screening efforts", "TREATMENT", 173, 198], ["high-risk", "OBSERVATION_MODIFIER", 32, 41], ["disease", "OBSERVATION", 74, 81]]], ["This mitochondrial genome scaffold has already indicated that the UK population is tentatively related to non-native populations of demon shrimp collected from the Rhine and Main rivers in Germany (Grabner et al., 2015) and Vistula, Poland.", [["mitochondrial", "ANATOMY", 5, 18], ["mitochondrial", "CELLULAR_COMPONENT", 5, 18], ["UK", "GENE_OR_GENE_PRODUCT", 66, 68], ["This mitochondrial genome scaffold", "PROBLEM", 0, 34], ["demon shrimp", "PROBLEM", 132, 144], ["genome scaffold", "OBSERVATION", 19, 34], ["Poland", "ANATOMY", 233, 239]]], ["In these locations, disease has also been observed from the lethal microsporidian parasite, C. ornata (aka: Microsporidium sp.", [["C. ornata", "ORGANISM", 92, 101], ["aka: Microsporidium sp", "ORGANISM", 103, 125], ["C. ornata", "SPECIES", 92, 101], ["C. ornata", "SPECIES", 92, 101], ["disease", "PROBLEM", 20, 27], ["the lethal microsporidian parasite", "PROBLEM", 56, 90], ["Microsporidium sp", "PROBLEM", 108, 125], ["disease", "OBSERVATION", 20, 27], ["microsporidian parasite", "OBSERVATION", 67, 90]]], ["G) (Bojko et al., 2015; Grabner et al., 2015; Bojko et al., 2017) and in the related D. villosus (Bacela-Spychalska et al., 2012).Tracking biological invasions associated with disease introduction ::: DiscussionThere has been high success in the tracking of populations of invasive amphipods through Europe to their native range(s) using population genetics (Rewicz et al., 2015, 2017).", [["D. villosus", "ORGANISM", 85, 96], ["D. villosus", "SPECIES", 85, 96], ["D. villosus", "SPECIES", 85, 96], ["invasive amphipods", "TREATMENT", 273, 291], ["invasions", "OBSERVATION", 150, 159], ["high", "OBSERVATION_MODIFIER", 226, 230], ["success", "OBSERVATION_MODIFIER", 231, 238]]], ["Increased availability of molecular tools may allow a phylogeographic understanding for the origins of D. haemobaphes and potentially its parasites.", [["D. haemobaphes", "ORGANISM", 103, 117], ["D. haemobaphes", "SPECIES", 103, 117], ["D. haemobaphes", "SPECIES", 103, 117], ["molecular tools", "PROBLEM", 26, 41], ["D. haemobaphes", "PROBLEM", 103, 117]]], ["This capability also extends to future invasions, such as the impending threat of invasion to the Great Lakes (USA), whereby multiple Ponto-Caspian species (e.g. Dreissina polymorpha Boettger, 1913) have already successfully invaded (Ricciardi & MacIsaac, 2000).", [["Dreissina polymorpha", "ORGANISM", 162, 182], ["Dreissina polymorpha", "SPECIES", 162, 182], ["Dreissina polymorpha", "SPECIES", 162, 182], ["invasion", "PROBLEM", 82, 90], ["multiple Ponto-Caspian species", "PROBLEM", 125, 155], ["invasions", "OBSERVATION", 39, 48], ["invasion", "OBSERVATION", 82, 90], ["Great Lakes", "ANATOMY", 98, 109], ["multiple", "OBSERVATION_MODIFIER", 125, 133], ["Caspian species", "OBSERVATION", 140, 155]]], ["Whether these species have introduced disease to the Great Lakes remains unknown.Tracking biological invasions associated with disease introduction ::: DiscussionThe mitochondrial data provided herein for D. haemobaphes represent only a single specimen, but based on the16S data, it constituted a unique haplotype.", [["mitochondrial", "ANATOMY", 166, 179], ["specimen", "ANATOMY", 244, 252], ["mitochondrial", "CELLULAR_COMPONENT", 166, 179], ["D. haemobaphes", "ORGANISM", 205, 219], ["16S", "DNA", 270, 273], ["D. haemobaphes", "SPECIES", 205, 219], ["these species", "PROBLEM", 8, 21], ["introduced disease", "PROBLEM", 27, 45], ["the16S data", "TEST", 267, 278], ["a unique haplotype", "PROBLEM", 295, 313], ["Great", "OBSERVATION_MODIFIER", 53, 58], ["Lakes", "OBSERVATION", 59, 64], ["invasions", "OBSERVATION", 101, 110]]], ["The 16S gene showed closest similarity to D. haemobaphes (AJ440888) from Poland (97%).", [["16S", "GENE_OR_GENE_PRODUCT", 4, 7], ["16S gene", "DNA", 4, 12], ["D. haemobaphes", "SPECIES", 42, 56], ["D. haemobaphes", "SPECIES", 42, 56], ["The 16S gene", "TEST", 0, 12]]], ["The cox1 gene of the UK individual is 100% identical over a 658 bp region to D. haemobaphes \u2018haplotype 1\u2019 from Germany (North Rhine-Westphalia).", [["cox1", "GENE_OR_GENE_PRODUCT", 4, 8], ["UK", "GENE_OR_GENE_PRODUCT", 21, 23], ["cox1 gene", "DNA", 4, 13], ["658 bp region", "DNA", 60, 73], ["D. haemobaphes", "SPECIES", 77, 91], ["haplotype", "TEST", 93, 102]]], ["In conclusion, it appears that the D. haemobaphes in the UK (Carlton Brook) likely arrived from invasive populations in central Europe and not from the native range.Evolutionary history of Dikerogammarus haemobaphes ::: DiscussionThe genus Dikerogammarus (Gammaridea) contains freshwater and brackish amphipods and was first described by Stebbing (1899).", [["Gammaridea", "CHEMICAL", 256, 266], ["D. haemobaphes", "ORGANISM", 35, 49], ["UK", "GENE_OR_GENE_PRODUCT", 57, 59], ["Carlton Brook", "ORGANISM", 61, 74], ["Dikerogammarus haemobaphes", "ORGANISM", 189, 215], ["Dikerogammarus", "ORGANISM", 240, 254], ["Gammaridea", "ORGANISM", 256, 266], ["D. haemobaphes", "SPECIES", 35, 49], ["Dikerogammarus haemobaphes", "SPECIES", 189, 215], ["invasive", "OBSERVATION_MODIFIER", 96, 104], ["central", "ANATOMY_MODIFIER", 120, 127], ["brackish amphipods", "OBSERVATION", 292, 310]]], ["The genus contains nine species to date: D. aralychensis, D. bispinosus, D. caspius, D. fluvitalis, D. gruberi, D. istanbulensis, D. oskari, D. villosus and D. haemobaphes (\u00d6zbek & \u00d6zkan, 2011).", [["D. aralychensis", "ORGANISM", 41, 56], ["D. bispinosus", "ORGANISM", 58, 71], ["D. caspius", "ORGANISM", 73, 83], ["D. fluvitalis", "ORGANISM", 85, 98], ["D. gruberi", "ORGANISM", 100, 110], ["D. istanbulensis", "ORGANISM", 112, 128], ["D. oskari", "ORGANISM", 130, 139], ["D. villosus", "ORGANISM", 141, 152], ["D. haemobaphes", "ORGANISM", 157, 171], ["D. aralychensis", "SPECIES", 41, 56], ["D. bispinosus", "SPECIES", 58, 71], ["D. caspius", "SPECIES", 73, 83], ["D. fluvitalis", "SPECIES", 85, 98], ["D. gruberi", "SPECIES", 100, 110], ["D. istanbulensis", "SPECIES", 112, 128], ["D. oskari", "SPECIES", 130, 139], ["D. villosus", "SPECIES", 141, 152], ["D. haemobaphes", "SPECIES", 157, 171], ["D. aralychensis", "SPECIES", 41, 56], ["D. bispinosus", "SPECIES", 58, 71], ["D. caspius", "SPECIES", 73, 83], ["D. fluvitalis", "SPECIES", 85, 98], ["D. gruberi", "SPECIES", 100, 110], ["D. istanbulensis", "SPECIES", 112, 128], ["D. oskari", "SPECIES", 130, 139], ["D. villosus", "SPECIES", 141, 152], ["D. haemobaphes", "SPECIES", 157, 171], ["genus", "ANATOMY", 4, 9], ["nine species", "OBSERVATION", 19, 31]]], ["These species are naturally distributed around the Ponto-Caspian region (Black Sea, Caspian Sea and Sea of Azov) and several have become invasive throughout Europe and on the island of the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 189, 191], ["These species", "PROBLEM", 0, 13], ["Azov", "TREATMENT", 107, 111], ["Caspian", "ANATOMY", 57, 64], ["region", "ANATOMY_MODIFIER", 65, 71], ["invasive", "OBSERVATION", 137, 145]]], ["Dikerogammarus villosus and D. haemobaphes have both invaded the UK and continue to impact freshwater systems, both directly and through the introduction of pathogens (Bojko et al., 2013, 2018b).Evolutionary history of Dikerogammarus haemobaphes ::: DiscussionThe mitochondrial genome of D. haemobaphes shares synteny and gene similarity with closely related amphipods, excluding the presence of some duplicate gene regions and a tRNA rearrangement (Figs.", [["mitochondrial", "ANATOMY", 264, 277], ["Dikerogammarus villosus", "ORGANISM", 0, 23], ["D. haemobaphes", "ORGANISM", 28, 42], ["UK", "GENE_OR_GENE_PRODUCT", 65, 67], ["Dikerogammarus haemobaphes", "ORGANISM", 219, 245], ["mitochondrial", "CELLULAR_COMPONENT", 264, 277], ["D. haemobaphes", "ORGANISM", 288, 302], ["mitochondrial genome", "DNA", 264, 284], ["D. haemobaphes", "DNA", 288, 302], ["duplicate gene regions", "DNA", 401, 423], ["Dikerogammarus villosus", "SPECIES", 0, 23], ["D. haemobaphes", "SPECIES", 28, 42], ["D. haemobaphes", "SPECIES", 288, 302], ["Dikerogammarus villosus", "SPECIES", 0, 23], ["D. haemobaphes", "SPECIES", 28, 42], ["Dikerogammarus haemobaphes", "SPECIES", 219, 245], ["D. haemobaphes", "SPECIES", 288, 302], ["D. haemobaphes", "PROBLEM", 28, 42], ["some duplicate gene regions", "PROBLEM", 396, 423], ["a tRNA rearrangement", "TREATMENT", 428, 448], ["tRNA rearrangement", "OBSERVATION", 430, 448]]], ["Specifically, the presence of a duplicated atp8 gene (atp8-1) on the opposite coding strand (Fig. 1) is absent from other Gammaridae.", [["atp8", "GENE_OR_GENE_PRODUCT", 43, 47], ["atp8-1", "GENE_OR_GENE_PRODUCT", 54, 60], ["atp8 gene", "DNA", 43, 52], ["atp8", "DNA", 54, 58], ["opposite coding strand", "DNA", 69, 91], ["a duplicated atp8 gene", "PROBLEM", 30, 52], ["atp8", "TEST", 54, 58]]], ["This gene shows no genetic similarity to other Gammaridae and may be a motif specific to this species, or possibly the Dikerogammarus genus pending further research.", [["Gammaridae", "GENE_OR_GENE_PRODUCT", 47, 57], ["the Dikerogammarus genus", "PROBLEM", 115, 139], ["no", "UNCERTAINTY", 16, 18]]], ["If this is the case it could be a clear molecular tag for use in future systematics of the Dikerogammarus group.Evolutionary history of Dikerogammarus haemobaphes ::: DiscussionPhylogenetically and morphologically, Dikerogammarus sp. have been identified as members of the Gammaridae and this study supports their inclusion using mitochondrial data from a D. haemobaphes representative (M\u00fcller et al., 2002).", [["mitochondrial", "ANATOMY", 330, 343], ["Dikerogammarus", "CHEMICAL", 91, 105], ["Dikerogammarus haemobaphes", "ORGANISM", 136, 162], ["Dikerogammarus sp", "ORGANISM", 215, 232], ["Gammaridae", "GENE_OR_GENE_PRODUCT", 273, 283], ["mitochondrial", "CELLULAR_COMPONENT", 330, 343], ["Dikerogammarus haemobaphes", "SPECIES", 136, 162], ["D. haemobaphes", "SPECIES", 356, 370], ["this study", "TEST", 288, 298], ["mitochondrial data", "TEST", 330, 348]]], ["The phylogenetic data in Fig. 4 suggest that D. haemobaphes is likely an early member of the Gammaridae [sensu Hou and Sket (2016)], branching with strong support before the other members.", [["D. haemobaphes", "ORGANISM", 45, 59], ["D. haemobaphes", "SPECIES", 45, 59], ["D. haemobaphes", "SPECIES", 45, 59], ["The phylogenetic data", "TEST", 0, 21]]], ["Eurythenes maldoror d\u2019Udekem, d\u2019Acoz, Havermans, 2015 and Onisimus nanseni (Sars, 1900) both branch at the node separating the Gammaridae and Eurytheneidae/Uristidae and greater numbers of sequenced amphipods in both the Dikerogammarus and other related genera would greatly increase the evolutionary detail of the early formation of the Gammaridae.Evolution of microparasites in the Gammaridae ::: DiscussionDikerogammarus sp. are thought to be high invasion risks to the UK, including their co-invasive diseases [summarised in Bojko et al., (2018b)], which are of importance to freshwater ecosystem health (Roy et al., 2017, 2019).", [["node", "ANATOMY", 107, 111], ["d\u2019Acoz", "CELL", 30, 36], ["Onisimus nanseni", "ORGANISM", 58, 74], ["node", "MULTI-TISSUE_STRUCTURE", 107, 111], ["Eurytheneidae", "GENE_OR_GENE_PRODUCT", 142, 155], ["Uristidae", "GENE_OR_GENE_PRODUCT", 156, 165], ["DiscussionDikerogammarus sp", "ORGANISM", 399, 426], ["Onisimus nanseni", "SPECIES", 58, 74], ["Onisimus nanseni", "SPECIES", 58, 74], ["the Gammaridae", "TREATMENT", 123, 137], ["Eurytheneidae/Uristidae", "TREATMENT", 142, 165], ["sequenced amphipods", "TREATMENT", 189, 208], ["microparasites", "PROBLEM", 362, 376], ["high invasion risks", "PROBLEM", 446, 465], ["their co-invasive diseases", "PROBLEM", 487, 513], ["branch", "ANATOMY_MODIFIER", 93, 99], ["node", "OBSERVATION", 107, 111], ["greater", "OBSERVATION_MODIFIER", 170, 177], ["microparasites", "OBSERVATION", 362, 376], ["thought to be", "UNCERTAINTY", 432, 445], ["high", "OBSERVATION_MODIFIER", 446, 450], ["invasion", "OBSERVATION", 451, 459]]], ["The data presented herein have identified that the D. haemobaphes population seeding the UK invasion was likely originating in central Europe and not the native range, which means that the diseases identified from extensive screening in the UK are likely also present in the European range (Bojko et al., 2015, 2018b).", [["D. haemobaphes", "ORGANISM", 51, 65], ["UK", "GENE_OR_GENE_PRODUCT", 89, 91], ["UK", "GENE_OR_GENE_PRODUCT", 241, 243], ["D. haemobaphes", "SPECIES", 51, 65], ["the D. haemobaphes population", "PROBLEM", 47, 76], ["the UK invasion", "PROBLEM", 85, 100], ["the diseases", "PROBLEM", 185, 197], ["extensive screening", "TEST", 214, 233], ["invasion", "OBSERVATION", 92, 100], ["central", "ANATOMY_MODIFIER", 127, 134], ["diseases", "OBSERVATION", 189, 197]]], ["Many of these diseases can impact the activity of their host, but also cause mortality in non-target amphipod hosts, such as G. pulex, potentially threatening biodiversity (Bojko et al., 2018b).Evolution of microparasites in the Gammaridae ::: DiscussionDisease screening in the Gammaridae is lacking in research effort; however, some studies have provided insight the parasite diversity of some that also have mitochondrial genomes available (Madyarova et al., 2015; Bojko, 2017; Bojko et al., 2017; Dimova et al., 2018; Bacela-Spychalska et al., 2018; Ironside & Wilkinson, 2018; Bojko & Ovcharenko, 2019).", [["mitochondrial", "ANATOMY", 411, 424], ["G. pulex", "ORGANISM", 125, 133], ["mitochondrial", "CELLULAR_COMPONENT", 411, 424], ["G. pulex", "SPECIES", 125, 133], ["G. pulex", "SPECIES", 125, 133], ["these diseases", "PROBLEM", 8, 22], ["microparasites", "PROBLEM", 207, 221], ["DiscussionDisease screening", "TEST", 244, 271], ["some studies", "TEST", 330, 342], ["diseases", "OBSERVATION", 14, 22], ["microparasites", "OBSERVATION", 207, 221]]], ["Combining data from any disease screening efforts with the phylogenetics conducted herein indicated that Microsporidia [Cucumispora sp. (including candidatus species) and Dictyocoela sp.] are present across the Gammaridae, with the exception of P. kessleri and C. tuberculatus, likely due to a lack of screening effort.", [["Cucumispora sp", "ORGANISM", 120, 134], ["candidatus species", "ORGANISM", 147, 165], ["Dictyocoela sp.", "ORGANISM", 171, 186], ["P. kessleri", "ORGANISM", 245, 256], ["C. tuberculatus", "ORGANISM", 261, 276], ["Dictyocoela sp.", "SPECIES", 171, 186], ["P. kessleri", "SPECIES", 245, 256], ["C. tuberculatus", "SPECIES", 261, 276], ["Dictyocoela sp.", "SPECIES", 171, 186], ["P. kessleri", "SPECIES", 245, 256], ["C. tuberculatus", "SPECIES", 261, 276], ["any disease screening efforts", "PROBLEM", 20, 49], ["the phylogenetics", "TEST", 55, 72], ["Microsporidia", "PROBLEM", 105, 118], ["candidatus species", "PROBLEM", 147, 165], ["Dictyocoela sp.", "PROBLEM", 171, 186], ["P. kessleri and C. tuberculatus", "PROBLEM", 245, 276], ["C. tuberculatus", "OBSERVATION", 261, 276]]], ["Gregarine parasites (Apicomplexa) are present in Eulimnogammarus sp., Gammarus sp. and D. haemobaphes, suggesting that this group is also likely present across the Gammaridae.", [["Gregarine parasites", "ORGANISM", 0, 19], ["Eulimnogammarus sp.", "ORGANISM", 49, 68], ["Gammarus sp.", "ORGANISM", 70, 82], ["D. haemobaphes", "ORGANISM", 87, 101], ["Eulimnogammarus sp.", "SPECIES", 49, 68], ["D. haemobaphes", "SPECIES", 87, 101], ["Eulimnogammarus sp.", "SPECIES", 49, 68], ["D. haemobaphes", "SPECIES", 87, 101], ["Gregarine parasites", "PROBLEM", 0, 19], ["parasites", "OBSERVATION", 10, 19], ["Apicomplexa", "OBSERVATION_MODIFIER", 21, 32]]], ["The recent discovery of \u2018Candidatus Aquirickettsiella gammari\u2019Bojko, Dunn, Stebbing, van Aerle, Bacela-Spychalska, Bean, Urrutia, Stentiford 2018b and similar pathologies in D. haemobaphes (Bojko, 2017) and G. roeselii (Bojko et al., 2017) suggest that increased screening will also discover related pathogens across the Gammaridae.", [["Aquirickettsiella gammari", "ORGANISM", 36, 61], ["D. haemobaphes", "ORGANISM", 174, 188], ["G. roeselii", "ORGANISM", 207, 218], ["Aquirickettsiella gammari", "SPECIES", 36, 61], ["D. haemobaphes", "SPECIES", 174, 188], ["G. roeselii", "SPECIES", 207, 218], ["D. haemobaphes", "SPECIES", 174, 188], ["G. roeselii", "SPECIES", 207, 218], ["Bacela", "TEST", 96, 102], ["increased screening", "PROBLEM", 253, 272], ["Bacela", "ANATOMY", 96, 102]]], ["Finally, bacilliform viruses in the hepatopancreas of crustaceans (now thought to be part of the Nudiviridae) have been found in multiple Gammaridae, including: Dikerogammarus sp.", [["hepatopancreas", "ANATOMY", 36, 50], ["bacilliform viruses", "ORGANISM", 9, 28], ["hepatopancreas", "ORGAN", 36, 50], ["Nudiviridae", "CANCER", 97, 108], ["Dikerogammarus sp", "ORGANISM", 161, 178], ["bacilliform viruses", "PROBLEM", 9, 28], ["the Nudiviridae", "TREATMENT", 93, 108], ["viruses", "OBSERVATION", 21, 28], ["hepatopancreas", "ANATOMY", 36, 50]]], ["(Bojko et al., 2013; 2018b) and Gammarus sp.", [["Gammarus sp", "ORGANISM", 32, 43]]], ["The presence of this virus in this early branching gammarid host suggests the viral group are also likely present in the other Gammaridae (Fig. 5).Concluding remarksDikerogammarus haemobaphes is the earliest member of the Gammaridae identified to date using concatenated mitochondrial phylogenetics.", [["mitochondrial", "ANATOMY", 271, 284], ["remarksDikerogammarus haemobaphes", "ORGANISM", 158, 191], ["Gammaridae", "GENE_OR_GENE_PRODUCT", 222, 232], ["mitochondrial", "CELLULAR_COMPONENT", 271, 284], ["Gammaridae", "DNA", 222, 232], ["remarksDikerogammarus haemobaphes", "SPECIES", 158, 191], ["this virus", "PROBLEM", 16, 26], ["virus", "OBSERVATION", 21, 26], ["branching", "OBSERVATION_MODIFIER", 41, 50], ["gammarid host", "OBSERVATION", 51, 64], ["viral group", "OBSERVATION", 78, 89]]], ["Knowledge of its diseases suggests that many of the other Gammaridae likely also co-evolved with microsporidian, protistan, bacterial and viral diseases; many yet to be discovered.Concluding remarksThe mitochondrial genome of this host will provide further insight into the development of genetic identification tools and the ability to track this species and its diseases, perhaps in combination with eDNA tools to explore invasion presence (Mauvisseau et al., 2019).", [["mitochondrial", "ANATOMY", 202, 215], ["bacterial and viral diseases", "DISEASE", 124, 152], ["Gammaridae", "GENE_OR_GENE_PRODUCT", 58, 68], ["mitochondrial", "CELLULAR_COMPONENT", 202, 215], ["mitochondrial genome", "DNA", 202, 222], ["its diseases", "PROBLEM", 13, 25], ["microsporidian", "PROBLEM", 97, 111], ["bacterial and viral diseases", "PROBLEM", 124, 152], ["genetic identification tools", "PROBLEM", 289, 317], ["its diseases", "PROBLEM", 360, 372], ["invasion presence", "PROBLEM", 424, 441], ["viral diseases", "OBSERVATION", 138, 152], ["mitochondrial genome", "OBSERVATION", 202, 222]]], ["Knowledge of the mitochondrial genome will help to differentiate host haplotypes to explore disease susceptibility and identify regions of similarity and difference between Dikerogammarus populations.Concluding remarksFinally, this study has determined that the population in the UK seems to have been seeded by populations in Europe and not the native range, suggesting that the diseases in the UK are likely to be present in continental Europe and may pose risk to native Gammarids and the related freshwater ecology.", [["mitochondrial", "ANATOMY", 17, 30], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["Dikerogammarus populations", "CELL", 173, 199], ["UK", "GENE_OR_GENE_PRODUCT", 280, 282], ["UK", "GENE_OR_GENE_PRODUCT", 396, 398], ["mitochondrial genome", "DNA", 17, 37], ["the mitochondrial genome", "PROBLEM", 13, 37], ["host haplotypes", "PROBLEM", 65, 80], ["disease susceptibility", "PROBLEM", 92, 114], ["Dikerogammarus populations", "PROBLEM", 173, 199], ["this study", "TEST", 227, 237], ["the diseases", "PROBLEM", 376, 388], ["diseases", "OBSERVATION", 380, 388], ["likely to be", "UNCERTAINTY", 403, 415]]]], "924313134ea2e38b9e48ceaa1177afb92f7a5c03": [["BackgroundNovel human pathogens appear at a continually increasing rate.", [["human", "ORGANISM", 16, 21], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["BackgroundNovel human pathogens", "PROBLEM", 0, 31], ["human pathogens", "OBSERVATION", 16, 31]]], ["Among wildlife sources, bats, mammals of the order Chiroptera, are perhaps the most striking, serving as the primary natural reservoirs for many human pathogens [2] [3] [4] [5] , including several viruses of notorious lethality in humans: Nipah virus [6] , Hendra virus [7] , Ebola and Marburg Viruses [8, 9] , and Rabies virus.", [["[2] [3] [4] [5]", "CHEMICAL", 161, 176], ["Nipah virus", "DISEASE", 239, 250], ["Hendra virus", "DISEASE", 257, 269], ["Ebola", "DISEASE", 276, 281], ["Marburg Viruses", "DISEASE", 286, 301], ["Rabies virus", "DISEASE", 315, 327], ["human", "ORGANISM", 145, 150], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 161, 176], ["humans", "ORGANISM", 231, 237], ["Nipah virus [6]", "ORGANISM", 239, 254], ["Hendra virus", "ORGANISM", 257, 269], ["Ebola", "ORGANISM", 276, 281], ["Marburg Viruses", "ORGANISM", 286, 301], ["Rabies virus", "ORGANISM", 315, 327], ["human", "SPECIES", 145, 150], ["humans", "SPECIES", 231, 237], ["Nipah virus", "SPECIES", 239, 250], ["Hendra virus", "SPECIES", 257, 269], ["Ebola", "SPECIES", 276, 281], ["Rabies virus", "SPECIES", 315, 327], ["human", "SPECIES", 145, 150], ["humans", "SPECIES", 231, 237], ["Nipah virus", "SPECIES", 239, 250], ["Hendra virus", "SPECIES", 257, 269], ["Rabies virus", "SPECIES", 315, 327], ["the primary natural reservoirs", "TREATMENT", 105, 135], ["many human pathogens", "PROBLEM", 140, 160], ["notorious lethality", "PROBLEM", 208, 227], ["Nipah virus", "PROBLEM", 239, 250], ["Hendra virus", "PROBLEM", 257, 269], ["Ebola and Marburg Viruses", "TEST", 276, 301], ["Rabies virus", "PROBLEM", 315, 327]]], ["Rabies virus is regarded as the most lethal of all human pathogens, and has been found in bats for over a century [10] .", [["Rabies virus", "DISEASE", 0, 12], ["Rabies virus", "ORGANISM", 0, 12], ["human", "ORGANISM", 51, 56], ["Rabies virus", "SPECIES", 0, 12], ["human", "SPECIES", 51, 56], ["Rabies virus", "SPECIES", 0, 12], ["human", "SPECIES", 51, 56], ["Rabies virus", "PROBLEM", 0, 12]]], ["Rabies and other Lyssaviruses are now found in many other animals, but phylogenetic studies indicate that these viruses first evolved in bats and transferred to animals of the order Carnivora more recently [11] .", [["Rabies", "DISEASE", 0, 6], ["Rabies", "ORGANISM", 0, 6], ["Lyssaviruses", "GENE_OR_GENE_PRODUCT", 17, 29], ["phylogenetic studies", "TEST", 71, 91], ["these viruses", "PROBLEM", 106, 119], ["viruses", "OBSERVATION", 112, 119]]], ["SARS-like Coronaviruses have also been found in bats [12, 13] and so far provide the closest link to the agent of human SARS.BackgroundInfection by each of these viruses in bats appears to be asymptomatic or of greatly reduced pathology.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 120, 124], ["BackgroundInfection", "DISEASE", 125, 144], ["SARS-like Coronaviruses", "ORGANISM", 0, 23], ["human", "ORGANISM", 114, 119], ["bats", "ORGANISM", 173, 177], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["SARS", "PROBLEM", 0, 4], ["Coronaviruses", "PROBLEM", 10, 23], ["BackgroundInfection", "TREATMENT", 125, 144], ["asymptomatic", "PROBLEM", 192, 204], ["greatly reduced pathology", "PROBLEM", 211, 236], ["viruses", "OBSERVATION", 162, 169], ["appears to be", "UNCERTAINTY", 178, 191], ["greatly", "OBSERVATION_MODIFIER", 211, 218], ["reduced", "OBSERVATION_MODIFIER", 219, 226], ["pathology", "OBSERVATION", 227, 236]]], ["Even Rabies virus, for which we have a great wealth of experimental data, and which is regarded as invariably lethal in other mammals, has been shown repeatedly to have decreased virulence in bats [14] .BackgroundThe association of so many human-lethal viruses with bats may be partially attributable to the fact that the order Chiroptera to which the bats belong, is the second largest mammalian order, behind only Rodentia in total species [15] .", [["Rabies virus", "DISEASE", 5, 17], ["Rabies virus", "ORGANISM", 5, 17], ["human", "ORGANISM", 240, 245], ["human", "SPECIES", 240, 245], ["Rabies virus", "SPECIES", 5, 17], ["human", "SPECIES", 240, 245], ["Rabies virus", "PROBLEM", 5, 17], ["lethal viruses", "PROBLEM", 246, 260], ["Rabies virus", "OBSERVATION", 5, 17]]], ["On the other hand, the unique lifestyles and ecological circumstances of bats makes plausible the idea that the coevolution of bats and their viruses produced unusually virulent viruses and a host antiviral response tuned to suppress them.BackgroundIf the latter is the case, it will be of great interest to understand the ways in which the several components of the bat antiviral response differ from those in humans and other mammals.", [["bats", "ORGANISM", 127, 131], ["bat", "ORGANISM", 367, 370], ["humans", "ORGANISM", 411, 417], ["humans", "SPECIES", 411, 417], ["humans", "SPECIES", 411, 417], ["their viruses", "PROBLEM", 136, 149], ["unusually virulent viruses", "PROBLEM", 159, 185], ["a host antiviral response", "TREATMENT", 190, 215], ["virulent viruses", "OBSERVATION", 169, 185]]], ["The main hurdle to the pursuit of this goal is our paucity of knowledge of bat immunology and almost complete lack of reagents to initiate such studies.", [["bat", "ORGANISM", 75, 78], ["such studies", "TEST", 139, 151], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This information resides, for the most part, in partially-or unassembled genome sequences, and is not practically available for such purposes without further technical developments.BackgroundOur aims in this paper are to describe the method we have devised for the partial assembly of genome sequencing traces for the inference of gene families, to validate this method on the human interferon alpha family, and to use it for the inference of the type-I interferon families in the bats Myotis lucifugus (little brown bat) and Pteropus vampyrus (large flying fox).BackgroundMost pathogenic viruses, including all of the viruses listed above, possess one or more genes that directly antagonize the type-I interferon response [16] [17] [18] [19] , indicating a strong coevolutionary pressure between these viruses and the type-I interferon system.", [["human", "ORGANISM", 377, 382], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 383, 399], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 447, 464], ["bats", "ORGANISM", 481, 485], ["Myotis lucifugus", "ORGANISM", 486, 502], ["brown bat", "ORGANISM", 511, 520], ["Pteropus vampyrus", "ORGANISM", 526, 543], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 696, 713], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 723, 742], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 819, 836], ["unassembled genome sequences", "DNA", 61, 89], ["human interferon alpha family", "PROTEIN", 377, 406], ["type-I interferon families", "PROTEIN", 447, 473], ["human", "SPECIES", 377, 382], ["Myotis lucifugus", "SPECIES", 486, 502], ["brown bat", "SPECIES", 511, 520], ["Pteropus vampyrus", "SPECIES", 526, 543], ["human", "SPECIES", 377, 382], ["Myotis lucifugus", "SPECIES", 486, 502], ["brown bat", "SPECIES", 511, 520], ["Pteropus vampyrus (large flying fox", "SPECIES", 526, 561], ["such purposes", "TEST", 128, 141], ["the type-I interferon families", "TREATMENT", 443, 473], ["little brown bat)", "PROBLEM", 504, 521], ["Pteropus vampyrus", "PROBLEM", 526, 543], ["BackgroundMost pathogenic viruses", "PROBLEM", 563, 596], ["a strong coevolutionary pressure between these viruses", "PROBLEM", 756, 810], ["the type-I interferon system", "TREATMENT", 815, 843], ["Pteropus vampyrus", "OBSERVATION", 526, 543], ["pathogenic", "OBSERVATION_MODIFIER", 578, 588], ["viruses", "OBSERVATION", 589, 596], ["viruses", "OBSERVATION", 619, 626], ["pressure", "OBSERVATION", 780, 788], ["viruses", "OBSERVATION", 803, 810]]], ["In experimental infections of mice with Rabies virus, the investigators noted a marked correlation between survival and IFN production [20] .BackgroundType I inteferons are the primary mediators of one of the earliest stages of the antiviral response in mammals.", [["infections", "DISEASE", 16, 26], ["Rabies virus", "DISEASE", 40, 52], ["mice", "ORGANISM", 30, 34], ["Rabies virus", "ORGANISM", 40, 52], ["IFN", "GENE_OR_GENE_PRODUCT", 120, 123], ["Type I inteferons", "GENE_OR_GENE_PRODUCT", 151, 168], ["IFN", "PROTEIN", 120, 123], ["Type I inteferons", "PROTEIN", 151, 168], ["mice", "SPECIES", 30, 34], ["Rabies virus", "SPECIES", 40, 52], ["mice", "SPECIES", 30, 34], ["Rabies virus", "SPECIES", 40, 52], ["Rabies virus", "PROBLEM", 40, 52], ["infections", "OBSERVATION", 16, 26], ["antiviral response", "OBSERVATION", 232, 250]]], ["They are induced rapidly and secreted upon viral infection.", [["viral infection", "DISEASE", 43, 58], ["viral infection", "PROBLEM", 43, 58], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58]]], ["Cells exposed to these cytokines enter an infection-refractory state induced by signaling through the common type-I interferon receptor complex.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 42, 51], ["Cells", "CELL", 0, 5], ["type-I interferon receptor", "GENE_OR_GENE_PRODUCT", 109, 135], ["cytokines", "PROTEIN", 23, 32], ["common type-I interferon receptor complex", "PROTEIN", 102, 143], ["these cytokines", "TEST", 17, 32], ["an infection", "PROBLEM", 39, 51], ["refractory state", "PROBLEM", 52, 68], ["infection", "OBSERVATION", 42, 51]]], ["In this state, transcription and translation of viral gene products is inhibited, MHC class I expression is upregulated, RNA and protein degradation are accelerated (reviewed in depth in refs [21] [22] [23] ).", [["MHC class I", "GENE_OR_GENE_PRODUCT", 82, 93], ["viral gene products", "PROTEIN", 48, 67], ["MHC class I", "PROTEIN", 82, 93], ["viral gene products", "TREATMENT", 48, 67], ["RNA and protein degradation", "PROBLEM", 121, 148]]], ["There are 13 human functional IFN\u03b1 genes, as well as single functional genes for IFN\u03b2, IFN\u03b5, IFN\u03c9, and IFN The type 1 interferons are highly pleiomorphic, exhibiting both distinct and complex overlapping function [21, 24] .", [["human", "ORGANISM", 13, 18], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 30, 34], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 81, 85], ["IFN\u03b5", "GENE_OR_GENE_PRODUCT", 87, 91], ["IFN\u03c9", "GENE_OR_GENE_PRODUCT", 93, 97], ["type 1 interferons", "GENE_OR_GENE_PRODUCT", 111, 129], ["human functional IFN\u03b1 genes", "DNA", 13, 40], ["IFN\u03b2", "PROTEIN", 81, 85], ["IFN\u03b5", "PROTEIN", 87, 91], ["IFN\u03c9", "PROTEIN", 93, 97], ["IFN", "PROTEIN", 103, 106], ["type 1 interferons", "PROTEIN", 111, 129], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["distinct", "OBSERVATION_MODIFIER", 171, 179], ["complex", "OBSERVATION_MODIFIER", 184, 191], ["overlapping", "OBSERVATION_MODIFIER", 192, 203]]], ["All of the known mammalian type-I interferons genes are intronless; their transcripts are neither spliced nor edited before translation, and expression is controlled at the transcriptional level [23, 25, 26] .Bat Genome ProjectsThere are two bat whole-genome sequencing projects in progress, but neither is complete at this point.", [["type-I interferons", "GENE_OR_GENE_PRODUCT", 27, 45], ["mammalian type-I interferons genes", "DNA", 17, 51]]], ["One of them will provide coverage at a level that will not produce a reliable assembly.", [["coverage", "TREATMENT", 25, 33]]], ["There are in fact a great many sequencing projects underway for which there is no intent to do full coverage [27] .", [["great", "OBSERVATION_MODIFIER", 20, 25], ["no", "UNCERTAINTY", 79, 81]]], ["The Myotis lucifugus genome sequencing project has completed sequencing to approximately 7-fold coverage with 27,486,306 traces thus far.", [["Myotis lucifugus", "CELL", 4, 20], ["Myotis lucifugus genome", "DNA", 4, 27], ["Myotis lucifugus", "SPECIES", 4, 20], ["Myotis lucifugus", "SPECIES", 4, 20]]], ["The genome is, as of this writing, being assembled http://www. broadinstitute.org/science/projects/mammals-models/ brown-bat/little-brown-bat.", [["broadinstitute.org", "TEST", 63, 81], ["/mammals-models", "TEST", 98, 113], ["bat", "ANATOMY", 121, 124], ["bat", "ANATOMY", 138, 141]]], ["The Pteropus vampyrus genome sequencing project has produced 8,051,001 genome traces http://www.hgsc.bcm.tmc.edu/project-species-m-Megabat.hgsc?pageLocation=Megabat and is slated for completion with 2x coverage.", [["8,051,001 genome traces", "DNA", 61, 84], ["Pteropus vampyrus", "SPECIES", 4, 21], ["2x coverage", "TREATMENT", 199, 210], ["Pteropus", "OBSERVATION", 4, 12], ["vampyrus genome", "OBSERVATION", 13, 28]]], ["The Pteropus project is based on samples from a single individual bat (personal communication).Bat Genome ProjectsThe consequence of incomplete coverage is the exacerbation of one of the shortcomings of whole-genome shotgun sequencing: the difficulty of resolving repetitive DNA segments [28] .", [["DNA", "CELLULAR_COMPONENT", 275, 278], ["repetitive DNA segments", "DNA", 264, 287], ["whole-genome shotgun sequencing", "TREATMENT", 203, 234], ["repetitive DNA segments", "PROBLEM", 264, 287], ["Pteropus", "OBSERVATION_MODIFIER", 4, 12]]], ["If two sequencing traces contain regions of similarity, it may be difficult or impossible to determine whether these traces are derived from the same underlying DNA or from two distinct DNA segments that are themselves paralogous.", [["DNA", "CELLULAR_COMPONENT", 161, 164], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["DNA segments", "DNA", 186, 198], ["the same underlying DNA", "PROBLEM", 141, 164], ["distinct", "OBSERVATION_MODIFIER", 177, 185], ["DNA segments", "OBSERVATION", 186, 198]]], ["This difficulty is not limited to the assembly of highly repetitious intergenic regions, but to the inference of gene families as well.Bat Genome ProjectsThis latter problem is particularly unfortunate, because gene duplication is a major source of innovative potential in evolution, and the comparative study of gene families among related species is therefore of great interest [29] .", [["repetitious intergenic regions", "DNA", 57, 87], ["highly repetitious intergenic regions", "PROBLEM", 50, 87], ["gene duplication", "PROBLEM", 211, 227], ["the comparative study", "TEST", 288, 309]]], ["Furthermore, a large proportion of genes in eukaryotic genomes reside in families, including the genes that encode the type-I interferons.Bat Genome ProjectsIn this paper, we describe a method for the inference of gene family members from unassembled sequencing traces.", [["type-I interferons", "GENE_OR_GENE_PRODUCT", 119, 137], ["eukaryotic genomes", "DNA", 44, 62], ["type-I interferons", "PROTEIN", 119, 137], ["large", "OBSERVATION_MODIFIER", 15, 20], ["eukaryotic genomes", "OBSERVATION", 44, 62]]], ["This reconstruction provides an estimate of the number of genes in the family and posterior probability mass functions on the DNA sequences of these genes.Bat Genome ProjectsWe first present the model and the algorithm we have developed to minimize the description length and thereby infer the structure of the gene family.", [["DNA", "CELLULAR_COMPONENT", 126, 129], ["DNA sequences", "DNA", 126, 139], ["This reconstruction", "TREATMENT", 0, 19], ["posterior probability mass functions", "PROBLEM", 82, 118], ["the DNA sequences", "TEST", 122, 139], ["posterior", "ANATOMY_MODIFIER", 82, 91], ["mass", "OBSERVATION", 104, 108]]], ["We validate the methods by reconstructing the human type-I interferon family genes from sequencing traces from the human genome project.", [["human", "ORGANISM", 46, 51], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 52, 69], ["human", "ORGANISM", 115, 120], ["human type-I interferon family genes", "DNA", 46, 82], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 115, 120]]], ["We use this method to infer the type-I interferon families from the sequencing traces from the Myotis lucifugus and Pteropus vampyrus genome sequencing projects.", [["type-I interferon", "GENE_OR_GENE_PRODUCT", 32, 49], ["Myotis lucifugus", "ORGANISM", 95, 111], ["I interferon families", "PROTEIN", 37, 58], ["Myotis lucifugus", "SPECIES", 95, 111], ["Pteropus vampyrus", "SPECIES", 116, 133], ["Myotis lucifugus", "SPECIES", 95, 111], ["Pteropus vampyrus", "SPECIES", 116, 133], ["this method", "TREATMENT", 7, 18], ["the type-I interferon families", "TREATMENT", 28, 58], ["the Myotis lucifugus", "TREATMENT", 91, 111], ["Pteropus vampyrus genome sequencing", "TREATMENT", 116, 151], ["Myotis lucifugus", "ANATOMY", 95, 111]]], ["We examine these genes in comparison with the orthologous families in humans and other mammals.", [["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76]]], ["Finally, we confirm our inferences by cloning and sequencing genes from four of the interferon families.Inference of Gene Families From Trace ArchivesIn this section, we present the mathematical basis of the assembly method we have developed and provide a concise algorithmic implementation.Inference of Gene Families From Trace ArchivesWe assume a set S of sequencing traces containing regions with similarity to some given gene or genes.", [["interferon", "GENE_OR_GENE_PRODUCT", 84, 94], ["interferon families", "PROTEIN", 84, 103], ["Gene Families", "DNA", 117, 130], ["Gene Families", "DNA", 304, 317], ["the interferon families", "TREATMENT", 80, 103]]], ["In practice, this seed gene would be an ortholog of the genes one is attempting to infer; one collects S using similarity searching on the complete trace archive for the species of interest.Inference of Gene Families From Trace ArchivesThere are g genes in the family, where g is an unknown integer.", [["seed gene", "DNA", 18, 27], ["Gene Families", "DNA", 203, 216], ["g genes", "DNA", 246, 253], ["g genes", "OBSERVATION_MODIFIER", 246, 253]]], ["Each of these genes is related to a common ancestor \u03b1 (whose sequence is also unknown) and differs from \u03b1 by the accumulation of mutations, including insertions and deletions.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 52, 53], ["\u03b1", "GENE_OR_GENE_PRODUCT", 104, 105], ["\u03b1", "DNA", 52, 53], ["\u03b1", "DNA", 104, 105], ["mutations", "PROBLEM", 129, 138], ["insertions and deletions", "TREATMENT", 150, 174]]], ["Each sequencing trace results from direct templating from one of these genes, and differs from it by sequencing error only.", [["direct templating", "TREATMENT", 35, 52]]], ["Figure 1 illustrates the statistical model used for the inferential procedure.Inference of Gene Families From Trace ArchivesGiven any two sequencing traces in S, they are related either through sharing the same immediate template (traces 5 and 6 in figure 1, for example), or indirectly, through the ancestor, \u03b1, with each having a distinct immediate template.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 310, 311], ["Gene Families", "DNA", 91, 104], ["immediate template", "DNA", 211, 229], ["\u03b1", "DNA", 310, 311], ["the inferential procedure", "TREATMENT", 52, 77], ["a distinct immediate template", "TREATMENT", 330, 359]]], ["These two alternatives correspond to two different likelihoods.", [["two different likelihoods", "PROBLEM", 37, 62], ["two", "OBSERVATION_MODIFIER", 37, 40], ["different", "OBSERVATION_MODIFIER", 41, 50], ["likelihoods", "OBSERVATION", 51, 62]]], ["In the first, the differences between the two traces are attributable to sequencing error only, and must be consistent with the reported position-specific quality scores.", [["sequencing error", "OBSERVATION", 73, 89], ["must be consistent with", "UNCERTAINTY", 100, 123]]], ["The difference in description lengths under these two models provides a criterion for choosing between the models.", [["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Briefly, the description length is the information required to encode the data and the values of the model parameters.", [["the data", "TEST", 70, 78]]], ["For any sub-model for pairs of traces that involves mutations from the common ancestor, the description length must account for the information required to encode the mutation rate.", [["the mutation rate", "TEST", 163, 180]]], ["If y is the overlap in nucleotides between the two sequencing traces, the cost of encoding the mutation rate is log y.Inference of Gene Families From Trace ArchivesThe objective of the assembly procedure is the minimization of the description length over all topologies of the form shown in figure 1 , but there is no method for finding this minimum, short of exhaustive enumeration over all topologies, which is ruled out by practical considerations for all but the smallest S. We therefore adopt a greedy progressive method familiar from its use in multiple sequence alignment.", [["nucleotides", "CHEMICAL", 23, 34], ["Gene Families", "DNA", 131, 144], ["the assembly procedure", "TREATMENT", 181, 203], ["exhaustive enumeration", "PROBLEM", 360, 382], ["no", "UNCERTAINTY", 315, 317]]], ["The process continues until there are no remaining moves that lead to a description length reduction.Inference of Gene Families From Trace ArchivesThe following section provides the details for the probability model.Quality scores and conditional probabilitiesThe base-calling software reads the raw sequencing trace and, for each position, reports a single base and a quality score.", [["Gene Families", "DNA", 114, 127], ["a description length reduction", "TREATMENT", 70, 100], ["Quality scores", "TEST", 216, 230], ["conditional probabilities", "PROBLEM", 235, 260], ["no", "UNCERTAINTY", 38, 40], ["base", "ANATOMY_MODIFIER", 264, 268]]], ["If the reported base is X, and the reported quality score is q, we take the output to represent a posterior probability mass function (pmf) on the latent nucleotide state at that position, given byQuality scores and conditional probabilitieswhere D represents the data conditioning the estimate, and \u03b5(q) is defined byQuality scores and conditional probabilitiesIt is not necessary to specify a likelihood function, or even to describe what the nature of D is, so we simply write p j i ( ) \uf078 for the posterior probability mass function on \u03be in the jth position in the ith sequencing trace.", [["nucleotide", "CHEMICAL", 154, 164], ["the output", "TEST", 72, 82], ["a posterior probability mass function", "PROBLEM", 96, 133], ["the latent nucleotide state", "PROBLEM", 143, 170], ["byQuality scores", "PROBLEM", 195, 211], ["the estimate", "TEST", 282, 294], ["the posterior probability mass function", "PROBLEM", 496, 535], ["base", "ANATOMY_MODIFIER", 16, 20], ["posterior", "ANATOMY_MODIFIER", 98, 107], ["mass", "OBSERVATION", 120, 124], ["not necessary", "UNCERTAINTY", 368, 381], ["posterior", "ANATOMY_MODIFIER", 500, 509], ["mass", "OBSERVATION", 522, 526]]], ["For simplicity in this presentation, we will assume that the prior pmf on \u03be is uniform on A, C, G, T, -.", [["T", "GENE_OR_GENE_PRODUCT", 99, 100], ["pmf", "DNA", 67, 70]]], ["We will also need the posterior pmf on the ancestral state \u03b1, which is obtained by specifying a model for the accumulation of mutations from \u03b1 to \u03be, and summing over the unobserved state, \u03be.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 59, 60], ["posterior pmf", "PROTEIN", 22, 35], ["\u03b1 to \u03be", "PROTEIN", 141, 147], ["the accumulation of mutations", "PROBLEM", 106, 135]]], ["We take a simple reversible mutation modelQuality scores and conditional probabilitiesand letQuality scores and conditional probabilitiesConsider the model partially described by having position i in trace 1 aligned with position j in trace 2.", [["a simple reversible mutation modelQuality scores", "PROBLEM", 8, 56], ["conditional probabilitiesand letQuality scores", "PROBLEM", 61, 107], ["conditional probabilities", "PROBLEM", 112, 137]]], ["The posterior pmf for the latent true nucleotide state isQuality scores and conditional probabilitieswhere k is the position in the assembly corresponding to i and j in traces 1 and 2, respectively. \uf06a ij 12 is given byQuality scores and conditional probabilitiesSince the criterion is the minimization of the description length we compare any two models by the difference in their description lengths.", [["nucleotide", "CHEMICAL", 38, 48], ["nucleotide", "CHEMICAL", 38, 48], ["posterior pmf", "PROTEIN", 4, 17], ["the latent true nucleotide state isQuality scores", "PROBLEM", 22, 71], ["ij", "TREATMENT", 201, 203], ["posterior", "ANATOMY_MODIFIER", 4, 13], ["position", "OBSERVATION_MODIFIER", 116, 124], ["ij", "ANATOMY", 201, 203]]], ["The alignment cost, then, is the difference in description length between the model in which these positions are aligned (given the alignment) and the one in which they are independent, and is give byQuality scores and conditional probabilitiesDenote by A(k) the vector whose components are the indices for the aligned traces corresponding to the kth position in the resulting assembly.", [["A(k) the vector", "TREATMENT", 254, 269], ["alignment", "OBSERVATION_MODIFIER", 4, 13]]], ["The quantity of primary importance for us is the cost difference between the direct and indirect models for a given pair of tracesQuality scores and conditional probabilitiesThe logarithmic term is the cost of encoding the mutation rate that minimizes the alignment score [30] ; the argument o A 12 ( ) \uf06d is the number of nucleotides in the overlap of traces 1 and 2 in the optimal alignment, ie, the number of degrees of freedom available to estimate \u03bc.", [["nucleotides", "CHEMICAL", 322, 333], ["Quality scores", "TEST", 130, 144], ["conditional probabilities", "PROBLEM", 149, 174], ["quantity", "OBSERVATION_MODIFIER", 4, 12]]], ["When c is positive, the indirect model is the more efficient; when c is negative, the direct model is more efficient.Quality scores and conditional probabilitiesFor progressive alignment, note that the posterior assembly pmf and the cost are composed from the individual sequential alignments.", [["posterior assembly pmf", "DNA", 202, 224], ["Quality scores", "TEST", 117, 131], ["conditional probabilities", "PROBLEM", 136, 161], ["progressive alignment", "PROBLEM", 165, 186], ["positive", "OBSERVATION", 10, 18], ["negative", "OBSERVATION", 72, 80], ["progressive", "OBSERVATION_MODIFIER", 165, 176], ["alignment", "OBSERVATION_MODIFIER", 177, 186], ["posterior", "ANATOMY_MODIFIER", 202, 211], ["pmf", "OBSERVATION", 221, 224]]], ["So, for the example of figure 2, we haveQuality scores and conditional probabilitiesIt is then straightforward to show that the alignment scores are additive: and that the assembly posterior pmfs are obtained by compositionQuality scores and conditional probabilitiesWe have shown that the total cost for the composite alignment is given by the sum of the sum of alignment costs, but, as with all progressive alignment methods, the minimum-cost composite alignment may not be the global minimum cost alignment.Quality scores and conditional probabilitiesThe complete procedure, then, is 1.", [["all progressive alignment methods", "PROBLEM", 393, 426], ["the minimum-cost composite alignment", "TREATMENT", 428, 464], ["Quality scores", "TEST", 510, 524], ["conditional probabilities", "PROBLEM", 529, 554], ["The complete procedure", "TREATMENT", 554, 576], ["posterior", "ANATOMY_MODIFIER", 181, 190], ["total", "OBSERVATION_MODIFIER", 290, 295], ["cost", "OBSERVATION", 296, 300], ["progressive", "OBSERVATION_MODIFIER", 397, 408], ["alignment", "OBSERVATION_MODIFIER", 409, 418], ["may not be", "UNCERTAINTY", 465, 475]]], ["Compute all of the minimum pairwise alignment costs c ij using dynamic programming.", [["dynamic programming", "TREATMENT", 63, 82], ["ij", "ANATOMY", 54, 56]]], ["Compute the pairwise costs between the remaining subassemblies and the new assembly.Quality scores and conditional probabilities3.", [["Quality scores", "TEST", 84, 98], ["conditional probabilities3", "PROBLEM", 103, 129], ["pairwise", "OBSERVATION_MODIFIER", 12, 20], ["costs", "OBSERVATION", 21, 26], ["remaining", "OBSERVATION_MODIFIER", 39, 48], ["subassemblies", "OBSERVATION", 49, 62], ["new", "OBSERVATION_MODIFIER", 71, 74]]], ["Continue at step 2 until total assembly cost can no longer be reduced.ValidationWe validated the method by inferring the human interferon-alpha (IFNA) gene family directly from the human whole-genome sequencing trace archives, and comparing the results to IFNA gene sequences known from the finished human genome (as well as from decades of molecular biology on the human IFNA).", [["human", "ORGANISM", 121, 126], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 127, 143], ["IFNA", "GENE_OR_GENE_PRODUCT", 145, 149], ["human", "ORGANISM", 181, 186], ["IFNA", "GENE_OR_GENE_PRODUCT", 256, 260], ["human", "ORGANISM", 300, 305], ["human", "ORGANISM", 366, 371], ["IFNA", "CANCER", 372, 376], ["human interferon-alpha (IFNA) gene family", "DNA", 121, 162], ["IFNA gene sequences", "DNA", 256, 275], ["finished human genome", "DNA", 291, 312], ["human IFNA", "PROTEIN", 366, 376], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 366, 371], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 366, 371], ["IFNA gene sequences", "TEST", 256, 275], ["no longer", "UNCERTAINTY", 49, 58]]], ["We performed this procedure in three different ways.", [["this procedure", "TREATMENT", 13, 27]]], ["First, we collected relevant sequencing traces by performing a BLAST search using the 567 nt-long proteincoding portion of the human IFNA2 transcript (NM_000605) and retrieved 291 traces with expected values less than 10 -6 .", [["human", "ORGANISM", 127, 132], ["IFNA2", "GENE_OR_GENE_PRODUCT", 133, 138], ["567 nt-long proteincoding portion", "DNA", 86, 119], ["human IFNA2 transcript", "RNA", 127, 149], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["a BLAST search", "TEST", 61, 75]]], ["We trimmed each sequence and applied the assembly method described above.ValidationThe procedure resulted in 15 final assemblies.", [["The procedure", "TREATMENT", 83, 96]]], ["We compared the inferred genes to the human genome reference assembly.", [["human", "ORGANISM", 38, 43], ["human genome", "DNA", 38, 50], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43]]], ["Each of these 15 assemblies maps unambiguously to one of the 13 known IFNA genes or the single whole pseudogene at an average error rate of 6.0 \u00d7 10 -4 per base (14 mismatches in 23374 bases).", [["IFNA", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFNA genes", "DNA", 70, 80], ["an average error rate", "TEST", 115, 136]]], ["In one case, a pair of assemblies mapped to a single genomic gene, IFNA17.", [["IFNA17", "GENE_OR_GENE_PRODUCT", 67, 73], ["genomic gene", "DNA", 53, 65], ["IFNA17", "DNA", 67, 73]]], ["There are 2 single nucleotide differences between the two assemblies mapping to IFNA17 and one dinucleotide difference.", [["nucleotide", "CHEMICAL", 19, 29], ["dinucleotide", "CHEMICAL", 95, 107], ["IFNA17", "GENE_OR_GENE_PRODUCT", 80, 86], ["IFNA17", "DNA", 80, 86], ["2 single nucleotide differences", "PROBLEM", 10, 41], ["one dinucleotide difference", "PROBLEM", 91, 118]]], ["Each of the single nucleotide differences is strongly supported, with multiple high-quality reads supporting the inference.", [["nucleotide", "CHEMICAL", 19, 29], ["the single nucleotide differences", "PROBLEM", 8, 41], ["multiple", "OBSERVATION_MODIFIER", 70, 78], ["high", "OBSERVATION_MODIFIER", 79, 83]]], ["The dinucleotide difference is less well supported, with just a single trace covering it in one assembly, though the corresponding bases in this trace are good quality.", [["dinucleotide", "CHEMICAL", 4, 16], ["dinucleotide", "CHEMICAL", 4, 16], ["dinucleotide", "SIMPLE_CHEMICAL", 4, 16], ["The dinucleotide difference", "PROBLEM", 0, 27], ["dinucleotide difference", "OBSERVATION", 4, 27], ["less well supported", "OBSERVATION_MODIFIER", 31, 50], ["single", "OBSERVATION_MODIFIER", 64, 70], ["trace", "OBSERVATION_MODIFIER", 71, 76], ["one assembly", "OBSERVATION_MODIFIER", 92, 104], ["bases", "ANATOMY_MODIFIER", 131, 136], ["trace", "OBSERVATION_MODIFIER", 145, 150], ["good", "OBSERVATION_MODIFIER", 155, 159], ["quality", "OBSERVATION_MODIFIER", 160, 167]]], ["The evidence strongly suggests that the two assemblies do map to two different alleles of the same gene.", [["alleles", "DNA", 79, 86]]], ["Accepting this conclusion reduces the error rate to less than 4 \u00d7 10 -4 per base.", [["the error rate", "TEST", 34, 48]]], ["The 10 remaining mismatches include a single 4-nucleotide deletion relative to the genomic sequence.ValidationFor the next two validation procedures, our intent was to more accurately represent the situation in which the assembler would be used.", [["4-nucleotide deletion", "DNA", 45, 66], ["genomic sequence", "DNA", 83, 99], ["a single 4-nucleotide deletion", "PROBLEM", 36, 66], ["mismatches", "OBSERVATION", 17, 27]]], ["For this purpose, we used one of the P.vampyrus putative IFNA genes rather than human IFNA2 as the BLAST query, and selected a subsample of the retrieved sequences to simulate low coverage.ValidationThere were 74 trace reads in the subset produced by the Whitehead Institute.", [["IFNA", "GENE_OR_GENE_PRODUCT", 57, 61], ["human", "ORGANISM", 80, 85], ["IFNA2", "GENE_OR_GENE_PRODUCT", 86, 91], ["P.vampyrus putative IFNA genes", "DNA", 37, 67], ["human IFNA2", "DNA", 80, 91], ["BLAST query", "DNA", 99, 110], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85]]], ["Assembling these reads using our method produced 13 distinct assemblies with two or more reads in each, mapping (as described above) to 12 different human genomic regions: 7 IFNAs, human IFNW1, LOC100130866 (annotated by NCBI as similar to IFNW1), 2 IFNA pseudogenes and 1 IFNW pseudogene.", [["human", "ORGANISM", 149, 154], ["human", "ORGANISM", 181, 186], ["IFNW1", "GENE_OR_GENE_PRODUCT", 187, 192], ["LOC100130866", "GENE_OR_GENE_PRODUCT", 194, 206], ["IFNW1", "GENE_OR_GENE_PRODUCT", 240, 245], ["IFNA", "GENE_OR_GENE_PRODUCT", 250, 254], ["IFNW", "GENE_OR_GENE_PRODUCT", 273, 277], ["human genomic regions", "DNA", 149, 170], ["IFNAs", "DNA", 174, 179], ["human IFNW1", "DNA", 181, 192], ["LOC100130866", "DNA", 194, 206], ["NCBI", "DNA", 221, 225], ["IFNW1", "DNA", 240, 245], ["IFNA pseudogenes", "DNA", 250, 266], ["IFNW pseudogene", "DNA", 273, 288], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 181, 186], ["our method", "TREATMENT", 29, 39], ["LOC", "PROBLEM", 194, 197]]], ["One pair of distinct assemblies was mapped, erroneously, to a single IFNA.", [["IFNA", "PROTEIN", 69, 73], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["assemblies", "OBSERVATION", 21, 31]]], ["The subset of trace reads from the Venter Institute consisted of 103 sequences, producing 22 distinct assemblies with 2 or more reads, mapping to 22 different regions of the human genome: all 13 IFNAs, 1 IFNA pseudogene, IFNW1, and 6 regions annotated as either IFNW-like or IFNW pseudogenes.", [["human", "ORGANISM", 174, 179], ["IFNAs", "GENE_OR_GENE_PRODUCT", 195, 200], ["IFNA", "GENE_OR_GENE_PRODUCT", 204, 208], ["IFNW1", "GENE_OR_GENE_PRODUCT", 221, 226], ["IFNW", "GENE_OR_GENE_PRODUCT", 262, 266], ["IFNW", "GENE_OR_GENE_PRODUCT", 275, 279], ["human genome", "DNA", 174, 186], ["IFNAs", "DNA", 195, 200], ["IFNA pseudogene", "DNA", 204, 219], ["IFNW1", "DNA", 221, 226], ["IFNW-like or IFNW pseudogenes", "DNA", 262, 291], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["mapping", "TEST", 135, 142], ["IFNAs", "TEST", 195, 200], ["1 IFNA pseudogene, IFNW1, and 6 regions", "PROBLEM", 202, 241], ["IFNW", "TEST", 262, 266], ["IFNW pseudogenes", "PROBLEM", 275, 291], ["trace reads", "OBSERVATION", 14, 25], ["human genome", "ANATOMY", 174, 186]]], ["The alignments of these assemblies to the genome revealed 3 mismatches in 31531 total bases.", [["3 mismatches", "OBSERVATION", 58, 70], ["bases", "ANATOMY_MODIFIER", 86, 91]]], ["One pair of assemblies was erroneously mapped to a single IFNA pseudogene.Type I interferons in Myotis lucifugus and Pteropus vampyrusWe used the protein-coding portions of the human genes IFNA2, IFNK, IFNB, and IFNE, the bovine gene IFNT, and murine gene IFNZ in blast searches against the whole genome shotgun sequence trace archives for Pteropus vampyrus and Myotis lucifugus.", [["IFNA", "GENE_OR_GENE_PRODUCT", 58, 62], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 74, 92], ["Myotis lucifugus", "ORGANISM", 96, 112], ["Pteropus vampyrusWe", "ORGANISM", 117, 136], ["human", "ORGANISM", 177, 182], ["IFNA2", "GENE_OR_GENE_PRODUCT", 189, 194], ["IFNK", "GENE_OR_GENE_PRODUCT", 196, 200], ["IFNB", "GENE_OR_GENE_PRODUCT", 202, 206], ["IFNE", "GENE_OR_GENE_PRODUCT", 212, 216], ["bovine", "ORGANISM", 222, 228], ["IFNT", "GENE_OR_GENE_PRODUCT", 234, 238], ["murine", "ORGANISM", 244, 250], ["IFNZ", "GENE_OR_GENE_PRODUCT", 256, 260], ["Pteropus vampyrus", "ORGANISM", 340, 357], ["Myotis lucifugus", "ORGANISM", 362, 378], ["IFNA pseudogene", "DNA", 58, 73], ["Type I interferons", "PROTEIN", 74, 92], ["human genes", "DNA", 177, 188], ["IFNA2", "DNA", 189, 194], ["IFNK", "DNA", 196, 200], ["IFNB", "DNA", 202, 206], ["IFNE", "DNA", 212, 216], ["bovine gene IFNT", "DNA", 222, 238], ["murine gene IFNZ", "DNA", 244, 260], ["Myotis lucifugus", "SPECIES", 96, 112], ["Pteropus vampyrusWe", "SPECIES", 117, 136], ["human", "SPECIES", 177, 182], ["bovine", "SPECIES", 222, 228], ["murine", "SPECIES", 244, 250], ["Pteropus vampyrus", "SPECIES", 340, 357], ["Myotis lucifugus", "SPECIES", 362, 378], ["Myotis lucifugus", "SPECIES", 96, 112], ["Pteropus vampyrusWe", "SPECIES", 117, 136], ["human", "SPECIES", 177, 182], ["Pteropus vampyrus", "SPECIES", 340, 357], ["Myotis lucifugus", "SPECIES", 362, 378], ["a single IFNA pseudogene", "TREATMENT", 49, 73], ["Type I interferons in Myotis lucifugus", "PROBLEM", 74, 112], ["Pteropus vampyrusWe", "TREATMENT", 117, 136], ["IFNA2", "TEST", 189, 194], ["IFNK", "TEST", 196, 200], ["IFNB", "TEST", 202, 206], ["the bovine gene IFNT", "TEST", 218, 238], ["blast searches", "TEST", 264, 278], ["Pteropus vampyrus", "PROBLEM", 340, 357], ["Myotis lucifugus", "OBSERVATION", 362, 378]]], ["The sequences retrieved in each of the blast searches were then assembled using the methods described above.Type I interferons in Myotis lucifugus and Pteropus vampyrusWe obtained unique final assemblies for IFNB in each bat.", [["Type I interferons", "GENE_OR_GENE_PRODUCT", 108, 126], ["Myotis lucifugus", "ORGANISM", 130, 146], ["Pteropus vampyrusWe", "ORGANISM", 151, 170], ["IFNB", "GENE_OR_GENE_PRODUCT", 208, 212], ["Type I interferons", "PROTEIN", 108, 126], ["IFNB", "PROTEIN", 208, 212], ["Myotis lucifugus", "SPECIES", 130, 146], ["Pteropus vampyrusWe", "SPECIES", 151, 170], ["Myotis lucifugus", "SPECIES", 130, 146], ["Pteropus vampyrusWe", "SPECIES", 151, 170], ["The sequences", "TEST", 0, 13], ["Type I interferons in Myotis lucifugus", "PROBLEM", 108, 146]]], ["Each of these final assemblies contained an intact ORF which, when BLASTed against the NCBI nucleotide sequence database, returned multiple hits on the corresponding gene in several mammals.", [["ORF", "DNA", 51, 54], ["NCBI nucleotide sequence database", "DNA", 87, 120], ["an intact ORF", "PROBLEM", 41, 54], ["the NCBI nucleotide sequence database", "TEST", 83, 120], ["multiple hits", "PROBLEM", 131, 144], ["intact ORF", "OBSERVATION", 44, 54], ["multiple", "OBSERVATION_MODIFIER", 131, 139], ["hits", "OBSERVATION", 140, 144]]], ["The greatest similarity was to horse, pig, and cow sequences, with about 80% nucleotide identity.Type I interferons in Myotis lucifugus and Pteropus vampyrusMyotis produced two final assemblies for IFNE, both of which contain intact ORFs and appear, on close examination, to be genuinely distinct sequences.", [["nucleotide", "CHEMICAL", 77, 87], ["nucleotide", "CHEMICAL", 77, 87], ["horse", "ORGANISM_SUBDIVISION", 31, 36], ["pig", "ORGANISM", 38, 41], ["cow", "ORGANISM", 47, 50], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 97, 115], ["Myotis lucifugus", "ORGANISM", 119, 135], ["Pteropus vampyrusMyotis", "ORGANISM", 140, 163], ["IFNE", "GENE_OR_GENE_PRODUCT", 198, 202], ["horse, pig, and cow sequences", "DNA", 31, 60], ["Type I interferons", "PROTEIN", 97, 115], ["IFNE", "PROTEIN", 198, 202], ["ORFs", "DNA", 233, 237], ["horse", "SPECIES", 31, 36], ["pig", "SPECIES", 38, 41], ["cow", "SPECIES", 47, 50], ["Myotis lucifugus", "SPECIES", 119, 135], ["Pteropus vampyrusMyotis", "SPECIES", 140, 163], ["pig", "SPECIES", 38, 41], ["cow", "SPECIES", 47, 50], ["Myotis lucifugus", "SPECIES", 119, 135], ["Pteropus vampyrusMyotis", "SPECIES", 140, 163], ["Type I interferons in Myotis lucifugus", "PROBLEM", 97, 135], ["Pteropus vampyrusMyotis", "PROBLEM", 140, 163], ["IFNE", "PROBLEM", 198, 202], ["close examination", "TEST", 253, 270], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["Pteropus vampyrusMyotis", "OBSERVATION", 140, 163], ["intact ORFs", "OBSERVATION", 226, 237]]], ["Pteropus produced a single final assembly, which had an intact ORF.Type I interferons in Myotis lucifugus and Pteropus vampyrusThe sequencing traces returned in the search on IFNA2 produced multiple final assemblies that fall into three distinct families with clear similarity to IFNA, IFNW, and IFND (Table 1) , respectively.Type I interferons in Myotis lucifugus and Pteropus vampyrusNo relevant hits to murine IFNZ were found in either chiropteran genome.", [["Pteropus", "CHEMICAL", 0, 8], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 67, 85], ["Myotis lucifugus", "ORGANISM", 89, 105], ["Pteropus vampyrus", "ORGANISM", 110, 127], ["IFNA2", "GENE_OR_GENE_PRODUCT", 175, 180], ["IFNA", "GENE_OR_GENE_PRODUCT", 280, 284], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 326, 344], ["Myotis lucifugus", "ORGANISM", 348, 364], ["Pteropus vampyrusNo", "ORGANISM", 369, 388], ["murine", "ORGANISM", 406, 412], ["IFNZ", "GENE_OR_GENE_PRODUCT", 413, 417], ["ORF", "DNA", 63, 66], ["Type I interferons", "PROTEIN", 67, 85], ["IFNA2", "DNA", 175, 180], ["IFNA", "PROTEIN", 280, 284], ["IFNW", "DNA", 286, 290], ["IFND", "DNA", 296, 300], ["Type I interferons", "PROTEIN", 326, 344], ["murine IFNZ", "DNA", 406, 417], ["chiropteran genome", "DNA", 439, 457], ["Myotis lucifugus", "SPECIES", 89, 105], ["Pteropus vampyrus", "SPECIES", 110, 127], ["Myotis lucifugus", "SPECIES", 348, 364], ["Pteropus vampyrusNo", "SPECIES", 369, 388], ["murine", "SPECIES", 406, 412], ["Myotis lucifugus", "SPECIES", 89, 105], ["Pteropus vampyrus", "SPECIES", 110, 127], ["Myotis lucifugus", "SPECIES", 348, 364], ["Pteropus", "PROBLEM", 0, 8], ["Type I interferons in Myotis lucifugus", "PROBLEM", 67, 105], ["Pteropus vampyrus", "PROBLEM", 110, 127], ["The sequencing traces", "TEST", 127, 148], ["Type I interferons in Myotis lucifugus", "PROBLEM", 326, 364], ["Pteropus vampyrusNo", "TREATMENT", 369, 388], ["intact", "OBSERVATION_MODIFIER", 56, 62], ["ORF", "OBSERVATION", 63, 66], ["Pteropus vampyrus", "OBSERVATION", 110, 127], ["interferons", "OBSERVATION_MODIFIER", 333, 344], ["Pteropus vampyrusNo", "OBSERVATION", 369, 388], ["chiropteran genome", "OBSERVATION", 439, 457]]], ["No hits to bovine IFNT beyond those already obtained using other queries were found.Chiropteran Type II interferonIn mammals, the type I interferons have a single exon of fewer than 700 bases.", [["Type II interferon", "CHEMICAL", 96, 114], ["bovine", "ORGANISM", 11, 17], ["IFNT", "GENE_OR_GENE_PRODUCT", 18, 22], ["Type II interferon", "GENE_OR_GENE_PRODUCT", 96, 114], ["type I interferons", "GENE_OR_GENE_PRODUCT", 130, 148], ["bovine IFNT", "PROTEIN", 11, 22], ["Chiropteran Type II interferon", "PROTEIN", 84, 114], ["type I interferons", "PROTEIN", 130, 148], ["bovine", "SPECIES", 11, 17], ["bovine", "SPECIES", 11, 17], ["hits to bovine IFNT", "PROBLEM", 3, 22], ["Chiropteran Type II interferon", "TREATMENT", 84, 114], ["hits", "OBSERVATION", 3, 7]]], ["IFNG, the type II interferon, has multiple exons.", [["IFNG", "GENE_OR_GENE_PRODUCT", 0, 4], ["type II interferon", "GENE_OR_GENE_PRODUCT", 10, 28], ["IFNG", "PROTEIN", 0, 4], ["type II interferon", "PROTEIN", 10, 28], ["exons", "DNA", 43, 48], ["the type II interferon", "TREATMENT", 6, 28], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["exons", "OBSERVATION", 43, 48]]], ["We used our methods to infer the type-II interferon genes in the two bats by using the fulllength human IFNG gene comprising introns and exons (4972 bases, NC_000012 REGION: complement (68548550..68553521)).", [["type-II interferon", "GENE_OR_GENE_PRODUCT", 33, 51], ["human", "ORGANISM", 98, 103], ["IFNG", "GENE_OR_GENE_PRODUCT", 104, 108], ["type-II interferon genes", "DNA", 33, 57], ["fulllength human IFNG gene", "DNA", 87, 113], ["introns", "DNA", 125, 132], ["exons", "DNA", 137, 142], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["our methods", "TREATMENT", 8, 19], ["the type-II interferon genes", "TREATMENT", 29, 57], ["the fulllength human IFNG gene comprising introns", "TREATMENT", 83, 132]]], ["All exons were clearly identifiable and all intronic splice signals were conserved.", [["exons", "DNA", 4, 9], ["all intronic splice signals", "PROBLEM", 40, 67]]], ["Table 2 shows the sequence similarity among the human and bat sequences.PhylogeneticsThe intact ORFs of the inferred sequences were aligned with the type-I interferons from humans and from the domestic pig, Sus scrofa (which is substantially more closely related to bats than is the human), and as an outgroup, the IFNB and IFNA gene sequences from the duckbill platypus (Ornithorhynchus anatinus).", [["human", "ORGANISM", 48, 53], ["type-I interferons", "GENE_OR_GENE_PRODUCT", 149, 167], ["humans", "ORGANISM", 173, 179], ["domestic pig", "ORGANISM", 193, 205], ["Sus scrofa", "ORGANISM", 207, 217], ["human", "ORGANISM", 283, 288], ["IFNB", "GENE_OR_GENE_PRODUCT", 315, 319], ["IFNA", "GENE_OR_GENE_PRODUCT", 324, 328], ["duckbill platypus", "ORGANISM", 353, 370], ["Ornithorhynchus anatinus", "ORGANISM", 372, 396], ["human and bat sequences", "DNA", 48, 71], ["ORFs", "DNA", 96, 100], ["type-I interferons", "PROTEIN", 149, 167], ["IFNB and IFNA gene sequences", "DNA", 315, 343], ["human", "SPECIES", 48, 53], ["humans", "SPECIES", 173, 179], ["pig", "SPECIES", 202, 205], ["Sus scrofa", "SPECIES", 207, 217], ["human", "SPECIES", 283, 288], ["duckbill platypus", "SPECIES", 353, 370], ["Ornithorhynchus anatinus", "SPECIES", 372, 396], ["human", "SPECIES", 48, 53], ["humans", "SPECIES", 173, 179], ["pig", "SPECIES", 202, 205], ["Sus scrofa", "SPECIES", 207, 217], ["human", "SPECIES", 283, 288], ["duckbill platypus", "SPECIES", 353, 370], ["Ornithorhynchus anatinus", "SPECIES", 372, 396], ["the human and bat sequences", "TEST", 44, 71], ["the IFNB and IFNA gene sequences", "TEST", 311, 343], ["intact ORFs", "OBSERVATION", 89, 100]]], ["The phylogenetic tree relating these genes was inferred using maximum likelihood (Figure 3) .PhylogeneticsThe features of the inferred phylogenetic tree are consistent with those found in previous investigations [31] .", [["previous investigations", "TEST", 188, 211], ["phylogenetic tree", "OBSERVATION", 4, 21], ["phylogenetic tree", "OBSERVATION", 135, 152], ["consistent with", "UNCERTAINTY", 157, 172]]], ["In particular, the interferon families fall into distinct clades, with the exception of the platypus IFNA genes, which appear ancestral to the IFNA, IFNW, and IFND genes of the other species.", [["interferon", "GENE_OR_GENE_PRODUCT", 19, 29], ["platypus", "ORGANISM", 92, 100], ["IFNA", "GENE_OR_GENE_PRODUCT", 101, 105], ["IFNA", "GENE_OR_GENE_PRODUCT", 143, 147], ["IFNW", "GENE_OR_GENE_PRODUCT", 149, 153], ["IFND", "GENE_OR_GENE_PRODUCT", 159, 163], ["interferon families", "PROTEIN", 19, 38], ["platypus IFNA genes", "DNA", 92, 111], ["IFNA, IFNW, and IFND genes", "DNA", 143, 169], ["the platypus IFNA genes", "PROBLEM", 88, 111], ["the other species", "PROBLEM", 173, 190]]], ["Within each of the families, the genes fall into clades according to species, with no interdigitation of genes from different species in any clade ( Figure 3 ).", [["the genes fall", "PROBLEM", 29, 43], ["interdigitation of genes", "PROBLEM", 86, 110], ["different species", "PROBLEM", 116, 133]]], ["Additionally, the bat genes from one bat species are typically, but not universally, more closely related to the orthologous genes from the other bat species than to those of pigs or humans.", [["bat", "ORGANISM", 37, 40], ["pigs", "ORGANISM", 175, 179], ["humans", "ORGANISM", 183, 189], ["bat genes", "DNA", 18, 27], ["orthologous genes", "DNA", 113, 130], ["pigs", "SPECIES", 175, 179], ["humans", "SPECIES", 183, 189], ["pigs", "SPECIES", 175, 179], ["humans", "SPECIES", 183, 189], ["the bat genes", "PROBLEM", 14, 27], ["one bat species", "PROBLEM", 33, 48], ["the orthologous genes", "PROBLEM", 109, 130], ["one bat", "OBSERVATION_MODIFIER", 33, 40], ["species", "OBSERVATION", 41, 48]]], ["The bat genes are typically but not universally more closely related to the orthologous pig genes than to the orthologous human genes.SequencingWe used the inferred sequences to design sequencing primers and make several clones from each of IFNA, IFNB, IFND, and IFNK.", [["bat", "ORGANISM", 4, 7], ["pig", "ORGANISM", 88, 91], ["human", "ORGANISM", 122, 127], ["IFNA", "GENE_OR_GENE_PRODUCT", 241, 245], ["IFNB", "GENE_OR_GENE_PRODUCT", 247, 251], ["IFND", "GENE_OR_GENE_PRODUCT", 253, 257], ["IFNK", "GENE_OR_GENE_PRODUCT", 263, 267], ["bat genes", "DNA", 4, 13], ["orthologous pig genes", "DNA", 76, 97], ["orthologous human genes", "DNA", 110, 133], ["IFNA", "PROTEIN", 241, 245], ["IFNB", "PROTEIN", 247, 251], ["IFND", "PROTEIN", 253, 257], ["IFNK", "PROTEIN", 263, 267], ["human", "SPECIES", 122, 127], ["pig", "SPECIES", 88, 91], ["human", "SPECIES", 122, 127], ["sequencing primers", "TEST", 185, 203]]], ["The results are as follows.SequencingWe obtained DNA sequences from 19 independent IFNB clones from two individual bats.", [["IFNB clones", "ANATOMY", 83, 94], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["IFNB clones", "CELL", 83, 94], ["DNA sequences", "DNA", 49, 62], ["IFNB clones", "CELL_LINE", 83, 94], ["DNA sequences", "TEST", 49, 62]]], ["One sequence is identical to the consensus of all 19 sequences, and is found in 7 of 12 clones from one bat, and all the clones from the other.", [["clones", "OBSERVATION", 121, 127]]], ["Given this interpretation, the overall frequency of pre-sequencing PCR error was 1.6 \u00d7 10 -3 per base (17 errors in 10792 bases) The inferred IFNB genes are 91% identical to an IFNB isolated from Rousettus aegyptiacus [4] and 80% identical to IFNB from the domestic pig, Sus scrofa.", [["IFNB", "GENE_OR_GENE_PRODUCT", 142, 146], ["IFNB", "GENE_OR_GENE_PRODUCT", 177, 181], ["Rousettus aegyptiacus [4", "CELL", 196, 220], ["IFNB", "GENE_OR_GENE_PRODUCT", 243, 247], ["pig", "ORGANISM", 266, 269], ["Sus scrofa", "ORGANISM", 271, 281], ["IFNB genes", "DNA", 142, 152], ["IFNB", "DNA", 177, 181], ["IFNB", "PROTEIN", 243, 247], ["Rousettus aegyptiacus", "SPECIES", 196, 217], ["pig", "SPECIES", 266, 269], ["Sus scrofa", "SPECIES", 271, 281], ["Rousettus aegyptiacus", "SPECIES", 196, 217], ["pig", "SPECIES", 266, 269], ["Sus scrofa", "SPECIES", 271, 281], ["pre-sequencing PCR error", "TEST", 52, 76], ["The inferred IFNB genes", "TEST", 129, 152], ["Rousettus aegyptiacus", "PROBLEM", 196, 217], ["domestic pig", "OBSERVATION", 257, 269]]], ["Using IFNK primers, we obtained sequences from 7 clones from a single animal, and found two distinct genes, differing from each other in two nucleotides.", [["nucleotides", "CHEMICAL", 141, 152], ["IFNK", "GENE_OR_GENE_PRODUCT", 6, 10], ["IFNK primers", "DNA", 6, 18], ["IFNK primers", "TREATMENT", 6, 18], ["sequences", "TEST", 32, 41], ["distinct", "OBSERVATION_MODIFIER", 92, 100], ["genes", "OBSERVATION", 101, 106]]], ["The error rate was consistent with that found in the IFNB genes at 1.7 \u00d7 10 -3 per base (6 errors in 3430 bases).SequencingFor IFND and IFNA, respectively, we collected sequences from 32 and 52 clones from a single animal.", [["IFNB", "CANCER", 53, 57], ["IFNB genes", "DNA", 53, 63], ["IFND", "DNA", 127, 131], ["IFNA", "DNA", 136, 140], ["The error rate", "TEST", 0, 14], ["SequencingFor IFND and IFNA", "TEST", 113, 140], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Because PCR was used in an amplification step prior to cloning (unlike the process used for genomic sequencing), it is difficult to discern the expected genetic variability from sequencing error.", [["PCR", "TEST", 8, 11], ["genomic sequencing", "TEST", 92, 110]]], ["For IFNA, four sequences were recovered multiple times from independent procedures.", [["IFNA", "CANCER", 4, 8], ["IFNA", "DNA", 4, 8], ["four sequences", "TEST", 10, 24], ["independent procedures", "TREATMENT", 60, 82]]], ["The mean number of mismatches in pairwise comparisons is just under 7.", [["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["mismatches", "OBSERVATION", 19, 29]]], ["The four sequences are within 1, 2, 5 and 6 bases of the most similar inferred IFNA gene.", [["IFNA", "GENE_OR_GENE_PRODUCT", 79, 83], ["1, 2, 5 and 6 bases", "DNA", 30, 49], ["IFNA gene", "DNA", 79, 88], ["The four sequences", "TEST", 0, 18]]], ["For IFND, there are three multiply-represented sequences.", [["IFND", "CANCER", 4, 8]]], ["Two of these genes differ at 9 bases; the third, which represents a pseudogene, differs from the other two by more than 20 bases.", [["a pseudogene", "PROBLEM", 66, 78], ["bases", "ANATOMY_MODIFIER", 31, 36], ["third", "ANATOMY_MODIFIER", 42, 47], ["pseudogene", "OBSERVATION", 68, 78]]], ["These genes differ from their nearest inferred IFND sequences by 7, 12, and 20 bases, respectively.", [["IFND sequences", "DNA", 47, 61], ["bases", "ANATOMY_MODIFIER", 79, 84]]], ["Additional file 2 contains an alignment of the three multiply-represented IFND clones compared to the IFND assemblies.SequencingSince it was not possible to determine by inspection what the underlying true gene sequences are or how many there are.", [["IFND clones", "CELL", 74, 85], ["IFND clones", "CELL_LINE", 74, 85], ["IFND assemblies", "DNA", 102, 117], ["IFND clones", "PROBLEM", 74, 85], ["alignment", "OBSERVATION_MODIFIER", 30, 39]]], ["We instead estimated the posterior probability on the number of genes in each family as described in Methods (Figure 4 ).", [["posterior", "OBSERVATION_MODIFIER", 25, 34]]], ["For IFNA, the posterior probability is maximized at g = 9 genes; the 90% credible interval is (6, 17) .", [["IFNA", "GENE_OR_GENE_PRODUCT", 4, 8], ["IFNA", "PROTEIN", 4, 8], ["IFNA", "PROBLEM", 4, 8], ["posterior", "ANATOMY_MODIFIER", 14, 23]]], ["For IFND, the greatest posterior probability occurs at g = 19 genes, and the 90% credible interval is (15, 28) .Gene expressionTo test whether the inferred genes are expressed under conditions known to induce type I interferons, we designed primers to Pteropus IFNB and to a control housekeeping gene (PPIA) and a gene (OAS2) induced by paracrine IFNB signaling.", [["IFND", "CANCER", 4, 8], ["type I interferons", "GENE_OR_GENE_PRODUCT", 209, 227], ["Pteropus IFNB", "GENE_OR_GENE_PRODUCT", 252, 265], ["PPIA", "GENE_OR_GENE_PRODUCT", 302, 306], ["OAS2", "GENE_OR_GENE_PRODUCT", 320, 324], ["IFNB", "GENE_OR_GENE_PRODUCT", 347, 351], ["type I interferons", "PROTEIN", 209, 227], ["Pteropus IFNB", "DNA", 252, 265], ["housekeeping gene", "DNA", 283, 300], ["PPIA", "DNA", 302, 306], ["OAS2", "DNA", 320, 324], ["IFNB", "PROTEIN", 347, 351], ["type I interferons", "PROBLEM", 209, 227], ["Pteropus IFNB", "TREATMENT", 252, 265], ["a control housekeeping gene (PPIA", "TREATMENT", 273, 306], ["a gene (OAS2)", "TREATMENT", 312, 325], ["greatest", "OBSERVATION_MODIFIER", 14, 22], ["posterior", "OBSERVATION_MODIFIER", 23, 32]]], ["The latter two genes were also inferred by the methods described.Gene expressionFresh Pteropus PBMCs from two individual animals were cultured under four different conditions: with With LPS or poly(I:C) treatment, IFNB mRNA expression was increased 20-50 fold by 2 hours and decreased slowly to near the starting value by 24 hours.", [["PBMCs", "ANATOMY", 95, 100], ["LPS", "CHEMICAL", 186, 189], ["poly(I:C", "CHEMICAL", 193, 201], ["poly(I:C", "CHEMICAL", 193, 201], ["animals", "ORGANISM", 121, 128], ["LPS", "SIMPLE_CHEMICAL", 186, 189], ["poly(I:C", "SIMPLE_CHEMICAL", 193, 201], ["IFNB", "SIMPLE_CHEMICAL", 214, 218], ["PBMCs", "CELL_TYPE", 95, 100], ["IFNB mRNA", "RNA", 214, 223], ["Gene expressionFresh Pteropus PBMCs", "PROBLEM", 65, 100], ["C) treatment", "TREATMENT", 200, 212], ["IFNB mRNA expression", "TEST", 214, 234], ["Pteropus PBMCs", "OBSERVATION", 86, 100]]], ["OAS expression lagged behind that of IFNB, reaching its peak value by 8 hours, declining from the peak level only partially by 24 hours.", [["IFNB", "GENE_OR_GENE_PRODUCT", 37, 41], ["OAS", "PROTEIN", 0, 3], ["IFNB", "PROTEIN", 37, 41]]], ["In contrast, cells treated with VSV had peak levels of IFNB appear by 8 hours and remain almost unchanged to 24 hours; OAS expression rose more slowly, and had not reached a maximum level by 24 hours (Figure 5 ).DiscussionRecent research has demonstrated very clearly that the rate of emergence of human pathogens continues to increasing steadily, and that the source of the majority of these agents is wildlife [1] .", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["VSV", "ORGANISM", 32, 35], ["IFNB", "GENE_OR_GENE_PRODUCT", 55, 59], ["human", "ORGANISM", 298, 303], ["IFNB", "PROTEIN", 55, 59], ["OAS", "PROTEIN", 119, 122], ["human", "SPECIES", 298, 303], ["VSV", "SPECIES", 32, 35], ["human", "SPECIES", 298, 303], ["VSV", "TREATMENT", 32, 35], ["peak levels", "TEST", 40, 51], ["human pathogens", "PROBLEM", 298, 313], ["unchanged", "OBSERVATION_MODIFIER", 96, 105]]], ["One of the most intriguing findings of late is that bats are the natural reservoirs of many of the most pathogenic viruses in humans.DiscussionWhile it is known that microbe-host coevolution drives pathogenicity in the natural host, the effect of such coevolution on alternative hosts has not been described.", [["humans", "ORGANISM", 126, 132], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["alternative hosts", "TREATMENT", 267, 284], ["most intriguing", "OBSERVATION_MODIFIER", 11, 26], ["late", "OBSERVATION_MODIFIER", 39, 43], ["natural", "OBSERVATION_MODIFIER", 65, 72], ["reservoirs", "OBSERVATION_MODIFIER", 73, 83], ["most", "OBSERVATION_MODIFIER", 99, 103], ["pathogenic", "OBSERVATION_MODIFIER", 104, 114], ["viruses", "OBSERVATION", 115, 122], ["natural host", "OBSERVATION_MODIFIER", 219, 231]]], ["The development of many genome sequencing projects extending beyond domesticated animals provides an opportunity to begin such inquiries.", [["many genome sequencing projects", "TREATMENT", 19, 50], ["many", "OBSERVATION_MODIFIER", 19, 23], ["genome", "OBSERVATION_MODIFIER", 24, 30]]], ["The low coverage levels of these projects and the fact that so many genes with immunological functions appear in large families of very similar genes requires the development of more precise inferential tools for their study.DiscussionToward that end, we have developed a method for the assembly of genome sequence fragments for use in the inference of gene family members when the genome coverage is too low for reliable complete assembly.", [["genome sequence fragments", "DNA", 299, 324], ["gene family members", "DNA", 353, 372], ["immunological functions", "PROBLEM", 79, 102], ["their study", "TEST", 213, 224], ["genome sequence fragments", "TREATMENT", 299, 324], ["the genome coverage", "TREATMENT", 378, 397], ["low coverage", "OBSERVATION_MODIFIER", 4, 16], ["large", "OBSERVATION_MODIFIER", 113, 118]]], ["We validated the method on raw, unassembled traces from the human genome sequencing project, finding that we could assemble the known interferon alpha sequences accurately, and further, identify at least one case in which two alleles are present.DiscussionIt should be noted that our method requires more computation than assembly methods currently in use due to the numerical minimization over the mutation frequency required in Eq(10), and is therefore not suitable for large-scale assembly.DiscussionUsing this method, we inferred a total of 61 type-I interferon genes with intact ORFs from the whole-genome shotgun trace archives for two chiropteran species, Pteropus vampyrus and Myotis lucifugus.", [["human", "ORGANISM", 60, 65], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 134, 150], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 548, 565], ["Pteropus vampyrus", "ORGANISM", 663, 680], ["Myotis lucifugus", "ORGANISM", 685, 701], ["interferon alpha sequences", "DNA", 134, 160], ["61 type-I interferon genes", "DNA", 545, 571], ["ORFs", "DNA", 584, 588], ["human", "SPECIES", 60, 65], ["Pteropus vampyrus", "SPECIES", 663, 680], ["Myotis lucifugus", "SPECIES", 685, 701], ["human", "SPECIES", 60, 65], ["Pteropus vampyrus", "SPECIES", 663, 680], ["Myotis lucifugus", "SPECIES", 685, 701], ["the known interferon alpha sequences", "TEST", 124, 160], ["type-I interferon genes", "TREATMENT", 548, 571], ["intact ORFs", "PROBLEM", 577, 588], ["two chiropteran species", "TREATMENT", 638, 661], ["Pteropus vampyrus", "TREATMENT", 663, 680], ["Pteropus vampyrus", "OBSERVATION", 663, 680], ["Myotis lucifugus", "OBSERVATION", 685, 701]]], ["We find that the largest of the IFN-I gene families in both bats comprises genes orthologous to the IFNW genes in other mammals.", [["IFN-I", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFNW", "GENE_OR_GENE_PRODUCT", 100, 104], ["IFN-I gene families", "DNA", 32, 51], ["IFNW genes", "DNA", 100, 110], ["largest", "OBSERVATION_MODIFIER", 17, 24]]], ["In humans, mice and pigs, there is just one IFNW gene but up to two dozen members in each bat.", [["humans", "ORGANISM", 3, 9], ["mice", "ORGANISM", 11, 15], ["pigs", "ORGANISM", 20, 24], ["IFNW", "GENE_OR_GENE_PRODUCT", 44, 48], ["bat", "ORGANISM", 90, 93], ["IFNW gene", "DNA", 44, 53], ["humans", "SPECIES", 3, 9], ["mice", "SPECIES", 11, 15], ["pigs", "SPECIES", 20, 24], ["humans", "SPECIES", 3, 9], ["mice", "SPECIES", 11, 15], ["pigs", "SPECIES", 20, 24]]], ["A recent analysis of bovine type-I interferons from the assembled Bos taurus genome [32] finds 26 intact IFNW genes, providing precedent for our otherwise striking results.", [["bovine", "ORGANISM", 21, 27], ["type-I interferons", "GENE_OR_GENE_PRODUCT", 28, 46], ["Bos taurus", "ORGANISM", 66, 76], ["IFNW", "GENE_OR_GENE_PRODUCT", 105, 109], ["bovine type-I interferons", "PROTEIN", 21, 46], ["IFNW genes", "DNA", 105, 115], ["bovine", "SPECIES", 21, 27], ["Bos taurus", "SPECIES", 66, 76], ["bovine type-I", "SPECIES", 21, 34], ["Bos taurus", "SPECIES", 66, 76], ["A recent analysis", "TEST", 0, 17], ["bovine type-I interferons", "TREATMENT", 21, 46], ["the assembled Bos taurus genome", "PROBLEM", 52, 83]]], ["In contrast, the IFNA family is the largest IFN-I family in several mammals, including humans, mice and pigs, but appears to be smaller in Pteropus and absent but for pseudogenes in Myotis.", [["IFNA", "GENE_OR_GENE_PRODUCT", 17, 21], ["IFN-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["humans", "ORGANISM", 87, 93], ["mice", "ORGANISM", 95, 99], ["pigs", "ORGANISM", 104, 108], ["Pteropus", "CANCER", 139, 147], ["IFNA family", "PROTEIN", 17, 28], ["IFN-I family", "PROTEIN", 44, 56], ["humans", "SPECIES", 87, 93], ["mice", "SPECIES", 95, 99], ["pigs", "SPECIES", 104, 108], ["humans", "SPECIES", 87, 93], ["mice", "SPECIES", 95, 99], ["pigs", "SPECIES", 104, 108], ["pseudogenes in Myotis", "PROBLEM", 167, 188], ["smaller", "OBSERVATION_MODIFIER", 128, 135]]], ["The gene family assembly from trace archives indicates that there are 7 intact IFNA in Pteropus; analysis of direct sequencing from PBMCs gives maximum posterior probability to the presence of 9 IFNA genes (Figure 4) , with a 90% credible interval containing 6 to 16 genes.", [["PBMCs", "ANATOMY", 132, 137], ["IFNA", "GENE_OR_GENE_PRODUCT", 79, 83], ["PBMCs", "CELL", 132, 137], ["IFNA", "GENE_OR_GENE_PRODUCT", 195, 199], ["IFNA", "DNA", 79, 83], ["PBMCs", "CELL_TYPE", 132, 137], ["IFNA genes", "DNA", 195, 205], ["direct sequencing", "TEST", 109, 126], ["PBMCs", "TEST", 132, 137]]], ["Cattle have 13 IFNA genes in spite of having a greatly enlarged IFNW family [32] .DiscussionBoth bats have multiple members in the IFND family with five intact members and seven pseudogenes in Pteropus, and twelve intact members in Myotis.", [["Cattle", "ORGANISM", 0, 6], ["IFNA", "GENE_OR_GENE_PRODUCT", 15, 19], ["IFND", "CANCER", 131, 135], ["13 IFNA genes", "DNA", 12, 25], ["IFNW family", "PROTEIN", 64, 75], ["IFND family", "PROTEIN", 131, 142], ["Cattle", "SPECIES", 0, 6], ["Cattle", "SPECIES", 0, 6], ["enlarged", "OBSERVATION", 55, 63]]], ["IFND has been found as a functional gene only in pigs, where the gene product is expressed in the placenta and plays a role in embryonic development [33] , but is not suspected of involvement in the response to viruses.", [["placenta", "ANATOMY", 98, 106], ["embryonic", "ANATOMY", 127, 136], ["IFND", "CHEMICAL", 0, 4], ["IFND", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 49, 53], ["placenta", "ORGAN", 98, 106], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 127, 136], ["IFND", "PROTEIN", 0, 4], ["pigs", "SPECIES", 49, 53], ["pigs", "SPECIES", 49, 53], ["placenta", "ANATOMY", 98, 106], ["not suspected", "UNCERTAINTY", 163, 176]]], ["It is striking to us that this family seems to have been so dramatically enlarged in bats.", [["dramatically", "OBSERVATION_MODIFIER", 60, 72], ["enlarged", "OBSERVATION", 73, 81]]], ["The size of this family suggests that it may still be involved in host defense in bats even if it has lost that function in pigs.", [["bats", "ORGANISM", 82, 86], ["pigs", "ORGANISM", 124, 128], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 124, 128], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["Walker and Roberts [32] report finding three IFND pseudogenes, but no intact IFND in the cow.", [["IFND", "GENE_OR_GENE_PRODUCT", 45, 49], ["IFND", "GENE_OR_GENE_PRODUCT", 77, 81], ["cow", "ORGANISM", 89, 92], ["IFND pseudogenes", "DNA", 45, 61], ["IFND", "PROTEIN", 77, 81], ["cow", "SPECIES", 89, 92], ["cow", "SPECIES", 89, 92]]], ["It is worth noting that the placental type-I interferon in cattle is IFNT rather than IFND [34] .", [["placental", "ANATOMY", 28, 37], ["placental", "GENE_OR_GENE_PRODUCT", 28, 37], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 38, 55], ["cattle", "ORGANISM", 59, 65], ["IFNT", "GENE_OR_GENE_PRODUCT", 69, 73], ["placental type-I interferon", "PROTEIN", 28, 55], ["IFNT", "PROTEIN", 69, 73], ["cattle", "SPECIES", 59, 65], ["cattle", "SPECIES", 59, 65], ["the placental type-I interferon", "TREATMENT", 24, 55]]], ["Searching the bat trace archives with bovine IFNT did not produce hits that had not been returned with the other searches.", [["bovine", "ORGANISM", 38, 44], ["bovine IFNT", "DNA", 38, 49], ["bovine", "SPECIES", 38, 44], ["bovine", "SPECIES", 38, 44]]], ["We find no evidence of IFNT or IFNZ in either bat.DiscussionFor IFNB, IFNK, and IFNE, we find one member of each in P. vampyrus, and one or two in M. lucifugus.", [["IFNT", "GENE_OR_GENE_PRODUCT", 23, 27], ["IFNZ", "GENE_OR_GENE_PRODUCT", 31, 35], ["IFNB", "GENE_OR_GENE_PRODUCT", 64, 68], ["IFNK", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFNE", "GENE_OR_GENE_PRODUCT", 80, 84], ["P. vampyrus", "ORGANISM", 116, 127], ["M. lucifugus", "ORGANISM", 147, 159], ["IFNT", "PROTEIN", 23, 27], ["IFNZ", "PROTEIN", 31, 35], ["IFNB", "PROTEIN", 64, 68], ["IFNK", "PROTEIN", 70, 74], ["IFNE", "PROTEIN", 80, 84], ["P. vampyrus", "SPECIES", 116, 127], ["M. lucifugus", "SPECIES", 147, 159], ["P. vampyrus", "SPECIES", 116, 127], ["M. lucifugus", "SPECIES", 147, 159], ["IFNT", "PROBLEM", 23, 27], ["IFNZ", "PROBLEM", 31, 35], ["no evidence of", "UNCERTAINTY", 8, 22], ["IFNT", "OBSERVATION", 23, 27]]], ["In the case where we do find two genes, we are confident that there the genes are distinct, though they may represent alleles rather than paralogs.DiscussionWe used the inferred sequences for P. vampyrus IFNA, IFNB, IFND, and IFNK to design oligonucleotide primers for cloning and sequencing and recovered a total of 110 sequences.", [["IFNB", "GENE_OR_GENE_PRODUCT", 210, 214], ["IFNK", "GENE_OR_GENE_PRODUCT", 226, 230], ["IFNB", "PROTEIN", 210, 214], ["IFND", "PROTEIN", 216, 220], ["IFNK", "PROTEIN", 226, 230], ["110 sequences", "DNA", 317, 330], ["P. vampyrus", "SPECIES", 192, 203], ["oligonucleotide primers", "TREATMENT", 241, 264]]], ["The directly cloned sequences validate much of the gene family inferences; most of the repeated sequences are within a few bases of the nearest inferred gene.", [["nearest inferred gene", "DNA", 136, 157], ["The directly cloned sequences", "TEST", 0, 29], ["the repeated sequences", "TEST", 83, 105]]], ["A minority of the directly sequenced genes are surprisingly far from the nearest inferred gene.", [["nearest inferred gene", "DNA", 73, 94]]], ["This circumstance may be an indication that there are additional type-I interferon genes not covered by the Pteropus sequencing traces, and may also reflect significant population polymorphism in the wild bat population.DiscussionWe used these same primers to show, using quantitative RT-PRC, that the P. vampyrus candidate IFNB and OAS2 (a gene induced by IFNB in other mammals), are expressed upon stimulation by type-I inducing agents.", [["type-I interferon", "GENE_OR_GENE_PRODUCT", 65, 82], ["P. vampyrus", "ORGANISM", 302, 313], ["IFNB", "GENE_OR_GENE_PRODUCT", 324, 328], ["OAS2", "GENE_OR_GENE_PRODUCT", 333, 337], ["IFNB", "GENE_OR_GENE_PRODUCT", 357, 361], ["type-I inducing agents", "GENE_OR_GENE_PRODUCT", 415, 437], ["type-I interferon genes", "DNA", 65, 88], ["P. vampyrus candidate IFNB", "DNA", 302, 328], ["OAS2", "DNA", 333, 337], ["IFNB", "PROTEIN", 357, 361], ["P. vampyrus", "SPECIES", 302, 313], ["P. vampyrus", "SPECIES", 302, 313], ["type-I interferon genes", "TREATMENT", 65, 88], ["the Pteropus sequencing traces", "TEST", 104, 134], ["significant population polymorphism", "PROBLEM", 157, 192], ["type-I inducing agents", "TREATMENT", 415, 437], ["may be", "UNCERTAINTY", 18, 24], ["may also reflect", "UNCERTAINTY", 140, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["population", "OBSERVATION", 169, 179]]], ["Furthermore, the temporal trajectories of this expression is consistent with the known mechanisms of such signaling.", [["such signaling", "PROBLEM", 101, 115], ["consistent with", "UNCERTAINTY", 61, 76]]], ["The expression of IFNB under viral infection was delayed compared to that under stimulation by the TLR ligands poly(I:C) and LPS.ConclusionsThe bat has been implicated as a major reservoir for viruses of extreme pathogenicity in humans, and suffers substantially less disease when infected by these viruses than humans do.", [["viral infection", "DISEASE", 29, 44], ["poly(I:C", "CHEMICAL", 111, 119], ["LPS", "CHEMICAL", 125, 128], ["IFNB", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR", "GENE_OR_GENE_PRODUCT", 99, 102], ["poly(I:C", "SIMPLE_CHEMICAL", 111, 119], ["LPS", "SIMPLE_CHEMICAL", 125, 128], ["bat", "ORGANISM", 144, 147], ["humans", "ORGANISM", 229, 235], ["humans", "ORGANISM", 312, 318], ["IFNB", "PROTEIN", 18, 22], ["TLR ligands", "PROTEIN", 99, 110], ["humans", "SPECIES", 229, 235], ["humans", "SPECIES", 312, 318], ["humans", "SPECIES", 229, 235], ["humans", "SPECIES", 312, 318], ["IFNB under viral infection", "PROBLEM", 18, 44], ["LPS", "PROBLEM", 125, 128], ["a major reservoir", "TREATMENT", 171, 188], ["extreme pathogenicity in humans", "PROBLEM", 204, 235], ["substantially less disease", "PROBLEM", 249, 275], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infection", "OBSERVATION", 35, 44], ["extreme", "OBSERVATION_MODIFIER", 204, 211], ["pathogenicity", "OBSERVATION", 212, 225], ["less", "OBSERVATION_MODIFIER", 263, 267], ["disease", "OBSERVATION", 268, 275], ["viruses", "OBSERVATION", 299, 306]]], ["In addition, bat populations in North America are declining rapidly as a result of white-nose syndrome, an emergent disease associated with a fungal pathogen [35] .", [["white-nose syndrome", "DISEASE", 83, 102], ["nose", "ORGANISM_SUBDIVISION", 89, 93], ["white-nose syndrome", "PROBLEM", 83, 102], ["an emergent disease", "PROBLEM", 104, 123], ["a fungal pathogen", "PROBLEM", 140, 157], ["populations", "OBSERVATION_MODIFIER", 17, 28], ["fungal", "OBSERVATION_MODIFIER", 142, 148]]], ["These facts, and others, suggest that the study of host defense and immunity in these unique creatures would benefit the pursuit of ecological and human health.", [["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["the study", "TEST", 38, 47]]], ["The major obstacle in this undertaking is the lack of reagents that would make such investigations possible.", [["such investigations", "TEST", 79, 98], ["major", "OBSERVATION_MODIFIER", 4, 9], ["obstacle", "OBSERVATION_MODIFIER", 10, 18]]], ["One way to get this effort underway is to take advantage of the rich store of information contained in existing partial genome sequences.", [["partial genome sequences", "DNA", 112, 136]]], ["Although the information available in these genome databases requires more careful treatment for its extraction than is required for a complete, assembled genome, we have developed methods that facilitate this task, and have demonstrated their utility.Ethics StatementAll animals were handled in strict accordance with good animal practice as defined by the relevant national and/ or local animal welfare bodies, and all animal work was covered by an IACUC protocol from the Lubee Bat Conservancy (USDA Research Facility #58-R-0131).Animals and sample collectionSubjects for this study included 10 male Large Flying Foxes (Pteropus vampyrus) Some of the animals were wild caught, and some were laboratory born; all were reproductively mature, ranging in age from 4 to 21 yrs.", [["Pteropus vampyrus", "ORGANISM", 623, 640], ["animals", "ORGANISM", 654, 661], ["Pteropus vampyrus", "SPECIES", 623, 640], ["Pteropus vampyrus", "SPECIES", 623, 640], ["careful treatment", "TREATMENT", 75, 92], ["its extraction", "TREATMENT", 97, 111], ["an IACUC protocol", "TREATMENT", 448, 465], ["this study", "TEST", 575, 585], ["Large Flying Foxes (Pteropus vampyrus)", "TREATMENT", 603, 641]]], ["Animals were housed in captivity at the Lubee Bat Conservancy in Gainesville, Florida, USA.", [["Animals", "ORGANISM", 0, 7]]], ["Animals were housed together with conspecifics in an indoor/outdoor circular flight enclosure and were fed a mixture of fruit, vegetables, commercial primate chow, and a vitamin supplement.", [["fruit", "ANATOMY", 120, 125], ["vegetables", "ANATOMY", 127, 137], ["vitamin", "CHEMICAL", 170, 177], ["Animals", "ORGANISM", 0, 7], ["fruit", "ORGANISM_SUBDIVISION", 120, 125], ["vegetables", "ORGANISM_SUBDIVISION", 127, 137], ["primate", "ORGANISM", 150, 157], ["chow", "ORGANISM_SUBDIVISION", 158, 162], ["vitamin", "SIMPLE_CHEMICAL", 170, 177], ["a vitamin supplement", "TREATMENT", 168, 188]]], ["The bats were captured manually, anesthesia was mask-induced with 5% isoflurane in oxygen (3 L/min), and the bats were maintained with 2.5% isoflurane.", [["isoflurane", "CHEMICAL", 69, 79], ["oxygen", "CHEMICAL", 83, 89], ["isoflurane", "CHEMICAL", 140, 150], ["isoflurane", "CHEMICAL", 69, 79], ["oxygen", "CHEMICAL", 83, 89], ["isoflurane", "CHEMICAL", 140, 150], ["bats", "ORGANISM", 4, 8], ["isoflurane", "SIMPLE_CHEMICAL", 69, 79], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["bats", "ORGANISM", 109, 113], ["isoflurane", "SIMPLE_CHEMICAL", 140, 150], ["anesthesia", "TREATMENT", 33, 43], ["mask", "TREATMENT", 48, 52], ["5% isoflurane in oxygen", "TREATMENT", 66, 89], ["2.5% isoflurane", "TREATMENT", 135, 150]]], ["Blood was collected from the left and right brachial veins using 3-ml syringes and 25-gauge needles.", [["Blood", "ANATOMY", 0, 5], ["left", "ANATOMY", 29, 33], ["right brachial veins", "ANATOMY", 38, 58], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["brachial veins", "MULTI-TISSUE_STRUCTURE", 44, 58], ["Blood", "TEST", 0, 5], ["3-ml syringes", "TREATMENT", 65, 78], ["25-gauge needles", "TREATMENT", 83, 99], ["left", "ANATOMY_MODIFIER", 29, 33], ["right", "ANATOMY_MODIFIER", 38, 43], ["brachial veins", "ANATOMY", 44, 58]]], ["Blood samples were transferred to heparanized tubes, maintained and shipped at room temperature (22\u00b0C) via overnight courier.Cloning and SequencingGenomic DNA was prepared from whole unfractionated peripheral blood from Pteropus vampyrus bats.", [["Blood samples", "ANATOMY", 0, 13], ["peripheral blood", "ANATOMY", 198, 214], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["peripheral blood", "ORGANISM_SUBSTANCE", 198, 214], ["Pteropus vampyrus bats", "ORGANISM", 220, 242], ["Genomic DNA", "DNA", 147, 158], ["Pteropus vampyrus", "SPECIES", 220, 237], ["Pteropus vampyrus bats", "SPECIES", 220, 242], ["Blood samples", "TEST", 0, 13], ["heparanized tubes", "TREATMENT", 34, 51], ["SequencingGenomic DNA", "PROBLEM", 137, 158], ["Pteropus vampyrus bats", "OBSERVATION", 220, 242]]], ["Using primers derived from the inferred interferon gene sequences and encoded for restriction enzyme cloning sites, the genes were PCR amplified from the genomic DNA.", [["DNA", "CELLULAR_COMPONENT", 162, 165], ["interferon gene sequences", "DNA", 40, 65], ["restriction enzyme cloning sites", "DNA", 82, 114], ["genomic DNA", "DNA", 154, 165], ["primers", "TREATMENT", 6, 13], ["the inferred interferon gene sequences", "TREATMENT", 27, 65], ["restriction enzyme cloning sites", "PROBLEM", 82, 114], ["PCR", "TEST", 131, 134], ["the genomic DNA", "PROBLEM", 150, 165], ["genomic DNA", "OBSERVATION", 154, 165]]], ["The forward and reverse primers encoded restriction sites for NheI and XhoI respectively, which allowed cloning of the full length gene into mammalian expression vector pcDNA3.1(+).", [["NheI", "GENE_OR_GENE_PRODUCT", 62, 66], ["XhoI", "GENE_OR_GENE_PRODUCT", 71, 75], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 169, 175], ["forward and reverse primers", "DNA", 4, 31], ["restriction sites", "DNA", 40, 57], ["XhoI", "DNA", 71, 75], ["full length gene", "DNA", 119, 135], ["mammalian expression vector pcDNA3", "DNA", 141, 175], ["reverse primers encoded restriction sites", "TREATMENT", 16, 57], ["NheI and XhoI", "TREATMENT", 62, 75], ["the full length gene", "TREATMENT", 115, 135], ["mammalian expression vector pcDNA3", "TREATMENT", 141, 175]]], ["The PCR program consisted of an initialization step at 94\u00b0C for 5 minutes, then 30 cycles of amplification consisting of denaturation at 94\u00b0C for 1 minute, annealing at 55\u00b0C for 30 seconds, and elongation at 72\u00b0for 1 minute.", [["The PCR program", "TEST", 0, 15], ["30 cycles of amplification", "TREATMENT", 80, 106], ["denaturation", "TREATMENT", 121, 133], ["elongation", "TEST", 194, 204]]], ["Amplification was followed by a final elongation step at 72\u00b0C for 5 minutes and samples held at 4\u00b0C. PCR was performed on a P \u00d7 2 Thermal Cycler from ThermoElectron Corporation (Waltham, MA).Cloning and SequencingAfter purification, the inserted genes were sequenced using vector primers downstream and upstream of the insert site.", [["samples", "ANATOMY", 80, 87], ["inserted genes", "DNA", 237, 251], ["vector primers downstream", "DNA", 273, 298], ["insert site", "DNA", 319, 330], ["samples", "TEST", 80, 87], ["PCR", "TEST", 101, 104], ["purification", "TREATMENT", 219, 231], ["the inserted genes", "TREATMENT", 233, 251], ["vector primers downstream", "TREATMENT", 273, 298]]], ["Pteropus vampyrus IFNB, IFNK, IFND, and IFNA sequences have been submitted to Genbank (GU126493, HM63650, HM636501, and HM636502).Quantitative RT-PCRWhole anticoagulated blood was collected from the brachial vein and layered over lymphocyte separation medium (Lympholyte M, Cedarlane Labs).", [["blood", "ANATOMY", 170, 175], ["brachial vein", "ANATOMY", 199, 212], ["lymphocyte", "ANATOMY", 230, 240], ["Pteropus vampyrus IFNB", "ORGANISM", 0, 22], ["IFNK", "GENE_OR_GENE_PRODUCT", 24, 28], ["IFND", "GENE_OR_GENE_PRODUCT", 30, 34], ["IFNA", "GENE_OR_GENE_PRODUCT", 40, 44], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["brachial vein", "MULTI-TISSUE_STRUCTURE", 199, 212], ["lymphocyte", "CELL", 230, 240], ["Pteropus vampyrus IFNB, IFNK, IFND, and IFNA sequences", "DNA", 0, 54], ["Pteropus vampyrus", "SPECIES", 0, 17], ["IFNA sequences", "TEST", 40, 54], ["Quantitative RT", "TREATMENT", 130, 145], ["PCRWhole anticoagulated blood", "TREATMENT", 146, 175], ["layered over lymphocyte separation medium", "TREATMENT", 217, 258], ["brachial vein", "ANATOMY", 199, 212]]], ["Cells were collected from the interface, washed, and plated on 24 well flat-bottom tissue culture plates (2 \u00d7 10 6 cells/well) in a total volume of 250 \u03bcl.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 115, 120], ["Cells", "CELL", 0, 5], ["cells", "CELL", 115, 120], ["Cells", "TEST", 0, 5], ["bottom tissue culture plates", "TEST", 76, 104], ["a total volume", "TEST", 130, 144]]], ["Cells were treated as indicated with either poly(I:C)(Invivogen), LPS (Sigma), or VSV (Ramsburg lab stocks confirmed endotoxin free using LAL assay).", [["Cells", "ANATOMY", 0, 5], ["poly(I:C", "CHEMICAL", 44, 52], ["LPS", "CHEMICAL", 66, 69], ["endotoxin", "CHEMICAL", 117, 126], ["poly(I:C)", "CHEMICAL", 44, 53], ["Invivogen", "CHEMICAL", 54, 63], ["Cells", "CELL", 0, 5], ["poly(I:C", "SIMPLE_CHEMICAL", 44, 52], ["Invivogen", "SIMPLE_CHEMICAL", 54, 63], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["Sigma", "SIMPLE_CHEMICAL", 71, 76], ["VSV", "ORGANISM", 82, 85], ["endotoxin", "SIMPLE_CHEMICAL", 117, 126], ["endotoxin", "PROTEIN", 117, 126], ["LAL", "PROTEIN", 138, 141], ["VSV", "SPECIES", 82, 85], ["VSV", "PROBLEM", 82, 85]]], ["Stimulants were diluted such that the addition of 250 \u03bcl stimulant would give a final concentration of 10 \u03bcg/ml poly I:C, 1 \u03bcg/ml LPS, or an MOI of 5 for VSV.", [["poly I:C", "CHEMICAL", 112, 120], ["LPS", "CHEMICAL", 130, 133], ["poly I:C", "CHEMICAL", 112, 120], ["poly I:C", "SIMPLE_CHEMICAL", 112, 120], ["LPS", "SIMPLE_CHEMICAL", 130, 133], ["VSV", "ORGANISM", 154, 157], ["VSV", "SPECIES", 154, 157], ["Stimulants", "TREATMENT", 0, 10], ["a final concentration", "TREATMENT", 78, 99], ["VSV", "PROBLEM", 154, 157]]], ["500 \u03bcl of complete medium was added to the unstimulated control wells.", [["complete medium", "TREATMENT", 10, 25], ["the unstimulated control wells", "TREATMENT", 39, 69]]], ["Cells were incubated at 37' and 5% CO2 for the indicated times, after which cells were harvested into RNA lysis buffer (Qiagen RNEasy kit) according to the manufacturer's instructions.Quantitative RT-PCRPurified RNA was prepared from these whole-cell lysates as described in the protocols accompanying the Qiagen RNeasy kit, Qiashedder, and Qiagen RNeasy Mini kit and Qiagen DNase-Free DNase Set. cDNA synthesis was performed using the Invitrogen two-step qRT-PCR kit according to the manufacturer's protocol.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 76, 81], ["whole-cell lysates", "ANATOMY", 240, 258], ["CO2", "CHEMICAL", 35, 38], ["CO2", "CHEMICAL", 35, 38], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 35, 38], ["cells", "CELL", 76, 81], ["cell lysates", "ORGANISM_SUBSTANCE", 246, 258], ["DNase", "GENE_OR_GENE_PRODUCT", 375, 380], ["PCRPurified RNA", "RNA", 200, 215], ["Qiagen DNase", "PROTEIN", 368, 380], ["DNase", "PROTEIN", 386, 391], ["Cells", "TEST", 0, 5], ["RNA lysis buffer", "TREATMENT", 102, 118], ["Qiagen RNEasy kit", "TREATMENT", 120, 137], ["Quantitative RT-PCRPurified RNA", "PROBLEM", 184, 215], ["these whole-cell lysates", "TREATMENT", 234, 258], ["the Qiagen RNeasy kit", "TREATMENT", 302, 323], ["Qiashedder", "TREATMENT", 325, 335], ["Qiagen RNeasy Mini kit", "TREATMENT", 341, 363], ["Qiagen DNase", "TREATMENT", 368, 380], ["Free DNase Set. cDNA synthesis", "TREATMENT", 381, 411], ["the Invitrogen", "TREATMENT", 432, 446], ["the manufacturer's protocol", "TREATMENT", 481, 508]]], ["Quantitative real-time PCR was performed in an Eppendorf Mastercycler ep realplex thermal cycler using SYBRGreenER qPCR Supermix and primers designed from the inferred gene sequences (additional file 3).", [["inferred gene sequences", "DNA", 159, 182], ["Quantitative real-time PCR", "TEST", 0, 26], ["an Eppendorf Mastercycler ep", "TREATMENT", 44, 72], ["thermal cycler", "TREATMENT", 82, 96], ["SYBRGreenER qPCR Supermix", "TREATMENT", 103, 128]]], ["The log 2 expression level of IFNB and OAS2 relative to the housekeeping gene PPIA was estimated by subtracting the mean Ct value for each gene and treatment/time point combination from the corresponding mean Ct value for PPIA.Estimation of Gene Family SizeThe likelihood function for the observed set S of sequences is a function of the true number, g, of genes and the sample size, n, by summing over the unobserved number, c, of distinct genes sampled.Estimation of Gene Family SizeThe pmf on c is given by the recursionEstimation of Gene Family Sizewith P c (1 | g,1) = 1 and P c (c | g,1) = 0 for c \u2260 1.", [["log 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["IFNB", "GENE_OR_GENE_PRODUCT", 30, 34], ["OAS2", "GENE_OR_GENE_PRODUCT", 39, 43], ["PPIA", "GENE_OR_GENE_PRODUCT", 78, 82], ["PPIA", "GENE_OR_GENE_PRODUCT", 222, 226], ["IFNB", "PROTEIN", 30, 34], ["OAS2", "PROTEIN", 39, 43], ["housekeeping gene PPIA", "DNA", 60, 82], ["PPIA", "PROTEIN", 222, 226], ["pmf", "PROTEIN", 489, 492], ["P c", "DNA", 580, 583], ["Ct value", "TEST", 121, 129], ["treatment", "TREATMENT", 148, 157], ["Ct value", "TEST", 209, 217], ["PPIA", "PROBLEM", 222, 226], ["PPIA", "OBSERVATION", 222, 226], ["Size", "OBSERVATION_MODIFIER", 253, 257], ["size", "OBSERVATION_MODIFIER", 378, 382], ["Size", "OBSERVATION_MODIFIER", 481, 485]]], ["P S (S | c) is approximated by minimizing the number, m, of mutations over the assignments of observed sequences to c groups.", [["P S", "DNA", 0, 3], ["mutations", "PROBLEM", 60, 69]]], ["P S is then the posterior probability of getting m mutations given the observed number of mutations in the IFNB and IFNK datasets.Estimation of Gene Family SizeNote that this technique is independent of the assembly methods described elsewhere in the paper.Phylogenetic InferenceThe set consisting of type-I interferon amino acid sequences from human (Homo sapiens), domestic pig (Sus scrofa), duckbill platypus (Ornithorhynchus anatinus) and the amino acid sequences corresponding to the Chiropteran genes inferred in this paper was submitted to multiple sequence alignment by CLUSTALW 2.0.10 [36] and ProbCons 1.12 [37] .", [["amino acid", "CHEMICAL", 319, 329], ["amino acid", "CHEMICAL", 447, 457], ["amino acid", "CHEMICAL", 319, 329], ["amino acid", "CHEMICAL", 447, 457], ["IFNB", "GENE_OR_GENE_PRODUCT", 107, 111], ["IFNK", "GENE_OR_GENE_PRODUCT", 116, 120], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 301, 318], ["amino acid", "AMINO_ACID", 319, 329], ["human", "ORGANISM", 345, 350], ["Homo sapiens", "ORGANISM", 352, 364], ["domestic pig", "ORGANISM", 367, 379], ["Sus scrofa", "ORGANISM", 381, 391], ["duckbill platypus", "ORGANISM", 394, 411], ["Ornithorhynchus anatinus", "ORGANISM", 413, 437], ["amino acid", "AMINO_ACID", 447, 457], ["P S", "DNA", 0, 3], ["IFNB and IFNK datasets", "DNA", 107, 129], ["type-I interferon amino acid sequences", "DNA", 301, 339], ["Chiropteran genes", "DNA", 489, 506], ["human", "SPECIES", 345, 350], ["Homo sapiens", "SPECIES", 352, 364], ["domestic pig", "SPECIES", 367, 379], ["Sus scrofa", "SPECIES", 381, 391], ["duckbill platypus", "SPECIES", 394, 411], ["Ornithorhynchus anatinus", "SPECIES", 413, 437], ["human", "SPECIES", 345, 350], ["Homo sapiens", "SPECIES", 352, 364], ["pig", "SPECIES", 376, 379], ["Sus scrofa", "SPECIES", 381, 391], ["duckbill platypus", "SPECIES", 394, 411], ["Ornithorhynchus anatinus", "SPECIES", 413, 437], ["m mutations", "PROBLEM", 49, 60], ["mutations", "PROBLEM", 90, 99], ["type-I interferon amino acid sequences", "TREATMENT", 301, 339], ["human (Homo sapiens)", "TREATMENT", 345, 365], ["domestic pig (Sus scrofa)", "TREATMENT", 367, 392], ["duckbill platypus", "TREATMENT", 394, 411], ["the amino acid sequences", "TEST", 443, 467], ["the Chiropteran genes", "TREATMENT", 485, 506], ["CLUSTALW", "TEST", 578, 586], ["ProbCons", "TEST", 603, 611]]], ["Maximum likelihood and minimum evolution phylogenies were inferred from each resulting multiple sequence alignment.", [["Maximum likelihood and minimum evolution phylogenies", "PROBLEM", 0, 52]]], ["Maximum likelihood phylogenies were inferred with proml found in the PHYLIP 3.68 package [38] .", [["Maximum likelihood phylogenies", "PROBLEM", 0, 30]]], ["Minimum evolution phylogenies were inferred using fastme [39] based on the distance matrix calculated with protdist found in PHYLIP.", [["Minimum evolution phylogenies", "PROBLEM", 0, 29], ["the distance matrix", "TREATMENT", 71, 90], ["protdist", "TREATMENT", 107, 115]]], ["In both cases, 1000 boot-strap replications were generated using seqboot and the consensus phylogeny was assembled with consense, both from the PHYLIP package.Additional materialAdditional file 1: All IFNG.bio.", [["consensus phylogeny", "DNA", 81, 100], ["PHYLIP package", "DNA", 144, 158], ["1000 boot-strap replications", "TREATMENT", 15, 43], ["seqboot", "TREATMENT", 65, 72], ["the PHYLIP package", "TREATMENT", 140, 158]]], ["An alignment of IFNG gene sequences from Homo sapiens, Pterops vampyrus, and Myotis lucifugus as follows: first row: genomic sequence of human IFNG. rows 2, 3: predicted genomic sequence of IFNG in M. lucifugus and P. vampyrus, respectively. rows 4-7: exons for human IFNG. rows 8-11: predicted exons for M. lucifugus. rows 12-15: predicted exons for P. vampyrus. row 16: spliced coding region for human. rows 17,18: predicted spliced coding region for M. lucifugus and P. vampyrus. row 19: amino acid sequence for human interferon gamma. rows 20,21: predicted amino acid sequence for chiropteran interferon gamma.", [["amino acid", "CHEMICAL", 491, 501], ["amino acid", "CHEMICAL", 561, 571], ["amino acid", "CHEMICAL", 491, 501], ["amino acid", "CHEMICAL", 561, 571], ["IFNG", "GENE_OR_GENE_PRODUCT", 16, 20], ["Homo sapiens", "ORGANISM", 41, 53], ["Pterops vampyrus", "ORGANISM", 55, 71], ["Myotis lucifugus", "ORGANISM", 77, 93], ["human", "ORGANISM", 137, 142], ["IFNG", "GENE_OR_GENE_PRODUCT", 143, 147], ["IFNG", "GENE_OR_GENE_PRODUCT", 190, 194], ["M. lucifugus", "ORGANISM", 198, 210], ["P. vampyrus", "ORGANISM", 215, 226], ["human", "ORGANISM", 262, 267], ["IFNG", "GENE_OR_GENE_PRODUCT", 268, 272], ["M. lucifugus", "ORGANISM", 305, 317], ["P. vampyrus", "ORGANISM", 351, 362], ["human", "ORGANISM", 398, 403], ["M. lucifugus", "ORGANISM", 453, 465], ["P. vampyrus", "ORGANISM", 470, 481], ["amino acid", "AMINO_ACID", 491, 501], ["human", "ORGANISM", 515, 520], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 521, 537], ["amino acid", "AMINO_ACID", 561, 571], ["chiropteran interferon gamma", "GENE_OR_GENE_PRODUCT", 585, 613], ["IFNG gene sequences", "DNA", 16, 35], ["human IFNG", "PROTEIN", 137, 147], ["rows 2, 3: predicted genomic sequence", "DNA", 149, 186], ["IFNG", "PROTEIN", 190, 194], ["rows 4-7: exons", "DNA", 242, 257], ["human IFNG", "PROTEIN", 262, 272], ["exons", "DNA", 295, 300], ["exons", "DNA", 341, 346], ["human interferon gamma", "PROTEIN", 515, 537], ["chiropteran interferon gamma", "PROTEIN", 585, 613], ["Homo sapiens", "SPECIES", 41, 53], ["Pterops vampyrus", "SPECIES", 55, 71], ["Myotis lucifugus", "SPECIES", 77, 93], ["human", "SPECIES", 137, 142], ["M. lucifugus", "SPECIES", 198, 210], ["P. vampyrus", "SPECIES", 215, 226], ["human", "SPECIES", 262, 267], ["M. lucifugus", "SPECIES", 305, 317], ["P. vampyrus", "SPECIES", 351, 362], ["human", "SPECIES", 398, 403], ["M. lucifugus", "SPECIES", 453, 465], ["P. vampyrus", "SPECIES", 470, 481], ["human", "SPECIES", 515, 520], ["Homo sapiens", "SPECIES", 41, 53], ["Pterops vampyrus", "SPECIES", 55, 71], ["Myotis lucifugus", "SPECIES", 77, 93], ["human", "SPECIES", 137, 142], ["M. lucifugus", "SPECIES", 198, 210], ["P. vampyrus", "SPECIES", 215, 226], ["human", "SPECIES", 262, 267], ["M. lucifugus", "SPECIES", 305, 317], ["P. vampyrus", "SPECIES", 351, 362], ["human", "SPECIES", 398, 403], ["M. lucifugus", "SPECIES", 453, 465], ["P. vampyrus", "SPECIES", 470, 481], ["human", "SPECIES", 515, 520], ["An alignment of IFNG gene sequences", "TEST", 0, 35], ["P. vampyrus", "PROBLEM", 351, 362], ["M. lucifugus", "PROBLEM", 453, 465], ["amino acid sequence", "TEST", 491, 510], ["human interferon gamma", "TREATMENT", 515, 537], ["amino acid sequence", "TEST", 561, 580], ["chiropteran interferon gamma", "TREATMENT", 585, 613], ["alignment", "OBSERVATION_MODIFIER", 3, 12], ["human IFNG", "OBSERVATION", 137, 147], ["interferon gamma", "OBSERVATION", 521, 537], ["interferon gamma", "OBSERVATION", 597, 613]]], ["Examination of this. bio file requires the BioEdit program, which is freely available at http://www.mbio.ncsu.edu/BioEdit/bioedit.html.Additional materialAdditional file 2: Pva IFND clone-assembly comparison.fasta.", [["Examination", "TEST", 0, 11], ["the BioEdit program", "TREATMENT", 39, 58]]], ["This sequence alignment shows a comparison between Pteropus vampyrus IFND sequences obtained by 1) assembly from the genome sequencing trace archives, and 2) by direct cloning and sequencing.", [["Pteropus vampyrus IFND sequences", "DNA", 51, 83], ["Pteropus vampyrus", "SPECIES", 51, 68], ["This sequence alignment", "TEST", 0, 23]]], ["The cloned sequences include only those found in at least two independent clones.", [["clones", "CELL", 74, 80], ["The cloned sequences", "TEST", 0, 20], ["clones", "OBSERVATION", 74, 80]]], ["The assemblies include all those with intact ORFs plus three that appear to be pseudogenes.Additional materialAdditional file 3: Accession numbers and primers.", [["ORFs", "DNA", 45, 49], ["pseudogenes", "PROBLEM", 79, 90], ["pseudogenes", "OBSERVATION", 79, 90]]], ["The Genbank accession numbers of the IFN genes used in the phylogenetic. analysis and the PCR primers used in the P. vampyrus gene expression studies.Additional materialAdditional file 4: Mlu + Pva + Hsa + SscSelectedIntactOrfsAAaligned.fasta.", [["IFN", "GENE_OR_GENE_PRODUCT", 37, 40], ["vampyrus", "GENE_OR_GENE_PRODUCT", 117, 125], ["Mlu + Pva", "SIMPLE_CHEMICAL", 188, 197], ["IFN genes", "DNA", 37, 46], ["PCR primers", "DNA", 90, 101], ["Pva", "PROTEIN", 194, 197], ["Hsa", "PROTEIN", 200, 203], ["P. vampyrus", "SPECIES", 114, 125], ["the IFN genes", "TREATMENT", 33, 46], ["analysis", "TEST", 73, 81], ["the PCR primers", "TEST", 86, 101], ["expression studies", "TEST", 131, 149], ["Mlu", "TEST", 188, 191], ["Pva", "TEST", 194, 197], ["SscSelectedIntactOrfsAAaligned.fasta", "TREATMENT", 206, 242], ["Hsa", "ANATOMY", 200, 203]]], ["The amino acid sequences used in the phylogenetic analysis.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["The amino acid sequences", "TEST", 0, 24], ["the phylogenetic analysis", "TEST", 33, 58]]]], "30497f23bbf41b8312b258cf2de9018213326d48": [["and its effect to protect against cancer development in DOCK8-deficient patients.", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["DOCK8", "CHEMICAL", 56, 61], ["cancer", "CANCER", 34, 40], ["DOCK8", "GENE_OR_GENE_PRODUCT", 56, 61], ["patients", "ORGANISM", 72, 80], ["DOCK8", "PROTEIN", 56, 61], ["patients", "SPECIES", 72, 80], ["cancer development", "PROBLEM", 34, 52]]]], "bc757003245bc9d1a636364de3e858fe65e7ec57": [["INTRODUCTIONThe fat-soluble plant flavonoid rotenone is a well-known neurotoxic pesticide.", [["rotenone", "CHEMICAL", 44, 52], ["neurotoxic", "DISEASE", 69, 79], ["flavonoid", "CHEMICAL", 34, 43], ["rotenone", "CHEMICAL", 44, 52], ["fat", "SIMPLE_CHEMICAL", 16, 19], ["rotenone", "SIMPLE_CHEMICAL", 44, 52], ["The fat-soluble plant flavonoid rotenone", "TREATMENT", 12, 52], ["fat", "ANATOMY", 16, 19], ["flavonoid rotenone", "OBSERVATION", 34, 52]]], ["It can pass through the blood-brain barrier, bind to complex I, impair mitochondrial function, mediate oxidative stress, induce inflammation, and ultimately lead to cell death [1, 2] .", [["blood-brain barrier", "ANATOMY", 24, 43], ["mitochondrial", "ANATOMY", 71, 84], ["cell", "ANATOMY", 165, 169], ["inflammation", "DISEASE", 128, 140], ["death", "DISEASE", 170, 175], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 30, 43], ["complex I", "GENE_OR_GENE_PRODUCT", 53, 62], ["mitochondrial", "CELLULAR_COMPONENT", 71, 84], ["cell", "CELL", 165, 169], ["complex I", "PROTEIN", 53, 62], ["the blood-brain barrier", "TREATMENT", 20, 43], ["mediate oxidative stress", "PROBLEM", 95, 119], ["inflammation", "PROBLEM", 128, 140], ["cell death", "PROBLEM", 165, 175], ["brain", "ANATOMY", 30, 35], ["inflammation", "OBSERVATION", 128, 140]]], ["It has been reported that the mitochondrial dysfunction induced by rotenone is directly related to the inhibition of mitochondrial function in differentiated SH-SY5Y cells [2] .", [["mitochondrial", "ANATOMY", 30, 43], ["mitochondrial", "ANATOMY", 117, 130], ["SH-SY5Y cells", "ANATOMY", 158, 171], ["mitochondrial dysfunction", "DISEASE", 30, 55], ["rotenone", "CHEMICAL", 67, 75], ["rotenone", "CHEMICAL", 67, 75], ["mitochondrial", "CELLULAR_COMPONENT", 30, 43], ["rotenone", "SIMPLE_CHEMICAL", 67, 75], ["mitochondrial", "CELLULAR_COMPONENT", 117, 130], ["SH-SY5Y cells", "CELL", 158, 171], ["SH-SY5Y cells", "CELL_LINE", 158, 171], ["the mitochondrial dysfunction", "PROBLEM", 26, 55], ["rotenone", "TREATMENT", 67, 75], ["mitochondrial function", "PROBLEM", 117, 139], ["mitochondrial dysfunction", "OBSERVATION", 30, 55]]], ["In addition, rotenone can also inhibit autophagic flux, but its potential mechanism remains to be further studied.", [["autophagic", "ANATOMY", 39, 49], ["rotenone", "CHEMICAL", 13, 21], ["rotenone", "CHEMICAL", 13, 21], ["rotenone", "SIMPLE_CHEMICAL", 13, 21], ["rotenone", "TREATMENT", 13, 21], ["autophagic flux", "PROBLEM", 39, 54], ["autophagic flux", "OBSERVATION", 39, 54]]], ["More importantly, identifying drugs that activate autophagic flux to prevent the neurotoxicity of rotenone may provide a promising clue for neuroprotection [3] .INTRODUCTIONOlanzapine has been widely used to treat patients with schizophrenia due to its low incidence of extrapyramidal symptoms [4] .", [["neurotoxicity", "DISEASE", 81, 94], ["rotenone", "CHEMICAL", 98, 106], [".INTRODUCTIONOlanzapine", "CHEMICAL", 160, 183], ["schizophrenia", "DISEASE", 228, 241], ["extrapyramidal symptoms", "DISEASE", 270, 293], ["rotenone", "CHEMICAL", 98, 106], ["rotenone", "SIMPLE_CHEMICAL", 98, 106], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["drugs", "TREATMENT", 30, 35], ["autophagic flux", "PROBLEM", 50, 65], ["the neurotoxicity", "PROBLEM", 77, 94], ["rotenone", "TREATMENT", 98, 106], [".INTRODUCTIONOlanzapine", "TREATMENT", 160, 183], ["schizophrenia", "PROBLEM", 228, 241], ["extrapyramidal symptoms", "PROBLEM", 270, 293]]], ["The mechanisms underlying the adverse effects are the activation of the AMPactivated protein kinase (AMPK) [8] [9] [10] and autophagy-related mammalian target of rapamycin (mTOR) pathways [11] .", [["rapamycin", "CHEMICAL", 162, 171], ["rapamycin", "CHEMICAL", 162, 171], ["AMPactivated protein kinase (AMPK) [8] [9] [10]", "SIMPLE_CHEMICAL", 72, 119], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 142, 171], ["mTOR", "GENE_OR_GENE_PRODUCT", 173, 177], ["AMPactivated protein kinase", "PROTEIN", 72, 99], ["AMPK", "PROTEIN", 101, 105], ["mTOR", "PROTEIN", 173, 177], ["the adverse effects", "PROBLEM", 26, 45], ["the AMPactivated protein kinase", "TEST", 68, 99], ["autophagy", "TEST", 124, 133], ["rapamycin (mTOR", "TREATMENT", 162, 177]]], ["As a major metabolic energy sensor, AMPK has been reported to induce autophagy by indirectly inactivating mTORC1 [12] .", [["AMPK", "GENE_OR_GENE_PRODUCT", 36, 40], ["mTORC1 [12]", "GENE_OR_GENE_PRODUCT", 106, 117], ["AMPK", "PROTEIN", 36, 40], ["mTORC1", "PROTEIN", 106, 112]]], ["Olanzapine has been reported to induce autophagy in the SH-SY5Y cell line, increasing autophagic flux, the number of autophagic vesicles, and the expression of autophagy-related genes (ATGs) [13] .", [["SH-SY5Y cell line", "ANATOMY", 56, 73], ["autophagic vesicles", "ANATOMY", 117, 136], ["Olanzapine", "CHEMICAL", 0, 10], ["Olanzapine", "CHEMICAL", 0, 10], ["Olanzapine", "SIMPLE_CHEMICAL", 0, 10], ["SH-SY5Y cell line", "CELL", 56, 73], ["autophagic vesicles", "CELLULAR_COMPONENT", 117, 136], ["SH-SY5Y cell line", "CELL_LINE", 56, 73], ["autophagy-related genes", "DNA", 160, 183], ["ATGs", "DNA", 185, 189], ["Olanzapine", "TREATMENT", 0, 10], ["increasing autophagic flux", "PROBLEM", 75, 101], ["autophagic vesicles", "PROBLEM", 117, 136], ["cell line", "OBSERVATION", 64, 73], ["increasing", "OBSERVATION_MODIFIER", 75, 85], ["autophagic flux", "OBSERVATION", 86, 101], ["autophagic vesicles", "OBSERVATION", 117, 136]]], ["In addition, olanzapine has been reported to inhibit the activity of nuclear factor kappa-B (NF-\u03baB), a key factor in the inflammatory response and autophagy [14] .INTRODUCTIONAutophagy is a basic homeostatic process that causes the degradation of damaged or misfolded proteins and organelles [15] .", [["organelles", "ANATOMY", 281, 291], ["olanzapine", "CHEMICAL", 13, 23], ["olanzapine", "CHEMICAL", 13, 23], ["olanzapine", "SIMPLE_CHEMICAL", 13, 23], ["nuclear factor kappa-B", "GENE_OR_GENE_PRODUCT", 69, 91], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 93, 98], ["organelles", "CELLULAR_COMPONENT", 281, 291], ["nuclear factor kappa-B", "PROTEIN", 69, 91], ["NF-\u03baB", "PROTEIN", 93, 98], ["misfolded proteins", "PROTEIN", 258, 276], ["olanzapine", "TREATMENT", 13, 23], ["nuclear factor kappa", "TEST", 69, 89], ["a basic homeostatic process", "PROBLEM", 188, 215], ["damaged or misfolded proteins", "PROBLEM", 247, 276]]], ["A decrease in autophagy leads to the accumulation of misfolded proteins in neurons [16] and results in early neonatal lethality [17, 18] .", [["neurons", "ANATOMY", 75, 82], ["neurons", "CELL", 75, 82], ["misfolded proteins", "PROTEIN", 53, 71], ["A decrease in autophagy", "PROBLEM", 0, 23], ["misfolded proteins in neurons", "PROBLEM", 53, 82], ["early neonatal lethality", "PROBLEM", 103, 127], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["autophagy leads", "OBSERVATION", 14, 29], ["misfolded proteins", "OBSERVATION", 53, 71]]], ["On the other hand, the induction of autophagy by the overexpression of the ATG beclin-1 or an autophagy inducer eventually attenuates neuronal pathology [19] .", [["neuronal", "ANATOMY", 134, 142], ["ATG beclin-1", "GENE_OR_GENE_PRODUCT", 75, 87], ["neuronal", "CELL", 134, 142], ["ATG beclin-1", "PROTEIN", 75, 87], ["autophagy", "TREATMENT", 36, 45], ["the ATG beclin", "TEST", 71, 85]]], ["Taken together, these findings suggest that the enhancement of autophagy can activate protein degradation systems and accelerate the degradation of damaged mitochondria, thus alleviating nerve injury.", [["mitochondria", "ANATOMY", 156, 168], ["nerve", "ANATOMY", 187, 192], ["nerve injury", "DISEASE", 187, 199], ["mitochondria", "CELLULAR_COMPONENT", 156, 168], ["nerve", "MULTI-TISSUE_STRUCTURE", 187, 192], ["the enhancement of autophagy", "PROBLEM", 44, 72], ["protein degradation systems", "PROBLEM", 86, 113], ["damaged mitochondria", "PROBLEM", 148, 168], ["alleviating nerve injury", "PROBLEM", 175, 199], ["damaged mitochondria", "OBSERVATION", 148, 168], ["nerve", "ANATOMY", 187, 192], ["injury", "OBSERVATION", 193, 199]]], ["Accordingly, autophagy induction may be a promising strategy for some disorders [20] .INTRODUCTIONWe aimed to verify the hypothesis that olanzapine initiates autophagy by activating AMPK, thus preventing neuronal injury induced by rotenone.ChemicalsOlanzapine was purchased from Selleckchem (Houston, Texas, USA).", [["neuronal", "ANATOMY", 204, 212], ["olanzapine", "CHEMICAL", 137, 147], ["neuronal injury", "DISEASE", 204, 219], ["rotenone", "CHEMICAL", 231, 239], ["Olanzapine", "CHEMICAL", 249, 259], ["olanzapine", "CHEMICAL", 137, 147], ["rotenone", "CHEMICAL", 231, 239], ["Olanzapine", "CHEMICAL", 249, 259], ["olanzapine", "SIMPLE_CHEMICAL", 137, 147], ["AMPK", "GENE_OR_GENE_PRODUCT", 182, 186], ["neuronal", "CELL", 204, 212], ["rotenone", "SIMPLE_CHEMICAL", 231, 239], ["Olanzapine", "SIMPLE_CHEMICAL", 249, 259], ["AMPK", "PROTEIN", 182, 186], ["autophagy induction", "TREATMENT", 13, 32], ["some disorders", "PROBLEM", 65, 79], ["olanzapine", "TREATMENT", 137, 147], ["neuronal injury", "PROBLEM", 204, 219], ["rotenone", "TREATMENT", 231, 239], ["ChemicalsOlanzapine", "TREATMENT", 240, 259]]], ["Rotenone, the AMPK inhibitor compound C, 6-(4-(2-piperidin-1ylethoxy) phenyl)-3-pyridin-4-ylpyrazolo (1,5-a) pyrimidine and 3methyladenine (3-MA, an autophagy inhibitor) were obtained from Sigma Chemical Company (Saint Louis, Missouri, USA).", [["Rotenone", "CHEMICAL", 0, 8], ["compound C", "CHEMICAL", 29, 39], ["6-(4-(2-piperidin-1ylethoxy) phenyl)-3-pyridin-4-ylpyrazolo (1,5-a) pyrimidine", "CHEMICAL", 41, 119], ["3methyladenine", "CHEMICAL", 124, 138], ["3-MA", "CHEMICAL", 140, 144], ["Rotenone", "CHEMICAL", 0, 8], ["6-(4-(2-piperidin-1ylethoxy) phenyl)-3-pyridin-4-ylpyrazolo (1,5-a) pyrimidine", "CHEMICAL", 41, 119], ["3methyladenine", "CHEMICAL", 124, 138], ["3-MA", "CHEMICAL", 140, 144], ["Rotenone", "SIMPLE_CHEMICAL", 0, 8], ["AMPK", "GENE_OR_GENE_PRODUCT", 14, 18], ["compound C", "SIMPLE_CHEMICAL", 29, 39], ["6-(4-(2-piperidin-1ylethoxy) phenyl)-3-pyridin-4-ylpyrazolo (1,5-a) pyrimidine", "SIMPLE_CHEMICAL", 41, 119], ["3methyladenine", "SIMPLE_CHEMICAL", 124, 138], ["3-MA", "SIMPLE_CHEMICAL", 140, 144], ["Rotenone", "TREATMENT", 0, 8], ["the AMPK inhibitor", "TREATMENT", 10, 28], ["piperidin-1ylethoxy) phenyl)", "TREATMENT", 49, 77], ["pyridin", "TREATMENT", 80, 87], ["ylpyrazolo", "TREATMENT", 90, 100], ["pyrimidine", "TREATMENT", 109, 119], ["3methyladenine", "TREATMENT", 124, 138], ["an autophagy inhibitor", "TREATMENT", 146, 168]]], ["Olanzapine (200 mM), rotenone (10 mM), and the AMPK inhibitor compound C (10 mM) were separately prepared in dimethyl sulfoxide, and 10-\u03bcL aliquots were frozen at \u221280\u00b0C.ChemicalsCell culture and treatments PC12 cells were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China), and were routinely grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD, USA) and cultured at 37\u00b0C in a humidified 5% CO 2 atmosphere.ChemicalsImmunoblotting assay After the indicated treatment, the cells were harvested and lysed with ice-cold lysis buffer containing protease inhibitor cocktail (Roche, Mannheim, Germany).", [["Cell", "ANATOMY", 178, 182], ["PC12 cells", "ANATOMY", 206, 216], ["Cell", "ANATOMY", 263, 267], ["fetal bovine serum", "ANATOMY", 426, 444], ["cells", "ANATOMY", 597, 602], ["Olanzapine", "CHEMICAL", 0, 10], ["rotenone", "CHEMICAL", 21, 29], ["compound C", "CHEMICAL", 62, 72], ["dimethyl sulfoxide", "CHEMICAL", 109, 127], ["PC12", "CHEMICAL", 206, 210], ["Olanzapine", "CHEMICAL", 0, 10], ["rotenone", "CHEMICAL", 21, 29], ["dimethyl sulfoxide", "CHEMICAL", 109, 127], ["CO", "CHEMICAL", 516, 518], ["Olanzapine", "SIMPLE_CHEMICAL", 0, 10], ["rotenone", "SIMPLE_CHEMICAL", 21, 29], ["AMPK", "GENE_OR_GENE_PRODUCT", 47, 51], ["compound C", "SIMPLE_CHEMICAL", 62, 72], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 109, 127], ["Cell", "CELL", 178, 182], ["PC12 cells", "CELL", 206, 216], ["bovine", "ORGANISM", 432, 438], ["serum", "ORGANISM_SUBSTANCE", 439, 444], ["Gibco", "ORGANISM_SUBSTANCE", 446, 451], ["cells", "CELL", 597, 602], ["PC12 cells", "CELL_LINE", 206, 216], ["bovine", "SPECIES", 432, 438], ["bovine", "SPECIES", 432, 438], ["Olanzapine", "TREATMENT", 0, 10], ["rotenone", "TREATMENT", 21, 29], ["the AMPK inhibitor compound C (10 mM)", "TREATMENT", 43, 80], ["dimethyl sulfoxide", "TREATMENT", 109, 127], ["ChemicalsCell culture", "TEST", 169, 190], ["treatments PC12 cells", "TREATMENT", 195, 216], ["a humidified", "TREATMENT", 500, 512], ["ChemicalsImmunoblotting assay", "TEST", 532, 561], ["treatment", "TREATMENT", 582, 591], ["the cells", "TREATMENT", 593, 602], ["ice-cold lysis buffer", "TREATMENT", 633, 654], ["protease inhibitor cocktail", "TREATMENT", 666, 693]]], ["The protein concentration of the lysates was determined by a Protein Assay Kit (Thermo, Rockford, Illinois, USA), and equal amounts of protein were separated on a 10% sodium dodecyl sulfate-polyacrylamide electrophoresis gel and transferred to a nitrocellulose membrane.", [["lysates", "ANATOMY", 33, 40], ["membrane", "ANATOMY", 261, 269], ["sodium dodecyl sulfate", "CHEMICAL", 167, 189], ["sodium dodecyl sulfate", "CHEMICAL", 167, 189], ["polyacrylamide", "CHEMICAL", 190, 204], ["nitrocellulose", "CHEMICAL", 246, 260], ["lysates", "ORGANISM_SUBSTANCE", 33, 40], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 167, 189], ["membrane", "CELLULAR_COMPONENT", 261, 269], ["the lysates", "TEST", 29, 40], ["a 10% sodium dodecyl sulfate", "TREATMENT", 161, 189], ["polyacrylamide electrophoresis gel", "TREATMENT", 190, 224], ["a nitrocellulose membrane", "TREATMENT", 244, 269]]], ["Nonspecific protein binding was blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature.", [["serum", "ANATOMY", 55, 60], ["BSA", "CHEMICAL", 70, 73], ["bovine", "ORGANISM", 48, 54], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["albumin", "SIMPLE_CHEMICAL", 61, 68], ["BSA", "SIMPLE_CHEMICAL", 70, 73], ["bovine", "SPECIES", 48, 54], ["Nonspecific protein binding", "PROBLEM", 0, 27], ["5% bovine serum albumin (BSA", "TREATMENT", 45, 73], ["protein binding", "OBSERVATION", 12, 27]]], ["The membranes were then incubated with specific AMPK\u03b1 (1:1000), phospho-AMPK\u03b1 (p-AMPK; Thr172; 1:1000), p62 (1:1000), poly (ADP-ribose) polymerase (PARP), cleaved PARP (1:1000, Cell Signaling Technology, Massachusetts, USA), LC3 (1:1000), phospho-p70 S6 kinase (Thr389; 1:500, Abcam, Massachusetts, USA), cytochrome c (Cyt-c; 1:1000), Bcl-2 (1:1000), Bax (1:1000, Santa Cruz, State of California, USA), and \u03b2-actin (1:2000; MultiSciences, Hangzhou, China) primary antibodies overnight at 4\u00b0C. The membranes were washed the next day and incubated with secondary antibodies at room temperature for 1 h.", [["membranes", "ANATOMY", 4, 13], ["membranes", "ANATOMY", 497, 506], ["poly (ADP-ribose", "CHEMICAL", 118, 134], ["phospho", "CHEMICAL", 64, 71], ["Thr", "CHEMICAL", 87, 90], ["poly (ADP-ribose)", "CHEMICAL", 118, 135], ["phospho", "CHEMICAL", 239, 246], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["AMPK\u03b1", "GENE_OR_GENE_PRODUCT", 48, 53], ["1:1000", "GENE_OR_GENE_PRODUCT", 55, 61], ["phospho-AMPK\u03b1", "GENE_OR_GENE_PRODUCT", 64, 77], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 79, 85], ["1:1000", "GENE_OR_GENE_PRODUCT", 95, 101], ["p62", "GENE_OR_GENE_PRODUCT", 104, 107], ["1:1000", "GENE_OR_GENE_PRODUCT", 109, 115], ["poly (ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 118, 146], ["PARP", "GENE_OR_GENE_PRODUCT", 148, 152], ["PARP", "GENE_OR_GENE_PRODUCT", 163, 167], ["LC3", "GENE_OR_GENE_PRODUCT", 225, 228], ["phospho-p70 S6 kinase", "GENE_OR_GENE_PRODUCT", 239, 260], ["Abcam", "GENE_OR_GENE_PRODUCT", 277, 282], ["USA", "GENE_OR_GENE_PRODUCT", 299, 302], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 305, 317], ["Cyt-c", "GENE_OR_GENE_PRODUCT", 319, 324], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 335, 340], ["1:1000", "GENE_OR_GENE_PRODUCT", 342, 348], ["Bax", "GENE_OR_GENE_PRODUCT", 351, 354], ["membranes", "CELLULAR_COMPONENT", 497, 506], ["AMPK\u03b1", "PROTEIN", 48, 53], ["phospho", "PROTEIN", 64, 71], ["AMPK\u03b1", "PROTEIN", 72, 77], ["AMPK", "PROTEIN", 81, 85], ["p62", "PROTEIN", 104, 107], ["poly (ADP-ribose) polymerase", "PROTEIN", 118, 146], ["PARP", "PROTEIN", 148, 152], ["cleaved PARP", "PROTEIN", 155, 167], ["LC3", "PROTEIN", 225, 228], ["phospho", "PROTEIN", 239, 246], ["p70 S6 kinase", "PROTEIN", 247, 260], ["Thr389; 1:500, Abcam, Massachusetts, USA), cytochrome c (Cyt-c; 1:1000", "PROTEIN", 262, 332], ["Bcl", "PROTEIN", 335, 338], ["1:1000", "PROTEIN", 342, 348], ["Bax", "PROTEIN", 351, 354], ["\u03b2-actin", "PROTEIN", 407, 414], ["primary antibodies", "PROTEIN", 456, 474], ["secondary antibodies", "PROTEIN", 551, 571], ["specific AMPK", "TEST", 39, 52], ["phospho", "TEST", 64, 71], ["AMPK", "TEST", 72, 76], ["p-AMPK", "TEST", 79, 85], ["Thr", "TEST", 87, 90], ["p62", "TEST", 104, 107], ["poly (ADP-ribose) polymerase", "TEST", 118, 146], ["PARP", "TEST", 148, 152], ["PARP", "TEST", 163, 167], ["LC3", "TEST", 225, 228], ["phospho", "TEST", 239, 246], ["kinase", "TEST", 254, 260], ["Abcam", "TEST", 277, 282], ["cytochrome c (Cyt-c", "TEST", 305, 324], ["Bcl", "TEST", 335, 338], ["Bax", "TEST", 351, 354], ["primary antibodies", "TEST", 456, 474]]], ["After being washed with phosphate-buffered saline (PBS) three times, the membranes were incubated with secondary antibodies.", [["membranes", "ANATOMY", 73, 82], ["phosphate", "CHEMICAL", 24, 33], ["phosphate", "CHEMICAL", 24, 33], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 24, 49], ["membranes", "CELLULAR_COMPONENT", 73, 82], ["secondary antibodies", "PROTEIN", 103, 123], ["phosphate-buffered saline (PBS)", "TREATMENT", 24, 55], ["secondary antibodies", "PROBLEM", 103, 123], ["secondary antibodies", "OBSERVATION", 103, 123]]], ["The immunoblots were detected by the Odyssey Infrared Imaging System, and the data were quantified with ImageJ software.ChemicalsImmunofluorescence staining PC12 cells were seeded on coverslips.", [["PC12 cells", "ANATOMY", 157, 167], ["PC12 cells", "CELL", 157, 167], ["PC12 cells", "CELL_LINE", 157, 167], ["The immunoblots", "TEST", 0, 15], ["the data", "TEST", 74, 82], ["ImageJ software", "TEST", 104, 119], ["ChemicalsImmunofluorescence staining PC12 cells", "PROBLEM", 120, 167], ["PC12 cells", "OBSERVATION", 157, 167]]], ["After specific treatments, the cells were fixed with methanol for 10 min at 4\u00b0C, washed with PBS and permeabilized with 0.3% Triton X-100 for 10 min.", [["cells", "ANATOMY", 31, 36], ["methanol", "CHEMICAL", 53, 61], ["Triton X-100", "CHEMICAL", 125, 137], ["methanol", "CHEMICAL", 53, 61], ["cells", "CELL", 31, 36], ["methanol", "SIMPLE_CHEMICAL", 53, 61], ["Triton X-100", "SIMPLE_CHEMICAL", 125, 137], ["specific treatments", "TREATMENT", 6, 25], ["the cells", "TREATMENT", 27, 36], ["methanol", "TREATMENT", 53, 61], ["PBS", "TREATMENT", 93, 96]]], ["The cells were then incubated with blocking buffer (1% BSA and 0.1% Triton X-100) followed by a polyclonal anti-LC3 antibody overnight at 4\u00b0C. The cells were incubated with an Alex Fluor 488 (green)conjugated rabbit antibody (1:500; Molecular Probes, Australia) for 1 h at room temperature after rinsing three times with PBS.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 147, 152], ["Triton X-100", "CHEMICAL", 68, 80], ["Alex Fluor 488", "CHEMICAL", 176, 190], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 55, 58], ["Triton X-100", "SIMPLE_CHEMICAL", 68, 80], ["cells", "CELL", 147, 152], ["Alex Fluor 488", "SIMPLE_CHEMICAL", 176, 190], ["rabbit", "ORGANISM", 209, 215], ["polyclonal anti-LC3 antibody", "PROTEIN", 96, 124], ["Alex Fluor 488 (green)conjugated rabbit antibody", "PROTEIN", 176, 224], ["rabbit", "SPECIES", 209, 215], ["rabbit", "SPECIES", 209, 215], ["blocking buffer", "TREATMENT", 35, 50], ["1% BSA", "TREATMENT", 52, 58], ["a polyclonal anti-LC3 antibody", "TREATMENT", 94, 124], ["an Alex Fluor", "TEST", 173, 186], ["green)conjugated rabbit antibody", "TEST", 192, 224], ["PBS", "TREATMENT", 321, 324]]], ["Nuclei were counterstained with 4',6-diamino-2-phenyl indole (DAPI) for 15 min at room temperature.", [["Nuclei", "ANATOMY", 0, 6], ["4',6-diamino-2-phenyl indole", "CHEMICAL", 32, 60], ["DAPI", "CHEMICAL", 62, 66], ["4',6-diamino-2-phenyl indole", "CHEMICAL", 32, 60], ["DAPI", "CHEMICAL", 62, 66], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4',6-diamino-2-phenyl indole", "SIMPLE_CHEMICAL", 32, 60], ["DAPI", "SIMPLE_CHEMICAL", 62, 66], ["diamino", "TREATMENT", 37, 44], ["phenyl indole (DAPI", "TREATMENT", 47, 66]]], ["Coverslips were mounted on slides with Vectashield mounting medium for fluorescence and analyzed by confocal microscopy (Carl Zeiss, Jena, Germany).ChemicalsTransmission electron microscopy analysis The cells were fixed with 3% glutaraldehyde for 1 h at 4\u00b0C. The cells were then washed and fixed again in aqueous 2% osmium tetroxide, dehydrated in ethanol, and embedded in epoxy medium.", [["cells", "ANATOMY", 203, 208], ["cells", "ANATOMY", 263, 268], ["glutaraldehyde", "CHEMICAL", 228, 242], ["osmium tetroxide", "CHEMICAL", 316, 332], ["ethanol", "CHEMICAL", 348, 355], ["glutaraldehyde", "CHEMICAL", 228, 242], ["osmium tetroxide", "CHEMICAL", 316, 332], ["ethanol", "CHEMICAL", 348, 355], ["epoxy", "CHEMICAL", 373, 378], ["cells", "CELL", 203, 208], ["glutaraldehyde", "SIMPLE_CHEMICAL", 228, 242], ["cells", "CELL", 263, 268], ["osmium tetroxide", "SIMPLE_CHEMICAL", 316, 332], ["ethanol", "SIMPLE_CHEMICAL", 348, 355], ["microscopy analysis", "TEST", 179, 198], ["3% glutaraldehyde", "TREATMENT", 225, 242], ["aqueous 2% osmium tetroxide", "TREATMENT", 305, 332], ["epoxy medium", "OBSERVATION", 373, 385]]], ["Ultrathin sections were cut and stained with uranyl acetate and lead citrate for examination under a transmission electron microscope.ChemicalsCell survival assays Cell survival assays were performed using the Cell Counting Kit-8 (CCK-8; Beyotime, Haimen, China).", [["sections", "ANATOMY", 10, 18], ["Cell", "ANATOMY", 143, 147], ["Cell", "ANATOMY", 164, 168], ["Cell", "ANATOMY", 210, 214], ["uranyl acetate", "CHEMICAL", 45, 59], ["lead citrate", "CHEMICAL", 64, 76], ["uranyl acetate", "CHEMICAL", 45, 59], ["citrate", "CHEMICAL", 69, 76], ["sections", "MULTI-TISSUE_STRUCTURE", 10, 18], ["uranyl acetate", "SIMPLE_CHEMICAL", 45, 59], ["lead citrate", "SIMPLE_CHEMICAL", 64, 76], ["Cell", "CELL", 143, 147], ["Cell", "CELL", 164, 168], ["Ultrathin sections", "TEST", 0, 18], ["uranyl acetate", "TREATMENT", 45, 59], ["lead citrate", "TREATMENT", 64, 76], ["examination", "TEST", 81, 92], ["ChemicalsCell survival assays", "TEST", 134, 163], ["Cell survival assays", "TEST", 164, 184], ["the Cell Counting Kit", "TEST", 206, 227], ["CCK", "TEST", 231, 234]]], ["Briefly, PC12 cells were seeded in 96-well plates at a density of 2 \u00d7 10 3 cells per well and allowed to adhere overnight.", [["PC12 cells", "ANATOMY", 9, 19], ["cells", "ANATOMY", 75, 80], ["PC12 cells", "CELL", 9, 19], ["cells", "CELL", 75, 80], ["PC12 cells", "CELL_LINE", 9, 19], ["PC12 cells", "TEST", 9, 19]]], ["After specific treatment, 10 \u03bcL CCK-8 solution was added to each well, and the plate was incubated at 37\u00b0C for 1 h.", [["CCK-8", "CHEMICAL", 32, 37], ["CCK-8", "SIMPLE_CHEMICAL", 32, 37], ["specific treatment", "TREATMENT", 6, 24], ["10 \u03bcL CCK-8 solution", "TREATMENT", 26, 46]]], ["The optical density value of each well at 450 nm wavelength was measured using a microplate reader.", [["a microplate reader", "TREATMENT", 79, 98], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19]]], ["The assay was repeated three times.ChemicalsHoechst 33258 staining Treated cells grown in 24-well chamber slides were washed three times with PBS, fixed with methanol for 10 min at 4\u00b0C, and incubated with Hoechst 33258 (Beyotime, Haimen, China) for 10 min at room temperature.", [["cells", "ANATOMY", 75, 80], ["ChemicalsHoechst 33258", "CHEMICAL", 35, 57], ["methanol", "CHEMICAL", 158, 166], ["Hoechst 33258", "CHEMICAL", 205, 218], ["ChemicalsHoechst 33258", "CHEMICAL", 35, 57], ["methanol", "CHEMICAL", 158, 166], ["Hoechst 33258", "CHEMICAL", 205, 218], ["cells", "CELL", 75, 80], ["methanol", "SIMPLE_CHEMICAL", 158, 166], ["Hoechst 33258", "SIMPLE_CHEMICAL", 205, 218], ["The assay", "TEST", 0, 9], ["PBS", "TREATMENT", 142, 145], ["methanol", "TREATMENT", 158, 166]]], ["The nuclei were observed with a fluorescence microscope.", [["nuclei", "ANATOMY", 4, 10], ["nuclei", "CELLULAR_COMPONENT", 4, 10], ["a fluorescence microscope", "TEST", 30, 55], ["nuclei", "ANATOMY", 4, 10]]], ["Ten subfields from each slide were randomly selected to count and calculate the percentage of apoptotic cells in three independent experiments.", [["cells", "ANATOMY", 104, 109], ["cells", "CELL", 104, 109], ["apoptotic cells", "CELL_TYPE", 94, 109], ["each slide", "TEST", 19, 29], ["count", "TEST", 56, 61], ["apoptotic cells", "TREATMENT", 94, 109], ["apoptotic cells", "OBSERVATION", 94, 109]]], ["TUNEL assay Treated cells were cultured on glass slides in a 12-well culture chamber, washed with PBS, fixed with methanol for 30 min, incubated with terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay (TUNEL) reaction mixture according to the manufacturer's instructions (Beyotime, Haimen, China) in the dark (room temperature) for 60 min, washed with PBS three times, restained with DAPI, and washed, and apoptosis was observed by fluorescence microscopy.Chemicals\u25b3\u03a8m assay Mitochondrial membrane potential (\u25b3\u03a8m) was detected utilizing a Mitochondrial Membrane Potential Detection Kit with 5,5\u2032,6,6\u2032tetrachloro-1,1\u2032,3,3\u2032-tet-raethylbenzimidazolylcarbocyanine iodide (JC-1) dye (Beyotime, Haimen, China) in accordance with the manufacturer's protocol.", [["cells", "ANATOMY", 20, 25], ["Mitochondrial membrane", "ANATOMY", 507, 529], ["Mitochondrial", "ANATOMY", 571, 584], ["dUTP-biotin", "CHEMICAL", 197, 208], ["5,5\u2032,6,6\u2032tetrachloro-1,1\u2032,3,3\u2032-tet-raethylbenzimidazolylcarbocyanine iodide", "CHEMICAL", 623, 698], ["JC-1) dye", "CHEMICAL", 700, 709], ["methanol", "CHEMICAL", 114, 122], ["dUTP", "CHEMICAL", 197, 201], ["biotin", "CHEMICAL", 202, 208], ["DAPI", "CHEMICAL", 416, 420], ["5,5\u2032,6,6\u2032tetrachloro-1,1\u2032,3,3\u2032-tet-raethylbenzimidazolylcarbocyanine iodide", "CHEMICAL", 623, 698], ["JC-1", "CHEMICAL", 700, 704], ["cells", "CELL", 20, 25], ["methanol", "SIMPLE_CHEMICAL", 114, 122], ["terminal deoxynucleotidyl transferase", "GENE_OR_GENE_PRODUCT", 150, 187], ["dUTP", "SIMPLE_CHEMICAL", 197, 201], ["DAPI", "SIMPLE_CHEMICAL", 416, 420], ["5,5\u2032,6,6\u2032tetrachloro-1,1\u2032,3,3\u2032-tet-raethylbenzimidazolylcarbocyanine iodide", "SIMPLE_CHEMICAL", 623, 698], ["JC-1) dye", "SIMPLE_CHEMICAL", 700, 709], ["Beyotime", "SIMPLE_CHEMICAL", 711, 719], ["terminal deoxynucleotidyl transferase", "PROTEIN", 150, 187], ["TUNEL assay", "TEST", 0, 11], ["glass slides", "TEST", 43, 55], ["PBS", "TREATMENT", 98, 101], ["methanol", "TREATMENT", 114, 122], ["terminal deoxynucleotidyl transferase", "TEST", 150, 187], ["PBS", "TREATMENT", 384, 387], ["DAPI", "TREATMENT", 416, 420], ["apoptosis", "PROBLEM", 438, 447], ["fluorescence microscopy", "TEST", 464, 487], ["Chemicals", "TEST", 488, 497], ["Kit", "TEST", 614, 617], ["\u2032tetrachloro", "TEST", 631, 643], ["tet-raethylbenzimidazolylcarbocyanine iodide", "TREATMENT", 654, 698], ["the manufacturer's protocol", "TREATMENT", 755, 782]]], ["In brief, 5.0 \u00d7 10 5 cells were collected and suspended in the medium.", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26]]], ["After the addition of JC-1 dye working solution, the cells were well mixed and incubated in a humidified incubator containing 5% CO 2 at 37\u00b0C for 20 min.", [["cells", "ANATOMY", 53, 58], ["JC-1 dye", "CHEMICAL", 22, 30], ["CO 2", "CHEMICAL", 129, 133], ["JC-1 dye", "SIMPLE_CHEMICAL", 22, 30], ["cells", "CELL", 53, 58], ["JC-1 dye working solution", "TREATMENT", 22, 47], ["a humidified incubator", "TREATMENT", 92, 114]]], ["Then, the cells were washed with JC-1 staining buffer, centrifuged to remove the supernatant, and resuspended with JC-1 staining buffer for flow cytometry analysis.Statistical analysisThe data are expressed as the mean \u00b1 SEM.", [["cells", "ANATOMY", 10, 15], ["supernatant", "ANATOMY", 81, 92], ["cells", "CELL", 10, 15], ["JC-1", "GENE_OR_GENE_PRODUCT", 33, 37], ["JC-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["the cells", "TREATMENT", 6, 15], ["JC-1 staining buffer", "TREATMENT", 33, 53], ["the supernatant", "TREATMENT", 77, 92], ["JC", "TREATMENT", 115, 117], ["flow cytometry analysis", "TEST", 140, 163], ["Statistical analysis", "TEST", 164, 184]]], ["Statistical analysis was conducted via one-way analysis of variance followed by Dunnett's t-test, and P < 0.05 was considered significant.", [["Statistical analysis", "TEST", 0, 20], ["Dunnett's t-test", "TEST", 80, 96], ["P", "TEST", 102, 103]]], ["All experiments were repeated at least three times.RESULTSOlanzapine activated AMPK and induced autophagy in PC12 cells Olanzapine is usually administered at a starting dose of 5 mg/d (16 \u03bcM) and at a maintenance dose of 10 mg/d (32 \u03bcM).", [["PC12 cells", "ANATOMY", 109, 119], ["RESULTSOlanzapine", "CHEMICAL", 51, 68], ["Olanzapine", "CHEMICAL", 120, 130], ["RESULTSOlanzapine", "CHEMICAL", 51, 68], ["Olanzapine", "CHEMICAL", 120, 130], ["AMPK", "GENE_OR_GENE_PRODUCT", 79, 83], ["PC12 cells", "CELL", 109, 119], ["Olanzapine", "SIMPLE_CHEMICAL", 120, 130], ["AMPK", "PROTEIN", 79, 83], ["PC12 cells", "CELL_LINE", 109, 119], ["RESULTSOlanzapine activated AMPK", "TREATMENT", 51, 83], ["induced autophagy in PC12 cells", "TREATMENT", 88, 119], ["Olanzapine", "TREATMENT", 120, 130], ["PC12 cells", "OBSERVATION", 109, 119]]], ["To investigate whether olanzapine activated AMPK, we treated PC12 cells with 0, 10, 20, or 40 \u03bcM olanzapine for 24 h.", [["PC12 cells", "ANATOMY", 61, 71], ["olanzapine", "CHEMICAL", 23, 33], ["olanzapine", "CHEMICAL", 97, 107], ["olanzapine", "CHEMICAL", 23, 33], ["olanzapine", "CHEMICAL", 97, 107], ["olanzapine", "SIMPLE_CHEMICAL", 23, 33], ["AMPK", "GENE_OR_GENE_PRODUCT", 44, 48], ["PC12 cells", "CELL", 61, 71], ["olanzapine", "SIMPLE_CHEMICAL", 97, 107], ["AMPK", "PROTEIN", 44, 48], ["PC12 cells", "CELL_LINE", 61, 71], ["olanzapine activated AMPK", "TREATMENT", 23, 48], ["PC12 cells", "TREATMENT", 61, 71], ["olanzapine", "TREATMENT", 97, 107]]], ["The expression of activated AMPK, as measured by the p-AMPK/total AMPK (p-AMPK/AMPK) ratio, increased in a dose-and timedependent manner (Fig. 1a, b) .", [["AMPK", "GENE_OR_GENE_PRODUCT", 28, 32], ["AMPK", "GENE_OR_GENE_PRODUCT", 55, 59], ["AMPK", "GENE_OR_GENE_PRODUCT", 66, 70], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 72, 78], ["AMPK", "GENE_OR_GENE_PRODUCT", 79, 83], ["AMPK", "PROTEIN", 28, 32], ["AMPK", "PROTEIN", 55, 59], ["AMPK", "PROTEIN", 66, 70], ["AMPK", "PROTEIN", 74, 78], ["AMPK", "PROTEIN", 79, 83], ["activated AMPK", "TEST", 18, 32], ["total AMPK", "TEST", 60, 70], ["p-AMPK/AMPK", "TREATMENT", 72, 83], ["ratio", "TEST", 85, 90], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["Moreover, the peak p-AMPK/AMPK ratio was observed with 20 \u03bcM olanzapine and at 48 h.", [["olanzapine", "CHEMICAL", 61, 71], ["olanzapine", "CHEMICAL", 61, 71], ["AMPK", "GENE_OR_GENE_PRODUCT", 21, 25], ["AMPK", "GENE_OR_GENE_PRODUCT", 26, 30], ["olanzapine", "SIMPLE_CHEMICAL", 61, 71], ["AMPK", "PROTEIN", 21, 25], ["AMPK", "PROTEIN", 26, 30], ["the peak p", "TEST", 10, 20], ["AMPK/AMPK ratio", "TEST", 21, 36], ["20 \u03bcM olanzapine", "TREATMENT", 55, 71]]], ["Therefore, olanzapine was administered 24 h before rotenone exposure in subsequent experiments.RESULTSImmunoblot assays revealed that the ratio of LC3-II/LC3-I was increased, while the protein level of p62 (the substrate of autophagy) was decreased dose-dependently by olanzapine treatment (Fig. 2a) , indicating that olanzapine-induced autophagy in PC12 cells.", [["PC12 cells", "ANATOMY", 350, 360], ["olanzapine", "CHEMICAL", 11, 21], ["rotenone", "CHEMICAL", 51, 59], ["olanzapine", "CHEMICAL", 269, 279], ["olanzapine", "CHEMICAL", 318, 328], ["olanzapine", "CHEMICAL", 11, 21], ["rotenone", "CHEMICAL", 51, 59], ["olanzapine", "CHEMICAL", 269, 279], ["olanzapine", "CHEMICAL", 318, 328], ["olanzapine", "SIMPLE_CHEMICAL", 11, 21], ["rotenone", "SIMPLE_CHEMICAL", 51, 59], ["LC3-II", "GENE_OR_GENE_PRODUCT", 147, 153], ["LC3-I", "GENE_OR_GENE_PRODUCT", 154, 159], ["p62", "GENE_OR_GENE_PRODUCT", 202, 205], ["olanzapine", "SIMPLE_CHEMICAL", 269, 279], ["olanzapine", "SIMPLE_CHEMICAL", 318, 328], ["PC12 cells", "CELL", 350, 360], ["LC3", "PROTEIN", 147, 150], ["LC3-I", "PROTEIN", 154, 159], ["p62", "PROTEIN", 202, 205], ["PC12 cells", "CELL_LINE", 350, 360], ["olanzapine", "TREATMENT", 11, 21], ["RESULTSImmunoblot assays", "TEST", 95, 119], ["the ratio", "TEST", 134, 143], ["LC3", "TEST", 147, 150], ["the protein level", "TEST", 181, 198], ["olanzapine treatment", "TREATMENT", 269, 289], ["olanzapine", "TREATMENT", 318, 328], ["autophagy in PC12 cells", "PROBLEM", 337, 360], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["PC12 cells", "OBSERVATION", 350, 360]]], ["The decrease in the level of p70-S6K, which is phosphorylated by mTOR (Fig. 2a) , was consistent with the increase in LC3-II.", [["p70", "GENE_OR_GENE_PRODUCT", 29, 32], ["S6K", "GENE_OR_GENE_PRODUCT", 33, 36], ["mTOR", "GENE_OR_GENE_PRODUCT", 65, 69], ["Fig. 2a", "GENE_OR_GENE_PRODUCT", 71, 78], ["LC3-II.", "GENE_OR_GENE_PRODUCT", 118, 125], ["p70", "PROTEIN", 29, 32], ["S6K", "PROTEIN", 33, 36], ["mTOR", "PROTEIN", 65, 69], ["LC3", "PROTEIN", 118, 121], ["The decrease", "PROBLEM", 0, 12], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["consistent with", "UNCERTAINTY", 86, 101], ["increase", "OBSERVATION_MODIFIER", 106, 114]]], ["This indicated the involvement of mTOR kinase signaling in the induction of autophagy by olanzapine.", [["olanzapine", "CHEMICAL", 89, 99], ["olanzapine", "CHEMICAL", 89, 99], ["mTOR kinase", "GENE_OR_GENE_PRODUCT", 34, 45], ["olanzapine", "SIMPLE_CHEMICAL", 89, 99], ["mTOR kinase", "PROTEIN", 34, 45], ["mTOR kinase signaling", "PROBLEM", 34, 55], ["olanzapine", "TREATMENT", 89, 99], ["mTOR kinase", "OBSERVATION", 34, 45]]], ["Additionally, the LC3-II/LC3-I ratio reached its peak 48 h after olanzapine treatment (Fig. 2b) .", [["olanzapine", "CHEMICAL", 65, 75], ["olanzapine", "CHEMICAL", 65, 75], ["LC3-II", "GENE_OR_GENE_PRODUCT", 18, 24], ["LC3-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["olanzapine", "SIMPLE_CHEMICAL", 65, 75], ["LC3", "PROTEIN", 18, 21], ["LC3", "PROTEIN", 25, 28], ["the LC3", "TEST", 14, 21], ["I ratio", "TEST", 29, 36], ["olanzapine treatment", "TREATMENT", 65, 85]]], ["The time course of p62 and p70-S6K expression was consistent with the changes in LC3-II.", [["p62", "GENE_OR_GENE_PRODUCT", 19, 22], ["p70-S6K", "GENE_OR_GENE_PRODUCT", 27, 34], ["LC3-II.", "GENE_OR_GENE_PRODUCT", 81, 88], ["p62", "PROTEIN", 19, 22], ["p70", "PROTEIN", 27, 30], ["S6K", "PROTEIN", 31, 34], ["LC3", "PROTEIN", 81, 84], ["p62", "TEST", 19, 22], ["p70", "TEST", 27, 30], ["the changes in LC3", "PROBLEM", 66, 84], ["consistent with", "UNCERTAINTY", 50, 65]]], ["Immunostaining analysis of LC3 indicated that the treatment with olanzapine induced a distinct pattern of LC3 fluorescence in the cell cytoplasm (Fig. 2c ).", [["cell cytoplasm", "ANATOMY", 130, 144], ["olanzapine", "CHEMICAL", 65, 75], ["olanzapine", "CHEMICAL", 65, 75], ["LC3", "GENE_OR_GENE_PRODUCT", 27, 30], ["olanzapine", "SIMPLE_CHEMICAL", 65, 75], ["LC3", "GENE_OR_GENE_PRODUCT", 106, 109], ["cell", "ORGANISM_SUBSTANCE", 130, 134], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["LC3", "PROTEIN", 27, 30], ["LC3", "PROTEIN", 106, 109], ["Immunostaining analysis", "TEST", 0, 23], ["LC3", "TEST", 27, 30], ["the treatment", "TREATMENT", 46, 59], ["olanzapine", "TREATMENT", 65, 75], ["LC3 fluorescence", "PROBLEM", 106, 122], ["LC3 fluorescence", "OBSERVATION", 106, 122], ["cell cytoplasm", "OBSERVATION", 130, 144]]], ["In addition, electron microscopy experiments showed that the number of autophagic vacuoles in cells treated with olanzapine was increased compared to that in untreated cells and that lysosomes were significantly activated Neuroprotective effects of olanzapine YJ Xiong et al.RESULTS( Fig. 2d) , which further confirmed the activation of autophagy by olanzapine.", [["autophagic vacuoles", "ANATOMY", 71, 90], ["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 168, 173], ["lysosomes", "ANATOMY", 183, 192], ["olanzapine", "CHEMICAL", 113, 123], ["olanzapine", "CHEMICAL", 249, 259], ["olanzapine", "CHEMICAL", 350, 360], ["olanzapine", "CHEMICAL", 113, 123], ["olanzapine", "CHEMICAL", 249, 259], ["olanzapine", "CHEMICAL", 350, 360], ["autophagic vacuoles", "CELLULAR_COMPONENT", 71, 90], ["cells", "CELL", 94, 99], ["olanzapine", "SIMPLE_CHEMICAL", 113, 123], ["cells", "CELL", 168, 173], ["lysosomes", "CELLULAR_COMPONENT", 183, 192], ["olanzapine", "SIMPLE_CHEMICAL", 350, 360], ["untreated cells", "CELL_TYPE", 158, 173], ["electron microscopy experiments", "TEST", 13, 44], ["autophagic vacuoles in cells", "PROBLEM", 71, 99], ["olanzapine", "TREATMENT", 113, 123], ["olanzapine", "TREATMENT", 249, 259], ["olanzapine", "TREATMENT", 350, 360], ["autophagic vacuoles", "OBSERVATION", 71, 90]]], ["We also found that pretreatment with the autophagy inhibitor 3-MA eliminated the increase in the LC3-II/LC3-I ratio and the decrease in p62 levels induced by olanzapine (Fig. 2e) .RESULTSNeuroprotective effects of olanzapine against rotenone-induced apoptosis in PC12 cells We questioned whether olanzapine attenuated the damage to PC12 cells induced by rotenone.", [["PC12 cells", "ANATOMY", 263, 273], ["PC12 cells", "ANATOMY", 332, 342], ["3-MA", "CHEMICAL", 61, 65], ["olanzapine", "CHEMICAL", 158, 168], ["olanzapine", "CHEMICAL", 214, 224], ["rotenone", "CHEMICAL", 233, 241], ["olanzapine", "CHEMICAL", 296, 306], ["rotenone", "CHEMICAL", 354, 362], ["3-MA", "CHEMICAL", 61, 65], ["olanzapine", "CHEMICAL", 158, 168], ["olanzapine", "CHEMICAL", 214, 224], ["rotenone", "CHEMICAL", 233, 241], ["olanzapine", "CHEMICAL", 296, 306], ["rotenone", "CHEMICAL", 354, 362], ["3-MA", "SIMPLE_CHEMICAL", 61, 65], ["LC3-II", "GENE_OR_GENE_PRODUCT", 97, 103], ["LC3-I", "GENE_OR_GENE_PRODUCT", 104, 109], ["p62", "GENE_OR_GENE_PRODUCT", 136, 139], ["olanzapine", "SIMPLE_CHEMICAL", 158, 168], ["olanzapine", "SIMPLE_CHEMICAL", 214, 224], ["rotenone", "SIMPLE_CHEMICAL", 233, 241], ["PC12 cells", "CELL", 263, 273], ["olanzapine", "SIMPLE_CHEMICAL", 296, 306], ["PC12 cells", "CELL", 332, 342], ["rotenone", "SIMPLE_CHEMICAL", 354, 362], ["LC3", "PROTEIN", 97, 100], ["LC3-I", "PROTEIN", 104, 109], ["p62", "PROTEIN", 136, 139], ["PC12 cells", "CELL_LINE", 263, 273], ["PC12 cells", "CELL_LINE", 332, 342], ["the autophagy inhibitor", "TREATMENT", 37, 60], ["the LC3", "TEST", 93, 100], ["the decrease in p62 levels", "PROBLEM", 120, 146], ["olanzapine", "TREATMENT", 158, 168], ["olanzapine", "TREATMENT", 214, 224], ["rotenone", "TREATMENT", 233, 241], ["apoptosis in PC12 cells", "PROBLEM", 250, 273], ["olanzapine", "TREATMENT", 296, 306], ["the damage", "PROBLEM", 318, 328], ["PC12 cells", "TREATMENT", 332, 342], ["rotenone", "TREATMENT", 354, 362], ["increase", "OBSERVATION_MODIFIER", 81, 89], ["decrease", "OBSERVATION_MODIFIER", 124, 132], ["p62 levels", "OBSERVATION", 136, 146], ["PC12 cells", "OBSERVATION", 263, 273], ["PC12 cells", "OBSERVATION", 332, 342]]], ["Rotenone has been reported to induce PC12 cell apoptosis, leading to cell damage [21] .", [["PC12 cell", "ANATOMY", 37, 46], ["cell", "ANATOMY", 69, 73], ["Rotenone", "CHEMICAL", 0, 8], ["Rotenone", "CHEMICAL", 0, 8], ["Rotenone", "SIMPLE_CHEMICAL", 0, 8], ["PC12 cell", "CELL", 37, 46], ["cell", "CELL", 69, 73], ["PC12 cell", "CELL_LINE", 37, 46], ["Rotenone", "TREATMENT", 0, 8], ["PC12 cell apoptosis", "PROBLEM", 37, 56], ["cell damage", "PROBLEM", 69, 80], ["PC12 cell apoptosis", "OBSERVATION", 37, 56], ["cell damage", "OBSERVATION", 69, 80]]], ["Nuclear condensation and DNA fragmentation are hallmarks of cell apoptosis.", [["Nuclear", "ANATOMY", 0, 7], ["cell", "ANATOMY", 60, 64], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["cell", "CELL", 60, 64], ["Nuclear condensation", "PROBLEM", 0, 20], ["DNA fragmentation", "PROBLEM", 25, 42], ["cell apoptosis", "PROBLEM", 60, 74], ["condensation", "OBSERVATION", 8, 20], ["DNA fragmentation", "OBSERVATION", 25, 42], ["hallmarks", "OBSERVATION_MODIFIER", 47, 56], ["of cell apoptosis", "OBSERVATION", 57, 74]]], ["To evaluate the protective effects of olanzapine on rotenone-induced nuclear condensation and DNA fragmentation, cells were stained with Hoechst 33258 and examined using microscopy.", [["nuclear", "ANATOMY", 69, 76], ["cells", "ANATOMY", 113, 118], ["olanzapine", "CHEMICAL", 38, 48], ["rotenone", "CHEMICAL", 52, 60], ["Hoechst 33258", "CHEMICAL", 137, 150], ["olanzapine", "CHEMICAL", 38, 48], ["rotenone", "CHEMICAL", 52, 60], ["Hoechst 33258", "CHEMICAL", 137, 150], ["olanzapine", "SIMPLE_CHEMICAL", 38, 48], ["rotenone", "SIMPLE_CHEMICAL", 52, 60], ["nuclear", "CELLULAR_COMPONENT", 69, 76], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["cells", "CELL", 113, 118], ["Hoechst 33258", "SIMPLE_CHEMICAL", 137, 150], ["olanzapine", "TREATMENT", 38, 48], ["rotenone", "TREATMENT", 52, 60], ["nuclear condensation", "PROBLEM", 69, 89], ["DNA fragmentation", "PROBLEM", 94, 111], ["microscopy", "TEST", 170, 180], ["nuclear condensation", "OBSERVATION", 69, 89]]], ["As illustrated in Fig. 3a , control PC12 cells had regular and round-shaped nuclei, while cells treated with rotenone for 24 h exhibited nuclear condensation and fragmentation, and were reduced in size.", [["PC12 cells", "ANATOMY", 36, 46], ["nuclei", "ANATOMY", 76, 82], ["cells", "ANATOMY", 90, 95], ["nuclear", "ANATOMY", 137, 144], ["rotenone", "CHEMICAL", 109, 117], ["rotenone", "CHEMICAL", 109, 117], ["PC12 cells", "CELL", 36, 46], ["nuclei", "CELLULAR_COMPONENT", 76, 82], ["cells", "CELL", 90, 95], ["rotenone", "SIMPLE_CHEMICAL", 109, 117], ["nuclear", "CELLULAR_COMPONENT", 137, 144], ["PC12 cells", "CELL_LINE", 36, 46], ["round-shaped nuclei", "PROBLEM", 63, 82], ["rotenone", "TREATMENT", 109, 117], ["nuclear condensation", "PROBLEM", 137, 157], ["fragmentation", "PROBLEM", 162, 175], ["round", "OBSERVATION_MODIFIER", 63, 68], ["shaped", "OBSERVATION_MODIFIER", 69, 75], ["nuclei", "OBSERVATION", 76, 82], ["condensation", "OBSERVATION", 145, 157], ["fragmentation", "OBSERVATION", 162, 175], ["reduced", "OBSERVATION_MODIFIER", 186, 193], ["size", "OBSERVATION_MODIFIER", 197, 201]]], ["PC12 cells pretreated with olanzapine for 24 h exhibited many fewer condensed and fragmented nuclei than those treated with rotenone alone.", [["PC12 cells", "ANATOMY", 0, 10], ["nuclei", "ANATOMY", 93, 99], ["olanzapine", "CHEMICAL", 27, 37], ["rotenone", "CHEMICAL", 124, 132], ["olanzapine", "CHEMICAL", 27, 37], ["rotenone", "CHEMICAL", 124, 132], ["PC12 cells", "CELL", 0, 10], ["olanzapine", "SIMPLE_CHEMICAL", 27, 37], ["nuclei", "CELLULAR_COMPONENT", 93, 99], ["rotenone", "SIMPLE_CHEMICAL", 124, 132], ["PC12 cells", "CELL_LINE", 0, 10], ["PC12 cells", "PROBLEM", 0, 10], ["olanzapine", "TREATMENT", 27, 37], ["many fewer condensed and fragmented nuclei", "PROBLEM", 57, 99], ["rotenone", "TREATMENT", 124, 132], ["fewer", "OBSERVATION_MODIFIER", 62, 67], ["condensed", "OBSERVATION", 68, 77], ["fragmented", "OBSERVATION_MODIFIER", 82, 92], ["nuclei", "OBSERVATION_MODIFIER", 93, 99]]], ["Quantification analysis showed that the number of apoptotic rotenone-exposed cells was significantly increased by 35.42% compared with the number of apoptotic control cells.", [["cells", "ANATOMY", 77, 82], ["cells", "ANATOMY", 167, 172], ["rotenone", "CHEMICAL", 60, 68], ["rotenone", "CHEMICAL", 60, 68], ["rotenone", "SIMPLE_CHEMICAL", 60, 68], ["cells", "CELL", 77, 82], ["cells", "CELL", 167, 172], ["apoptotic rotenone-exposed cells", "CELL_LINE", 50, 82], ["apoptotic control cells", "CELL_TYPE", 149, 172], ["Quantification analysis", "TEST", 0, 23], ["apoptotic rotenone-exposed cells", "PROBLEM", 50, 82], ["significantly", "OBSERVATION_MODIFIER", 87, 100], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["apoptotic control cells", "OBSERVATION", 149, 172]]], ["Olanzapine pretreatment, however, protected cells from rotenone toxicity by reducing the number of apoptotic cells to 14.79% (Fig. 3c) .", [["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 109, 114], ["Olanzapine", "CHEMICAL", 0, 10], ["rotenone", "CHEMICAL", 55, 63], ["toxicity", "DISEASE", 64, 72], ["Olanzapine", "CHEMICAL", 0, 10], ["rotenone", "CHEMICAL", 55, 63], ["Olanzapine", "SIMPLE_CHEMICAL", 0, 10], ["cells", "CELL", 44, 49], ["rotenone", "SIMPLE_CHEMICAL", 55, 63], ["cells", "CELL", 109, 114], ["apoptotic cells", "CELL_TYPE", 99, 114], ["Olanzapine pretreatment", "TREATMENT", 0, 23], ["rotenone toxicity", "PROBLEM", 55, 72], ["apoptotic cells", "TEST", 99, 114], ["rotenone toxicity", "OBSERVATION", 55, 72]]], ["For further confirmation of rotenone-induced apoptosis, we also used a TUNEL mixture to stain PC12 cells.", [["PC12 cells", "ANATOMY", 94, 104], ["rotenone", "CHEMICAL", 28, 36], ["rotenone", "CHEMICAL", 28, 36], ["rotenone", "SIMPLE_CHEMICAL", 28, 36], ["PC12 cells", "CELL", 94, 104], ["PC12 cells", "CELL_LINE", 94, 104], ["further confirmation", "TEST", 4, 24], ["rotenone-induced apoptosis", "PROBLEM", 28, 54], ["a TUNEL mixture", "TREATMENT", 69, 84], ["PC12 cells", "OBSERVATION", 94, 104]]], ["The results showed that red fluorescence was obvious in the rotenone group, indicating that rotenone-induced apoptosis, while olanzapine alleviated the apoptosis induced by rotenone (Fig. 3b) .", [["rotenone", "CHEMICAL", 60, 68], ["rotenone", "CHEMICAL", 92, 100], ["olanzapine", "CHEMICAL", 126, 136], ["rotenone", "CHEMICAL", 173, 181], ["rotenone", "CHEMICAL", 60, 68], ["rotenone", "CHEMICAL", 92, 100], ["olanzapine", "CHEMICAL", 126, 136], ["rotenone", "CHEMICAL", 173, 181], ["rotenone", "SIMPLE_CHEMICAL", 60, 68], ["rotenone", "SIMPLE_CHEMICAL", 92, 100], ["olanzapine", "SIMPLE_CHEMICAL", 126, 136], ["rotenone", "SIMPLE_CHEMICAL", 173, 181], ["red fluorescence", "PROBLEM", 24, 40], ["rotenone-induced apoptosis", "PROBLEM", 92, 118], ["olanzapine", "TREATMENT", 126, 136], ["the apoptosis", "PROBLEM", 148, 161], ["red fluorescence", "OBSERVATION", 24, 40]]], ["The results of the CCK-8 assay demonstrated that olanzapine pretreatment markedly increased the percentage of viable cells following exposure to rotenone.", [["cells", "ANATOMY", 117, 122], ["olanzapine", "CHEMICAL", 49, 59], ["rotenone", "CHEMICAL", 145, 153], ["olanzapine", "CHEMICAL", 49, 59], ["rotenone", "CHEMICAL", 145, 153], ["CCK-8", "GENE_OR_GENE_PRODUCT", 19, 24], ["olanzapine", "SIMPLE_CHEMICAL", 49, 59], ["cells", "CELL", 117, 122], ["rotenone", "SIMPLE_CHEMICAL", 145, 153], ["viable cells", "CELL_TYPE", 110, 122], ["the CCK", "TEST", 15, 22], ["olanzapine pretreatment", "PROBLEM", 49, 72], ["rotenone", "TREATMENT", 145, 153], ["viable cells", "OBSERVATION", 110, 122]]], ["The cells pretreated with olanzapine displayed a viability that was 21% greater than that of the rotenone group (Fig. 3d) , suggesting that olanzapine had a protective effect on rotenone-induced neurotoxicity.RESULTS\u25b3\u03a8m is closely associated with cell apoptosis.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 247, 251], ["olanzapine", "CHEMICAL", 26, 36], ["rotenone", "CHEMICAL", 97, 105], ["olanzapine", "CHEMICAL", 140, 150], ["rotenone", "CHEMICAL", 178, 186], ["neurotoxicity", "DISEASE", 195, 208], ["olanzapine", "CHEMICAL", 26, 36], ["rotenone", "CHEMICAL", 97, 105], ["olanzapine", "CHEMICAL", 140, 150], ["rotenone", "CHEMICAL", 178, 186], ["cells", "CELL", 4, 9], ["olanzapine", "SIMPLE_CHEMICAL", 26, 36], ["rotenone", "SIMPLE_CHEMICAL", 97, 105], ["olanzapine", "SIMPLE_CHEMICAL", 140, 150], ["rotenone", "SIMPLE_CHEMICAL", 178, 186], ["cell", "CELL", 247, 251], ["olanzapine", "TREATMENT", 26, 36], ["olanzapine", "TREATMENT", 140, 150], ["rotenone", "TREATMENT", 178, 186], ["neurotoxicity", "PROBLEM", 195, 208], ["cell apoptosis", "PROBLEM", 247, 261], ["closely associated with", "UNCERTAINTY", 223, 246], ["cell apoptosis", "OBSERVATION", 247, 261]]], ["A decrease in \u25b3\u03a8m is considered one of the earliest hallmarks of apoptosis.", [["\u25b3\u03a8m", "GENE_OR_GENE_PRODUCT", 14, 17], ["\u25b3\u03a8m", "PROTEIN", 14, 17], ["A decrease in \u25b3\u03a8m", "PROBLEM", 0, 17], ["apoptosis", "PROBLEM", 65, 74], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["apoptosis", "OBSERVATION", 65, 74]]], ["The lipophilic cation JC-1 was used to assess \u25b3\u03a8m.", [["\u03a8m", "PROTEIN", 47, 49], ["The lipophilic cation JC", "TREATMENT", 0, 24], ["lipophilic cation", "OBSERVATION", 4, 21]]], ["Rotenone significantly depolarized \u25b3\u03a8m, as manifested by the decreased red/green fluorescence ratio of JC-1 compared to that of the control group (Fig. 3e ).", [["Rotenone", "CHEMICAL", 0, 8], ["Rotenone", "CHEMICAL", 0, 8], ["Rotenone", "SIMPLE_CHEMICAL", 0, 8], ["JC-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["JC-1", "SPECIES", 103, 107], ["the decreased red/green fluorescence ratio", "PROBLEM", 57, 99], ["decreased", "OBSERVATION_MODIFIER", 61, 70], ["green fluorescence", "OBSERVATION", 75, 93]]], ["This effect was significantly counteracted by olanzapine pretreatment.RESULTSRotenone-induced apoptosis was further investigated.", [["olanzapine", "CHEMICAL", 46, 56], ["RESULTSRotenone", "CHEMICAL", 70, 85], ["olanzapine", "CHEMICAL", 46, 56], ["RESULTSRotenone", "CHEMICAL", 70, 85], ["olanzapine", "SIMPLE_CHEMICAL", 46, 56], ["RESULTSRotenone", "SIMPLE_CHEMICAL", 70, 85], ["olanzapine pretreatment", "TREATMENT", 46, 69], ["RESULTSRotenone", "TEST", 70, 85], ["apoptosis", "OBSERVATION", 94, 103]]], ["As shown, olanzapine diminished the rotenone-induced increase in cleaved PARP protein and Bax (Fig. 4a ).", [["olanzapine", "CHEMICAL", 10, 20], ["rotenone", "CHEMICAL", 36, 44], ["olanzapine", "CHEMICAL", 10, 20], ["rotenone", "CHEMICAL", 36, 44], ["olanzapine", "SIMPLE_CHEMICAL", 10, 20], ["rotenone", "SIMPLE_CHEMICAL", 36, 44], ["PARP", "GENE_OR_GENE_PRODUCT", 73, 77], ["Bax", "GENE_OR_GENE_PRODUCT", 90, 93], ["PARP protein", "PROTEIN", 73, 85], ["Bax", "PROTEIN", 90, 93], ["olanzapine", "TREATMENT", 10, 20], ["the rotenone", "TREATMENT", 32, 44], ["cleaved PARP protein", "TREATMENT", 65, 85], ["increase", "OBSERVATION_MODIFIER", 53, 61]]], ["In addition, Pink 1, Parkin, and Cyt-c are the key regulating factors of the mitochondrial pathway.", [["mitochondrial", "ANATOMY", 77, 90], ["Pink 1", "GENE_OR_GENE_PRODUCT", 13, 19], ["Parkin", "GENE_OR_GENE_PRODUCT", 21, 27], ["Cyt-c", "GENE_OR_GENE_PRODUCT", 33, 38], ["mitochondrial", "CELLULAR_COMPONENT", 77, 90], ["Pink 1", "PROTEIN", 13, 19], ["Parkin", "PROTEIN", 21, 27], ["Cyt-c", "PROTEIN", 33, 38], ["Cyt-c", "TEST", 33, 38], ["Pink", "OBSERVATION_MODIFIER", 13, 17]]], ["Pink 1/Parkin has been reported to mediate mitochondrial autophagy [22] .", [["mitochondrial", "ANATOMY", 43, 56], ["Pink 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Parkin", "GENE_OR_GENE_PRODUCT", 7, 13], ["mitochondrial", "CELLULAR_COMPONENT", 43, 56], ["Parkin", "PROTEIN", 7, 13]]], ["Furthermore, the cell supernatant and mitochondria of PC12 cells were isolated, and then Western blotting was used to detect Cyt-c levels in the supernatant and mitochondria.", [["cell supernatant", "ANATOMY", 17, 33], ["mitochondria", "ANATOMY", 38, 50], ["PC12 cells", "ANATOMY", 54, 64], ["supernatant", "ANATOMY", 145, 156], ["mitochondria", "ANATOMY", 161, 173], ["cell", "CELL", 17, 21], ["mitochondria", "CELLULAR_COMPONENT", 38, 50], ["PC12 cells", "CELL", 54, 64], ["Cyt-c", "GENE_OR_GENE_PRODUCT", 125, 130], ["mitochondria", "CELLULAR_COMPONENT", 161, 173], ["PC12 cells", "CELL_LINE", 54, 64], ["Cyt", "PROTEIN", 125, 128], ["the cell supernatant", "TEST", 13, 33], ["PC12 cells", "PROBLEM", 54, 64], ["Western blotting", "TEST", 89, 105], ["Cyt-c levels", "TEST", 125, 137], ["cell supernatant", "OBSERVATION", 17, 33], ["PC12 cells", "OBSERVATION", 54, 64]]], ["As shown in Fig. 4b , the expression of Pink 1 and Parkin was markedly increased by rotenone, and this effect was abolished by olanzapine pretreatment in the mitochondria.", [["mitochondria", "ANATOMY", 158, 170], ["rotenone", "CHEMICAL", 84, 92], ["olanzapine", "CHEMICAL", 127, 137], ["rotenone", "CHEMICAL", 84, 92], ["olanzapine", "CHEMICAL", 127, 137], ["Pink 1", "GENE_OR_GENE_PRODUCT", 40, 46], ["Parkin", "GENE_OR_GENE_PRODUCT", 51, 57], ["rotenone", "SIMPLE_CHEMICAL", 84, 92], ["olanzapine", "SIMPLE_CHEMICAL", 127, 137], ["mitochondria", "CELLULAR_COMPONENT", 158, 170], ["Pink 1", "PROTEIN", 40, 46], ["Parkin", "PROTEIN", 51, 57], ["rotenone", "TREATMENT", 84, 92], ["olanzapine pretreatment", "TREATMENT", 127, 150], ["Pink", "OBSERVATION", 40, 44], ["increased", "OBSERVATION_MODIFIER", 71, 80]]], ["There was also a significant increase in Cyt-c after rotenone treatment in the cell supernatant, and olanzapine pretreatment suppressed the expression of rotenone-induced Cyt-c.RESULTSTo determine whether olanzapine mitigated rotenone-induced mitochondrial damage, cells were treated with rotenone for 24 h with or without olanzapine pretreatment, and stained with MitoTracker and LysoTracker.", [["cell supernatant", "ANATOMY", 79, 95], ["mitochondrial", "ANATOMY", 243, 256], ["cells", "ANATOMY", 265, 270], ["rotenone", "CHEMICAL", 53, 61], ["olanzapine", "CHEMICAL", 101, 111], ["rotenone", "CHEMICAL", 154, 162], ["olanzapine", "CHEMICAL", 205, 215], ["rotenone", "CHEMICAL", 226, 234], ["mitochondrial damage", "DISEASE", 243, 263], ["rotenone", "CHEMICAL", 289, 297], ["olanzapine", "CHEMICAL", 323, 333], ["rotenone", "CHEMICAL", 53, 61], ["olanzapine", "CHEMICAL", 101, 111], ["rotenone", "CHEMICAL", 154, 162], ["olanzapine", "CHEMICAL", 205, 215], ["rotenone", "CHEMICAL", 226, 234], ["rotenone", "CHEMICAL", 289, 297], ["olanzapine", "CHEMICAL", 323, 333], ["Cyt-c", "GENE_OR_GENE_PRODUCT", 41, 46], ["rotenone", "SIMPLE_CHEMICAL", 53, 61], ["cell", "CELL", 79, 83], ["olanzapine", "SIMPLE_CHEMICAL", 101, 111], ["rotenone", "SIMPLE_CHEMICAL", 154, 162], ["olanzapine", "SIMPLE_CHEMICAL", 205, 215], ["rotenone", "SIMPLE_CHEMICAL", 226, 234], ["mitochondrial", "CELLULAR_COMPONENT", 243, 256], ["cells", "CELL", 265, 270], ["rotenone", "SIMPLE_CHEMICAL", 289, 297], ["olanzapine", "SIMPLE_CHEMICAL", 323, 333], ["MitoTracker", "SIMPLE_CHEMICAL", 365, 376], ["LysoTracker", "SIMPLE_CHEMICAL", 381, 392], ["Cyt", "PROTEIN", 41, 44], ["a significant increase in Cyt-c", "PROBLEM", 15, 46], ["rotenone treatment", "TREATMENT", 53, 71], ["the cell supernatant", "TREATMENT", 75, 95], ["olanzapine pretreatment", "TREATMENT", 101, 124], ["rotenone", "TREATMENT", 154, 162], ["olanzapine mitigated rotenone", "TREATMENT", 205, 234], ["mitochondrial damage", "PROBLEM", 243, 263], ["rotenone", "TREATMENT", 289, 297], ["olanzapine pretreatment", "TREATMENT", 323, 346], ["MitoTracker", "TREATMENT", 365, 376], ["LysoTracker", "TREATMENT", 381, 392], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["Cyt", "ANATOMY", 41, 44], ["mitochondrial damage", "OBSERVATION", 243, 263]]], ["We found that rotenone had a significant effect on MitoTracker fluorescence, which was consistent with the partial inhibition of \u25b3\u03a8m (Fig. 4c) .", [["rotenone", "CHEMICAL", 14, 22], ["rotenone", "CHEMICAL", 14, 22], ["rotenone", "SIMPLE_CHEMICAL", 14, 22], ["MitoTracker", "SIMPLE_CHEMICAL", 51, 62], ["rotenone", "PROBLEM", 14, 22], ["MitoTracker fluorescence", "TEST", 51, 75], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["effect", "OBSERVATION_MODIFIER", 41, 47], ["MitoTracker fluorescence", "OBSERVATION", 51, 75], ["consistent with", "UNCERTAINTY", 87, 102]]], ["Correspondingly, pretreatment with olanzapine reduced mitochondrial damage induced by rotenone, indicating that olanzapine had a neuroprotective effect against rotenone-induced toxicity in PC12 cells.RESULTSInhibition of AMPK or autophagy abolished the neuroprotective effect of olanzapine We also investigated the relationship between AMPK activation and autophagy induction.", [["mitochondrial", "ANATOMY", 54, 67], ["PC12 cells", "ANATOMY", 189, 199], ["olanzapine", "CHEMICAL", 35, 45], ["mitochondrial damage", "DISEASE", 54, 74], ["rotenone", "CHEMICAL", 86, 94], ["olanzapine", "CHEMICAL", 112, 122], ["rotenone", "CHEMICAL", 160, 168], ["toxicity", "DISEASE", 177, 185], ["olanzapine", "CHEMICAL", 279, 289], ["olanzapine", "CHEMICAL", 35, 45], ["rotenone", "CHEMICAL", 86, 94], ["olanzapine", "CHEMICAL", 112, 122], ["rotenone", "CHEMICAL", 160, 168], ["olanzapine", "CHEMICAL", 279, 289], ["olanzapine", "SIMPLE_CHEMICAL", 35, 45], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["rotenone", "SIMPLE_CHEMICAL", 86, 94], ["olanzapine", "SIMPLE_CHEMICAL", 112, 122], ["rotenone", "SIMPLE_CHEMICAL", 160, 168], ["PC12 cells", "CELL", 189, 199], ["AMPK", "GENE_OR_GENE_PRODUCT", 221, 225], ["olanzapine", "SIMPLE_CHEMICAL", 279, 289], ["AMPK", "GENE_OR_GENE_PRODUCT", 336, 340], ["PC12 cells", "CELL_LINE", 189, 199], ["AMPK", "PROTEIN", 221, 225], ["AMPK", "PROTEIN", 336, 340], ["olanzapine", "TREATMENT", 35, 45], ["mitochondrial damage", "PROBLEM", 54, 74], ["rotenone", "TREATMENT", 86, 94], ["olanzapine", "TREATMENT", 112, 122], ["rotenone-induced toxicity in PC12 cells", "PROBLEM", 160, 199], ["AMPK", "TREATMENT", 221, 225], ["autophagy", "PROBLEM", 229, 238], ["olanzapine", "TREATMENT", 279, 289], ["AMPK activation", "TREATMENT", 336, 351], ["autophagy induction", "TREATMENT", 356, 375], ["PC12 cells", "OBSERVATION", 189, 199]]], ["PC12 cells were pretreated with 2.5 \u03bcM compound C, a potent AMPK inhibitor that has been widely used to study AMPK signaling.", [["PC12 cells", "ANATOMY", 0, 10], ["PC12 cells", "CELL", 0, 10], ["C", "SIMPLE_CHEMICAL", 48, 49], ["AMPK", "GENE_OR_GENE_PRODUCT", 60, 64], ["AMPK", "GENE_OR_GENE_PRODUCT", 110, 114], ["PC12 cells", "CELL_LINE", 0, 10], ["AMPK", "PROTEIN", 110, 114], ["PC12 cells", "PROBLEM", 0, 10], ["a potent AMPK inhibitor", "TREATMENT", 51, 74]]], ["We found that compound C prevented the olanzapine-induced activation of AMPK and that this effect was accompanied by a decrease in LC3 and an increase in p62 (Fig. 5) , indicating that autophagy inhibition was in accordance with the inhibition of AMPK.RESULTSTo explore whether AMPK activation was involved in the neuroprotective effects of olanzapine, PC12 cells were pretreated with 2.5 \u03bcM compound C for 3 h before olanzapine and rotenone treatment.", [["PC12 cells", "ANATOMY", 353, 363], ["compound C", "CHEMICAL", 14, 24], ["olanzapine", "CHEMICAL", 39, 49], ["olanzapine", "CHEMICAL", 341, 351], ["olanzapine", "CHEMICAL", 418, 428], ["rotenone", "CHEMICAL", 433, 441], ["olanzapine", "CHEMICAL", 39, 49], ["olanzapine", "CHEMICAL", 341, 351], ["olanzapine", "CHEMICAL", 418, 428], ["rotenone", "CHEMICAL", 433, 441], ["compound C", "SIMPLE_CHEMICAL", 14, 24], ["olanzapine", "SIMPLE_CHEMICAL", 39, 49], ["AMPK", "GENE_OR_GENE_PRODUCT", 72, 76], ["LC3", "GENE_OR_GENE_PRODUCT", 131, 134], ["p62", "GENE_OR_GENE_PRODUCT", 154, 157], ["AMPK", "GENE_OR_GENE_PRODUCT", 247, 251], ["AMPK", "GENE_OR_GENE_PRODUCT", 278, 282], ["olanzapine", "SIMPLE_CHEMICAL", 341, 351], ["PC12 cells", "CELL", 353, 363], ["olanzapine", "SIMPLE_CHEMICAL", 418, 428], ["rotenone", "SIMPLE_CHEMICAL", 433, 441], ["AMPK", "PROTEIN", 72, 76], ["LC3", "PROTEIN", 131, 134], ["p62", "PROTEIN", 154, 157], ["AMPK", "PROTEIN", 247, 251], ["AMPK", "PROTEIN", 278, 282], ["PC12 cells", "CELL_LINE", 353, 363], ["compound C", "PROBLEM", 14, 24], ["the olanzapine", "TREATMENT", 35, 49], ["a decrease in LC3", "PROBLEM", 117, 134], ["an increase in p62", "PROBLEM", 139, 157], ["autophagy inhibition", "PROBLEM", 185, 205], ["AMPK activation", "PROBLEM", 278, 293], ["olanzapine", "TREATMENT", 341, 351], ["PC12 cells", "TREATMENT", 353, 363], ["olanzapine", "TREATMENT", 418, 428], ["rotenone treatment", "TREATMENT", 433, 451], ["decrease", "OBSERVATION_MODIFIER", 119, 127], ["LC3", "OBSERVATION_MODIFIER", 131, 134], ["increase", "OBSERVATION_MODIFIER", 142, 150], ["autophagy inhibition", "OBSERVATION", 185, 205]]], ["The CCK-8 assay results showed that compound C pretreatment reduced cell viability by 27.58% (P < 0.05 compared to the Rot + Ola group, Fig. 6a ).", [["cell", "ANATOMY", 68, 72], ["compound C", "CHEMICAL", 36, 46], ["CCK-8", "GENE_OR_GENE_PRODUCT", 4, 9], ["compound C", "SIMPLE_CHEMICAL", 36, 46], ["cell", "CELL", 68, 72], ["The CCK", "TEST", 0, 7], ["compound C pretreatment reduced cell viability", "PROBLEM", 36, 82], ["P", "TEST", 94, 95], ["cell viability", "OBSERVATION", 68, 82]]], ["Moreover, 3-MA (1 mM) was used to determine whether autophagy affected the neuroprotective effect of olanzapine in PC12 cells.", [["PC12 cells", "ANATOMY", 115, 125], ["3-MA", "CHEMICAL", 10, 14], ["olanzapine", "CHEMICAL", 101, 111], ["3-MA", "CHEMICAL", 10, 14], ["olanzapine", "CHEMICAL", 101, 111], ["3-MA", "SIMPLE_CHEMICAL", 10, 14], ["olanzapine", "SIMPLE_CHEMICAL", 101, 111], ["PC12 cells", "CELL", 115, 125], ["PC12 cells", "CELL_LINE", 115, 125], ["autophagy", "PROBLEM", 52, 61], ["olanzapine in PC12 cells", "TREATMENT", 101, 125]]], ["As shown in Fig. 6c , the rotenone-reduced expression of Bcl-2 was alleviated by the presence of olanzapine, but this effect was abolished by 3-MA pretreatment.", [["rotenone", "CHEMICAL", 26, 34], ["olanzapine", "CHEMICAL", 97, 107], ["3-MA", "CHEMICAL", 142, 146], ["rotenone", "CHEMICAL", 26, 34], ["olanzapine", "CHEMICAL", 97, 107], ["3-MA", "CHEMICAL", 142, 146], ["Fig. 6c", "GENE_OR_GENE_PRODUCT", 12, 19], ["rotenone", "SIMPLE_CHEMICAL", 26, 34], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["olanzapine", "SIMPLE_CHEMICAL", 97, 107], ["3-MA", "SIMPLE_CHEMICAL", 142, 146], ["Bcl-2", "PROTEIN", 57, 62], ["the rotenone", "TREATMENT", 22, 34], ["olanzapine", "TREATMENT", 97, 107]]], ["Meanwhile, after 3-MA pretreatment, Bax and Cyt-c expression was still increased by rotenone, even under olanzapine exposure.", [["3-MA", "CHEMICAL", 17, 21], ["rotenone", "CHEMICAL", 84, 92], ["olanzapine", "CHEMICAL", 105, 115], ["3-MA", "CHEMICAL", 17, 21], ["rotenone", "CHEMICAL", 84, 92], ["olanzapine", "CHEMICAL", 105, 115], ["3-MA", "GENE_OR_GENE_PRODUCT", 17, 21], ["Bax", "GENE_OR_GENE_PRODUCT", 36, 39], ["Cyt-c", "GENE_OR_GENE_PRODUCT", 44, 49], ["rotenone", "SIMPLE_CHEMICAL", 84, 92], ["olanzapine", "SIMPLE_CHEMICAL", 105, 115], ["Bax", "PROTEIN", 36, 39], ["Cyt", "PROTEIN", 44, 47], ["3-MA pretreatment", "TREATMENT", 17, 34], ["Bax", "TREATMENT", 36, 39], ["Cyt-c expression", "TREATMENT", 44, 60], ["rotenone", "TREATMENT", 84, 92], ["olanzapine exposure", "TREATMENT", 105, 124]]], ["We also measured the effect of olanzapine on the rotenone-induced depolarization \u25b3\u03a8m with or without 3-MA.", [["olanzapine", "CHEMICAL", 31, 41], ["rotenone", "CHEMICAL", 49, 57], ["3-MA", "CHEMICAL", 101, 105], ["olanzapine", "CHEMICAL", 31, 41], ["rotenone", "CHEMICAL", 49, 57], ["3-MA", "CHEMICAL", 101, 105], ["olanzapine", "SIMPLE_CHEMICAL", 31, 41], ["rotenone", "SIMPLE_CHEMICAL", 49, 57], ["3-MA", "GENE_OR_GENE_PRODUCT", 101, 105], ["olanzapine", "TREATMENT", 31, 41], ["the rotenone", "TREATMENT", 45, 57]]], ["We found that 3-MA significantly counteracted the repolarization effect of olanzapine against rotenone (Fig. 6b) .DISCUSSIONIn this study, we demonstrated the neuroprotective effects of olanzapine against rotenone-induced injury in PC12 cells.", [["PC12 cells", "ANATOMY", 232, 242], ["3-MA", "CHEMICAL", 14, 18], ["olanzapine", "CHEMICAL", 75, 85], ["rotenone", "CHEMICAL", 94, 102], ["olanzapine", "CHEMICAL", 186, 196], ["rotenone", "CHEMICAL", 205, 213], ["3-MA", "CHEMICAL", 14, 18], ["olanzapine", "CHEMICAL", 75, 85], ["rotenone", "CHEMICAL", 94, 102], ["olanzapine", "CHEMICAL", 186, 196], ["rotenone", "CHEMICAL", 205, 213], ["3-MA", "SIMPLE_CHEMICAL", 14, 18], ["olanzapine", "SIMPLE_CHEMICAL", 75, 85], ["rotenone", "SIMPLE_CHEMICAL", 94, 102], ["olanzapine", "SIMPLE_CHEMICAL", 186, 196], ["rotenone", "SIMPLE_CHEMICAL", 205, 213], ["PC12 cells", "CELL", 232, 242], ["PC12 cells", "CELL_LINE", 232, 242], ["olanzapine", "TREATMENT", 75, 85], ["rotenone", "TREATMENT", 94, 102], ["this study", "TEST", 127, 137], ["olanzapine", "TREATMENT", 186, 196], ["rotenone", "TREATMENT", 205, 213], ["induced injury in PC12 cells", "PROBLEM", 214, 242], ["repolarization effect", "OBSERVATION", 50, 71], ["injury", "OBSERVATION", 222, 228], ["PC12 cells", "OBSERVATION", 232, 242]]], ["The arrowheads indicated the presence of autophagic vacuoles.", [["autophagic vacuoles", "ANATOMY", 41, 60], ["autophagic vacuoles", "CELLULAR_COMPONENT", 41, 60], ["autophagic vacuoles", "PROBLEM", 41, 60], ["autophagic vacuoles", "OBSERVATION", 41, 60]]], ["At higher magnification, autophagosomes containing lysosomes were found in cells treated with Ola (iii-v). e PC12 cells were treated with 3-MA (1 mM) before Ola treatment, LC3 and p62 levels were evaluated by immunoblotting assay (P < 0.001 vs. control; # P < 0.05, ### P < 0.001 compared with the Ola group) effect of olanzapine was evidenced by increased cell viability, decreased cell apoptosis, and downregulation of cleaved PARP.", [["autophagosomes", "ANATOMY", 25, 39], ["lysosomes", "ANATOMY", 51, 60], ["cells", "ANATOMY", 75, 80], ["PC12 cells", "ANATOMY", 109, 119], ["cell", "ANATOMY", 357, 361], ["cell", "ANATOMY", 383, 387], ["3-MA", "CHEMICAL", 138, 142], ["olanzapine", "CHEMICAL", 319, 329], ["Ola (iii-v)", "CHEMICAL", 94, 105], ["3-MA", "CHEMICAL", 138, 142], ["olanzapine", "CHEMICAL", 319, 329], ["autophagosomes", "CELLULAR_COMPONENT", 25, 39], ["lysosomes", "CELLULAR_COMPONENT", 51, 60], ["cells", "CELL", 75, 80], ["PC12 cells", "CELL", 109, 119], ["3-MA", "SIMPLE_CHEMICAL", 138, 142], ["LC3", "GENE_OR_GENE_PRODUCT", 172, 175], ["p62", "GENE_OR_GENE_PRODUCT", 180, 183], ["olanzapine", "SIMPLE_CHEMICAL", 319, 329], ["cell", "CELL", 357, 361], ["cell", "CELL", 383, 387], ["PARP", "GENE_OR_GENE_PRODUCT", 429, 433], ["PC12 cells", "CELL_LINE", 109, 119], ["LC3", "PROTEIN", 172, 175], ["p62", "PROTEIN", 180, 183], ["cleaved PARP", "PROTEIN", 421, 433], ["autophagosomes containing lysosomes", "PROBLEM", 25, 60], ["e PC12 cells", "TREATMENT", 107, 119], ["Ola treatment", "TREATMENT", 157, 170], ["LC3", "TEST", 172, 175], ["p62 levels", "TEST", 180, 190], ["immunoblotting assay", "TEST", 209, 229], ["P", "TEST", 231, 232], ["P", "TEST", 256, 257], ["olanzapine", "TREATMENT", 319, 329], ["increased cell viability", "PROBLEM", 347, 371], ["decreased cell apoptosis", "PROBLEM", 373, 397], ["downregulation of cleaved PARP", "PROBLEM", 403, 433], ["PC12 cells", "OBSERVATION", 109, 119], ["increased cell viability", "OBSERVATION", 347, 371], ["decreased cell apoptosis", "OBSERVATION", 373, 397]]], ["We found that the phosphorylation levels of Thr172 in the active site of the AMPK catalytic subunit (p-AMPK) were increased in a dose-and time-dependent manner after olanzapine treatment (Fig. 1) .", [["olanzapine", "CHEMICAL", 166, 176], ["Thr172", "CHEMICAL", 44, 50], ["olanzapine", "CHEMICAL", 166, 176], ["Thr172", "GENE_OR_GENE_PRODUCT", 44, 50], ["AMPK catalytic subunit", "GENE_OR_GENE_PRODUCT", 77, 99], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 101, 107], ["olanzapine", "SIMPLE_CHEMICAL", 166, 176], ["Thr172", "PROTEIN", 44, 50], ["AMPK catalytic subunit", "PROTEIN", 77, 99], ["p-AMPK", "PROTEIN", 101, 107], ["the phosphorylation levels", "TEST", 14, 40], ["the AMPK catalytic subunit (p-AMPK)", "TREATMENT", 73, 108], ["olanzapine treatment", "TREATMENT", 166, 186]]], ["These results were consistent with previous reports that olanzapine activates AMPK [8, 9] .DISCUSSIONPrevious studies have suggested that AMPK directly inactivates mTORC1 by phosphorylating Raptor [23] and indirectly by phosphorylating TSC2 [24, 25] , ultimately resulting in the induction of autophagy.", [["olanzapine", "CHEMICAL", 57, 67], ["olanzapine", "CHEMICAL", 57, 67], ["olanzapine", "SIMPLE_CHEMICAL", 57, 67], ["AMPK", "GENE_OR_GENE_PRODUCT", 78, 82], ["AMPK", "GENE_OR_GENE_PRODUCT", 138, 142], ["mTORC1", "GENE_OR_GENE_PRODUCT", 164, 170], ["Raptor [23]", "GENE_OR_GENE_PRODUCT", 190, 201], ["TSC2", "GENE_OR_GENE_PRODUCT", 236, 240], ["AMPK", "PROTEIN", 78, 82], ["AMPK", "PROTEIN", 138, 142], ["mTORC1", "PROTEIN", 164, 170], ["TSC2", "PROTEIN", 236, 240], ["olanzapine activates AMPK", "TREATMENT", 57, 82], ["DISCUSSIONPrevious studies", "TEST", 91, 117], ["consistent with", "UNCERTAINTY", 19, 34]]], ["In addition, a recent study indicated that AMPK initiates autophagy by phosphorylating ULK1 [26, 27] .", [["AMPK", "GENE_OR_GENE_PRODUCT", 43, 47], ["ULK1", "GENE_OR_GENE_PRODUCT", 87, 91], ["AMPK", "PROTEIN", 43, 47], ["ULK1", "PROTEIN", 87, 91], ["a recent study", "TEST", 13, 27], ["phosphorylating ULK1", "TEST", 71, 91]]], ["Activated AMPK can induce autophagy in different ways.", [["AMPK", "GENE_OR_GENE_PRODUCT", 10, 14], ["AMPK", "PROTEIN", 10, 14], ["Activated AMPK", "TREATMENT", 0, 14]]], ["In this study, we confirmed that olanzapine-induced autophagy in PC12 cells in a dose-and time-dependent manner.", [["PC12 cells", "ANATOMY", 65, 75], ["olanzapine", "CHEMICAL", 33, 43], ["olanzapine", "CHEMICAL", 33, 43], ["olanzapine", "SIMPLE_CHEMICAL", 33, 43], ["PC12 cells", "CELL", 65, 75], ["PC12 cells", "CELL_LINE", 65, 75], ["this study", "TEST", 3, 13], ["olanzapine", "TREATMENT", 33, 43], ["PC12 cells", "TREATMENT", 65, 75], ["PC12 cells", "OBSERVATION", 65, 75]]], ["Moreover, the finding that AMPK decreased the protein level of p70-S6K (Fig. 2) , a downstream target of mTOR, suggests that AMPK initiated autophagy via the inactivation of mTOR kinase signaling.", [["AMPK", "GENE_OR_GENE_PRODUCT", 27, 31], ["p70-S6K", "GENE_OR_GENE_PRODUCT", 63, 70], ["Fig. 2", "GENE_OR_GENE_PRODUCT", 72, 78], ["mTOR", "GENE_OR_GENE_PRODUCT", 105, 109], ["AMPK", "GENE_OR_GENE_PRODUCT", 125, 129], ["mTOR kinase", "GENE_OR_GENE_PRODUCT", 174, 185], ["AMPK", "PROTEIN", 27, 31], ["p70", "PROTEIN", 63, 66], ["S6K", "PROTEIN", 67, 70], ["Fig. 2", "PROTEIN", 72, 78], ["mTOR", "PROTEIN", 105, 109], ["AMPK", "PROTEIN", 125, 129], ["mTOR kinase", "PROTEIN", 174, 185], ["AMPK", "TEST", 27, 31], ["the protein level", "TEST", 42, 59], ["mTOR kinase signaling", "PROBLEM", 174, 195]]], ["In addition, upon pretreatment with the AMPK inhibitor compound C, the effect on autophagy induction was blocked (Fig. 4) , while 3-MA pretreatment had no effect on p-AMPK levels (data not shown), indicating that olanzapine initiated autophagy by activating AMPK.DISCUSSIONAMPK is a well-known cellular energy sensor that is also involved in many other metabolic functions and can be affected by many drugs, such as olanzapine.", [["cellular", "ANATOMY", 294, 302], ["compound C", "CHEMICAL", 55, 65], ["3-MA", "CHEMICAL", 130, 134], ["olanzapine", "CHEMICAL", 213, 223], ["olanzapine", "CHEMICAL", 416, 426], ["3-MA", "CHEMICAL", 130, 134], ["olanzapine", "CHEMICAL", 213, 223], ["olanzapine", "CHEMICAL", 416, 426], ["AMPK", "GENE_OR_GENE_PRODUCT", 40, 44], ["compound C", "SIMPLE_CHEMICAL", 55, 65], ["3-MA", "SIMPLE_CHEMICAL", 130, 134], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 165, 171], ["olanzapine", "SIMPLE_CHEMICAL", 213, 223], ["AMPK", "GENE_OR_GENE_PRODUCT", 258, 262], ["cellular", "CELL", 294, 302], ["olanzapine", "SIMPLE_CHEMICAL", 416, 426], ["AMPK", "PROTEIN", 40, 44], ["AMPK", "PROTEIN", 167, 171], ["AMPK", "PROTEIN", 258, 262], ["the AMPK inhibitor", "TREATMENT", 36, 54], ["autophagy induction", "TREATMENT", 81, 100], ["p-AMPK levels", "TEST", 165, 178], ["olanzapine", "TREATMENT", 213, 223], ["olanzapine", "TREATMENT", 416, 426]]], ["Studies have reported that AMPK is activated by the antipsychotic drug olanzapine in acute settings, and research has shown that olanzapine antagonizes several receptors, including histaminergic, muscarinic, serotonergic, dopaminergic, and adrenergic receptors.", [["olanzapine", "CHEMICAL", 71, 81], ["olanzapine", "CHEMICAL", 129, 139], ["olanzapine", "CHEMICAL", 71, 81], ["olanzapine", "CHEMICAL", 129, 139], ["AMPK", "GENE_OR_GENE_PRODUCT", 27, 31], ["olanzapine", "SIMPLE_CHEMICAL", 71, 81], ["olanzapine", "SIMPLE_CHEMICAL", 129, 139], ["adrenergic receptors", "GENE_OR_GENE_PRODUCT", 240, 260], ["AMPK", "PROTEIN", 27, 31], ["serotonergic, dopaminergic, and adrenergic receptors", "PROTEIN", 208, 260], ["the antipsychotic drug olanzapine", "TREATMENT", 48, 81], ["olanzapine antagonizes", "TREATMENT", 129, 151], ["histaminergic", "TREATMENT", 181, 194], ["muscarinic", "TREATMENT", 196, 206], ["serotonergic", "TREATMENT", 208, 220], ["dopaminergic", "TREATMENT", 222, 234], ["adrenergic receptors", "TREATMENT", 240, 260]]], ["Studies have shown that olanzapine significantly upregulates the mRNA and protein expression of the H1 receptor and that olanzapine-induced AMPK activation may be at least partially related to the antagonistic effect of olanzapine on the H1 receptor.", [["olanzapine", "CHEMICAL", 24, 34], ["olanzapine", "CHEMICAL", 121, 131], ["olanzapine", "CHEMICAL", 220, 230], ["olanzapine", "CHEMICAL", 24, 34], ["olanzapine", "CHEMICAL", 121, 131], ["olanzapine", "CHEMICAL", 220, 230], ["olanzapine", "SIMPLE_CHEMICAL", 24, 34], ["H1 receptor", "GENE_OR_GENE_PRODUCT", 100, 111], ["olanzapine", "SIMPLE_CHEMICAL", 121, 131], ["AMPK", "GENE_OR_GENE_PRODUCT", 140, 144], ["olanzapine", "SIMPLE_CHEMICAL", 220, 230], ["H1 receptor", "GENE_OR_GENE_PRODUCT", 238, 249], ["H1 receptor", "PROTEIN", 100, 111], ["AMPK", "PROTEIN", 140, 144], ["H1 receptor", "PROTEIN", 238, 249], ["Studies", "TEST", 0, 7], ["olanzapine", "TREATMENT", 24, 34], ["the H1 receptor", "TREATMENT", 96, 111], ["olanzapine", "TREATMENT", 121, 131], ["AMPK activation", "PROBLEM", 140, 155], ["olanzapine", "TREATMENT", 220, 230], ["the H1 receptor", "TREATMENT", 234, 249]]], ["These results suggest that olanzapine activates AMPK by antagonizing histamine H1 receptors, dopamine D2 receptors, and \u03b11-adrenoceptors [28] [29] [30] [31] [32] .", [["olanzapine", "CHEMICAL", 27, 37], ["histamine", "CHEMICAL", 69, 78], ["dopamine", "CHEMICAL", 93, 101], ["olanzapine", "CHEMICAL", 27, 37], ["histamine", "CHEMICAL", 69, 78], ["dopamine", "CHEMICAL", 93, 101], ["olanzapine", "SIMPLE_CHEMICAL", 27, 37], ["AMPK", "GENE_OR_GENE_PRODUCT", 48, 52], ["histamine H1 receptors", "GENE_OR_GENE_PRODUCT", 69, 91], ["dopamine D2 receptors", "GENE_OR_GENE_PRODUCT", 93, 114], ["\u03b11-adrenoceptors [28] [29] [30] [31] [32]", "SIMPLE_CHEMICAL", 120, 161], ["AMPK", "PROTEIN", 48, 52], ["histamine H1 receptors", "PROTEIN", 69, 91], ["dopamine D2 receptors", "PROTEIN", 93, 114], ["\u03b11", "PROTEIN", 120, 122], ["olanzapine activates AMPK", "TREATMENT", 27, 52], ["antagonizing histamine H1 receptors", "TREATMENT", 56, 91], ["dopamine D2 receptors", "TREATMENT", 93, 114]]], ["It should be noted that our results showed that olanzapine activated the AMPK pathway and that AMPK inhibition diminished the neuroprotective effects of olanzapine, suggesting that AMPK activation was involved in neuroprotection by olanzapine.", [["olanzapine", "CHEMICAL", 48, 58], ["olanzapine", "CHEMICAL", 153, 163], ["olanzapine", "CHEMICAL", 232, 242], ["olanzapine", "CHEMICAL", 48, 58], ["olanzapine", "CHEMICAL", 153, 163], ["olanzapine", "CHEMICAL", 232, 242], ["olanzapine", "SIMPLE_CHEMICAL", 48, 58], ["AMPK", "GENE_OR_GENE_PRODUCT", 73, 77], ["AMPK", "GENE_OR_GENE_PRODUCT", 95, 99], ["olanzapine", "SIMPLE_CHEMICAL", 153, 163], ["AMPK", "GENE_OR_GENE_PRODUCT", 181, 185], ["olanzapine", "SIMPLE_CHEMICAL", 232, 242], ["AMPK", "PROTEIN", 73, 77], ["AMPK", "PROTEIN", 95, 99], ["AMPK", "PROTEIN", 181, 185], ["olanzapine", "TREATMENT", 48, 58], ["the AMPK pathway", "TREATMENT", 69, 85], ["AMPK inhibition", "PROBLEM", 95, 110], ["olanzapine", "TREATMENT", 153, 163], ["AMPK activation", "PROBLEM", 181, 196], ["olanzapine", "TREATMENT", 232, 242]]], ["As mentioned above, AMPK activation is required for the induction of autophagy.", [["AMPK", "GENE_OR_GENE_PRODUCT", 20, 24], ["AMPK", "PROTEIN", 20, 24], ["AMPK activation", "TREATMENT", 20, 35], ["the induction of autophagy", "TREATMENT", 52, 78]]], ["As AMPK inhibition blocked autophagy induction, we speculate that autophagy is involved in the neuroprotective effects of olanzapine.", [["olanzapine", "CHEMICAL", 122, 132], ["olanzapine", "CHEMICAL", 122, 132], ["AMPK", "GENE_OR_GENE_PRODUCT", 3, 7], ["olanzapine", "SIMPLE_CHEMICAL", 122, 132], ["AMPK", "PROTEIN", 3, 7], ["AMPK inhibition", "TREATMENT", 3, 18], ["autophagy induction", "TREATMENT", 27, 46], ["olanzapine", "TREATMENT", 122, 132]]], ["However, this protective effect was diminished by the AMPK inhibitor compound C, suggesting that AMPK activation is a prerequisite for the neuroprotective effects of olanzapine.DISCUSSIONAutophagy is regarded as a survival mechanism that occurs under stress conditions to promote cell survival induced by various stimuli.", [["cell", "ANATOMY", 280, 284], ["compound C", "CHEMICAL", 69, 79], ["olanzapine", "CHEMICAL", 166, 176], ["olanzapine", "CHEMICAL", 166, 176], ["AMPK", "GENE_OR_GENE_PRODUCT", 54, 58], ["compound C", "SIMPLE_CHEMICAL", 69, 79], ["AMPK", "GENE_OR_GENE_PRODUCT", 97, 101], ["olanzapine", "SIMPLE_CHEMICAL", 166, 176], ["cell", "CELL", 280, 284], ["AMPK", "PROTEIN", 54, 58], ["AMPK", "PROTEIN", 97, 101], ["AMPK activation", "PROBLEM", 97, 112], ["olanzapine", "TREATMENT", 166, 176], ["AMPK activation", "OBSERVATION", 97, 112]]], ["The activation of autophagy may play a cell protective role through a variety of intracellular events, including the elimination of dysfunctional mitochondria and other damaged proteins.", [["cell", "ANATOMY", 39, 43], ["intracellular", "ANATOMY", 81, 94], ["mitochondria", "ANATOMY", 146, 158], ["cell", "CELL", 39, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["mitochondria", "CELLULAR_COMPONENT", 146, 158], ["damaged proteins", "PROTEIN", 169, 185], ["a cell protective role", "TREATMENT", 37, 59], ["intracellular events", "PROBLEM", 81, 101], ["dysfunctional mitochondria", "PROBLEM", 132, 158], ["other damaged proteins", "PROBLEM", 163, 185]]], ["Mitochondrial dysfunction not only leads to the Fig. 3 Ola alleviated the rotenone-induced cell death and apoptosis. a Cells were pretreated with 20 \u00b5M Ola for 24 h, exposed to rotenone for another 24 h, then subjected to Hoechst 33258 staining, and b TUNEL staining. c Quantitative analysis of morphological changes in different groups. d CCK-8 assay. e \u25b3\u03a8m analysis using JC-1 (P < 0.001 vs. control; # P < 0.05 compared with the Rot group)DISCUSSIONbreakdown of biological energy that directly damages neurons but also leads to the excessive generation of reactive oxygen species, resulting in oxidative stress, which further destroys the cellular functions of mitochondria.", [["Mitochondrial", "ANATOMY", 0, 13], ["cell", "ANATOMY", 91, 95], ["Cells", "ANATOMY", 119, 124], ["neurons", "ANATOMY", 505, 512], ["cellular", "ANATOMY", 642, 650], ["mitochondria", "ANATOMY", 664, 676], ["Mitochondrial dysfunction", "DISEASE", 0, 25], ["rotenone", "CHEMICAL", 74, 82], ["death", "DISEASE", 96, 101], ["rotenone", "CHEMICAL", 177, 185], ["Hoechst 33258", "CHEMICAL", 222, 235], ["oxygen", "CHEMICAL", 568, 574], ["rotenone", "CHEMICAL", 74, 82], ["rotenone", "CHEMICAL", 177, 185], ["Hoechst 33258", "CHEMICAL", 222, 235], ["oxygen", "CHEMICAL", 568, 574], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["rotenone", "SIMPLE_CHEMICAL", 74, 82], ["cell", "CELL", 91, 95], ["Cells", "CELL", 119, 124], ["rotenone", "SIMPLE_CHEMICAL", 177, 185], ["Hoechst 33258", "SIMPLE_CHEMICAL", 222, 235], ["CCK-8", "GENE_OR_GENE_PRODUCT", 340, 345], ["JC-1", "GENE_OR_GENE_PRODUCT", 374, 378], ["neurons", "CELL", 505, 512], ["reactive oxygen species", "SIMPLE_CHEMICAL", 559, 582], ["cellular", "CELL", 642, 650], ["mitochondria", "CELLULAR_COMPONENT", 664, 676], ["Mitochondrial dysfunction", "PROBLEM", 0, 25], ["the rotenone-induced cell death", "PROBLEM", 70, 101], ["apoptosis", "PROBLEM", 106, 115], ["rotenone", "TREATMENT", 177, 185], ["b TUNEL staining", "PROBLEM", 250, 266], ["Quantitative analysis", "TEST", 270, 291], ["morphological changes in different groups", "PROBLEM", 295, 336], ["d CCK", "TEST", 338, 343], ["JC", "TEST", 374, 376], ["biological energy", "PROBLEM", 465, 482], ["directly damages neurons", "PROBLEM", 488, 512], ["reactive oxygen species", "PROBLEM", 559, 582], ["oxidative stress", "PROBLEM", 597, 613], ["dysfunction", "OBSERVATION", 14, 25], ["rotenone", "OBSERVATION_MODIFIER", 74, 82], ["-induced", "OBSERVATION_MODIFIER", 82, 90], ["cell death", "OBSERVATION", 91, 101], ["apoptosis", "OBSERVATION_MODIFIER", 106, 115], ["TUNEL staining", "OBSERVATION", 252, 266], ["morphological changes", "OBSERVATION", 295, 316], ["reactive", "OBSERVATION_MODIFIER", 559, 567], ["oxygen species", "OBSERVATION", 568, 582], ["oxidative stress", "OBSERVATION", 597, 613]]], ["Thus, the timely removal of dysfunctional mitochondria can protect cells from environmental toxicity.", [["mitochondria", "ANATOMY", 42, 54], ["cells", "ANATOMY", 67, 72], ["toxicity", "DISEASE", 92, 100], ["mitochondria", "CELLULAR_COMPONENT", 42, 54], ["cells", "CELL", 67, 72], ["the timely removal", "TREATMENT", 6, 24], ["dysfunctional mitochondria", "PROBLEM", 28, 54], ["environmental toxicity", "PROBLEM", 78, 100]]], ["Many studies have shown that mitochondria appear to be the target of many environmental toxins, such as rotenone, which is a specific inhibitor of mitochondrial complex I. Many studies have shown that mitochondria are targets of many environmental toxins, such as rotenone [33] .", [["mitochondria", "ANATOMY", 29, 41], ["mitochondrial", "ANATOMY", 147, 160], ["mitochondria", "ANATOMY", 201, 213], ["rotenone", "CHEMICAL", 104, 112], ["rotenone", "CHEMICAL", 264, 272], ["rotenone", "CHEMICAL", 104, 112], ["rotenone", "CHEMICAL", 264, 272], ["mitochondria", "CELLULAR_COMPONENT", 29, 41], ["rotenone", "SIMPLE_CHEMICAL", 104, 112], ["mitochondrial", "CELLULAR_COMPONENT", 147, 160], ["mitochondria", "CELLULAR_COMPONENT", 201, 213], ["rotenone", "SIMPLE_CHEMICAL", 264, 272], ["Many studies", "TEST", 0, 12], ["mitochondria", "PROBLEM", 29, 41], ["many environmental toxins", "PROBLEM", 69, 94], ["rotenone", "TREATMENT", 104, 112], ["many environmental toxins", "PROBLEM", 229, 254]]], ["The inhibition of mitochondrial complex I may lead to respiratory depression and increased cellular oxidative stress.", [["mitochondrial", "ANATOMY", 18, 31], ["respiratory", "ANATOMY", 54, 65], ["cellular", "ANATOMY", 91, 99], ["respiratory depression", "DISEASE", 54, 76], ["mitochondrial", "CELLULAR_COMPONENT", 18, 31], ["complex I", "GENE_OR_GENE_PRODUCT", 32, 41], ["cellular", "CELL", 91, 99], ["mitochondrial complex I", "PROTEIN", 18, 41], ["respiratory depression", "PROBLEM", 54, 76], ["increased cellular oxidative stress", "PROBLEM", 81, 116], ["mitochondrial complex", "OBSERVATION", 18, 39], ["may lead to", "UNCERTAINTY", 42, 53], ["respiratory depression", "OBSERVATION", 54, 76], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["cellular oxidative stress", "OBSERVATION", 91, 116]]], ["Therefore, the activation of autophagy by olanzapine may be beneficial for the clearance of damaged mitochondria and thereby contribute to mitochondrial function Fig. 4 Ola alleviated the rotenone-induced apoptosis and mitochondrial damage. a Total cell lysates were subjected to Western blot analysis to determine the protein levels of Bcl-2, cleaved PARP, and Bax. b Western blot analysis was used to determine the protein levels of Pink 1, Parkin, and Cyt-c. c Representative images of cells treated with rotenone (0.5 \u00b5M, 24 h) with or without olanzapine pretreatment loaded with MitoTracker and LysoTracker dye (100 nM and 50 nM respectively; P < 0.001 vs. control; # P < 0.05 compared with the Rot group) Fig. 5 The neuroprotective effect of Ola was mediated by p-AMPK activation.", [["mitochondria", "ANATOMY", 100, 112], ["mitochondrial", "ANATOMY", 139, 152], ["mitochondrial", "ANATOMY", 219, 232], ["Total cell lysates", "ANATOMY", 243, 261], ["cells", "ANATOMY", 489, 494], ["olanzapine", "CHEMICAL", 42, 52], ["rotenone", "CHEMICAL", 188, 196], ["mitochondrial damage", "DISEASE", 219, 239], ["rotenone", "CHEMICAL", 508, 516], ["olanzapine", "CHEMICAL", 548, 558], ["LysoTracker dye", "CHEMICAL", 600, 615], ["Ola", "CHEMICAL", 748, 751], ["olanzapine", "CHEMICAL", 42, 52], ["rotenone", "CHEMICAL", 188, 196], ["rotenone", "CHEMICAL", 508, 516], ["olanzapine", "CHEMICAL", 548, 558], ["Rot", "CHEMICAL", 700, 703], ["olanzapine", "SIMPLE_CHEMICAL", 42, 52], ["mitochondria", "CELLULAR_COMPONENT", 100, 112], ["mitochondrial", "CELLULAR_COMPONENT", 139, 152], ["rotenone", "SIMPLE_CHEMICAL", 188, 196], ["mitochondrial", "CELLULAR_COMPONENT", 219, 232], ["cell lysates", "ORGANISM_SUBSTANCE", 249, 261], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 337, 342], ["PARP", "GENE_OR_GENE_PRODUCT", 352, 356], ["Bax", "GENE_OR_GENE_PRODUCT", 362, 365], ["Pink 1", "GENE_OR_GENE_PRODUCT", 435, 441], ["Parkin", "GENE_OR_GENE_PRODUCT", 443, 449], ["Cyt-c. c", "GENE_OR_GENE_PRODUCT", 455, 463], ["cells", "CELL", 489, 494], ["rotenone", "SIMPLE_CHEMICAL", 508, 516], ["olanzapine", "SIMPLE_CHEMICAL", 548, 558], ["MitoTracker", "SIMPLE_CHEMICAL", 584, 595], ["LysoTracker dye", "SIMPLE_CHEMICAL", 600, 615], ["Ola", "ORGANISM", 748, 751], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 768, 774], ["Bcl-2", "PROTEIN", 337, 342], ["cleaved PARP", "PROTEIN", 344, 356], ["Bax", "PROTEIN", 362, 365], ["Pink 1", "PROTEIN", 435, 441], ["Parkin", "PROTEIN", 443, 449], ["Cyt", "PROTEIN", 455, 458], ["AMPK", "PROTEIN", 770, 774], ["autophagy", "TREATMENT", 29, 38], ["olanzapine", "TREATMENT", 42, 52], ["damaged mitochondria", "PROBLEM", 92, 112], ["mitochondrial function Fig", "PROBLEM", 139, 165], ["the rotenone-induced apoptosis", "PROBLEM", 184, 214], ["mitochondrial damage", "PROBLEM", 219, 239], ["a Total cell lysates", "TEST", 241, 261], ["blot analysis", "TEST", 288, 301], ["the protein levels", "TEST", 315, 333], ["Bcl", "TEST", 337, 340], ["PARP", "TEST", 352, 356], ["Bax", "TREATMENT", 362, 365], ["b Western blot analysis", "TEST", 367, 390], ["the protein levels", "TEST", 413, 431], ["Pink", "TEST", 435, 439], ["Parkin", "TEST", 443, 449], ["Cyt", "TEST", 455, 458], ["rotenone", "TREATMENT", 508, 516], ["olanzapine pretreatment", "TREATMENT", 548, 571], ["MitoTracker", "TREATMENT", 584, 595], ["LysoTracker dye", "TREATMENT", 600, 615], ["the Rot group)", "TREATMENT", 696, 710], ["rotenone", "OBSERVATION", 188, 196], ["-induced", "OBSERVATION_MODIFIER", 196, 204], ["apoptosis", "OBSERVATION", 205, 214], ["mitochondrial damage", "OBSERVATION", 219, 239], ["Cyt", "ANATOMY", 455, 458]]], ["PC12 cells were pretreated with compound C (2.5 \u00b5M) for 3 h followed by the addition of Ola, p-AMPK, LC3, and p62 levels were evaluated by immunoblotting assay (P < 0.05, **P < 0.01 compared with control; # P < 0.05 compared with the Rot group; & P < 0.05 compared with the Rot + Ola group)", [["PC12 cells", "ANATOMY", 0, 10], ["compound C", "CHEMICAL", 32, 42], ["PC12 cells", "CELL", 0, 10], ["compound C", "SIMPLE_CHEMICAL", 32, 42], ["p-AMPK", "GENE_OR_GENE_PRODUCT", 93, 99], ["LC3", "GENE_OR_GENE_PRODUCT", 101, 104], ["p62", "GENE_OR_GENE_PRODUCT", 110, 113], ["PC12 cells", "CELL_LINE", 0, 10], ["AMPK", "PROTEIN", 95, 99], ["LC3", "PROTEIN", 101, 104], ["p62", "PROTEIN", 110, 113], ["PC12 cells", "PROBLEM", 0, 10], ["LC3", "TEST", 101, 104], ["p62 levels", "TEST", 110, 120], ["immunoblotting assay", "TEST", 139, 159], ["P", "TEST", 161, 162], ["P", "TEST", 173, 174], ["P", "TEST", 207, 208]]]], "fbeea449dcb9dd2140b6b740ce03bbfa8b5baf15": [["INTRODUCTIONThe current pandemic of corona virus disease-2019 (COVID-19) caused by severe acute respiratory syndrome corona virus-2 (SARS CoV-2) led to complete lockdown in many countries contributing to major socio-economic crisis and irreparable recession, globally.", [["corona virus disease", "DISEASE", 36, 56], ["COVID-19", "CHEMICAL", 63, 71], ["acute respiratory syndrome", "DISEASE", 90, 116], ["corona virus", "ORGANISM", 36, 48], ["severe acute respiratory syndrome corona virus-2", "ORGANISM", 83, 131], ["corona virus", "SPECIES", 117, 129], ["corona virus disease-2019 (COVID-19", "SPECIES", 36, 71], ["severe acute respiratory syndrome corona virus-2", "SPECIES", 83, 131], ["corona virus disease", "PROBLEM", 36, 56], ["COVID", "TEST", 63, 68], ["severe acute respiratory syndrome corona virus", "PROBLEM", 83, 129], ["SARS CoV", "TEST", 133, 141], ["economic crisis", "PROBLEM", 216, 231], ["irreparable recession", "PROBLEM", 236, 257], ["corona virus disease", "OBSERVATION", 36, 56], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116], ["economic crisis", "OBSERVATION", 216, 231], ["irreparable recession", "OBSERVATION", 236, 257]]], ["SARS CoV-2, a novel \u03b2 CoV was first identified in adults presenting with acute lower respiratory tract infection of unexplained etiology in China.", [["lower respiratory tract", "ANATOMY", 79, 102], ["respiratory tract infection", "DISEASE", 85, 112], ["\u03b2 CoV", "ORGANISM", 20, 25], ["tract", "ORGANISM_SUBDIVISION", 97, 102], ["\u03b2 CoV", "PROTEIN", 20, 25], ["SARS CoV", "SPECIES", 0, 8], ["\u03b2 CoV", "SPECIES", 20, 25], ["SARS CoV", "TEST", 0, 8], ["a novel \u03b2 CoV", "PROBLEM", 12, 25], ["acute lower respiratory tract infection", "PROBLEM", 73, 112], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["lower", "ANATOMY_MODIFIER", 79, 84], ["respiratory tract", "ANATOMY", 85, 102], ["infection", "OBSERVATION", 103, 112]]], ["[1] Though no age group is spared, severe forms occur in patients older than 60 years specifically with co-morbidities.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["co-morbidities", "PROBLEM", 104, 118], ["no", "UNCERTAINTY", 11, 13], ["severe", "OBSERVATION_MODIFIER", 35, 41]]], ["The majority of the infected individuals are asymptomatic or with mild form of disease and are potential transmitters.", [["individuals", "ORGANISM", 29, 40], ["the infected individuals", "PROBLEM", 16, 40], ["asymptomatic", "PROBLEM", 45, 57], ["disease", "PROBLEM", 79, 86], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["infected", "OBSERVATION", 20, 28], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["disease", "OBSERVATION", 79, 86]]], ["This disease is highly contagious and mainly spread through respiratory droplets, close contact with infected cases or materials (fomites) and nosocomially to other patients and health care workers in the hospitals.", [["respiratory droplets", "ANATOMY", 60, 80], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["This disease", "PROBLEM", 0, 12], ["respiratory droplets", "PROBLEM", 60, 80], ["disease", "OBSERVATION", 5, 12], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["contagious", "OBSERVATION_MODIFIER", 23, 33], ["respiratory droplets", "OBSERVATION", 60, 80]]], ["[2, 3] COVID-19 has a much lower case fatality ratio and significantly greater transmission rate than 2003 SARS pandemic.", [["SARS", "DISEASE", 107, 111], ["COVID", "TEST", 7, 12]]], ["[4, 5] Currently RT-PCR of upper and lower respiratory swabs or samples is the gold standard diagnostic test.", [["lower respiratory swabs", "ANATOMY", 37, 60], ["samples", "ANATOMY", 64, 71], ["upper", "ORGANISM_SUBDIVISION", 27, 32], ["RT-PCR", "TEST", 17, 23], ["upper and lower respiratory swabs", "PROBLEM", 27, 60], ["upper", "ANATOMY_MODIFIER", 27, 32], ["lower", "ANATOMY_MODIFIER", 37, 42], ["respiratory swabs", "ANATOMY", 43, 60]]], ["Serological tests based on antibody detection, though not helpful during the early phases of disease, can be used to confirm infection in later phase.", [["infection", "DISEASE", 125, 134], ["Serological tests", "TEST", 0, 17], ["antibody detection", "TEST", 27, 45], ["disease", "PROBLEM", 93, 100], ["infection", "PROBLEM", 125, 134], ["disease", "OBSERVATION", 93, 100], ["infection", "OBSERVATION", 125, 134]]], ["A thorough literature search (PubMed, preprint servers and google scholar) using terms COVID-19 and pathology/pathogenesis, SARS CoV-2 and pathology/pathogenesis and 2019-nCoV and pathology/pathogenesis was done to maximize the yield of literature, which ended on 24 May 2020.", [["SARS", "DISEASE", 124, 128], ["COVID", "TEST", 87, 92], ["pathology", "TEST", 100, 109], ["pathogenesis", "PROBLEM", 110, 122], ["SARS CoV", "TEST", 124, 132], ["pathology", "TEST", 139, 148], ["pathogenesis", "TEST", 149, 161], ["pathology", "TEST", 180, 189], ["pathogenesis", "PROBLEM", 190, 202]]], ["In this review, we have comprehensively discussed all aspects of COVID-19 with special emphasis on the pathology including pathogenesis and therapeutic targets.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "CELL", 65, 73], ["COVID", "TEST", 65, 70], ["the pathology", "TEST", 99, 112], ["pathogenesis", "PROBLEM", 123, 135]]], ["It forms a ready resource for clinicians, pathologists, and researchers including epidemiologists aiding them in the diagnosis and treatment of these patients, and may also pave way to further research.2.EPIDEMIOLOGYThe earliest case of SARS CoV-2 infection currently known was reported on 31st2.EPIDEMIOLOGYDecember 2019 in Wuhan, Hubei province of China.", [["SARS CoV-2 infection", "DISEASE", 237, 257], ["patients", "ORGANISM", 150, 158], ["SARS CoV-2", "ORGANISM", 237, 247], ["patients", "SPECIES", 150, 158], ["CoV-2", "SPECIES", 242, 247], ["SARS CoV-2", "SPECIES", 237, 247], ["SARS CoV", "PROBLEM", 237, 245], ["2 infection", "PROBLEM", 246, 257]]], ["[1] After this it spread rapidly to other parts of China as well as internationally affecting over 185 countries as of 23 April 2020, leading to the current global pandemic.", [["pandemic", "OBSERVATION", 164, 172]]], ["[2] The World Health Organization declared COVID-19 to be a Public Health Emergency of International Concern on 30 January 2020, and recognized it as a pandemic on 11 March 2020.[6,7] As of 24 May 2020, globally 5.48 million cases of COVID- 19 have been reported, resulting in 346,071 deaths and 2,290,776 people have recovered.", [["deaths", "DISEASE", 285, 291], ["people", "ORGANISM", 306, 312], ["people", "SPECIES", 306, 312], ["COVID", "TEST", 234, 239]]], ["[8] J o u r n a l P r e -p r o o f2.EPIDEMIOLOGYThe basic reproduction number (R0) of the SARS CoV-2 is estimated to be between 1.4 and 3.9, indicating its highly contagious nature.", [["SARS", "DISEASE", 90, 94], ["f2", "DNA", 33, 35], ["SARS CoV", "SPECIES", 90, 98], ["f2", "PROBLEM", 33, 35], ["the SARS CoV", "TEST", 86, 98], ["highly", "OBSERVATION_MODIFIER", 156, 162], ["contagious", "OBSERVATION", 163, 173]]], ["[9, 10] The R0 may be even higher in places of public gatherings like in cruise ships, religious/political/academic/business congregations as well as in hospitals non-compliant with personal protective measures.", [["personal protective measures", "TREATMENT", 182, 210], ["may be", "UNCERTAINTY", 15, 21], ["higher", "OBSERVATION_MODIFIER", 27, 33]]], ["[9, 10, 11] The incubation period and serial interval is estimated at 5-6 days and 8 days, respectively, which is similar to that for SARS CoV and MERS CoV.", [["SARS", "DISEASE", 134, 138], ["SARS CoV", "SPECIES", 134, 142], ["serial interval", "TEST", 38, 53], ["SARS CoV", "PROBLEM", 134, 142]]], ["[9, 12, 13, 14] Early in the pandemic, the case-fatality rate (CFR) was estimated to be between 0.9% and 3%, [15, 16] lower than other HCoVs (SARS CoV (6%-17%) and MERS CoV (20%-40%)).", [["SARS", "DISEASE", 142, 146], ["SARS CoV", "SPECIES", 142, 150], ["fatality rate", "TEST", 48, 61], ["CFR", "TEST", 63, 66], ["other HCoVs", "TEST", 129, 140], ["SARS CoV", "TEST", 142, 150], ["MERS CoV", "TEST", 164, 172]]], ["[17, 18, 19] However, by the 24 th of May 2020 many countries exhibited exponential rise in CFR.2.EPIDEMIOLOGY[8] (Table:I)Routes of transmissionUnlike SARS CoV, the high percentage of SARS CoV-2 infected individuals manifest as asymptomatic or pauci-symptomatic infection who escape detection and become potential transmitters.", [["SARS", "DISEASE", 185, 189], ["infection", "DISEASE", 263, 272], ["SARS CoV", "ORGANISM", 152, 160], ["SARS", "ORGANISM", 185, 189], ["CoV-2", "ORGANISM", 190, 195], ["individuals", "ORGANISM", 205, 216], ["CoV-", "SPECIES", 190, 194], ["SARS CoV", "SPECIES", 152, 160], ["SARS CoV-2", "SPECIES", 185, 195], ["exponential rise in CFR", "PROBLEM", 72, 95], ["SARS CoV", "PROBLEM", 152, 160], ["SARS CoV", "PROBLEM", 185, 193], ["asymptomatic", "PROBLEM", 229, 241], ["pauci-symptomatic infection", "PROBLEM", 245, 272], ["escape detection", "TEST", 277, 293], ["exponential", "OBSERVATION_MODIFIER", 72, 83], ["rise", "OBSERVATION_MODIFIER", 84, 88], ["SARS CoV", "OBSERVATION", 152, 160], ["high", "OBSERVATION_MODIFIER", 166, 170], ["percentage", "OBSERVATION_MODIFIER", 171, 181], ["pauci-symptomatic", "OBSERVATION_MODIFIER", 245, 262], ["infection", "OBSERVATION", 263, 272]]], ["[20, 21] It is important to note that, not all close contacts are infected suggesting a role for individual genetic susceptibility.", [["individual genetic susceptibility", "PROBLEM", 97, 130]]], ["[22, 23, 24] In humans, the virus usually gains entry through upper aero-digestive tract.", [["upper aero-digestive tract", "ANATOMY", 62, 88], ["humans", "ORGANISM", 16, 22], ["upper", "ORGANISM_SUBDIVISION", 62, 67], ["aero-digestive tract", "ORGANISM_SUBDIVISION", 68, 88], ["humans", "SPECIES", 16, 22], ["humans", "SPECIES", 16, 22], ["the virus", "PROBLEM", 24, 33], ["virus", "OBSERVATION", 28, 33], ["upper", "ANATOMY_MODIFIER", 62, 67], ["aero-digestive tract", "ANATOMY", 68, 88]]], ["More recently SARS CoV-2 was isolated from the feces of patients, indicating the possibility of fecal-oral spread.", [["feces", "ANATOMY", 47, 52], ["fecal", "ANATOMY", 96, 101], ["oral", "ANATOMY", 102, 106], ["fecal-oral spread", "DISEASE", 96, 113], ["SARS CoV-2", "ORGANISM", 14, 24], ["feces", "ORGANISM_SUBDIVISION", 47, 52], ["patients", "ORGANISM", 56, 64], ["fecal", "ORGANISM_SUBDIVISION", 96, 101], ["oral", "ORGANISM_SUBDIVISION", 102, 106], ["patients", "SPECIES", 56, 64], ["SARS CoV-2", "SPECIES", 14, 24], ["SARS CoV", "TEST", 14, 22], ["fecal-oral spread", "PROBLEM", 96, 113], ["indicating the possibility of", "UNCERTAINTY", 66, 95], ["fecal", "ANATOMY", 96, 101], ["oral", "ANATOMY", 102, 106], ["spread", "OBSERVATION", 107, 113]]], ["[24, 25] Furthermore, SARS CoV-2 infection in pregnant women raised a possibility of vertical transmission.", [["infection", "DISEASE", 33, 42], ["CoV-2", "ORGANISM", 27, 32], ["women", "ORGANISM", 55, 60], ["women", "SPECIES", 55, 60], ["SARS CoV", "SPECIES", 22, 30], ["SARS CoV-2 infection", "PROBLEM", 22, 42], ["vertical transmission", "PROBLEM", 85, 106], ["infection", "OBSERVATION", 33, 42]]], ["[26] However, the vertical transmission was ruled out based on negative testing for the virus on the swabs collected from the amniotic fluid, cord blood, neonatal throat and breast milk of the six infected pregnant women.", [["swabs", "ANATOMY", 101, 106], ["amniotic fluid", "ANATOMY", 126, 140], ["cord blood", "ANATOMY", 142, 152], ["throat", "ANATOMY", 163, 169], ["breast milk", "ANATOMY", 174, 185], ["amniotic fluid", "ORGANISM_SUBSTANCE", 126, 140], ["cord blood", "ORGANISM_SUBSTANCE", 142, 152], ["throat", "ORGANISM_SUBDIVISION", 163, 169], ["breast milk", "ORGANISM_SUBSTANCE", 174, 185], ["women", "ORGANISM", 215, 220], ["women", "SPECIES", 215, 220], ["the vertical transmission", "TEST", 14, 39], ["the virus", "PROBLEM", 84, 93], ["the swabs", "TEST", 97, 106], ["the amniotic fluid", "TEST", 122, 140], ["cord blood", "TEST", 142, 152], ["neonatal throat", "PROBLEM", 154, 169], ["amniotic fluid", "OBSERVATION", 126, 140], ["cord", "ANATOMY", 142, 146], ["throat", "ANATOMY", 163, 169], ["breast", "ANATOMY", 174, 180]]], ["[26] The long range airborne transmission is also speculated which depends on flow dynamics of the virus from the infected person and also on ventilation status of the area.", [["person", "SPECIES", 123, 129], ["The long range airborne transmission", "PROBLEM", 5, 41], ["the virus", "PROBLEM", 95, 104], ["infected", "OBSERVATION", 114, 122]]], ["[27] Moreover, the expansion and spread of COVID-19 can be visualized by mapping techniques like cartograms.", [["COVID-19", "CHEMICAL", 43, 51], ["COVID-19", "DNA", 43, 51], ["the expansion", "TEST", 15, 28], ["COVID", "TEST", 43, 48], ["expansion", "OBSERVATION_MODIFIER", 19, 28], ["spread", "OBSERVATION_MODIFIER", 33, 39]]], ["[28] The understanding of modes of transmission of SARS CoV-2 will enable application of appropriate containment measures.SusceptibilityThough there is generalized susceptibility to SARS CoV-2 infection for all age groups, body defense against infection as well as their underlying age related organ system compromise.", [["body", "ANATOMY", 223, 227], ["organ system", "ANATOMY", 294, 306], ["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 193, 202], ["infection", "DISEASE", 244, 253], ["CoV-2", "ORGANISM", 187, 192], ["body", "ORGANISM_SUBDIVISION", 223, 227], ["organ", "ORGAN", 294, 299], ["CoV-", "SPECIES", 187, 191], ["SARS CoV", "SPECIES", 51, 59], ["SARS CoV-2", "SPECIES", 182, 192], ["SARS CoV", "PROBLEM", 51, 59], ["appropriate containment measures", "TREATMENT", 89, 121], ["generalized susceptibility", "PROBLEM", 152, 178], ["SARS CoV", "PROBLEM", 182, 190], ["2 infection", "PROBLEM", 191, 202], ["infection", "PROBLEM", 244, 253], ["organ system compromise", "PROBLEM", 294, 317], ["generalized", "OBSERVATION_MODIFIER", 152, 163], ["susceptibility", "OBSERVATION", 164, 178], ["infection", "OBSERVATION", 193, 202], ["infection", "OBSERVATION", 244, 253]]], ["[22, 31, 32, 33] Similar to SARS CoV, a recent study reported non-O blood group specifically group A had higher infection and death rates due to COVID-19 owing to absence of protective anti-A IgM antibodies.", [["blood", "ANATOMY", 68, 73], ["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 112, 121], ["death", "DISEASE", 126, 131], ["SARS CoV", "ORGANISM", 28, 36], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["anti-A IgM antibodies", "GENE_OR_GENE_PRODUCT", 185, 206], ["protective anti-A IgM antibodies", "PROTEIN", 174, 206], ["SARS CoV", "SPECIES", 28, 36], ["SARS CoV", "TEST", 28, 36], ["a recent study", "TEST", 38, 52], ["higher infection", "PROBLEM", 105, 121], ["death rates", "PROBLEM", 126, 137], ["COVID", "TEST", 145, 150], ["A IgM antibodies", "TEST", 190, 206], ["higher", "OBSERVATION_MODIFIER", 105, 111], ["infection", "OBSERVATION", 112, 121]]], ["[34, 35] Many uncertainities still persist in the SARS CoV-2 epidemiology especially virus-host interaction including host susceptibility and the evolution of epidemic.3.VIROLOGYThe corona viruses (CoVs) are classified into \u03b1 and \u03b2 (seen in mammals including humans); \u03b3 and \u03b4 (seen in avian species). [ to pangolin CoV with a difference of only one amino acid.", [["SARS", "DISEASE", 50, 54], ["amino acid", "CHEMICAL", 349, 359], ["amino acid", "CHEMICAL", 349, 359], ["CoV-2", "ORGANISM", 55, 60], ["corona viruses", "ORGANISM", 182, 196], ["CoVs", "GENE_OR_GENE_PRODUCT", 198, 202], ["\u03b1", "GENE_OR_GENE_PRODUCT", 224, 225], ["\u03b2", "GENE_OR_GENE_PRODUCT", 230, 231], ["humans", "ORGANISM", 259, 265], ["\u03b3", "GENE_OR_GENE_PRODUCT", 268, 269], ["\u03b4", "GENE_OR_GENE_PRODUCT", 274, 275], ["pangolin CoV", "ORGANISM", 306, 318], ["amino acid", "AMINO_ACID", 349, 359], ["\u03b1 and \u03b2", "PROTEIN", 224, 231], ["pangolin CoV", "PROTEIN", 306, 318], ["humans", "SPECIES", 259, 265], ["SARS CoV", "SPECIES", 50, 58], ["humans", "SPECIES", 259, 265], ["the SARS CoV", "PROBLEM", 46, 58], ["host susceptibility", "PROBLEM", 118, 137], ["epidemic", "PROBLEM", 159, 167], ["one amino acid", "TREATMENT", 345, 359], ["host susceptibility", "OBSERVATION_MODIFIER", 118, 137], ["epidemic", "OBSERVATION_MODIFIER", 159, 167], ["corona", "OBSERVATION_MODIFIER", 182, 188], ["viruses", "OBSERVATION", 189, 196]]], ["[46] Recently another study suggested pangolin involvement in SARS CoV-2 origin due to evidence of re-assortment in CoVs.", [["pangolin", "GENE_OR_GENE_PRODUCT", 38, 46], ["CoV-2", "ORGANISM", 67, 72], ["CoVs", "SIMPLE_CHEMICAL", 116, 120], ["CoVs", "DNA", 116, 120], ["another study", "TEST", 14, 27], ["pangolin involvement", "PROBLEM", 38, 58], ["SARS CoV", "PROBLEM", 62, 70], ["re-assortment in CoVs", "PROBLEM", 99, 120], ["CoVs", "OBSERVATION", 116, 120]]], ["[47] SARS CoV-2 differs from other \u03b2 CoVs by the presence of unique polybasic cleavage site that contributes to increased pathogenicity and transmissibility.", [["\u03b2 CoVs", "GENE_OR_GENE_PRODUCT", 35, 41], ["\u03b2 CoVs", "PROTEIN", 35, 41], ["polybasic cleavage site", "PROTEIN", 68, 91], ["SARS CoV", "TEST", 5, 13], ["other \u03b2 CoVs", "PROBLEM", 29, 41], ["unique polybasic cleavage site", "PROBLEM", 61, 91], ["increased pathogenicity and transmissibility", "PROBLEM", 112, 156], ["polybasic cleavage", "OBSERVATION", 68, 86], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["pathogenicity", "OBSERVATION", 122, 135]]], ["[48] Each virion is a enveloped, non-segmented, positive sense single stranded RNA virusPATHOGENESISThe SARS CoV-2 because of its similarity with SARS CoV is presumed to infect human cells through its densely glycosylated spike (S) proteins S1 fraction with receptor binding domain (RBD) which binds to the angiotensin-converting enzyme 2 receptor (ACE-2 R) with 10 to 20 fold higher affinity than SARS CoV. [ [56, 57] After the virus gets attached to this receptor, the SARS CoV-2 with its unique polybasic S1/S2 protease cleavage site with SPRR insertion on the spike protein which is recognized and cleaved by transmembrane protease serine (TMPRSSs) expressed on host cells to expose the fusion protein (S2 fraction) that enables the fusion of both viral and the host cell J o u r n a l P r e -p r o o f membrane.", [["cells", "ANATOMY", 183, 188], ["cells", "ANATOMY", 671, 676], ["cell", "ANATOMY", 771, 775], ["membrane", "ANATOMY", 807, 815], ["SARS", "DISEASE", 146, 150], ["angiotensin", "CHEMICAL", 307, 318], ["SARS", "DISEASE", 398, 402], ["serine", "CHEMICAL", 636, 642], ["SARS CoV", "ORGANISM", 146, 154], ["human", "ORGANISM", 177, 182], ["cells", "CELL", 183, 188], ["angiotensin-converting enzyme 2 receptor", "GENE_OR_GENE_PRODUCT", 307, 347], ["ACE-2 R", "GENE_OR_GENE_PRODUCT", 349, 356], ["CoV-2", "GENE_OR_GENE_PRODUCT", 476, 481], ["serine", "AMINO_ACID", 636, 642], ["TMPRSSs", "GENE_OR_GENE_PRODUCT", 644, 651], ["host cells", "CELL", 666, 676], ["S2", "GENE_OR_GENE_PRODUCT", 707, 709], ["membrane", "CELLULAR_COMPONENT", 807, 815], ["human cells", "CELL_TYPE", 177, 188], ["densely glycosylated spike (S) proteins", "PROTEIN", 201, 240], ["S1", "PROTEIN", 241, 243], ["receptor binding domain", "PROTEIN", 258, 281], ["RBD", "PROTEIN", 283, 286], ["angiotensin-converting enzyme 2 receptor", "PROTEIN", 307, 347], ["ACE-2 R", "PROTEIN", 349, 356], ["SARS CoV-2", "PROTEIN", 471, 481], ["polybasic S1/S2 protease cleavage site", "PROTEIN", 498, 536], ["SPRR", "PROTEIN", 542, 546], ["spike protein", "PROTEIN", 564, 577], ["transmembrane protease serine", "PROTEIN", 613, 642], ["TMPRSSs", "PROTEIN", 644, 651], ["host cells", "CELL_TYPE", 666, 676], ["fusion protein", "PROTEIN", 691, 705], ["S2 fraction", "PROTEIN", 707, 718], ["human", "SPECIES", 177, 182], ["SARS CoV", "SPECIES", 146, 154], ["human", "SPECIES", 177, 182], ["SARS CoV", "TEST", 104, 112], ["SARS CoV", "PROBLEM", 146, 154], ["infect human cells", "PROBLEM", 170, 188], ["its densely glycosylated spike (S) proteins S1 fraction", "PROBLEM", 197, 252], ["receptor binding domain (RBD)", "PROBLEM", 258, 287], ["the angiotensin", "TEST", 303, 318], ["enzyme", "TEST", 330, 336], ["ACE", "TEST", 349, 352], ["SARS CoV.", "TEST", 398, 407], ["the virus", "PROBLEM", 425, 434], ["the SARS CoV", "TEST", 467, 479], ["its unique polybasic S1/S2 protease cleavage site", "TREATMENT", 487, 536], ["SPRR insertion", "TREATMENT", 542, 556], ["the spike protein", "PROBLEM", 560, 577], ["transmembrane protease serine (TMPRSSs)", "TREATMENT", 613, 652], ["host cells", "TREATMENT", 666, 676], ["the fusion protein (S2 fraction", "TREATMENT", 687, 718], ["the fusion", "TREATMENT", 733, 743], ["membrane", "PROBLEM", 807, 815], ["presumed to", "UNCERTAINTY", 158, 169], ["host cell", "OBSERVATION", 766, 775], ["f membrane", "ANATOMY_MODIFIER", 805, 815]]], ["[56] It has been demonstrated that ACE-2 R and TMPRSSs are highly co-expressed in alveolar type 2 pneumocytes, epithelium of upper esophagus and absorptive enterocytes, forming the basis of speculation that the SARS CoV-2 can gain access into host through esophageal and intestinal epithelium apart from alveolar epithelium.", [["alveolar type 2 pneumocytes", "ANATOMY", 82, 109], ["epithelium", "ANATOMY", 111, 121], ["upper esophagus", "ANATOMY", 125, 140], ["absorptive enterocytes", "ANATOMY", 145, 167], ["esophageal", "ANATOMY", 256, 266], ["intestinal epithelium", "ANATOMY", 271, 292], ["alveolar epithelium", "ANATOMY", 304, 323], ["SARS", "DISEASE", 211, 215], ["ACE-2 R", "GENE_OR_GENE_PRODUCT", 35, 42], ["TMPRSSs", "GENE_OR_GENE_PRODUCT", 47, 54], ["alveolar type 2 pneumocytes", "CELL", 82, 109], ["epithelium", "TISSUE", 111, 121], ["upper esophagus", "ORGAN", 125, 140], ["absorptive enterocytes", "TISSUE", 145, 167], ["CoV-2", "GENE_OR_GENE_PRODUCT", 216, 221], ["esophageal", "MULTI-TISSUE_STRUCTURE", 256, 266], ["intestinal epithelium", "TISSUE", 271, 292], ["alveolar epithelium", "TISSUE", 304, 323], ["ACE-2 R", "PROTEIN", 35, 42], ["TMPRSSs", "PROTEIN", 47, 54], ["alveolar type 2 pneumocytes", "CELL_TYPE", 82, 109], ["absorptive enterocytes", "CELL_TYPE", 145, 167], ["SARS CoV", "SPECIES", 211, 219], ["ACE", "TEST", 35, 38], ["TMPRSSs", "TEST", 47, 54], ["epithelium of upper esophagus", "PROBLEM", 111, 140], ["absorptive enterocytes", "PROBLEM", 145, 167], ["the SARS CoV", "PROBLEM", 207, 219], ["alveolar epithelium", "PROBLEM", 304, 323], ["alveolar", "ANATOMY_MODIFIER", 82, 90], ["pneumocytes", "OBSERVATION", 98, 109], ["epithelium", "ANATOMY_MODIFIER", 111, 121], ["upper", "ANATOMY_MODIFIER", 125, 130], ["esophagus", "ANATOMY", 131, 140], ["absorptive enterocytes", "OBSERVATION", 145, 167], ["esophageal", "ANATOMY", 256, 266], ["intestinal epithelium", "ANATOMY", 271, 292], ["alveolar epithelium", "OBSERVATION", 304, 323]]], ["Hence, the potential target tissues for SARS CoV-2 should co-express ACE-2 R and TMPRSSs.5.PATHOLOGYThe current understanding of pathology stems from few case reports and autopsy case studies.", [["tissues", "ANATOMY", 28, 35], ["tissues", "TISSUE", 28, 35], ["CoV-2", "GENE_OR_GENE_PRODUCT", 45, 50], ["ACE-2 R", "GENE_OR_GENE_PRODUCT", 69, 76], ["TMPRSSs", "GENE_OR_GENE_PRODUCT", 81, 88], ["ACE-2 R and TMPRSSs", "PROTEIN", 69, 88], ["SARS CoV", "SPECIES", 40, 48], ["SARS CoV", "TEST", 40, 48], ["ACE", "TEST", 69, 72], ["TMPRSSs", "TREATMENT", 81, 88], ["autopsy case studies", "TEST", 171, 191]]], ["The gross features include heavy and boggy lungs, patchy consolidation along with pleural fibrinous exudate and /or fibrosis, sometimes with purulent inflammation due to secondary bacterial infection with/without evidence of pericarditis.", [["lungs", "ANATOMY", 43, 48], ["pleural fibrinous exudate", "ANATOMY", 82, 107], ["pleural fibrinous exudate", "DISEASE", 82, 107], ["fibrosis", "DISEASE", 116, 124], ["inflammation", "DISEASE", 150, 162], ["bacterial infection", "DISEASE", 180, 199], ["pericarditis", "DISEASE", 225, 237], ["lungs", "ORGAN", 43, 48], ["heavy and boggy lungs", "PROBLEM", 27, 48], ["patchy consolidation", "PROBLEM", 50, 70], ["pleural fibrinous exudate", "PROBLEM", 82, 107], ["fibrosis", "PROBLEM", 116, 124], ["purulent inflammation", "PROBLEM", 141, 162], ["secondary bacterial infection", "PROBLEM", 170, 199], ["pericarditis", "PROBLEM", 225, 237], ["gross", "OBSERVATION_MODIFIER", 4, 9], ["heavy", "OBSERVATION_MODIFIER", 27, 32], ["boggy", "OBSERVATION_MODIFIER", 37, 42], ["lungs", "ANATOMY", 43, 48], ["patchy", "OBSERVATION_MODIFIER", 50, 56], ["consolidation", "OBSERVATION", 57, 70], ["pleural", "ANATOMY", 82, 89], ["fibrinous", "OBSERVATION_MODIFIER", 90, 99], ["exudate", "OBSERVATION", 100, 107], ["fibrosis", "OBSERVATION", 116, 124], ["purulent", "OBSERVATION_MODIFIER", 141, 149], ["inflammation", "OBSERVATION", 150, 162], ["secondary", "OBSERVATION_MODIFIER", 170, 179], ["bacterial", "OBSERVATION_MODIFIER", 180, 189], ["infection", "OBSERVATION", 190, 199], ["without evidence of", "UNCERTAINTY", 205, 224], ["pericarditis", "OBSERVATION", 225, 237]]], ["[62] The microscopic features depend on stage and severity of the disease.", [["The microscopic features", "TEST", 5, 29], ["the disease", "PROBLEM", 62, 73], ["disease", "OBSERVATION", 66, 73]]], ["Early stages (asymptomatic/mildly symptomatic patients) show non-specific changes including pulmonary J o u r n a l P r e -p r o o f edema, focal pneumocyte hyperplasia, focal chronic inflammatory infiltrate and multinucleated giant cells with absence of prominent hyaline membrane formation.", [["pulmonary", "ANATOMY", 92, 101], ["focal pneumocyte hyperplasia", "ANATOMY", 140, 168], ["multinucleated giant cells", "ANATOMY", 212, 238], ["hyaline membrane", "ANATOMY", 265, 281], ["edema", "DISEASE", 133, 138], ["hyperplasia", "DISEASE", 157, 168], ["patients", "ORGANISM", 46, 54], ["edema", "PATHOLOGICAL_FORMATION", 133, 138], ["multinucleated giant cells", "CELL", 212, 238], ["hyaline membrane", "CELLULAR_COMPONENT", 265, 281], ["multinucleated giant cells", "CELL_TYPE", 212, 238], ["patients", "SPECIES", 46, 54], ["Early stages (asymptomatic/mildly symptomatic patients)", "PROBLEM", 0, 55], ["non-specific changes", "PROBLEM", 61, 81], ["edema", "PROBLEM", 133, 138], ["focal pneumocyte hyperplasia", "PROBLEM", 140, 168], ["focal chronic inflammatory infiltrate", "PROBLEM", 170, 207], ["multinucleated giant cells", "PROBLEM", 212, 238], ["prominent hyaline membrane formation", "PROBLEM", 255, 291], ["mildly", "OBSERVATION_MODIFIER", 27, 33], ["symptomatic", "OBSERVATION_MODIFIER", 34, 45], ["non-specific", "OBSERVATION_MODIFIER", 61, 73], ["pulmonary", "ANATOMY", 92, 101], ["edema", "OBSERVATION", 133, 138], ["focal", "OBSERVATION_MODIFIER", 140, 145], ["pneumocyte hyperplasia", "OBSERVATION", 146, 168], ["focal", "OBSERVATION_MODIFIER", 170, 175], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["inflammatory", "OBSERVATION_MODIFIER", 184, 196], ["infiltrate", "OBSERVATION", 197, 207], ["multinucleated", "OBSERVATION_MODIFIER", 212, 226], ["giant cells", "OBSERVATION", 227, 238], ["prominent", "OBSERVATION_MODIFIER", 255, 264], ["hyaline membrane formation", "OBSERVATION", 265, 291]]], ["[63] As, the disease progress there is diffuse alveolar damage with transparent hyaline membrane formation and severe pulmonary edema.", [["alveolar", "ANATOMY", 47, 55], ["hyaline membrane", "ANATOMY", 80, 96], ["pulmonary", "ANATOMY", 118, 127], ["alveolar damage", "DISEASE", 47, 62], ["pulmonary edema", "DISEASE", 118, 133], ["[63] As", "CHEMICAL", 0, 7], ["alveolar", "TISSUE", 47, 55], ["hyaline membrane", "TISSUE", 80, 96], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 118, 133], ["diffuse alveolar damage", "PROBLEM", 39, 62], ["transparent hyaline membrane formation", "PROBLEM", 68, 106], ["severe pulmonary edema", "PROBLEM", 111, 133], ["diffuse", "OBSERVATION_MODIFIER", 39, 46], ["alveolar damage", "OBSERVATION", 47, 62], ["transparent", "OBSERVATION_MODIFIER", 68, 79], ["hyaline membrane formation", "OBSERVATION", 80, 106], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["pulmonary", "ANATOMY", 118, 127], ["edema", "OBSERVATION", 128, 133]]], ["However, in SARS CoV-2, there is firbomyxoid exudates with visible fibrinous cords along with mucous plugging of bronchioles which has a bearing with respect to oxygen therapy.", [["firbomyxoid exudates", "ANATOMY", 33, 53], ["fibrinous cords", "ANATOMY", 67, 82], ["mucous", "ANATOMY", 94, 100], ["bronchioles", "ANATOMY", 113, 124], ["oxygen", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 161, 167], ["fibrinous cords", "PATHOLOGICAL_FORMATION", 67, 82], ["mucous", "TISSUE", 94, 100], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 113, 124], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["SARS CoV", "SPECIES", 12, 20], ["SARS CoV", "TEST", 12, 20], ["firbomyxoid exudates", "PROBLEM", 33, 53], ["visible fibrinous cords", "PROBLEM", 59, 82], ["mucous plugging of bronchioles", "PROBLEM", 94, 124], ["oxygen therapy", "TREATMENT", 161, 175], ["firbomyxoid", "ANATOMY", 33, 44], ["exudates", "OBSERVATION", 45, 53], ["visible", "OBSERVATION_MODIFIER", 59, 66], ["fibrinous cords", "OBSERVATION", 67, 82], ["mucous plugging", "OBSERVATION", 94, 109], ["bronchioles", "ANATOMY", 113, 124], ["oxygen therapy", "OBSERVATION", 161, 175]]], ["There is also widespread interstitial inflammatory infiltrates with severe epithelial damage,diffuse type II pneumocyte hyperplasia consistent with ARDS.", [["interstitial", "ANATOMY", 25, 37], ["epithelial", "ANATOMY", 75, 85], ["epithelial damage", "DISEASE", 75, 92], ["hyperplasia", "DISEASE", 120, 131], ["ARDS", "DISEASE", 148, 152], ["interstitial inflammatory infiltrates", "PATHOLOGICAL_FORMATION", 25, 62], ["epithelial", "TISSUE", 75, 85], ["widespread interstitial inflammatory infiltrates", "PROBLEM", 14, 62], ["severe epithelial damage", "PROBLEM", 68, 92], ["diffuse type II pneumocyte hyperplasia", "PROBLEM", 93, 131], ["ARDS", "PROBLEM", 148, 152], ["widespread", "OBSERVATION_MODIFIER", 14, 24], ["interstitial", "ANATOMY_MODIFIER", 25, 37], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50], ["infiltrates", "OBSERVATION", 51, 62], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["epithelial damage", "OBSERVATION", 75, 92], ["diffuse", "OBSERVATION_MODIFIER", 93, 100], ["type II", "OBSERVATION_MODIFIER", 101, 108], ["pneumocyte hyperplasia", "OBSERVATION", 109, 131], ["consistent with", "UNCERTAINTY", 132, 147], ["ARDS", "OBSERVATION", 148, 152]]], ["[64, 65, 66, 67, 68] One study reported massive pulmonary interstitial fibrosis with variable degree of hemorrhagic necrosis, chronic inflammation with multinucleate giant cells and intracytoplasmic viral inclusion bodies in severe cases.", [["pulmonary interstitial", "ANATOMY", 48, 70], ["multinucleate giant cells", "ANATOMY", 152, 177], ["fibrosis", "DISEASE", 71, 79], ["hemorrhagic", "DISEASE", 104, 115], ["necrosis", "DISEASE", 116, 124], ["inflammation", "DISEASE", 134, 146], ["pulmonary interstitial", "PATHOLOGICAL_FORMATION", 48, 70], ["multinucleate giant cells", "CELL", 152, 177], ["intracytoplasmic", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 198], ["multinucleate giant cells", "CELL_TYPE", 152, 177], ["One study", "TEST", 21, 30], ["massive pulmonary interstitial fibrosis", "PROBLEM", 40, 79], ["hemorrhagic necrosis", "PROBLEM", 104, 124], ["chronic inflammation", "PROBLEM", 126, 146], ["multinucleate giant cells", "PROBLEM", 152, 177], ["intracytoplasmic viral inclusion bodies in severe cases", "PROBLEM", 182, 237], ["massive", "OBSERVATION_MODIFIER", 40, 47], ["pulmonary", "ANATOMY", 48, 57], ["interstitial", "ANATOMY_MODIFIER", 58, 70], ["fibrosis", "OBSERVATION", 71, 79], ["variable", "OBSERVATION_MODIFIER", 85, 93], ["degree", "OBSERVATION_MODIFIER", 94, 100], ["hemorrhagic", "OBSERVATION_MODIFIER", 104, 115], ["necrosis", "OBSERVATION", 116, 124], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["inflammation", "OBSERVATION", 134, 146], ["multinucleate", "OBSERVATION_MODIFIER", 152, 165], ["giant cells", "OBSERVATION", 166, 177], ["intracytoplasmic", "OBSERVATION_MODIFIER", 182, 198], ["viral inclusion bodies", "OBSERVATION", 199, 221], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["cases", "OBSERVATION", 232, 237]]], ["[69] Interestingly, another study showed features of lymphocytic viral pneumonia in a patient who died early in the disease (5th day after development of symptoms), whereas five other patients who succumbed later (20th day after development of symptoms) exhibited acute fibrinous and organizing pneumonia (AFOP)5.PATHOLOGYshowing extensive fibrinous deposits forming balls/mounds but not hyaline membrane in their alveoli.", [["fibrinous", "ANATOMY", 270, 279], ["hyaline membrane", "ANATOMY", 388, 404], ["alveoli", "ANATOMY", 414, 421], ["viral pneumonia", "DISEASE", 65, 80], ["pneumonia", "DISEASE", 295, 304], ["AFOP", "DISEASE", 306, 310], ["patient", "ORGANISM", 86, 93], ["patients", "ORGANISM", 184, 192], ["fibrinous deposits", "PATHOLOGICAL_FORMATION", 340, 358], ["hyaline membrane", "CELLULAR_COMPONENT", 388, 404], ["alveoli", "MULTI-TISSUE_STRUCTURE", 414, 421], ["patient", "SPECIES", 86, 93], ["patients", "SPECIES", 184, 192], ["another study", "TEST", 20, 33], ["lymphocytic viral pneumonia", "PROBLEM", 53, 80], ["symptoms", "PROBLEM", 154, 162], ["symptoms", "PROBLEM", 244, 252], ["acute fibrinous and organizing pneumonia", "PROBLEM", 264, 304], ["extensive fibrinous deposits forming balls/mounds", "PROBLEM", 330, 379], ["hyaline membrane in their alveoli", "PROBLEM", 388, 421], ["lymphocytic", "OBSERVATION_MODIFIER", 53, 64], ["viral", "OBSERVATION_MODIFIER", 65, 70], ["pneumonia", "OBSERVATION", 71, 80], ["acute", "OBSERVATION_MODIFIER", 264, 269], ["fibrinous", "OBSERVATION", 270, 279], ["organizing", "OBSERVATION_MODIFIER", 284, 294], ["pneumonia", "OBSERVATION", 295, 304], ["extensive", "OBSERVATION_MODIFIER", 330, 339], ["fibrinous deposits", "OBSERVATION", 340, 358], ["forming balls", "OBSERVATION", 359, 372], ["not", "UNCERTAINTY", 384, 387], ["hyaline membrane", "OBSERVATION", 388, 404], ["alveoli", "ANATOMY", 414, 421]]], ["These patients also showed prominent vascular injury evidenced by endothelial cell detachment and prominent intracytoplasmic vacuolization in small and medium-sized pulmonary blood vessels.", [["vascular", "ANATOMY", 37, 45], ["endothelial cell", "ANATOMY", 66, 82], ["pulmonary blood vessels", "ANATOMY", 165, 188], ["vascular injury", "DISEASE", 37, 52], ["patients", "ORGANISM", 6, 14], ["vascular", "MULTI-TISSUE_STRUCTURE", 37, 45], ["endothelial cell", "CELL", 66, 82], ["intracytoplasmic vacuolization", "CELLULAR_COMPONENT", 108, 138], ["pulmonary blood vessels", "MULTI-TISSUE_STRUCTURE", 165, 188], ["patients", "SPECIES", 6, 14], ["prominent vascular injury", "PROBLEM", 27, 52], ["endothelial cell detachment", "PROBLEM", 66, 93], ["prominent intracytoplasmic vacuolization in small and medium-sized pulmonary blood vessels", "PROBLEM", 98, 188], ["prominent", "OBSERVATION_MODIFIER", 27, 36], ["vascular", "ANATOMY", 37, 45], ["injury", "OBSERVATION", 46, 52], ["endothelial cell detachment", "OBSERVATION", 66, 93], ["prominent", "OBSERVATION_MODIFIER", 98, 107], ["intracytoplasmic vacuolization", "OBSERVATION", 108, 138], ["small", "OBSERVATION_MODIFIER", 142, 147], ["medium", "OBSERVATION_MODIFIER", 152, 158], ["sized", "OBSERVATION_MODIFIER", 159, 164], ["pulmonary", "ANATOMY_MODIFIER", 165, 174], ["blood vessels", "ANATOMY", 175, 188]]], ["[70] Also, severe COVID-19 infection has been associated with a novel pulmonary-specific vasculopathy known as pulmonary intravascular coagulopathy (PIC), that parallels disease severity.", [["pulmonary", "ANATOMY", 70, 79], ["pulmonary intravascular", "ANATOMY", 111, 134], ["infection", "DISEASE", 27, 36], ["vasculopathy", "DISEASE", 89, 101], ["pulmonary intravascular coagulopathy", "DISEASE", 111, 147], ["PIC", "DISEASE", 149, 152], ["pulmonary", "ORGAN", 70, 79], ["pulmonary intravascular", "MULTI-TISSUE_STRUCTURE", 111, 134], ["COVID-19", "SPECIES", 18, 26], ["severe COVID-19 infection", "PROBLEM", 11, 36], ["a novel pulmonary-specific vasculopathy", "PROBLEM", 62, 101], ["pulmonary intravascular coagulopathy", "PROBLEM", 111, 147], ["parallels disease severity", "PROBLEM", 160, 186], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 27, 36], ["pulmonary", "ANATOMY", 70, 79], ["vasculopathy", "OBSERVATION", 89, 101], ["pulmonary", "ANATOMY", 111, 120], ["intravascular", "ANATOMY_MODIFIER", 121, 134], ["coagulopathy", "OBSERVATION", 135, 147], ["disease", "OBSERVATION_MODIFIER", 170, 177], ["severity", "OBSERVATION_MODIFIER", 178, 186]]], ["[71] These findings may be considered as important indicators of disease severity and prognosis.5.PATHOLOGYThe liver shows mild lobular lymphocytic infiltration and moderate micro-vesicular steatosis along with mild lobular activity, possibly related to the viral infection itself and ischemia.", [["liver", "ANATOMY", 111, 116], ["lobular lymphocytic", "ANATOMY", 128, 147], ["micro-vesicular", "ANATOMY", 174, 189], ["lobular", "ANATOMY", 216, 223], ["steatosis", "DISEASE", 190, 199], ["viral infection", "DISEASE", 258, 273], ["ischemia", "DISEASE", 285, 293], ["liver", "ORGAN", 111, 116], ["lobular lymphocytic", "PATHOLOGICAL_FORMATION", 128, 147], ["micro-vesicular steatosis", "PATHOLOGICAL_FORMATION", 174, 199], ["lobular", "CANCER", 216, 223], ["disease severity", "PROBLEM", 65, 81], ["mild lobular lymphocytic infiltration", "PROBLEM", 123, 160], ["moderate micro-vesicular steatosis", "PROBLEM", 165, 199], ["mild lobular activity", "PROBLEM", 211, 232], ["the viral infection itself", "PROBLEM", 254, 280], ["ischemia", "PROBLEM", 285, 293], ["may be considered", "UNCERTAINTY", 20, 37], ["liver", "ANATOMY", 111, 116], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["lobular", "OBSERVATION_MODIFIER", 128, 135], ["lymphocytic infiltration", "OBSERVATION", 136, 160], ["moderate", "OBSERVATION_MODIFIER", 165, 173], ["micro-vesicular", "OBSERVATION_MODIFIER", 174, 189], ["steatosis", "OBSERVATION", 190, 199], ["mild", "OBSERVATION_MODIFIER", 211, 215], ["lobular activity", "OBSERVATION", 216, 232], ["possibly related to", "UNCERTAINTY", 234, 253], ["viral", "OBSERVATION_MODIFIER", 258, 263], ["infection", "OBSERVATION", 264, 273], ["ischemia", "OBSERVATION", 285, 293]]], ["There were no obvious histological changes in heart tissue except for mild interstitial chronic mononuclear infiltrate.", [["heart tissue", "ANATOMY", 46, 58], ["interstitial chronic mononuclear infiltrate", "ANATOMY", 75, 118], ["interstitial chronic mononuclear infiltrate", "DISEASE", 75, 118], ["heart tissue", "TISSUE", 46, 58], ["obvious histological changes in heart tissue", "PROBLEM", 14, 58], ["mild interstitial chronic mononuclear infiltrate", "PROBLEM", 70, 118], ["no obvious", "UNCERTAINTY", 11, 21], ["histological", "OBSERVATION_MODIFIER", 22, 34], ["changes", "OBSERVATION", 35, 42], ["heart", "ANATOMY", 46, 51], ["tissue", "OBSERVATION", 52, 58], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["interstitial", "ANATOMY_MODIFIER", 75, 87], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["mononuclear", "OBSERVATION_MODIFIER", 96, 107], ["infiltrate", "OBSERVATION", 108, 118]]], ["[57, 64, 65] Hence the changes in the liver and heart are more likely secondary or related to the underlying diseases.", [["liver", "ANATOMY", 38, 43], ["heart", "ANATOMY", 48, 53], ["liver", "ORGAN", 38, 43], ["heart", "ORGAN", 48, 53], ["the changes in the liver and heart", "PROBLEM", 19, 53], ["the underlying diseases", "PROBLEM", 94, 117], ["liver", "ANATOMY", 38, 43], ["heart", "ANATOMY", 48, 53], ["more likely", "UNCERTAINTY", 58, 69], ["diseases", "OBSERVATION", 109, 117]]], ["[64] The pathology in other organs have not been elucidated.5.PATHOLOGYIt is too early to determine the specificity and consistency of these histopathological findings with respect to the stage and severity of the COVID-19 owing to the paucity of information obtained from few biopsy/autopsy case reports.", [["organs", "ANATOMY", 28, 34], ["organs", "ORGAN", 28, 34], ["The pathology", "TEST", 5, 18], ["the COVID", "TEST", 210, 219], ["organs", "ANATOMY", 28, 34]]], ["In addition, the histopathological features may be modified or altered by patients' immunity, presence of co-morbidities, secondary infections and therapy given to these patients especially steroids.", [["infections", "DISEASE", 132, 142], ["steroids", "CHEMICAL", 190, 198], ["steroids", "CHEMICAL", 190, 198], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 170, 178], ["steroids", "SIMPLE_CHEMICAL", 190, 198], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 170, 178], ["co-morbidities", "PROBLEM", 106, 120], ["secondary infections", "PROBLEM", 122, 142], ["therapy", "TREATMENT", 147, 154], ["steroids", "TREATMENT", 190, 198], ["infections", "OBSERVATION", 132, 142]]], ["Only few patients present with gastrointestinal symptoms like diarrhea (5.7%) and nausea/vomiting (6.1%).", [["gastrointestinal", "ANATOMY", 31, 47], ["gastrointestinal symptoms", "DISEASE", 31, 56], ["diarrhea", "DISEASE", 62, 70], ["nausea/vomiting", "DISEASE", 82, 97], ["patients", "ORGANISM", 9, 17], ["gastrointestinal", "ORGANISM_SUBDIVISION", 31, 47], ["patients", "SPECIES", 9, 17], ["gastrointestinal symptoms", "PROBLEM", 31, 56], ["diarrhea", "PROBLEM", 62, 70], ["nausea", "PROBLEM", 82, 88], ["vomiting", "PROBLEM", 89, 97], ["few", "OBSERVATION_MODIFIER", 5, 8], ["gastrointestinal", "ANATOMY", 31, 47], ["diarrhea", "OBSERVATION", 62, 70]]], ["[72] In 26.7% of COVID-19 patients there was at least one underlying co-morbidity(hypertension, diabetes, chronic cardiovascular/ pulmonary/ renal disease and cancer).", [["cardiovascular", "ANATOMY", 114, 128], ["pulmonary", "ANATOMY", 130, 139], ["renal", "ANATOMY", 141, 146], ["cancer", "ANATOMY", 159, 165], ["hypertension", "DISEASE", 82, 94], ["diabetes", "DISEASE", 96, 104], ["chronic cardiovascular/ pulmonary/ renal disease", "DISEASE", 106, 154], ["cancer", "DISEASE", 159, 165], ["patients", "ORGANISM", 26, 34], ["pulmonary", "ORGAN", 130, 139], ["renal", "ORGAN", 141, 146], ["cancer", "CANCER", 159, 165], ["patients", "SPECIES", 26, 34], ["COVID", "TEST", 17, 22], ["hypertension", "PROBLEM", 82, 94], ["diabetes", "PROBLEM", 96, 104], ["chronic cardiovascular/ pulmonary/ renal disease", "PROBLEM", 106, 154], ["cancer", "PROBLEM", 159, 165], ["co-morbidity", "OBSERVATION", 69, 81], ["hypertension", "OBSERVATION", 82, 94], ["diabetes", "OBSERVATION", 96, 104], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["cardiovascular", "ANATOMY", 114, 128], ["pulmonary", "ANATOMY", 130, 139], ["renal", "ANATOMY", 141, 146], ["disease", "OBSERVATION", 147, 154], ["cancer", "OBSERVATION", 159, 165]]], ["[72] The severe form is characterized by ARDS that necessitates mechanical ventilatory support in an intensive care unit (ICU), and also leads to multiorgan involvement resulting in shock, septicemia, and MODS with high mortality.", [["multiorgan", "ANATOMY", 146, 156], ["ARDS", "DISEASE", 41, 45], ["shock", "DISEASE", 182, 187], ["septicemia", "DISEASE", 189, 199], ["MODS", "DISEASE", 205, 209], ["ARDS", "PROBLEM", 41, 45], ["mechanical ventilatory support", "TREATMENT", 64, 94], ["multiorgan involvement", "PROBLEM", 146, 168], ["shock", "PROBLEM", 182, 187], ["septicemia", "PROBLEM", 189, 199], ["MODS", "PROBLEM", 205, 209], ["high mortality", "PROBLEM", 215, 229], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["ARDS", "OBSERVATION", 41, 45], ["mechanical ventilatory support", "OBSERVATION", 64, 94], ["shock", "OBSERVATION", 182, 187], ["septicemia", "OBSERVATION", 189, 199], ["MODS", "OBSERVATION", 205, 209], ["high", "OBSERVATION_MODIFIER", 215, 219]]], ["[73, 74] A substantial proportion of patients developed diarrhea during hospitalization, potentially aggravated by various drugs including antibiotics.", [["diarrhea", "DISEASE", 56, 64], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["diarrhea", "PROBLEM", 56, 64], ["various drugs", "TREATMENT", 115, 128], ["antibiotics", "TREATMENT", 139, 150], ["diarrhea", "OBSERVATION", 56, 64]]], ["[75] These patients may also present with cardiac sounding chest pain due to myocarditis and myocardial infarction.COVID-19 in childrenChildren are either asymptomatic or pauci-symptomatic (fever (50%), cough (38%), fatigue, rhinorrhoea or nasal congestion) and are less likely to have severe infections.", [["cardiac", "ANATOMY", 42, 49], ["chest", "ANATOMY", 59, 64], ["myocardial", "ANATOMY", 93, 103], ["nasal", "ANATOMY", 240, 245], ["cardiac sounding chest pain", "DISEASE", 42, 69], ["myocarditis", "DISEASE", 77, 88], ["myocardial infarction", "DISEASE", 93, 114], ["fever", "DISEASE", 190, 195], ["cough", "DISEASE", 203, 208], ["fatigue", "DISEASE", 216, 223], ["rhinorrhoea", "DISEASE", 225, 236], ["nasal congestion", "DISEASE", 240, 256], ["infections", "DISEASE", 293, 303], ["patients", "ORGANISM", 11, 19], ["cardiac", "ORGAN", 42, 49], ["myocardial", "MULTI-TISSUE_STRUCTURE", 93, 103], ["childrenChildren", "ORGANISM", 127, 143], ["nasal", "ORGANISM_SUBDIVISION", 240, 245], ["patients", "SPECIES", 11, 19], ["cardiac sounding chest pain", "PROBLEM", 42, 69], ["myocarditis", "PROBLEM", 77, 88], ["myocardial infarction", "PROBLEM", 93, 114], ["COVID", "TEST", 115, 120], ["asymptomatic", "PROBLEM", 155, 167], ["pauci-symptomatic", "PROBLEM", 171, 188], ["fever", "PROBLEM", 190, 195], ["cough", "PROBLEM", 203, 208], ["fatigue", "PROBLEM", 216, 223], ["rhinorrhoea", "PROBLEM", 225, 236], ["nasal congestion", "PROBLEM", 240, 256], ["severe infections", "PROBLEM", 286, 303], ["chest", "ANATOMY", 59, 64], ["myocarditis", "OBSERVATION", 77, 88], ["myocardial", "ANATOMY", 93, 103], ["infarction", "OBSERVATION", 104, 114], ["nasal", "ANATOMY", 240, 245], ["congestion", "OBSERVATION", 246, 256], ["severe", "OBSERVATION_MODIFIER", 286, 292], ["infections", "OBSERVATION", 293, 303]]], ["[82, 83] Gastrointestinal symptoms like diarrhoea, abdominal cramps and vomiting, common in children,Laboratory ParametersCOVID-19 positive patients frequently exhibit hematologic abnormalities in the form of lymphopenia, leukopenia, and thrombocytopenia, along with elevated levels of liver enzymes, lactate dehydrogenase, prothrombin time and D-dimers.", [["Gastrointestinal", "ANATOMY", 9, 25], ["abdominal", "ANATOMY", 51, 60], ["hematologic", "ANATOMY", 168, 179], ["liver", "ANATOMY", 286, 291], ["Gastrointestinal symptoms", "DISEASE", 9, 34], ["diarrhoea", "DISEASE", 40, 49], ["abdominal cramps", "DISEASE", 51, 67], ["vomiting", "DISEASE", 72, 80], ["hematologic abnormalities", "DISEASE", 168, 193], ["lymphopenia", "DISEASE", 209, 220], ["leukopenia", "DISEASE", 222, 232], ["thrombocytopenia", "DISEASE", 238, 254], ["lactate", "CHEMICAL", 301, 308], ["lactate", "CHEMICAL", 301, 308], ["abdominal", "ORGANISM_SUBDIVISION", 51, 60], ["children", "ORGANISM", 92, 100], ["patients", "ORGANISM", 140, 148], ["liver", "ORGAN", 286, 291], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 301, 322], ["prothrombin", "GENE_OR_GENE_PRODUCT", 324, 335], ["D-dimers", "SIMPLE_CHEMICAL", 345, 353], ["liver enzymes", "PROTEIN", 286, 299], ["lactate dehydrogenase", "PROTEIN", 301, 322], ["prothrombin time and D-dimers", "PROTEIN", 324, 353], ["children", "SPECIES", 92, 100], ["patients", "SPECIES", 140, 148], ["Gastrointestinal symptoms", "PROBLEM", 9, 34], ["diarrhoea", "PROBLEM", 40, 49], ["abdominal cramps", "PROBLEM", 51, 67], ["vomiting", "PROBLEM", 72, 80], ["Laboratory ParametersCOVID", "TEST", 101, 127], ["hematologic abnormalities", "PROBLEM", 168, 193], ["lymphopenia", "PROBLEM", 209, 220], ["leukopenia", "PROBLEM", 222, 232], ["thrombocytopenia", "PROBLEM", 238, 254], ["elevated levels of liver enzymes", "PROBLEM", 267, 299], ["lactate dehydrogenase", "TEST", 301, 322], ["prothrombin time", "TEST", 324, 340], ["D-dimers", "PROBLEM", 345, 353], ["Gastrointestinal", "ANATOMY", 9, 25], ["abdominal", "ANATOMY", 51, 60], ["cramps", "OBSERVATION", 61, 67], ["lymphopenia", "OBSERVATION", 209, 220], ["leukopenia", "OBSERVATION", 222, 232], ["thrombocytopenia", "OBSERVATION", 238, 254], ["liver", "ANATOMY", 286, 291]]], ["[72] Lymphopenia is associated with disease severity and mortality.", [["Lymphopenia", "DISEASE", 5, 16], ["Lymphopenia", "PROBLEM", 5, 16], ["disease severity", "PROBLEM", 36, 52], ["Lymphopenia", "OBSERVATION", 5, 16], ["associated with", "UNCERTAINTY", 20, 35], ["disease", "OBSERVATION", 36, 43]]], ["[1] Acute phase reactants such as CRP, ferritin and procalcitonin and pro-inflammatory cytokine levels were higher in COVID-19 than healthy adults.", [["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["ferritin", "GENE_OR_GENE_PRODUCT", 39, 47], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 52, 65], ["CRP", "PROTEIN", 34, 37], ["ferritin", "PROTEIN", 39, 47], ["procalcitonin", "PROTEIN", 52, 65], ["cytokine", "PROTEIN", 87, 95], ["Acute phase reactants", "PROBLEM", 4, 25], ["CRP", "TEST", 34, 37], ["ferritin", "TEST", 39, 47], ["procalcitonin", "TEST", 52, 65], ["pro-inflammatory cytokine levels", "TEST", 70, 102], ["COVID", "TEST", 118, 123], ["Acute", "OBSERVATION_MODIFIER", 4, 9]]], ["[86] COVID-19 patients needing ICU management when compared to non-ICU patients had higher plasma levels of pro-inflammatory cytokines (IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNF\u03b1), increased total WBC and neutrophil counts, higher levels of D-dimer, creatine kinase, and creatinine.", [["plasma", "ANATOMY", 91, 97], ["WBC", "ANATOMY", 204, 207], ["neutrophil", "ANATOMY", 212, 222], ["creatine", "CHEMICAL", 257, 265], ["creatinine", "CHEMICAL", 278, 288], ["creatine", "CHEMICAL", 257, 265], ["creatinine", "CHEMICAL", 278, 288], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 71, 79], ["plasma", "ORGANISM_SUBSTANCE", 91, 97], ["IL2", "GENE_OR_GENE_PRODUCT", 136, 139], ["IL7", "GENE_OR_GENE_PRODUCT", 141, 144], ["IL10", "GENE_OR_GENE_PRODUCT", 146, 150], ["GSCF", "GENE_OR_GENE_PRODUCT", 152, 156], ["IP10", "GENE_OR_GENE_PRODUCT", 158, 162], ["MCP1", "GENE_OR_GENE_PRODUCT", 164, 168], ["MIP1A", "GENE_OR_GENE_PRODUCT", 170, 175], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 181, 185], ["WBC", "CELL", 204, 207], ["neutrophil", "CELL", 212, 222], ["D-dimer", "GENE_OR_GENE_PRODUCT", 248, 255], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 257, 272], ["creatinine", "SIMPLE_CHEMICAL", 278, 288], ["pro-inflammatory cytokines", "PROTEIN", 108, 134], ["IL2", "PROTEIN", 136, 139], ["IL7", "PROTEIN", 141, 144], ["IL10", "PROTEIN", 146, 150], ["GSCF", "PROTEIN", 152, 156], ["IP10", "PROTEIN", 158, 162], ["MCP1", "PROTEIN", 164, 168], ["MIP1A", "PROTEIN", 170, 175], ["TNF\u03b1", "PROTEIN", 181, 185], ["D-dimer", "PROTEIN", 248, 255], ["creatine kinase", "PROTEIN", 257, 272], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 71, 79], ["ICU management", "TREATMENT", 31, 45], ["higher plasma levels", "PROBLEM", 84, 104], ["pro-inflammatory cytokines", "TEST", 108, 134], ["IL2", "TEST", 136, 139], ["IL7", "TEST", 141, 144], ["IL10", "TEST", 146, 150], ["GSCF", "TEST", 152, 156], ["IP10", "TEST", 158, 162], ["MCP1", "TEST", 164, 168], ["MIP1A", "TEST", 170, 175], ["TNF", "TEST", 181, 184], ["increased total WBC", "PROBLEM", 188, 207], ["neutrophil counts", "TEST", 212, 229], ["D-dimer", "TEST", 248, 255], ["creatine kinase", "TEST", 257, 272], ["creatinine", "TEST", 278, 288], ["pro-inflammatory cytokines", "OBSERVATION", 108, 134], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["neutrophil counts", "OBSERVATION", 212, 229]]], ["[31, 74] Similar laboratory findings were seen in Children with COVID-19.", [["COVID-19", "CHEMICAL", 64, 72], ["Children", "SPECIES", 50, 58], ["COVID", "TEST", 64, 69]]], ["[29]Radiological FeaturesFindings on chest imaging in SARS CoV-2 pneumonia seems to be similar to ordinary viral pneumonia, with some peculiarities.", [["chest", "ANATOMY", 37, 42], ["pneumonia", "DISEASE", 65, 74], ["pneumonia", "DISEASE", 113, 122], ["chest", "ORGAN", 37, 42], ["CoV-", "SPECIES", 59, 63], ["SARS CoV-2", "SPECIES", 54, 64], ["Radiological Features", "TEST", 4, 25], ["chest imaging", "TEST", 37, 50], ["SARS CoV", "PROBLEM", 54, 62], ["pneumonia", "PROBLEM", 65, 74], ["ordinary viral pneumonia", "PROBLEM", 98, 122], ["some peculiarities", "PROBLEM", 129, 147], ["chest", "ANATOMY", 37, 42], ["pneumonia", "OBSERVATION", 65, 74], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["pneumonia", "OBSERVATION", 113, 122]]], ["Chest X-ray and CT changes may be seen even before the detection of the virus from swab.", [["Chest X-ray", "TEST", 0, 11], ["CT changes", "TEST", 16, 26], ["the virus", "PROBLEM", 68, 77], ["swab", "TEST", 83, 87]]], ["In contrast, the chest X-ray may be normal in 31% of laboratory confirmed COVID-19 cases.", [["COVID", "DISEASE", 74, 79], ["the chest X-ray", "TEST", 13, 28], ["COVID", "TEST", 74, 79], ["chest", "ANATOMY", 17, 22], ["normal", "OBSERVATION", 36, 42]]], ["[87] The commonest feature on chest X-ray is presence of bilaterally symmetrical ground glass opacities with or without associated consolidation in the posterior and peripheral lung fields.", [["peripheral lung", "ANATOMY", 166, 181], ["posterior", "MULTI-TISSUE_STRUCTURE", 152, 161], ["peripheral lung", "MULTI-TISSUE_STRUCTURE", 166, 181], ["chest X-ray", "TEST", 30, 41], ["bilaterally symmetrical ground glass opacities", "PROBLEM", 57, 103], ["associated consolidation in the posterior and peripheral lung fields", "PROBLEM", 120, 188], ["chest", "ANATOMY", 30, 35], ["bilaterally", "ANATOMY_MODIFIER", 57, 68], ["symmetrical", "OBSERVATION_MODIFIER", 69, 80], ["ground glass opacities", "OBSERVATION", 81, 103], ["without", "UNCERTAINTY", 112, 119], ["consolidation", "OBSERVATION", 131, 144], ["posterior", "ANATOMY_MODIFIER", 152, 161], ["peripheral", "ANATOMY_MODIFIER", 166, 176], ["lung", "ANATOMY", 177, 181], ["fields", "ANATOMY_MODIFIER", 182, 188]]], ["[32] However, the CT findings vary with the duration of symptoms.", [["the CT findings", "TEST", 14, 29], ["symptoms", "PROBLEM", 56, 64]]], ["[88] In the initial Phase (Days 2-4) basal multifocal peripheral ground-glass opacities are noted.", [["basal multifocal peripheral ground-glass opacities", "PROBLEM", 37, 87], ["basal", "ANATOMY_MODIFIER", 37, 42], ["multifocal", "OBSERVATION_MODIFIER", 43, 53], ["peripheral", "ANATOMY_MODIFIER", 54, 64], ["ground-glass opacities", "OBSERVATION", 65, 87]]], ["With disease progression (mid Phase (Days 4-7) there is linear opacities developing on a background of ground-glass opacities (crazy pavement pattern).", [["opacities", "DISEASE", 63, 72], ["disease progression", "PROBLEM", 5, 24], ["linear opacities", "PROBLEM", 56, 72], ["ground-glass opacities", "PROBLEM", 103, 125], ["disease", "OBSERVATION", 5, 12], ["mid Phase", "OBSERVATION_MODIFIER", 26, 35], ["linear", "OBSERVATION_MODIFIER", 56, 62], ["opacities", "OBSERVATION", 63, 72], ["ground-glass opacities", "OBSERVATION", 103, 125]]], ["In the late Phase (Days 8-14) the central ground-glass opacities become surrounded by denser crescentic shaped consolidation (forming more than three-fourths of a circle) or form complete ring of at least 2 mm in thicknesscalled as 'reversed halo sign' or 'atoll sign' [88] Children also exhibit similar radiologic features.", [["Children", "SPECIES", 274, 282], ["the central ground-glass opacities", "PROBLEM", 30, 64], ["denser crescentic shaped consolidation", "PROBLEM", 86, 124], ["similar radiologic features", "PROBLEM", 296, 323], ["late Phase", "OBSERVATION_MODIFIER", 7, 17], ["central", "ANATOMY_MODIFIER", 34, 41], ["glass opacities", "OBSERVATION", 49, 64], ["denser", "OBSERVATION_MODIFIER", 86, 92], ["crescentic", "OBSERVATION_MODIFIER", 93, 103], ["shaped", "OBSERVATION_MODIFIER", 104, 110], ["consolidation", "OBSERVATION", 111, 124]]], ["[29] Chest CT suggesting COVID-19 had 97% sensitivity in concordance with positive These tests are complex, time consuming, expensive and need expertise to perform as well as to interpret.", [["Chest CT", "TEST", 5, 13], ["COVID", "TEST", 25, 30], ["These tests", "TEST", 83, 94], ["Chest", "ANATOMY", 5, 10]]], ["[91, 95, 96] The molecular test based on point of care testing using cartridges are rapid and needs less expertise.", [["The molecular test", "TEST", 13, 31], ["care testing", "TEST", 50, 62], ["cartridges", "TREATMENT", 69, 79]]], ["High throughput technologies including NGS can be used for simultaneous screening of large number of samples but its application is limited to research only due to high expenditure.", [["samples", "ANATOMY", 101, 108], ["samples", "CANCER", 101, 108], ["NGS", "TEST", 39, 42], ["simultaneous screening", "TEST", 59, 81], ["high expenditure", "PROBLEM", 164, 180], ["large", "OBSERVATION_MODIFIER", 85, 90]]], ["[97] The serological tests detects either the viral antigens (spike protein and nucleo-capsid being target antigens), or the antibody response to the virus by immunochromatography and ELISA methods.", [["spike protein", "GENE_OR_GENE_PRODUCT", 62, 75], ["viral antigens", "PROTEIN", 46, 60], ["spike protein", "PROTEIN", 62, 75], ["nucleo-capsid", "PROTEIN", 80, 93], ["target antigens", "PROTEIN", 100, 115], ["The serological tests", "TEST", 5, 26], ["the viral antigens", "PROBLEM", 42, 60], ["spike protein", "TEST", 62, 75], ["nucleo", "TEST", 80, 86], ["the antibody response", "PROBLEM", 121, 142], ["the virus", "PROBLEM", 146, 155], ["immunochromatography", "TEST", 159, 179], ["ELISA methods", "TEST", 184, 197]]], ["Specifically, the antibody testing is not helpful in the early phases of infection.", [["infection", "DISEASE", 73, 82], ["the antibody testing", "TEST", 14, 34], ["infection", "PROBLEM", 73, 82], ["infection", "OBSERVATION", 73, 82]]], ["Though simple, cost effective, easy to perform and interpret, there are chances of false positives especially due to cross reactive antibodies against other HCoVs.Radiological FeaturesAdditionally, a negative antibody test does not exclude SARS CoV-2 infection.", [["infection", "DISEASE", 251, 260], ["HCoVs", "GENE_OR_GENE_PRODUCT", 157, 162], ["CoV-2", "ORGANISM", 245, 250], ["cross reactive antibodies", "PROTEIN", 117, 142], ["HCoVs", "PROTEIN", 157, 162], ["SARS CoV-2", "SPECIES", 240, 250], ["false positives", "PROBLEM", 83, 98], ["cross reactive antibodies", "TEST", 117, 142], ["a negative antibody test", "TEST", 198, 222], ["SARS CoV", "PROBLEM", 240, 248], ["2 infection", "PROBLEM", 249, 260], ["false positives", "OBSERVATION", 83, 98], ["infection", "OBSERVATION", 251, 260]]], ["[95, 98] The role of virus isolation and culture as well as detection of the virus by its cytopathic effects on cell lines is highly limited due to requirements of bio-safety level-3 facility.", [["cell lines", "ANATOMY", 112, 122], ["cell lines", "CELL", 112, 122], ["cell lines", "CELL_LINE", 112, 122], ["virus isolation", "TREATMENT", 21, 36], ["culture", "TEST", 41, 48], ["the virus", "PROBLEM", 73, 82], ["its cytopathic effects", "PROBLEM", 86, 108], ["cell lines", "TREATMENT", 112, 122], ["virus isolation", "OBSERVATION", 21, 36], ["cytopathic", "OBSERVATION_MODIFIER", 90, 100], ["cell lines", "OBSERVATION", 112, 122]]], ["[99, 100] Hence it is not J o u r n a l P r e -p r o o f recommended by WHO for diagnostic purpose [101] Currently the diagnostic tests for detecting SARS CoV-2 infection is variable and non-uniform owing to the use of different probes, kits and reagents.PREVENTION AND THERAPEUTIC OPTIONSThough there are numerous reports claiming efficacy of various drugs and vaccine against COVID-19, none are effective and safe to receive approval by regulatory authorities.", [["SARS", "DISEASE", 150, 154], ["infection", "DISEASE", 161, 170], ["CoV-2", "ORGANISM", 155, 160], ["SARS CoV-2", "SPECIES", 150, 160], ["the diagnostic tests", "TEST", 115, 135], ["SARS CoV", "PROBLEM", 150, 158], ["2 infection", "PROBLEM", 159, 170], ["different probes", "TREATMENT", 219, 235], ["kits and reagents", "TREATMENT", 237, 254], ["various drugs", "TREATMENT", 344, 357], ["vaccine", "TREATMENT", 362, 369], ["COVID", "TEST", 378, 383], ["infection", "OBSERVATION", 161, 170]]], ["The management of COVID-19 mainly relies on effective implementation of infection preventive and control measures and delivery of timely supportive care including oxygen therapy and mechanical ventilation as and when indicated.Prevention and ControlAs the R0 value is >1 (range 1.4 to 3.9), [9, 10] Efficiency of intervention strategies such as screening of incoming people, wearing masks, quarantine for travellers has already been proved.Prevention and Control[102] Specifically, reducing travel volume to and from China has had a positive impact on transmission dynamics of covid-19.", [["COVID-19", "CHEMICAL", 18, 26], ["infection", "DISEASE", 72, 81], ["oxygen", "CHEMICAL", 163, 169], ["COVID-19", "CHEMICAL", 18, 26], ["oxygen", "CHEMICAL", 163, 169], ["oxygen", "SIMPLE_CHEMICAL", 163, 169], ["people", "ORGANISM", 367, 373], ["people", "SPECIES", 367, 373], ["COVID", "TEST", 18, 23], ["infection preventive", "TREATMENT", 72, 92], ["control measures", "TREATMENT", 97, 113], ["delivery", "TREATMENT", 118, 126], ["timely supportive care", "TREATMENT", 130, 152], ["oxygen therapy", "TREATMENT", 163, 177], ["mechanical ventilation", "TREATMENT", 182, 204], ["ControlAs the R0 value", "TEST", 242, 264], ["intervention strategies", "TREATMENT", 313, 336], ["quarantine", "TREATMENT", 390, 400], ["travellers", "PROBLEM", 405, 415], ["transmission dynamics", "TEST", 552, 573], ["covid", "TEST", 577, 582], ["infection", "OBSERVATION", 72, 81]]], ["[103] .Prevention and ControlThough preventive vaccines against SARS CoV-2 can be developed targeting the spike (S) glycoprotein or its receptor-binding domain (RBD), these are made ineffective due to generation of altered immunogens in the target proteins owing to rapid mutations and recombinations.", [["SARS", "DISEASE", 64, 68], ["SARS CoV-2", "ORGANISM", 64, 74], ["spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 106, 128], ["spike (S) glycoprotein", "PROTEIN", 106, 128], ["receptor-binding domain", "PROTEIN", 136, 159], ["RBD", "PROTEIN", 161, 164], ["target proteins", "PROTEIN", 241, 256], ["SARS CoV", "SPECIES", 64, 72], ["Prevention", "TREATMENT", 7, 17], ["preventive vaccines", "TREATMENT", 36, 55], ["SARS CoV", "TEST", 64, 72], ["the spike (S) glycoprotein", "PROBLEM", 102, 128], ["altered immunogens", "PROBLEM", 215, 233], ["rapid mutations", "PROBLEM", 266, 281]]], ["[104, 105] In SARS CoV, live attenuated vaccine with the deleted structural E gene mutant was effective in producing neutralizing antibodies which lowered viral loads and reduced disease severity.", [["SARS", "DISEASE", 14, 18], ["SARS CoV", "ORGANISM", 14, 22], ["E", "GENE_OR_GENE_PRODUCT", 76, 77], ["E gene mutant", "DNA", 76, 89], ["neutralizing antibodies", "PROTEIN", 117, 140], ["SARS CoV", "SPECIES", 14, 22], ["SARS CoV", "PROBLEM", 14, 22], ["live attenuated vaccine", "TREATMENT", 24, 47], ["the deleted structural E gene mutant", "PROBLEM", 53, 89], ["neutralizing antibodies", "PROBLEM", 117, 140], ["lowered viral loads", "PROBLEM", 147, 166], ["reduced disease severity", "PROBLEM", 171, 195], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["disease", "OBSERVATION", 179, 186]]], ["[106] The development of inactivated vaccines against SARS CoV was hindered due to occurrence of harmful immune and/or inflammatory responses post challenge.Prevention and ControlJ o u r n a l P r e -p r o o f 13 [107, 108, 109] Sub-unit vaccines (purified proteins combined with adjuvants) and viral vector (adeno virus) vaccines against S glycoprotein or its RBD and N protein of SARS CoV and MERS CoV elicited higher humoral response as well as enhanced mucosal immunity with intranasal administration.", [["mucosal", "ANATOMY", 457, 464], ["SARS", "DISEASE", 54, 58], ["SARS CoV", "ORGANISM", 54, 62], ["adeno virus", "ORGANISM", 309, 320], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 339, 353], ["RBD", "GENE_OR_GENE_PRODUCT", 361, 364], ["SARS CoV", "ORGANISM", 382, 390], ["MERS CoV", "ORGANISM", 395, 403], ["mucosal", "MULTI-TISSUE_STRUCTURE", 457, 464], ["purified proteins", "PROTEIN", 248, 265], ["S glycoprotein", "PROTEIN", 339, 353], ["RBD", "PROTEIN", 361, 364], ["N protein", "PROTEIN", 369, 378], ["SARS CoV", "SPECIES", 54, 62], ["adeno virus", "SPECIES", 309, 320], ["SARS CoV", "SPECIES", 382, 390], ["MERS CoV", "SPECIES", 395, 403], ["inactivated vaccines", "TREATMENT", 25, 45], ["SARS CoV", "PROBLEM", 54, 62], ["harmful immune", "PROBLEM", 97, 111], ["inflammatory responses", "PROBLEM", 119, 141], ["Prevention", "TEST", 157, 167], ["a l P r e -p r o o f", "TEST", 189, 209], ["Sub-unit vaccines", "TREATMENT", 229, 246], ["purified proteins", "PROBLEM", 248, 265], ["adjuvants", "TREATMENT", 280, 289], ["viral vector (adeno virus) vaccines", "TREATMENT", 295, 330], ["S glycoprotein", "TEST", 339, 353], ["its RBD", "TEST", 357, 364], ["SARS CoV", "PROBLEM", 382, 390], ["MERS CoV", "TEST", 395, 403], ["intranasal administration", "TREATMENT", 479, 504], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131]]], ["[110, 111, 112] Furthermore, DNA based vaccine against S glycoprotein of MERS CoV also showed robust neutralizing antibody response and is currently under clinical trial.", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["MERS CoV", "ORGANISM", 73, 81], ["S glycoprotein", "PROTEIN", 55, 69], ["MERS CoV", "PROTEIN", 73, 81], ["MERS CoV", "SPECIES", 73, 81], ["DNA based vaccine", "TREATMENT", 29, 46], ["MERS CoV", "TEST", 73, 81], ["robust neutralizing antibody response", "PROBLEM", 94, 131], ["robust", "OBSERVATION_MODIFIER", 94, 100], ["neutralizing antibody response", "OBSERVATION", 101, 131]]], ["[113] Based on these reports vaccines for SARS CoV-2 is likely possible.", [["SARS", "DISEASE", 42, 46], ["SARS CoV", "SPECIES", 42, 50], ["SARS CoV", "TEST", 42, 50], ["likely possible", "UNCERTAINTY", 56, 71]]], ["However, its efficacy and safety has to be proved before approval.Therapeutic optionsIn the absence of specific anti-viral therapy, treatment is mainly symptomatic and supportive that includes oxygen therapy, conservative fluid management, hemodynamic support and / or mechanical ventilation.", [["fluid", "ANATOMY", 222, 227], ["oxygen", "CHEMICAL", 193, 199], ["oxygen", "CHEMICAL", 193, 199], ["oxygen", "SIMPLE_CHEMICAL", 193, 199], ["Therapeutic options", "TREATMENT", 66, 85], ["specific anti-viral therapy", "TREATMENT", 103, 130], ["treatment", "TREATMENT", 132, 141], ["oxygen therapy", "TREATMENT", 193, 207], ["conservative fluid management", "TREATMENT", 209, 238], ["hemodynamic support", "TREATMENT", 240, 259], ["mechanical ventilation", "TREATMENT", 269, 291], ["anti-viral therapy", "OBSERVATION", 112, 130], ["oxygen therapy", "OBSERVATION", 193, 207], ["mechanical ventilation", "OBSERVATION", 269, 291]]], ["Mechanical ventilatory support with low tidal volume and low inspiratory pressure is indicated when the respiratory distress is refractory to conventional oxygen therapy or NIV.", [["respiratory", "ANATOMY", 104, 115], ["respiratory distress", "DISEASE", 104, 124], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 155, 161], ["NIV", "CHEMICAL", 173, 176], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["Mechanical ventilatory support", "TREATMENT", 0, 30], ["low tidal volume", "TREATMENT", 36, 52], ["low inspiratory pressure", "TREATMENT", 57, 81], ["the respiratory distress", "PROBLEM", 100, 124], ["conventional oxygen therapy", "TREATMENT", 142, 169], ["NIV", "TREATMENT", 173, 176], ["ventilatory support", "OBSERVATION", 11, 30], ["low", "OBSERVATION_MODIFIER", 36, 39], ["tidal volume", "OBSERVATION", 40, 52], ["inspiratory pressure", "OBSERVATION", 61, 81]]], ["[2] Extracorporeal membrane oxygenation (ECMO) is indicated in patients with refractory hypoxemia despite prone position mechanical ventilation.", [["Extracorporeal membrane", "ANATOMY", 4, 27], ["hypoxemia", "DISEASE", 88, 97], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Extracorporeal membrane oxygenation (ECMO", "TREATMENT", 4, 45], ["refractory hypoxemia", "PROBLEM", 77, 97], ["prone position mechanical ventilation", "TREATMENT", 106, 143], ["refractory", "OBSERVATION_MODIFIER", 77, 87], ["hypoxemia", "OBSERVATION", 88, 97], ["mechanical ventilation", "OBSERVATION", 121, 143]]], ["[2] A recent retrospective study identified older age, high sequential organ failure assessment score (SOFA) score, and D-dimer greater than 1 \u00b5g/mL as poor prognostic factors which aid the clinician early in instituting aggressive treatment and monitoring for such patients.", [["organ", "ANATOMY", 71, 76], ["high sequential organ failure", "DISEASE", 55, 84], ["organ", "ORGAN", 71, 76], ["D-dimer", "GENE_OR_GENE_PRODUCT", 120, 127], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["A recent retrospective study", "TEST", 4, 32], ["high sequential organ failure", "PROBLEM", 55, 84], ["SOFA) score", "TEST", 103, 114], ["D-dimer", "TEST", 120, 127], ["poor prognostic factors", "PROBLEM", 152, 175], ["aggressive treatment", "TREATMENT", 221, 241], ["monitoring", "TEST", 246, 256]]], ["[114] Steroids, and injudicious antibiotic use should be discouraged.", [["[114] Steroids", "CHEMICAL", 0, 14], ["[114] Steroids", "SIMPLE_CHEMICAL", 0, 14], ["Steroids", "TREATMENT", 6, 14], ["injudicious antibiotic use", "TREATMENT", 20, 46]]], ["Some studies report effective use of RNA polymerase inhibitors Remdesivir and Immucillin-A as prophylactic and therapeutic agents against HCoVs including SARS CoV-2.", [["Remdesivir", "CHEMICAL", 63, 73], ["Immucillin-A", "CHEMICAL", 78, 90], ["Remdesivir", "CHEMICAL", 63, 73], ["Immucillin-A", "CHEMICAL", 78, 90], ["Remdesivir", "SIMPLE_CHEMICAL", 63, 73], ["Immucillin-A", "SIMPLE_CHEMICAL", 78, 90], ["HCoVs", "CANCER", 138, 143], ["SARS CoV-2", "ORGANISM", 154, 164], ["HCoVs", "SPECIES", 138, 143], ["SARS CoV", "SPECIES", 154, 162], ["Some studies", "TEST", 0, 12], ["RNA polymerase inhibitors", "TREATMENT", 37, 62], ["Remdesivir", "TREATMENT", 63, 73], ["Immucillin", "TREATMENT", 78, 88], ["prophylactic", "TREATMENT", 94, 106], ["therapeutic agents", "TREATMENT", 111, 129], ["SARS CoV", "TEST", 154, 162]]], ["[115, 116] Anti-malarial drug chloroquine and its analogue may show protective effect against virus by decreasing intracellular pH but may cause cardiac arrythmias owing to prolonged QTc interval in some patients.", [["intracellular", "ANATOMY", 114, 127], ["cardiac", "ANATOMY", 145, 152], ["chloroquine", "CHEMICAL", 30, 41], ["cardiac arrythmias", "DISEASE", 145, 163], ["chloroquine", "CHEMICAL", 30, 41], ["[115, 116] Anti-malarial", "SIMPLE_CHEMICAL", 0, 24], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["cardiac", "ORGAN", 145, 152], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["Anti-malarial drug chloroquine", "TREATMENT", 11, 41], ["its analogue", "TREATMENT", 46, 58], ["virus", "PROBLEM", 94, 99], ["decreasing intracellular pH", "PROBLEM", 103, 130], ["cardiac arrythmias", "PROBLEM", 145, 163], ["prolonged QTc interval", "PROBLEM", 173, 195], ["arrythmias", "OBSERVATION", 153, 163]]], ["[117] Monoclonal antibodies against interleukin-6 (IL-6) like Sarilumab, Siltuximab, Tocilizumab and interleukin-1 (IL-1) inhibitor like Anakinra may be useful in severe cases and may control the effects of SIRS which is the main culprit in the pathogenesis of severe cases.", [["Sarilumab", "CHEMICAL", 62, 71], ["Siltuximab", "CHEMICAL", 73, 83], ["Tocilizumab", "CHEMICAL", 85, 96], ["Anakinra", "CHEMICAL", 137, 145], ["SIRS", "DISEASE", 207, 211], ["Siltuximab", "CHEMICAL", 73, 83], ["Anakinra", "CHEMICAL", 137, 145], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 36, 49], ["IL-6", "SIMPLE_CHEMICAL", 51, 55], ["Sarilumab", "SIMPLE_CHEMICAL", 62, 71], ["Siltuximab", "SIMPLE_CHEMICAL", 73, 83], ["Tocilizumab", "SIMPLE_CHEMICAL", 85, 96], ["interleukin-1 (IL-1", "SIMPLE_CHEMICAL", 101, 120], ["Anakinra", "SIMPLE_CHEMICAL", 137, 145], ["Monoclonal antibodies", "PROTEIN", 6, 27], ["interleukin-6", "PROTEIN", 36, 49], ["IL", "PROTEIN", 51, 53], ["Monoclonal antibodies", "TEST", 6, 27], ["interleukin", "TEST", 36, 47], ["IL", "TEST", 51, 53], ["Sarilumab", "TREATMENT", 62, 71], ["Siltuximab", "TREATMENT", 73, 83], ["Tocilizumab", "TREATMENT", 85, 96], ["interleukin-1 (IL-1) inhibitor", "TREATMENT", 101, 131], ["Anakinra", "TREATMENT", 137, 145], ["severe cases", "PROBLEM", 163, 175], ["SIRS", "PROBLEM", 207, 211], ["severe cases", "PROBLEM", 261, 273], ["severe", "OBSERVATION_MODIFIER", 261, 267]]], ["[118] Currently, there are 1,673 studies registered in clinical trials involving various investigational drugs and vaccine apart from those mentioned above and are still at phase-I level.Therapeutic options[119] Theoretically, molecules involved at each step of SARS CoV-2 pathogenesis may become potential therapeutic targets.", [["SARS", "DISEASE", 262, 266], ["CoV-2", "GENE_OR_GENE_PRODUCT", 267, 272], ["various investigational drugs", "TREATMENT", 81, 110], ["vaccine", "TREATMENT", 115, 122], ["Therapeutic options", "TREATMENT", 187, 206], ["SARS CoV", "TEST", 262, 270]]], ["(Figure: To conclude, SARS CoV-2 is highly infective and its control depends on strict implementation of preventive measures.", [["CoV-2", "ORGANISM", 27, 32], ["SARS CoV", "TEST", 22, 30], ["highly infective", "PROBLEM", 36, 52], ["preventive measures", "TREATMENT", 105, 124], ["infective", "OBSERVATION", 43, 52]]], ["Though RT-PCR is the gold standard for SARS CoV-2 diagnosis, the results are variable and there is scope of false negatives owing to either sampling errors or due to usage of different primers and reagents by different vendors.", [["SARS CoV", "SPECIES", 39, 47], ["RT-PCR", "TEST", 7, 13], ["SARS CoV", "TEST", 39, 47], ["false negatives", "PROBLEM", 108, 123], ["sampling errors", "PROBLEM", 140, 155], ["different primers", "TREATMENT", 175, 192], ["false negatives", "OBSERVATION", 108, 123]]], ["Serologic estimations of antibody titres though not helpful for diagnosis, may be useful for prognostication and follow-up.", [["Serologic estimations", "TEST", 0, 21], ["antibody titres", "TEST", 25, 40]]], ["Though currently available pathologic data is limited, it is of prime importance to unveil the pathogenesis which will enable the development of therapeutic options.", [["pathologic data", "TEST", 27, 42], ["therapeutic options", "TREATMENT", 145, 164]]], ["However, studies on larger cohorts are needed to validate the findings obtained for generalized application.Therapeutic optionsImportantly, due to limited availability of time and resources for research during the current emergency situation there is a huge lag and gap in understanding COVID-19; hence the current review removes the lag and bridges the gap and provides pathology centered understanding of the disease.", [["the findings", "TEST", 58, 70], ["generalized application", "TREATMENT", 84, 107], ["a huge lag and gap", "PROBLEM", 251, 269], ["COVID", "TEST", 287, 292], ["the disease", "PROBLEM", 407, 418], ["disease", "OBSERVATION", 411, 418]]], ["Furthermore, the currently approved clinical trials that are in various stages of development on all aspects of COVID-19 including vaccines and potential therapeutic targets will shed light in future.Conflict of Interest:There are no conflicts of interest to disclose.", [["COVID-19", "CHEMICAL", 112, 120], ["COVID-19", "CHEMICAL", 112, 120], ["COVID", "TEST", 112, 117], ["vaccines", "TREATMENT", 131, 139], ["no", "UNCERTAINTY", 231, 233]]]], "3b8ac793b15fa3c2401cb4ccb1cc73a6bbd8fa38": [["IntroductionThe outbreaks of emerging infectious diseases (EIDs), such as the ongoing Coronavirus Disease 2019 (COVID- 19) , always take a significant human toll and affect social stability [1, 2] .", [["infectious diseases", "DISEASE", 38, 57], ["EIDs", "DISEASE", 59, 63], ["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["Coronavirus Disease 2019 (COVID- 19", "SPECIES", 86, 121], ["human", "SPECIES", 151, 156], ["emerging infectious diseases", "PROBLEM", 29, 57], ["the ongoing Coronavirus Disease", "PROBLEM", 74, 105], ["COVID", "TEST", 112, 117], ["infectious", "OBSERVATION", 38, 48], ["Coronavirus Disease", "OBSERVATION", 86, 105]]], ["To protect the public from being infected via droplets and aerosols [3] , protective respirators are highly demanded.", [["protective respirators", "TREATMENT", 74, 96], ["infected", "OBSERVATION", 33, 41]]], ["Currently, respirators are mostly composed of micro-sized melt-blown fibers with large pore size (10-20 \u03bcm), rendering a low pressure drop thereby satisfying breathing comfort [4] .", [["fibers", "ANATOMY", 69, 75], ["pore", "ANATOMY", 87, 91], ["large pore size", "PROBLEM", 81, 96], ["a low pressure drop", "TREATMENT", 119, 138], ["blown fibers", "OBSERVATION", 63, 75], ["large", "OBSERVATION_MODIFIER", 81, 86], ["pore", "OBSERVATION_MODIFIER", 87, 91], ["size", "OBSERVATION_MODIFIER", 92, 96], ["low pressure", "OBSERVATION_MODIFIER", 121, 133]]], ["However, determined by the single filtration mechanism of size sieving, meltblown filters suffer from low filtration efficiency towards aerosols with small particle size, which is especially poisonous [5] .", [["size sieving", "TREATMENT", 58, 70], ["meltblown filters", "TREATMENT", 72, 89], ["low filtration efficiency", "PROBLEM", 102, 127], ["small particle size", "PROBLEM", 150, 169], ["size", "OBSERVATION_MODIFIER", 58, 62], ["low", "OBSERVATION_MODIFIER", 102, 105], ["filtration efficiency", "OBSERVATION", 106, 127], ["small", "OBSERVATION_MODIFIER", 150, 155], ["particle", "OBSERVATION_MODIFIER", 156, 164], ["size", "OBSERVATION_MODIFIER", 165, 169]]], ["Currently, increasing the fiber consumption has become a usual strategy to improve the protective ability.", [["fiber", "ANATOMY", 26, 31], ["fiber", "TISSUE", 26, 31], ["a usual strategy", "TREATMENT", 55, 71]]], ["However, this strategy causes the sharp increase of pressure drop simultaneously [6] .IntroductionElectret technology is effective in alleviating the conflict between filtration efficiency and pressure drop by endowing fibers with electrostatic effect, which contributes to particle adsorption while generating negligible impact on airflow [7, 8] .", [["fibers", "ANATOMY", 219, 225], ["the sharp increase of pressure drop simultaneously", "PROBLEM", 30, 80], ["filtration efficiency", "TREATMENT", 167, 188], ["pressure drop", "PROBLEM", 193, 206], ["electrostatic effect", "PROBLEM", 231, 251], ["particle adsorption", "PROBLEM", 274, 293], ["sharp", "OBSERVATION_MODIFIER", 34, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["pressure drop", "OBSERVATION", 52, 65], ["pressure drop", "OBSERVATION", 193, 206], ["electrostatic effect", "OBSERVATION", 231, 251]]], ["Compared to the current electret technologies [9, 10] , electrospinning can achieve the in-situ charging along with the formation of fibers, achieving the one-step production of electret fibers [11, 12] .", [["fibers", "ANATOMY", 133, 139], ["fibers", "CELLULAR_COMPONENT", 133, 139], ["the current electret technologies", "TEST", 12, 45], ["electrospinning", "TREATMENT", 56, 71]]], ["To enhance the electret effect of electrospun fibers, introducing nanoparticles is a state-of-art and common strategy [13] [14] [15] [16] .", [["electrospun fibers", "ANATOMY", 34, 52], ["[13] [14] [15] [16]", "CHEMICAL", 118, 137], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 118, 137], ["electrospun fibers", "TREATMENT", 34, 52]]], ["However, this strategy has two drawbacks: the intrinsic nano-agglomeration behavior makes nanoparticles hard to evenly distribute within fibers [11, 13] ; particles, especially the accumulated ones, can easily detach from fibers and be inhaled, yielding additional threaten to human health [17] .", [["fibers", "ANATOMY", 137, 143], ["fibers", "ANATOMY", 222, 228], ["fibers", "CELLULAR_COMPONENT", 222, 228], ["human", "ORGANISM", 277, 282], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 277, 282], ["the intrinsic nano-agglomeration behavior", "TREATMENT", 42, 83]]], ["The remaining challenge is to develop electrospun fibers with strong electret effect independent of particle charge enhancers.IntroductionHerein, we prepare all-polymer hybrid electret fibers by studying the complementarity of electric responses between electrospun polymers.", [["fibers", "ANATOMY", 50, 56], ["electret fibers", "CELL", 176, 191], ["particle charge enhancers", "DNA", 100, 125], ["electrospun fibers", "TREATMENT", 38, 56], ["particle charge enhancers", "TREATMENT", 100, 125], ["all-polymer hybrid electret fibers", "TREATMENT", 157, 191], ["electrospun polymers", "TREATMENT", 254, 274]]], ["The coupling of electric polarization behaviors of polystyrene (PS) and polyvinylidene fluoride (PVDF) enables the hybrid PS/PVDF fibers to show enhanced electret effect and high porosity.", [["polystyrene", "CHEMICAL", 51, 62], ["polyvinylidene fluoride", "CHEMICAL", 72, 95], ["polystyrene", "CHEMICAL", 51, 62], ["polyvinylidene fluoride", "CHEMICAL", 72, 95], ["PVDF", "CHEMICAL", 97, 101], ["PVDF", "CHEMICAL", 125, 129], ["polystyrene", "SIMPLE_CHEMICAL", 51, 62], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 72, 95], ["electric polarization behaviors of polystyrene (PS", "TREATMENT", 16, 66], ["polyvinylidene fluoride (PVDF", "TREATMENT", 72, 101], ["the hybrid PS/PVDF fibers", "TREATMENT", 111, 136], ["enhanced electret effect", "PROBLEM", 145, 169], ["high porosity", "PROBLEM", 174, 187], ["high porosity", "OBSERVATION", 174, 187]]], ["The protective respirator using PS/PVDF fibers as core layer exhibits high filtration efficiency, low air resistance, and long service life.Results and DiscussionThe premise to design all-polymer electret fibers is the reveal of electret mechanisms while electrospinning polymers with different dielectric properties.", [["PVDF", "CHEMICAL", 35, 39], ["The protective respirator", "TREATMENT", 0, 25], ["PS/PVDF fibers", "TREATMENT", 32, 46], ["high filtration efficiency", "PROBLEM", 70, 96], ["low air resistance", "PROBLEM", 98, 116], ["all-polymer electret fibers", "TREATMENT", 184, 211], ["electret mechanisms", "PROBLEM", 229, 248], ["electrospinning polymers", "TREATMENT", 255, 279], ["different dielectric properties", "TREATMENT", 285, 316], ["high filtration efficiency", "OBSERVATION", 70, 96], ["low", "OBSERVATION_MODIFIER", 98, 101], ["air resistance", "OBSERVATION", 102, 116]]], ["A general overview of electrospinning process in Fig. 1a .", [["electrospinning process", "TREATMENT", 22, 45]]], ["Under the high voltage, solutions were ejected from a metal needle and evolved into electrified jets, which finally deposited on a collector as solid fibers after being continuously elongated and charged, as well as the simultaneous phase separation [18] .", [["a metal needle", "TREATMENT", 52, 66], ["a collector as solid fibers", "TREATMENT", 129, 156], ["high voltage", "OBSERVATION_MODIFIER", 10, 22], ["electrified jets", "OBSERVATION", 84, 100], ["elongated", "OBSERVATION_MODIFIER", 182, 191]]], ["Obviously, electrospinning can in situ endow fibrous assemblies with electret effect during the evolution from solutions to solid fibers, implying that the electret property and structures could be simultaneously tailored by solution properties [19] .", [["solid fibers", "ANATOMY", 124, 136], ["solid fibers", "CELL", 124, 136], ["electrospinning", "TREATMENT", 11, 26], ["electret effect", "PROBLEM", 69, 84], ["solutions to solid fibers", "TREATMENT", 111, 136], ["fibrous assemblies", "OBSERVATION", 45, 63]]], ["PS and PVDF were selected bacause they belong to the weakly and strongly polar polymers due to their ultralow and ultrahigh dielectric constants, respectively [20, 21] .", [["PVDF", "CHEMICAL", 7, 11], ["PS", "SIMPLE_CHEMICAL", 0, 2], ["PS", "TREATMENT", 0, 2], ["PVDF", "TREATMENT", 7, 11]]], ["The dielectret property of PS and PVDF was provided in Fig. S1 , which also showed the relationship between dielectret property and polarity.Results and DiscussionThe dielectric properties of other commonly used electrospun polymers were provided in Fig. S1 for comparison.Results and DiscussionThe morphologies of PS and PVDF electrospun fibers ( Fig. 1b and c) indicated that fibrous assemblies composed of PS possessed larger fiber diameter and higher porosity (89%) than PVDF (Fig. 1d ).", [["fibrous assemblies", "ANATOMY", 378, 396], ["fiber", "ANATOMY", 429, 434], ["PVDF", "CHEMICAL", 34, 38], ["PVDF", "CHEMICAL", 322, 326], ["PVDF", "CHEMICAL", 475, 479], ["S1", "GENE_OR_GENE_PRODUCT", 60, 62], ["S1", "GENE_OR_GENE_PRODUCT", 255, 257], ["fiber", "TISSUE", 429, 434], ["S1", "PROTEIN", 60, 62], ["S1", "PROTEIN", 255, 257], ["The dielectret property of PS", "TREATMENT", 0, 29], ["PVDF", "TREATMENT", 34, 38], ["The dielectric properties", "TREATMENT", 163, 188], ["electrospun polymers", "TREATMENT", 212, 232], ["PS and PVDF electrospun fibers", "TREATMENT", 315, 345], ["fibrous assemblies", "PROBLEM", 378, 396], ["PS", "TREATMENT", 409, 411], ["polarity", "OBSERVATION_MODIFIER", 132, 140], ["fibrous", "OBSERVATION", 378, 385], ["larger", "OBSERVATION_MODIFIER", 422, 428], ["fiber", "OBSERVATION_MODIFIER", 429, 434], ["diameter", "OBSERVATION_MODIFIER", 435, 443], ["higher", "OBSERVATION_MODIFIER", 448, 454], ["porosity", "OBSERVATION_MODIFIER", 455, 463]]], ["The effect of dielectric property on structures was discussed in Supplementary Discussion 1.", [["dielectric property", "OBSERVATION_MODIFIER", 14, 33]]], ["The electret property of fibers was evaluated by the electric field intensity ( ) of E single fibers, which was deduced from the tested surface potential of fibrous assembilies ( ) U (Fig. 1d) .", [["fibers", "ANATOMY", 25, 31], ["surface", "ANATOMY", 136, 143], ["fibers", "CELLULAR_COMPONENT", 25, 31], ["E single fibers", "TREATMENT", 85, 100], ["fibrous assembilies", "OBSERVATION", 157, 176]]], ["Based on the non-contact measuring principle (Fig. 1e ), the were calculated by:Results and Discussionwhere is the charge density of single fiber, is the dielectric constant, L is the distance, \u03bb \u03be 0 \u03d5 and refer to the thickness and porosity of fibrous membranes, R and H are the radius of testing p samples and testing distance, respectively [22] .", [["fibrous membranes", "ANATOMY", 245, 262], ["fibrous membranes", "CELLULAR_COMPONENT", 245, 262], ["\u03d5", "PROTEIN", 200, 201], ["testing distance", "TEST", 312, 328], ["fibrous membranes", "OBSERVATION", 245, 262], ["radius", "ANATOMY_MODIFIER", 280, 286]]], ["PVDF membranes exhibited negtive surface potential, implying that dipole charges played a predominant role in PVDF fibers considering that was calculated by: UResults and Discussionwhere and resultting from space and dipole charges, respectively [23] .", [["PVDF membranes", "ANATOMY", 0, 14], ["surface", "ANATOMY", 33, 40], ["PVDF fibers", "ANATOMY", 110, 121], ["PVDF", "CHEMICAL", 0, 4], ["PVDF", "CHEMICAL", 110, 114], ["membranes", "CELLULAR_COMPONENT", 5, 14], ["fibers", "CELLULAR_COMPONENT", 115, 121], ["PVDF membranes", "PROBLEM", 0, 14], ["PVDF fibers", "TREATMENT", 110, 121]]], ["The comparison U s U d of among different fibers was intuitively visualized by color maps (Fig. 1f) .", [["fibers", "ANATOMY", 42, 48], ["fibers", "CELL", 42, 48], ["among different fibers", "TREATMENT", 26, 48], ["color maps", "TEST", 79, 89]]], ["The largest red E zones of PS fibers indicated the highest sensibility of electret effect on dielectric property.Results and DiscussionNamely, synthesizing polymers showing the similar dielectric propety with PS could be an effective strategy to acquire electrospun electret fibers with high positive .", [["PS fibers", "ANATOMY", 27, 36], ["electret fibers", "ANATOMY", 266, 281], ["PS", "CHEMICAL", 209, 211], ["PS", "SIMPLE_CHEMICAL", 209, 211], ["electret fibers", "CELL", 266, 281], ["The largest red E zones of PS fibers", "PROBLEM", 0, 36], ["dielectric property", "TREATMENT", 93, 112], ["synthesizing polymers", "TREATMENT", 143, 164], ["the similar dielectric propety", "TREATMENT", 173, 203], ["PS", "TREATMENT", 209, 211], ["electrospun electret fibers", "TREATMENT", 254, 281], ["high positive", "PROBLEM", 287, 300], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["E zones", "OBSERVATION_MODIFIER", 16, 23], ["PS fibers", "OBSERVATION", 27, 36], ["highest", "OBSERVATION_MODIFIER", 51, 58]]], ["The of PVDF E E fibers was negtive due to the negtive surface potential.", [["surface", "ANATOMY", 54, 61], ["PVDF", "CHEMICAL", 7, 11], ["The of PVDF E E fibers", "TEST", 0, 22]]], ["The electret effect of fibers composed of weakly and strongly polar polymers (typical for PS and PVDF) resulted from the injection of charges into polymer traps and the dipoles orientation, respectively (Fig. 1g) .", [["fibers", "ANATOMY", 23, 29], ["PVDF", "CHEMICAL", 97, 101], ["strongly polar polymers", "TREATMENT", 53, 76], ["PS and PVDF", "TREATMENT", 90, 101], ["the injection of charges into polymer traps", "TREATMENT", 117, 160]]], ["Orbital (LUMO) levels (Fig. 2b) , suggesting holes and electrons tended to be injected into PS and PVDF, respectively [25, 26] .", [["PVDF", "CHEMICAL", 99, 103], ["Orbital (LUMO) levels", "TEST", 0, 21], ["holes and electrons", "TREATMENT", 45, 64]]], ["The comparison of energy band density between PS and PVDF also indicated that charges were more likely to be trapped within PS ( Fig. S2 and SupplementaryResults and DiscussionDiscussion 2).", [["PVDF", "CHEMICAL", 53, 57], ["energy band density between PS and PVDF", "PROBLEM", 18, 57], ["band density", "OBSERVATION", 25, 37]]], ["Additionally, more charge traps resulting from physical defects were expected in PS since PS was amorphous with low crystalline (usually <30%), whereas PVDF was semicrystalline [27, 28] .Results and DiscussionThe dipole orientation was reflected by the intramolecular rotation of PS and PVDF monomers.", [["PVDF", "CHEMICAL", 152, 156], ["PVDF", "CHEMICAL", 287, 291], ["PS", "SIMPLE_CHEMICAL", 280, 282], ["PVDF monomers", "SIMPLE_CHEMICAL", 287, 300], ["more charge traps", "PROBLEM", 14, 31], ["physical defects", "PROBLEM", 47, 63], ["PS", "TREATMENT", 90, 92], ["low crystalline", "PROBLEM", 112, 127], ["the intramolecular rotation of PS and PVDF monomers", "TREATMENT", 249, 300], ["defects", "OBSERVATION", 56, 63], ["low crystalline", "OBSERVATION_MODIFIER", 112, 127]]], ["The charge density was calculated first to reveal the most easily rotating groups.Results and DiscussionAccording to Tab.", [["Tab", "PROTEIN", 117, 120], ["The charge density", "PROBLEM", 0, 18], ["charge", "OBSERVATION_MODIFIER", 4, 10], ["density", "OBSERVATION", 11, 18]]], ["S1 and S2, the highest and lowest charge densities were achieved by atoms H(9) (0.05) and H(13) (-0.165) in styrene, as well as atoms C(1) (0.573) and F(3) (-0.249) in VDF (Fig. 2c) .", [["styrene", "CHEMICAL", 108, 115], ["H", "CHEMICAL", 74, 75], ["H(13)", "CHEMICAL", 90, 95], ["styrene", "CHEMICAL", 108, 115], ["VDF", "CHEMICAL", 168, 171], ["H(13)", "SIMPLE_CHEMICAL", 90, 95], ["styrene", "SIMPLE_CHEMICAL", 108, 115], ["C(1)", "SIMPLE_CHEMICAL", 134, 138], ["F(3)", "SIMPLE_CHEMICAL", 151, 155], ["VDF", "SIMPLE_CHEMICAL", 168, 171], ["S1", "PROTEIN", 0, 2], ["S2", "PROTEIN", 7, 9], ["lowest charge densities", "PROBLEM", 27, 50], ["atoms C", "TEST", 128, 135], ["S2", "ANATOMY", 7, 9], ["highest", "OBSERVATION_MODIFIER", 15, 22]]], ["The energy needed for dipole orientation, including H(9)-H(13) and C(1)-F(3), could be reflected by the internal rotation barriers of molecular main chain (Fig. 2d, e, Fig. S3 ).Results and DiscussionThe internal rotation barrier of VDF was an order of magnitude lower than that of styrene, implying that dipole charges were predominant in electrospun PVDF fibers.", [["H", "CHEMICAL", 52, 53], ["styrene", "CHEMICAL", 282, 289], ["H(9)-H(13)", "CHEMICAL", 52, 62], ["C(1)-F(3)", "CHEMICAL", 67, 76], ["styrene", "CHEMICAL", 282, 289], ["PVDF", "CHEMICAL", 352, 356], ["C(1)-F(3)", "SIMPLE_CHEMICAL", 67, 76], ["VDF", "SIMPLE_CHEMICAL", 233, 236], ["styrene", "SIMPLE_CHEMICAL", 282, 289], ["fibers", "CELLULAR_COMPONENT", 357, 363], ["dipole orientation", "TEST", 22, 40], ["The internal rotation barrier of VDF", "TREATMENT", 200, 236], ["dipole charges", "PROBLEM", 305, 319], ["electrospun PVDF fibers", "TREATMENT", 340, 363], ["main chain", "ANATOMY", 144, 154], ["internal", "OBSERVATION_MODIFIER", 204, 212], ["rotation", "OBSERVATION_MODIFIER", 213, 221], ["dipole charges", "OBSERVATION", 305, 319], ["electrospun PVDF fibers", "OBSERVATION", 340, 363]]], ["However, the surface roughness appeared with the introduction of PVDF (Fig. S5 and Supplementary Discussion 4) .", [["surface", "ANATOMY", 13, 20], ["PVDF", "CHEMICAL", 65, 69], ["the surface roughness", "PROBLEM", 9, 30], ["PVDF (Fig", "TREATMENT", 65, 74], ["surface", "OBSERVATION_MODIFIER", 13, 20], ["roughness", "OBSERVATION_MODIFIER", 21, 30]]], ["The SEM-energy dispersive spectrometer image suggested the charge enhancer of PVDF evenly distributed in fibers (inset of Fig. 3b) .", [["fibers", "ANATOMY", 105, 111], ["PVDF", "CHEMICAL", 78, 82], ["fibers", "CELLULAR_COMPONENT", 105, 111], ["The SEM-energy dispersive spectrometer image", "TEST", 0, 44], ["PVDF", "PROBLEM", 78, 82], ["charge enhancer", "OBSERVATION", 59, 74], ["fibers", "OBSERVATION_MODIFIER", 105, 111]]], ["The surface potential achieved improved by 36% by introducing 2/16 content of PVDF (Fig. 3d) .", [["surface", "ANATOMY", 4, 11], ["PVDF", "CHEMICAL", 78, 82], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["improved", "OBSERVATION_MODIFIER", 31, 39]]], ["The contribution of PVDF on electret property was illustrated by Fig. 3e .", [["PVDF", "CHEMICAL", 20, 24], ["PVDF", "PROBLEM", 20, 24], ["PVDF", "OBSERVATION", 20, 24]]], ["Charges injected into the matrix PS fibers generated local electric fields exhibiting the same direction with the external electrostatic field; however, the dipoles orientation of PVDF generated local electric fields showing the opposite direction with the external one.", [["matrix PS fibers", "ANATOMY", 26, 42], ["PVDF", "CHEMICAL", 180, 184], ["Charges", "TREATMENT", 0, 7], ["the matrix PS fibers", "TREATMENT", 22, 42], ["local", "OBSERVATION_MODIFIER", 53, 58], ["external", "OBSERVATION_MODIFIER", 114, 122], ["electrostatic field", "OBSERVATION", 123, 142]]], ["Different electronic transport capabilities between PVDF and PS rendered the charge accmulation at the interfacial zones instead of being transferred from one to another [29] .", [["PVDF", "CHEMICAL", 52, 56], ["PVDF", "TREATMENT", 52, 56], ["PS", "TREATMENT", 61, 63], ["the charge accmulation", "TREATMENT", 73, 95]]], ["Thus, induced charges within PS were generated, which interestingly showed the same direction with the injected charges.", [["PS", "TEST", 29, 31]]], ["As a result, the electret effect of whole fibers was enhanced.Results and DiscussionPS/PVDF-3 membranes exhibited declined surface potential due to decreased interfacial zones.Results and DiscussionThe highest porosity was achieved by PS/PVDF-2 fibers (94.4%) and porosity exhibited the same variation trend as surface potential.", [["whole fibers", "ANATOMY", 36, 48], ["PVDF-3 membranes", "ANATOMY", 87, 103], ["surface", "ANATOMY", 123, 130], ["surface", "ANATOMY", 311, 318], ["PVDF", "CHEMICAL", 238, 242], ["DiscussionPS/PVDF-3 membranes", "TREATMENT", 74, 103], ["decreased interfacial zones", "PROBLEM", 148, 175], ["PS/PVDF", "TREATMENT", 235, 242], ["decreased", "OBSERVATION", 148, 157], ["interfacial", "ANATOMY_MODIFIER", 158, 169], ["zones", "ANATOMY_MODIFIER", 170, 175]]], ["The electric field intensity ( ) around single E PS/PVDF-2 fiber was calcultaed by eliminating the effects of porosity and thickness (Fig. S6 ).Results and DiscussionCompared to pure PS, a wider range of scale bar (from -4.2\u00d710 9 to 22\u00d710 9 ) implied a higher E (Fig. 3f) .", [["PVDF", "CHEMICAL", 52, 56], ["The electric field intensity", "TEST", 0, 28], ["single E PS/PVDF-2 fiber", "TREATMENT", 40, 64], ["porosity and thickness (Fig. S6", "TREATMENT", 110, 141], ["pure PS", "TEST", 178, 185], ["electric", "OBSERVATION_MODIFIER", 4, 12], ["field", "OBSERVATION_MODIFIER", 13, 18], ["intensity", "OBSERVATION_MODIFIER", 19, 28]]], ["Notably, the electret property was enhanced without relying on toxic nanoparticle as charge enhancers, which has never been reported in the previously developed electrospun PS/PVDF-2 membranes exhibited the highest filtration efficiency of 83.726%, improved by 12% than PS/PVDF-0 membranes (Fig. 3g) .", [["PVDF-2 membranes", "ANATOMY", 176, 192], ["PVDF-0 membranes", "ANATOMY", 273, 289], ["PVDF", "CHEMICAL", 176, 180], ["PVDF", "CHEMICAL", 273, 277], ["PVDF-2 membranes", "SIMPLE_CHEMICAL", 176, 192], ["electrospun PS/PVDF", "TEST", 161, 180], ["the highest filtration efficiency", "PROBLEM", 203, 236], ["PS/PVDF", "TEST", 270, 277], ["highest", "OBSERVATION_MODIFIER", 207, 214], ["filtration efficiency", "OBSERVATION", 215, 236]]], ["The pressure drops of various PS/PVDF membranes were extremely low (<10 Pa), less than 0.01% of atmosphere pressure.", [["membranes", "ANATOMY", 38, 47], ["PVDF", "CHEMICAL", 33, 37], ["The pressure drops", "TEST", 0, 18], ["various PS/PVDF membranes", "TREATMENT", 22, 47], ["extremely low", "PROBLEM", 53, 66], ["atmosphere pressure", "TEST", 96, 115], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["drops", "OBSERVATION_MODIFIER", 13, 18], ["PVDF membranes", "ANATOMY", 33, 47], ["low", "OBSERVATION_MODIFIER", 63, 66]]], ["The filtration efficiency was further increased to meet different protective requirments (Fig. S7) .Results and DiscussionThe excellent filtration performance of PS/PVDF fibers was highlighted by comparing with previously reported air filtration materials (Fig. 3h) [13, 16, [30] [31] [32] .", [["PVDF", "CHEMICAL", 165, 169], ["S7", "GENE_OR_GENE_PRODUCT", 95, 97], ["PS", "SIMPLE_CHEMICAL", 162, 164], ["[30] [31", "SIMPLE_CHEMICAL", 275, 283], ["S7", "PROTEIN", 95, 97], ["The filtration efficiency", "TREATMENT", 0, 25], ["different protective requirments", "TREATMENT", 56, 88], ["PS/PVDF fibers", "TREATMENT", 162, 176], ["filtration efficiency", "OBSERVATION", 4, 25], ["air filtration", "OBSERVATION", 231, 245]]], ["Furthermore, a wearable respirator was fabricated by using PS/PVDF membranes as the core functional layer (Fig. 3i) .Results and DiscussionThe filtration performance of this respirator was evaluated according to the method proposed by the National Institute for Occupational Safety and Health (NIOSH).", [["membranes", "ANATOMY", 67, 76], ["PVDF", "CHEMICAL", 62, 66], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["a wearable respirator", "TREATMENT", 13, 34], ["PS/PVDF membranes", "TREATMENT", 59, 76], ["this respirator", "TREATMENT", 169, 184]]], ["Its filtration efficiency (99.752%) met the requirements of N95 respirators for protective function (>95%).", [["Its filtration efficiency", "PROBLEM", 0, 25], ["N95 respirators", "TREATMENT", 60, 75], ["protective function", "TEST", 80, 99], ["filtration", "OBSERVATION_MODIFIER", 4, 14], ["efficiency", "OBSERVATION_MODIFIER", 15, 25]]], ["More importantly, its air resistance (72 Pa) was only one fifth of the maximum limit (~320 Pa) in detailed inforamtion were provided in Supplementary Discussion 6. respirator using PS/PVDF-2 fibers as the core material.ConclusionsAll-polymer hybrid electret fibers relying on the coupling behaviors of PS and PVDF in electric polarization were fabricated.", [["PVDF", "CHEMICAL", 184, 188], ["PVDF", "CHEMICAL", 309, 313], ["PS", "SIMPLE_CHEMICAL", 302, 304], ["its air resistance", "TEST", 18, 36], ["PS/PVDF", "TREATMENT", 181, 188], ["All-polymer hybrid electret fibers", "TREATMENT", 230, 264], ["PS", "TREATMENT", 302, 304], ["PVDF in electric polarization", "TREATMENT", 309, 338], ["air resistance", "OBSERVATION", 22, 36], ["electric polarization", "OBSERVATION", 317, 338]]], ["The electret effect of electrospun fibers, composed of polymers with ultralow and ultrahigh dielectret constants, came from the injection of charges into polymer traps and the dipoles orientation, respectively.ConclusionsMoreover, hybrid PS/PVDF fibers with structural continuity and enhanced electret effect were obtained, exhibiting high filtration efficiency (99.752%), low air resistance (72 Pa) and long service life.", [["electrospun fibers", "ANATOMY", 23, 41], ["fibers", "ANATOMY", 246, 252], ["PVDF", "CHEMICAL", 241, 245], ["electrospun fibers", "TREATMENT", 23, 41], ["polymers", "TREATMENT", 55, 63], ["ultralow and ultrahigh dielectret constants", "TREATMENT", 69, 112], ["charges into polymer traps", "TREATMENT", 141, 167], ["hybrid PS/PVDF fibers", "TREATMENT", 231, 252], ["enhanced electret effect", "PROBLEM", 284, 308], ["high filtration efficiency", "PROBLEM", 335, 361], ["low air resistance", "PROBLEM", 373, 391], ["electrospun fibers", "OBSERVATION", 23, 41], ["high", "OBSERVATION_MODIFIER", 335, 339], ["filtration efficiency", "OBSERVATION", 340, 361], ["low", "OBSERVATION_MODIFIER", 373, 376], ["air resistance", "OBSERVATION", 377, 391]]], ["They were promising candidate as the core mateirals of low-resistance N95 protective masks.", [["N95", "SIMPLE_CHEMICAL", 70, 73], ["low-resistance N95 protective masks", "TREATMENT", 55, 90]]]], "9a393882e77376fa1b0f0aeaef7136f35d392e05": [["Live and killed vaccines constitute the vast majority of vaccines currently in use.", [["Live and killed vaccines", "TREATMENT", 0, 24]]], ["Live vaccines are prepared from attenuated pathogens that are almost or completely devoid of pathogenicity but are capable of inducing a protective immune response.", [["Live vaccines", "TREATMENT", 0, 13], ["attenuated pathogens", "PROBLEM", 32, 52], ["pathogenicity", "PROBLEM", 93, 106], ["pathogenicity", "OBSERVATION", 93, 106]]], ["Dead vaccines are produced by killing and administering the whole pathogen, or by using a purified component of the pathogen.", [["Dead vaccines", "TREATMENT", 0, 13], ["the whole pathogen", "TREATMENT", 56, 74], ["the pathogen", "PROBLEM", 112, 124], ["pathogen", "OBSERVATION", 116, 124]]], ["There are both advantages and disadvantages of using live over dead vaccines.", [["dead vaccines", "TREATMENT", 63, 76]]], ["For example, live vaccines may be able to induce a greater degree of protection for a longer period of time.", [["live vaccines", "TREATMENT", 13, 26], ["greater degree", "OBSERVATION_MODIFIER", 51, 65]]], ["However, there is also a risk of reversion to virulence associated with the use of a live vaccine; obviously this is not a risk for killed vaccines.", [["virulence", "PROBLEM", 46, 55], ["a live vaccine", "TREATMENT", 83, 97], ["killed vaccines", "TREATMENT", 132, 147]]], ["Vaccines available for use in cattle in the UK are summarised in Table 1 (NB: This only includes products included in the NOAH Data Sheets Compendium).Herd immunityIn many respects, farm animals are an ideal target population for vaccination, as large groups of animalsCharlotte Inman PhD BVSc MRCVS Research Associate Chris Hudson BVSc CertCHP MRCVS Senior Farm Animal ClinicianUNIVERSITY OF BRISTOL, SCHOOL OF VETERINARY SCIENCE, LANGFORD HOUSE, LANGFORD, NORTH SOMERSET.", [["cattle", "ORGANISM", 30, 36], ["cattle", "SPECIES", 30, 36], ["cattle", "SPECIES", 30, 36], ["Charlotte Inman PhD BVSc MRCVS Research Associate Chris Hudson BVSc CertCHP MRCVS Senior Farm Animal ClinicianUNIVERSITY OF BRISTOL", "SPECIES", 269, 400], ["Vaccines", "TREATMENT", 0, 8], ["vaccination", "TREATMENT", 230, 241]]], ["BS40 5DU Cattle immunology: vaccination and immunological testing are under the control of a single owner and tend to have relatively little contact with animals on other holdings.", [["vaccination", "TREATMENT", 28, 39], ["immunological testing", "TEST", 44, 65]]], ["Compare this to the situation in human or small animal medicine, where the decision to vaccinate is taken at an individual level, so there is little effective ability to control the proportion of the population which is vaccinated against a disease.", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["a disease", "PROBLEM", 239, 248]]], ["It is well recognised that this is an important factor in the success of vaccination programmes to protect against infectious disease.Charlotte Inman PhD BVSc MRCVS Research Associate Chris Hudson BVSc CertCHP MRCVS Senior Farm Animal ClinicianUnfortunately, even in farm situations (where a complete population is under the control of the owner/manager), the phenomenon of 'herd immunity' is often not used to our advantage.", [["infectious disease", "DISEASE", 115, 133], ["herd", "ORGANISM_SUBDIVISION", 375, 379], ["vaccination programmes", "TREATMENT", 73, 95], ["infectious disease", "PROBLEM", 115, 133]]], ["Many vaccines rely on vaccination of the entire group of animals to decrease level of disease in the population, thereby decreasing the exposure of the animals to the pathogen and making protection provided by the vaccine more effective.", [["Many vaccines", "TREATMENT", 0, 13], ["vaccination", "TREATMENT", 22, 33], ["disease in the population", "PROBLEM", 86, 111], ["protection", "TREATMENT", 187, 197], ["the vaccine", "TREATMENT", 210, 221], ["disease", "OBSERVATION", 86, 93]]], ["Examples of situations in which this opportunity is commonly missed include: G vaccination against calf pneumonia of dairy-bred heifer calves intended as replacement stock, whilst not vaccinating the beef cross or dairy bull calves that are housed in the same accommodation G vaccination of a single cohort of animals within the adult herd (first lactation heifers are sometimes vaccinated in herds which do not vaccinate the cows against the same pathogen).Charlotte Inman PhD BVSc MRCVS Research Associate Chris Hudson BVSc CertCHP MRCVS Senior Farm Animal ClinicianIn these situations, vaccines may work less effectively than would be expected, as there will be less decrease in the exposure of the vaccinated animals to the infectious agent, thereby challenging the vaccinal immunity to a greater extent.Fluctuations of immunityAnother important concept is the understanding that immunity (vaccinal or natural) is not a 'binary' state (i.e. animals are not simply 'immune' or 'na\u00efve').", [["pneumonia", "DISEASE", 104, 113], ["G", "GENE_OR_GENE_PRODUCT", 77, 78], ["calf", "ORGANISM", 99, 103], ["calves", "ORGANISM", 135, 141], ["calves", "ORGANISM", 225, 231], ["cows", "ORGANISM_SUBDIVISION", 426, 430], ["calf", "SPECIES", 99, 103], ["calves", "SPECIES", 135, 141], ["beef", "SPECIES", 200, 204], ["calves", "SPECIES", 225, 231], ["cows", "SPECIES", 426, 430], ["calf", "SPECIES", 99, 103], ["beef", "SPECIES", 200, 204], ["bull", "SPECIES", 220, 224], ["G vaccination", "TREATMENT", 77, 90], ["calf pneumonia", "PROBLEM", 99, 113], ["replacement stock", "TREATMENT", 154, 171], ["vaccines", "TREATMENT", 589, 597], ["calf", "ANATOMY", 99, 103], ["pneumonia", "OBSERVATION", 104, 113], ["less", "OBSERVATION_MODIFIER", 665, 669], ["decrease", "OBSERVATION_MODIFIER", 670, 678], ["infectious", "OBSERVATION", 728, 738], ["greater extent", "OBSERVATION_MODIFIER", 793, 807], ["immunity", "OBSERVATION", 824, 832]]], ["Immunity tends to increase after vaccination, peak within a few days to weeks (depending on vaccine type and route of administration) and then gradually decline.", [["vaccination", "TREATMENT", 33, 44], ["vaccine", "TREATMENT", 92, 99]]], ["Vaccines are often licensed to provide a certain duration of cover, but it is still worth being aware that protection is likely to be more effective early in the period of cover.", [["Vaccines", "TREATMENT", 0, 8]]], ["Vaccines against bovine viral diarrhoea (BVD) and leptospirosis are amongst the most commonly used cattle vaccines in the UK, and vaccines with label claims for 12-month protection are available against both diseases.", [["viral diarrhoea", "DISEASE", 24, 39], ["BVD", "DISEASE", 41, 44], ["leptospirosis", "DISEASE", 50, 63], ["bovine", "ORGANISM", 17, 23], ["viral diarrhoea", "ORGANISM", 24, 39], ["BVD", "ORGANISM", 41, 44], ["cattle", "ORGANISM", 99, 105], ["bovine", "SPECIES", 17, 23], ["bovine", "SPECIES", 17, 23], ["BVD", "SPECIES", 41, 44], ["cattle", "SPECIES", 99, 105], ["Vaccines", "TREATMENT", 0, 8], ["bovine viral diarrhoea", "PROBLEM", 17, 39], ["BVD", "PROBLEM", 41, 44], ["leptospirosis", "PROBLEM", 50, 63], ["cattle vaccines", "TREATMENT", 99, 114], ["vaccines", "TREATMENT", 130, 138], ["both diseases", "PROBLEM", 203, 216]]], ["However, the principle that animals will be less well protected in the period before revaccination is due can still be useful: G Infection with leptospirosis is more likely at pasture: therefore peak coverage should logically apply during the grazing season, so annual vaccination should be timed to early spring G The major aim of BVD vaccination is to prevent cows becoming infected around the time of conception and early pregnancy (as this could lead to failure of conception, embryonic loss or production of a persistently infected calf): therefore vaccination should logically be completed before the breeding period.", [["embryonic", "ANATOMY", 481, 490], ["leptospirosis", "DISEASE", 144, 157], ["embryonic loss", "DISEASE", 481, 495], ["BVD", "ORGANISM", 332, 335], ["cows", "ORGANISM", 362, 366], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 481, 490], ["calf", "ORGANISM_SUBDIVISION", 537, 541], ["cows", "SPECIES", 362, 366], ["calf", "SPECIES", 537, 541], ["BVD", "SPECIES", 332, 335], ["cows", "SPECIES", 362, 366], ["revaccination", "TREATMENT", 85, 98], ["G Infection", "PROBLEM", 127, 138], ["leptospirosis", "PROBLEM", 144, 157], ["peak coverage", "TREATMENT", 195, 208], ["annual vaccination", "TREATMENT", 262, 280], ["BVD vaccination", "TREATMENT", 332, 347], ["cows", "PROBLEM", 362, 366], ["infected", "PROBLEM", 376, 384], ["early pregnancy", "PROBLEM", 419, 434], ["failure of conception", "PROBLEM", 458, 479], ["embryonic loss", "PROBLEM", 481, 495], ["a persistently infected calf)", "PROBLEM", 513, 542], ["vaccination", "TREATMENT", 554, 565], ["Infection", "OBSERVATION", 129, 138], ["leptospirosis", "OBSERVATION", 144, 157], ["BVD", "OBSERVATION", 332, 335], ["infected", "OBSERVATION", 376, 384], ["calf", "ANATOMY", 537, 541]]], ["In seasonally-calving herds, this is a practical possibility (and is often done), but in year-round calving herds would mean vaccinating smaller numbers of cows over the course of the year rather than vaccinating the herd as a batch.Vaccine handlingThe importance of correct handling of vaccine is well recognised amongst the veterinary profession, but this can still be a common reason for apparent vaccine failure in farm animals.", [["a batch", "TREATMENT", 225, 232], ["Vaccine", "TREATMENT", 233, 240], ["vaccine", "TREATMENT", 287, 294], ["apparent vaccine failure", "PROBLEM", 391, 415]]], ["The role of farm animal vets in communicating the importance of correct storage and use of vaccine (including the shelf life of the vaccine after the vial is breached or the vaccine reconstituted) is perhaps underestimated.", [["vaccine", "TREATMENT", 91, 98], ["the vaccine", "TREATMENT", 128, 139], ["the vaccine", "TREATMENT", 170, 181]]], ["Handouts detailing the key points of this advice can be useful when dispensed along with vaccine.Client information and expectations What protection is providedAnother area where it is important for the farm animal vet to communicate effectively with clients is in promoting understanding of exactly what protection is provided by a vaccine.", [["vaccine", "TREATMENT", 89, 96]]], ["Many vaccines prevent only a single strain of a disease, and may provide limited or no cross-protection against other strains.", [["Many vaccines", "TREATMENT", 0, 13], ["a disease", "PROBLEM", 46, 55], ["other strains", "PROBLEM", 112, 125], ["disease", "OBSERVATION", 48, 55]]], ["A good example of this is vaccination against bluetongue virus (BTV).", [["bluetongue virus", "DISEASE", 46, 62], ["bluetongue virus", "ORGANISM", 46, 62], ["BTV", "ORGANISM", 64, 67], ["bluetongue virus", "SPECIES", 46, 62], ["bluetongue virus", "SPECIES", 46, 62], ["BTV", "SPECIES", 64, 67], ["vaccination", "TREATMENT", 26, 37], ["bluetongue virus", "PROBLEM", 46, 62]]], ["The currently licensed vaccines in the UK protect only against BTV-8 (the strain that has been diagnosed in the UK); other strains of the virus are present in continental Europe and could easily enter the UK.", [["BTV-8", "CHEMICAL", 63, 68], ["UK", "GENE_OR_GENE_PRODUCT", 39, 41], ["BTV-8", "ORGANISM", 63, 68], ["UK", "GENE_OR_GENE_PRODUCT", 112, 114], ["UK", "GENE_OR_GENE_PRODUCT", 205, 207], ["BTV-8", "SPECIES", 63, 68], ["licensed vaccines", "TREATMENT", 14, 31], ["BTV", "TEST", 63, 66], ["the strain", "PROBLEM", 70, 80], ["other strains of the virus", "PROBLEM", 117, 143], ["virus", "OBSERVATION", 138, 143]]], ["Although many CATTLE G PRACTICE UK Vet -Vol 14 No 4 July 2009 3 farmers are well informed about BTV, there are still a large number that are unaware that the currentlyused vaccines do not protect against other strains which may be a threat.", [["BTV", "ORGANISM", 96, 99], ["BTV", "SPECIES", 96, 99], ["the currentlyused vaccines", "TREATMENT", 154, 180], ["other strains", "PROBLEM", 204, 217]]], ["This could potentially lead to disillusionment with the vaccination campaign should another strain enter the UK.Active vs. passive vaccinationIt is also important to be aware of the distinction between active and passive vaccination.", [["UK", "GENE_OR_GENE_PRODUCT", 109, 111], ["the vaccination campaign", "TREATMENT", 52, 76], ["passive vaccination", "TREATMENT", 123, 142], ["passive vaccination", "TREATMENT", 213, 232], ["active", "OBSERVATION_MODIFIER", 202, 208]]], ["Active vaccination is the process described above.", [["vaccination", "OBSERVATION", 7, 18]]], ["Passive vaccination effectively involves providing protection against a disease by giving exogenous antibody to the recipient -in practical terms in cattle, this means vaccinating the dam in order that the calf is protected via colostrum.", [["colostrum", "ANATOMY", 228, 237], ["cattle", "ORGANISM", 149, 155], ["calf", "ORGANISM", 206, 210], ["colostrum", "ORGANISM_SUBSTANCE", 228, 237], ["exogenous antibody", "PROTEIN", 90, 108], ["cattle", "SPECIES", 149, 155], ["calf", "SPECIES", 206, 210], ["cattle", "SPECIES", 149, 155], ["Passive vaccination", "TREATMENT", 0, 19], ["a disease", "PROBLEM", 70, 79], ["exogenous antibody", "TREATMENT", 90, 108], ["calf", "ANATOMY", 206, 210]]], ["The available vaccines against calf diarrhoea are good examples of this.", [["diarrhoea", "DISEASE", 36, 45], ["calf", "ORGANISM", 31, 35], ["calf", "SPECIES", 31, 35], ["calf", "SPECIES", 31, 35], ["The available vaccines", "TREATMENT", 0, 22], ["calf diarrhoea", "PROBLEM", 31, 45]]], ["It is obviously important when practising passive vaccination to ensure that the calf has a good colostral intake in order to maximise benefit from the vaccine.DIAGNOSTIC TESTING USING IMMUNOLOGICAL METHODSThe most commonly used immunodiagnostic tests in cattle include enzyme-linked immunosorbent assays (ELISAs), the serum neutralisation test (SNT), the complement fixation test (CFT) and the microscopic agglutination and serum agglutination tests (MAT and SAT).Enzyme-linked immunosorbent assay (ELISA)The basic ELISA technique can be used to detect either antigen from or antibody to specific pathogens (Figs.", [["serum", "ANATOMY", 319, 324], ["serum", "ANATOMY", 425, 430], ["calf", "ORGANISM", 81, 85], ["colostral", "ORGANISM_SUBSTANCE", 97, 106], ["cattle", "ORGANISM", 255, 261], ["serum", "ORGANISM_SUBSTANCE", 319, 324], ["serum", "ORGANISM_SUBSTANCE", 425, 430], ["enzyme", "PROTEIN", 270, 276], ["calf", "SPECIES", 81, 85], ["cattle", "SPECIES", 255, 261], ["cattle", "SPECIES", 255, 261], ["practising passive vaccination", "TREATMENT", 31, 61], ["the vaccine", "TREATMENT", 148, 159], ["DIAGNOSTIC TESTING", "TEST", 160, 178], ["immunodiagnostic tests", "TEST", 229, 251], ["enzyme-linked immunosorbent assays", "TEST", 270, 304], ["ELISAs", "TEST", 306, 312], ["the serum neutralisation test", "TEST", 315, 344], ["the complement fixation test", "TEST", 352, 380], ["CFT", "TEST", 382, 385], ["the microscopic agglutination", "TEST", 391, 420], ["serum agglutination tests", "TEST", 425, 450], ["MAT", "TEST", 452, 455], ["SAT", "TEST", 460, 463], ["Enzyme", "TEST", 465, 471], ["immunosorbent assay", "TEST", 479, 498], ["ELISA", "TEST", 500, 505], ["The basic ELISA technique", "TEST", 506, 531], ["antigen", "PROBLEM", 561, 568], ["antibody to specific pathogens", "PROBLEM", 577, 607], ["calf", "ANATOMY", 81, 85]]], ["Antibody ELISAs are commonly used to diagnose exposure to or infection with diseases such as infectious bovine rhinotracheitis (IBR) and Johne's disease, while an antigen ELISA is used to detect circulating BVD antigen.Enzyme-linked immunosorbent assay (ELISA)As an example: in order to detect antibody against Mycobacterium avium subsp. paratuberculosis (MAP), MAP antigen is coated on to the surface of plastic wells.", [["surface", "ANATOMY", 394, 401], ["infection", "DISEASE", 61, 70], ["infectious bovine rhinotracheitis", "DISEASE", 93, 126], ["IBR", "DISEASE", 128, 131], ["Johne's disease", "DISEASE", 137, 152], ["bovine rhinotracheitis", "ORGANISM", 104, 126], ["BVD antigen", "GENE_OR_GENE_PRODUCT", 207, 218], ["Mycobacterium avium", "ORGANISM", 311, 330], ["subsp", "ORGANISM", 331, 336], ["paratuberculosis", "ORGANISM", 338, 354], ["MAP", "GENE_OR_GENE_PRODUCT", 356, 359], ["MAP antigen", "GENE_OR_GENE_PRODUCT", 362, 373], ["surface", "CELLULAR_COMPONENT", 394, 401], ["BVD antigen", "PROTEIN", 207, 218], ["MAP antigen", "PROTEIN", 362, 373], ["bovine", "SPECIES", 104, 110], ["rhinotracheitis", "SPECIES", 111, 126], ["Johne", "SPECIES", 137, 142], ["Mycobacterium avium", "SPECIES", 311, 330], ["subsp", "SPECIES", 331, 336], ["paratuberculosis", "SPECIES", 338, 354], ["bovine rhinotracheitis", "SPECIES", 104, 126], ["IBR", "SPECIES", 128, 131], ["Johne", "SPECIES", 137, 142], ["BVD", "SPECIES", 207, 210], ["Mycobacterium avium", "SPECIES", 311, 330], ["paratuberculosis", "SPECIES", 338, 354], ["Antibody ELISAs", "TEST", 0, 15], ["infection", "PROBLEM", 61, 70], ["diseases", "PROBLEM", 76, 84], ["infectious bovine rhinotracheitis", "PROBLEM", 93, 126], ["Johne's disease", "PROBLEM", 137, 152], ["an antigen ELISA", "TEST", 160, 176], ["circulating BVD antigen", "PROBLEM", 195, 218], ["Enzyme", "TEST", 219, 225], ["immunosorbent assay", "TEST", 233, 252], ["antibody", "TEST", 294, 302], ["Mycobacterium avium subsp", "PROBLEM", 311, 336], ["paratuberculosis", "PROBLEM", 338, 354], ["MAP antigen", "TEST", 362, 373], ["infection", "OBSERVATION", 61, 70], ["infectious", "OBSERVATION_MODIFIER", 93, 103], ["plastic wells", "OBSERVATION", 405, 418]]], ["Serum from test animals is then added to the wells.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum from test animals", "TEST", 0, 23]]], ["Specific antibody produced in response to infection with MAP will then bind to the antigen on the plate.", [["infection", "DISEASE", 42, 51], ["MAP", "GENE_OR_GENE_PRODUCT", 57, 60], ["MAP", "PROTEIN", 57, 60], ["Specific antibody", "TEST", 0, 17], ["infection", "PROBLEM", 42, 51], ["MAP", "TEST", 57, 60], ["infection", "OBSERVATION", 42, 51], ["plate", "ANATOMY", 98, 103]]], ["Excess non-specific antibody is washed off and a second (anti-bovine immunoglobulin) antibody conjugated to an enzyme is added to the plates.", [["bovine", "ORGANISM", 62, 68], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 69, 83], ["non-specific antibody", "PROTEIN", 7, 28], ["bovine immunoglobulin) antibody", "PROTEIN", 62, 93], ["enzyme", "PROTEIN", 111, 117], ["bovine", "SPECIES", 62, 68], ["Excess non-specific antibody", "PROBLEM", 0, 28], ["a second (anti-bovine immunoglobulin) antibody", "TREATMENT", 47, 93], ["an enzyme", "TEST", 108, 117], ["non-specific", "OBSERVATION_MODIFIER", 7, 19], ["antibody", "OBSERVATION", 20, 28]]], ["This will bind the antigen-specific antibodies.", [["antigen-specific antibodies", "PROTEIN", 19, 46], ["the antigen", "TEST", 15, 26]]], ["The excess of the second antibody is washed away and a colourless substrate (degraded by the enzyme to a coloured product) is added.", [["enzyme", "PROTEIN", 93, 99], ["a colourless substrate", "PROBLEM", 53, 75]]], ["It is then possible to quantify the amount of antibody present in each well by measuring the absorbance of light by the coloured product (Fig. 1A) .Enzyme-linked immunosorbent assay (ELISA)Detection of antigen in a sample is possible in a similar way.", [["Enzyme", "TEST", 148, 154], ["immunosorbent assay", "TEST", 162, 181], ["ELISA", "TEST", 183, 188], ["amount", "OBSERVATION_MODIFIER", 36, 42], ["antibody", "OBSERVATION", 46, 54]]], ["Samples to be tested are coated on to the surface of the wells and antibody specific to the antigen is added to the plate; non-specific binding is prevented.", [["Samples", "ANATOMY", 0, 7], ["surface", "ANATOMY", 42, 49], ["surface", "CELLULAR_COMPONENT", 42, 49], ["Samples", "TEST", 0, 7], ["non-specific binding", "PROBLEM", 123, 143]]], ["This detection antibody is conjugated to an enzyme and addition of a substrate makes it possible to quantify the amount of antigen present in the sample (Fig. 1B) .", [["sample", "ANATOMY", 146, 152], ["This detection antibody", "TEST", 0, 23], ["an enzyme", "TEST", 41, 50], ["a substrate", "TREATMENT", 67, 78]]], ["A modification of this technique, called a sandwich ELISA, allows detection of soluble or secreted products.", [["secreted products", "PROTEIN", 90, 107], ["this technique", "TREATMENT", 18, 32], ["a sandwich ELISA", "TEST", 41, 57], ["soluble or secreted products", "TREATMENT", 79, 107]]], ["Here, antigenspecific antibodies are used to coat the plate where they can bind antigen when the test sample is added.", [["antigenspecific antibodies", "PROTEIN", 6, 32], ["antigenspecific antibodies", "TREATMENT", 6, 32], ["the test sample", "TEST", 93, 108]]], ["A second detection antibody that binds to a different epitope on the antigen is then added (Fig. 1C) .Serum neutralisation test (SNT)The SNT is sometimes used as an alternative to an ELISA for detection of antibody (for example against BVD).", [["Serum", "ANATOMY", 102, 107], ["Serum", "ORGANISM_SUBSTANCE", 102, 107], ["BVD", "ORGANISM", 236, 239], ["antibody", "PROTEIN", 206, 214], ["BVD", "SPECIES", 236, 239], ["A second detection antibody", "PROBLEM", 0, 27], ["a different epitope on the antigen", "TREATMENT", 42, 76], ["Serum neutralisation test", "TEST", 102, 127], ["an ELISA", "TEST", 180, 188], ["antibody", "PROBLEM", 206, 214], ["BVD", "PROBLEM", 236, 239]]], ["Serum samples from test animals are serially diluted and each dilution is incubated with the same quantity of virus.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples from test animals", "TEST", 0, 31], ["each dilution", "TEST", 57, 70], ["virus", "PROBLEM", 110, 115], ["virus", "OBSERVATION", 110, 115]]], ["Any anti-BVD antibody present will bind to the virus, 'neutralising' it.", [["anti-BVD antibody", "GENE_OR_GENE_PRODUCT", 4, 21], ["anti-BVD antibody", "PROTEIN", 4, 21], ["Any anti-BVD antibody", "PROBLEM", 0, 21]]], ["BVD susceptible cells are then added to the samples; if the virus is neutralised, no cytopathic effect on these cells will be visible on microscopy.", [["cells", "ANATOMY", 16, 21], ["samples", "ANATOMY", 44, 51], ["cells", "ANATOMY", 112, 117], ["BVD", "ORGANISM", 0, 3], ["cells", "CELL", 16, 21], ["cells", "CELL", 112, 117], ["BVD susceptible cells", "CELL_TYPE", 0, 21], ["BVD", "SPECIES", 0, 3], ["BVD susceptible cells", "PROBLEM", 0, 21], ["the samples", "TEST", 40, 51], ["the virus", "PROBLEM", 56, 65], ["cytopathic effect on these cells", "PROBLEM", 85, 117], ["microscopy", "TEST", 137, 147], ["susceptible cells", "OBSERVATION", 4, 21], ["no", "UNCERTAINTY", 82, 84], ["cytopathic", "OBSERVATION_MODIFIER", 85, 95]]], ["The dilution of serum (or its log equivalent) at which virus neutralisation no longer occurs is the reported result.Complement fixation test (CFT)The CFT (Fig. 2) is most commonly used to detect antibody against (and therefore exposure to) pathogens such as Brucella abortus and Histophilus somni.", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["Brucella abortus", "ORGANISM", 258, 274], ["Histophilus somni", "ORGANISM", 279, 296], ["Brucella abortus", "SPECIES", 258, 274], ["Histophilus somni", "SPECIES", 279, 296], ["Brucella abortus", "SPECIES", 258, 274], ["Histophilus somni", "SPECIES", 279, 296], ["The dilution of serum", "TEST", 0, 21], ["Complement fixation test", "TEST", 116, 140], ["CFT", "TEST", 142, 145], ["antibody", "PROBLEM", 195, 203], ["pathogens", "PROBLEM", 240, 249], ["Brucella abortus", "PROBLEM", 258, 274], ["fixation", "OBSERVATION", 127, 135]]], ["The test relies on the activation of the complement cascade via the classical pathway (Inman & Hudson, 2009 ).Complement fixation test (CFT)Here, the C1q complement protein binds to antigenantibody complexes, initiating the cascade.", [["C1q", "GENE_OR_GENE_PRODUCT", 150, 153], ["C1q complement protein", "PROTEIN", 150, 172], ["antigenantibody complexes", "PROTEIN", 182, 207], ["Complement fixation test", "TEST", 110, 134], ["the C1q complement protein binds", "PROBLEM", 146, 178], ["the cascade", "TREATMENT", 220, 231], ["fixation", "OBSERVATION", 121, 129]]], ["Where pathogen-specific antibody is present in serum, the addition of appropriate antigen will cause the CATTLE G PRACTICE UK Vet -Vol 14 No 4 July 2009 4 Fig. 1 : A. Antigen-specific antibody in the test sample is detected using antigen bound to the plate and an enzyme-linked detection antibody plus substrate; B. antigen in a test sample is detected by coating it onto the surface of the well and adding a detection antibody to bind it; C. a sandwich ELISA is used to detect soluble antigen -antigen-specific antibody is bound to the plate, the sample containing the antigen is added to bind this first antibody and a second enzymelinked antibody is used to detect bound antigen.", [["serum", "ANATOMY", 47, 52], ["sample", "ANATOMY", 205, 211], ["sample", "ANATOMY", 334, 340], ["surface", "ANATOMY", 376, 383], ["sample", "ANATOMY", 548, 554], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["B. antigen", "GENE_OR_GENE_PRODUCT", 313, 323], ["surface", "CELLULAR_COMPONENT", 376, 383], ["-antigen", "GENE_OR_GENE_PRODUCT", 494, 502], ["pathogen-specific antibody", "PROTEIN", 6, 32], ["1 : A. Antigen-specific antibody", "PROTEIN", 160, 192], ["enzyme-linked detection antibody", "PROTEIN", 264, 296], ["B. antigen", "PROTEIN", 313, 323], ["detection antibody", "PROTEIN", 409, 427], ["soluble antigen -antigen-specific antibody", "PROTEIN", 478, 520], ["enzymelinked antibody", "PROTEIN", 628, 649], ["pathogen", "PROBLEM", 6, 14], ["specific antibody", "TEST", 15, 32], ["serum", "TEST", 47, 52], ["A. Antigen", "TEST", 164, 174], ["specific antibody", "TEST", 175, 192], ["the test sample", "TEST", 196, 211], ["the plate", "TEST", 247, 256], ["an enzyme", "TEST", 261, 270], ["B. antigen", "TEST", 313, 323], ["a test sample", "TEST", 327, 340], ["a detection antibody", "TEST", 407, 427], ["a sandwich ELISA", "TEST", 443, 459], ["soluble antigen -antigen", "TEST", 478, 502], ["a second enzymelinked antibody", "TEST", 619, 649], ["bound antigen", "PROBLEM", 668, 681]]], ["Antigen-specific antibody is present in the test serum but not in the control; 2. antigen is added and binds to the antibody in the test serum; 3. complement proteins are added and are fixed to the antigen-antibody complexes in the test serum but remain unfixed in the control; 4. antibodycoated sheep red blood cells are added.", [["serum", "ANATOMY", 49, 54], ["serum", "ANATOMY", 137, 142], ["serum", "ANATOMY", 237, 242], ["red blood cells", "ANATOMY", 302, 317], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["antigen", "GENE_OR_GENE_PRODUCT", 82, 89], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["serum", "ORGANISM_SUBSTANCE", 237, 242], ["sheep", "ORGANISM", 296, 301], ["red blood cells", "CELL", 302, 317], ["Antigen-specific antibody", "PROTEIN", 0, 25], ["complement proteins", "PROTEIN", 147, 166], ["antigen-antibody complexes", "PROTEIN", 198, 224], ["antibodycoated sheep red blood cells", "CELL_TYPE", 281, 317], ["sheep", "SPECIES", 296, 301], ["sheep", "SPECIES", 296, 301], ["Antigen", "TEST", 0, 7], ["specific antibody", "TEST", 8, 25], ["the test serum", "TEST", 40, 54], ["antigen", "TEST", 82, 89], ["the antibody", "TEST", 112, 124], ["the test serum", "TEST", 128, 142], ["complement proteins", "TEST", 147, 166], ["the antigen", "TEST", 194, 205], ["the test serum", "TEST", 228, 242], ["antibodycoated sheep red blood cells", "TREATMENT", 281, 317]]], ["The unfixed complement in the control sample binds to the antibody on the surface of the cells, causing haemolysis.", [["sample", "ANATOMY", 38, 44], ["surface", "ANATOMY", 74, 81], ["cells", "ANATOMY", 89, 94], ["haemolysis", "DISEASE", 104, 114], ["surface", "CELLULAR_COMPONENT", 74, 81], ["cells", "CELL", 89, 94], ["haemolysis", "PROBLEM", 104, 114], ["cells", "ANATOMY", 89, 94], ["haemolysis", "OBSERVATION", 104, 114]]], ["In the test sample, this cannot occur as complement is already fixed.Complement fixation test (CFT)formation of antigen-antibody complexes.", [["antigen-antibody", "GENE_OR_GENE_PRODUCT", 112, 128], ["antigen-antibody complexes", "PROTEIN", 112, 138], ["the test sample", "TEST", 3, 18], ["Complement fixation test", "TEST", 69, 93], ["antigen", "TEST", 112, 119], ["fixation", "OBSERVATION", 80, 88]]], ["If no antibody is present, these complexes will not form and there will be no fixation of complement.", [["antibody", "PROBLEM", 6, 14], ["fixation of complement", "PROBLEM", 78, 100], ["no", "UNCERTAINTY", 3, 5], ["antibody", "OBSERVATION", 6, 14]]], ["Antibody-coated sheep red blood cells are then added to the test solution.", [["red blood cells", "ANATOMY", 22, 37], ["sheep", "ORGANISM", 16, 21], ["blood cells", "CELL", 26, 37], ["Antibody-coated sheep red blood cells", "CELL_LINE", 0, 37], ["sheep", "SPECIES", 16, 21], ["sheep", "SPECIES", 16, 21], ["Antibody", "TEST", 0, 8], ["coated sheep red blood cells", "TREATMENT", 9, 37], ["the test solution", "TREATMENT", 56, 73]]], ["If free complement is present, it will bind to the antibodies on the surface of the cells, initiating the cascade and causing haemolysis.", [["surface", "ANATOMY", 69, 76], ["cells", "ANATOMY", 84, 89], ["haemolysis", "DISEASE", 126, 136], ["surface", "CELLULAR_COMPONENT", 69, 76], ["cells", "CELL", 84, 89], ["antibodies", "PROTEIN", 51, 61], ["the cascade", "TREATMENT", 102, 113], ["haemolysis", "PROBLEM", 126, 136], ["haemolysis", "OBSERVATION", 126, 136]]], ["If no free complement is present due to fixation on the antigen-antibody complexes, no haemolysis will occur.", [["haemolysis", "DISEASE", 87, 97], ["antigen-antibody complexes", "PROTEIN", 56, 82], ["free complement", "PROBLEM", 6, 21], ["fixation", "TREATMENT", 40, 48], ["the antigen-antibody complexes", "TEST", 52, 82], ["haemolysis", "PROBLEM", 87, 97], ["fixation", "OBSERVATION", 40, 48], ["no", "UNCERTAINTY", 84, 86], ["haemolysis", "OBSERVATION", 87, 97]]], ["The absence of haemolysis therefore denotes a positive test.Microscopic agglutination test (MAT)The MAT is commonly used for the diagnosis of leptospirosis and basically allows the recognition of complexes formed from specific antibody in test serum and antigen added to the sample.", [["serum", "ANATOMY", 244, 249], ["sample", "ANATOMY", 275, 281], ["haemolysis", "DISEASE", 15, 25], ["leptospirosis", "DISEASE", 142, 155], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["MAT", "DNA", 100, 103], ["specific antibody", "PROTEIN", 218, 235], ["haemolysis", "PROBLEM", 15, 25], ["a positive test", "TEST", 44, 59], ["Microscopic agglutination test", "TEST", 60, 90], ["leptospirosis", "PROBLEM", 142, 155], ["specific antibody in test serum", "TEST", 218, 249], ["the sample", "TEST", 271, 281], ["haemolysis", "OBSERVATION", 15, 25], ["leptospirosis", "OBSERVATION", 142, 155]]], ["This involves incubating serial dilutions of serum with known concentrations of live cultures of the serovars of interest.", [["serum", "ANATOMY", 45, 50], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["live cultures", "TEST", 80, 93]]], ["The test is read by transferring a drop from each well on to a microscope slide and examining it by dark-field microscopy.", [["a microscope slide", "TEST", 61, 79], ["dark-field microscopy", "TEST", 100, 121]]], ["Again, the dilution of serum (titre) at which agglutination no longer occurs at a specific level is the reported result.", [["serum", "ANATOMY", 23, 28], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["the dilution of serum (titre", "TEST", 7, 35], ["agglutination", "TEST", 46, 59], ["no longer", "UNCERTAINTY", 60, 69]]], ["The basis of the SAT is essentially the same except that the agglutination is visualised macroscopically.Choice of testThere are various reasons that different diagnostic tests are chosen.", [["SAT", "TISSUE", 17, 20], ["the SAT", "TEST", 13, 20], ["the agglutination", "TEST", 57, 74], ["different diagnostic tests", "TEST", 150, 176], ["agglutination", "OBSERVATION", 61, 74]]], ["Broadly speaking, ELISA tests are rapid, inexpensive and have relatively good specificity and sensitivity.", [["ELISA tests", "TEST", 18, 29]]], ["Other tests are most often used where there is no ELISA, or where (often older) tests are specifically mentioned in legislation (for example relating to animal exports).Choice of testAs with all diagnostic tests, it is important to be aware of the properties of the test when interpreting results and to look at data critically before making decisions.", [["Other tests", "TEST", 0, 11], ["ELISA", "PROBLEM", 50, 55], ["all diagnostic tests", "TEST", 191, 211], ["the test", "TEST", 262, 270], ["no", "UNCERTAINTY", 47, 49]]], ["In particular, specificity and sensitivity of commonly used tests are important to be aware of (from a practical point of view the positive and negative predictive values are more useful, but these will vary according to the prevalence of disease in the population being tested).", [["tests", "TEST", 60, 65], ["disease", "PROBLEM", 239, 246]]], ["Some immunodiagnostic tests, such as the ELISA to detect serum antibodies to MAP in Johne's disease, have a relatively low sensitivity in certain circumstances (e.g. in animals early in the course of disease), which will decrease the negative predictive value of the test (i.e. decrease the probability that a negative result is correct).", [["serum", "ANATOMY", 57, 62], ["Johne's disease", "DISEASE", 84, 99], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["MAP", "GENE_OR_GENE_PRODUCT", 77, 80], ["serum antibodies", "PROTEIN", 57, 73], ["Johne", "SPECIES", 84, 89], ["Some immunodiagnostic tests", "TEST", 0, 27], ["the ELISA", "TEST", 37, 46], ["serum antibodies", "TEST", 57, 73], ["MAP", "TEST", 77, 80], ["Johne's disease", "PROBLEM", 84, 99], ["a relatively low sensitivity", "PROBLEM", 106, 134], ["disease", "PROBLEM", 200, 207], ["the test", "TEST", 263, 271]]], ["Properties of tests may also vary between laboratories depending on reagents and protocols used.", [["Properties of tests", "TEST", 0, 19]]], ["Laboratories should be able to give an idea of the sensitivity and specificity of the tests they offer, and this knowledge should be used in conjunction with test results.CONCLUSIONThis series of articles has attempted to put some current immunological knowledge into a clinical context for the cattle vet.", [["cattle", "ORGANISM", 295, 301], ["cattle", "SPECIES", 295, 301], ["the sensitivity", "TEST", 47, 62], ["the tests", "TEST", 82, 91]]], ["A sound understanding of the immunological principles underlying different disease states as well as the practice of vaccination and immunodiagnostic testing is extremely helpful in providing a good quality of service to farm clients.", [["different disease states", "PROBLEM", 65, 89], ["vaccination", "TREATMENT", 117, 128], ["immunodiagnostic testing", "TEST", 133, 157], ["different", "OBSERVATION_MODIFIER", 65, 74], ["disease", "OBSERVATION", 75, 82]]]], "31ce4647dd3ce32716212b10cfa8b05724dc32fd": [], "PMC5385097": [["BackgroundBovine respiratory disease complex (BRDC) is a global problem causing severe economic losses to the cattle farming industry through mortality, loss of production, and treatment costs [1, 2].", [["BackgroundBovine respiratory disease", "DISEASE", 0, 36], ["BRDC", "DISEASE", 46, 50], ["BackgroundBovine respiratory disease complex", "GENE_OR_GENE_PRODUCT", 0, 44], ["cattle", "SPECIES", 110, 116], ["cattle", "SPECIES", 110, 116], ["BackgroundBovine respiratory disease complex", "PROBLEM", 0, 44], ["a global problem", "PROBLEM", 55, 71], ["severe economic losses", "PROBLEM", 80, 102], ["loss of production", "PROBLEM", 153, 171], ["respiratory disease", "OBSERVATION", 17, 36], ["severe", "OBSERVATION_MODIFIER", 80, 86]]], ["It has a complex etiology that involves various pathogens, host factors, and environmental factors.", [["host factors", "PROTEIN", 59, 71], ["environmental factors", "PROTEIN", 77, 98], ["various pathogens", "PROBLEM", 40, 57], ["complex", "OBSERVATION_MODIFIER", 9, 16], ["various", "OBSERVATION_MODIFIER", 40, 47], ["pathogens", "OBSERVATION", 48, 57]]], ["Viruses such as bovine herpes 1 virus (BoHV-1, parainfluenza virus 3 (PBIV-3), bovine respiratory syncytial Virus (BRSV), respiratory bovine coronavirus (BoCoV) and bovine viral diarrhoea virus (BVDV) in conjunction with stress factors have been implicated as causes of respiratory tract infections of cattle by immunosuppression and damage to the respiratory epithelium [3].", [["respiratory tract", "ANATOMY", 270, 287], ["respiratory epithelium", "ANATOMY", 348, 370], ["respiratory syncytial Virus", "DISEASE", 86, 113], ["respiratory bovine coronavirus", "DISEASE", 122, 152], ["bovine viral diarrhoea virus", "DISEASE", 165, 193], ["respiratory tract infections", "DISEASE", 270, 298], ["bovine", "ORGANISM", 16, 22], ["herpes 1 virus", "ORGANISM", 23, 37], ["BoHV-1", "ORGANISM", 39, 45], ["parainfluenza virus 3", "ORGANISM", 47, 68], ["PBIV-3", "ORGANISM", 70, 76], ["bovine respiratory syncytial Virus", "ORGANISM", 79, 113], ["BRSV", "ORGANISM", 115, 119], ["respiratory bovine coronavirus", "ORGANISM", 122, 152], ["BoCoV", "ORGANISM", 154, 159], ["bovine viral diarrhoea virus", "ORGANISM", 165, 193], ["BVDV", "ORGANISM", 195, 199], ["respiratory tract", "ORGANISM_SUBDIVISION", 270, 287], ["cattle", "ORGANISM", 302, 308], ["bovine", "SPECIES", 16, 22], ["herpes 1 virus", "SPECIES", 23, 37], ["BoHV-1", "SPECIES", 39, 45], ["parainfluenza virus", "SPECIES", 47, 66], ["bovine", "SPECIES", 79, 85], ["respiratory syncytial Virus", "SPECIES", 86, 113], ["BRSV", "SPECIES", 115, 119], ["bovine", "SPECIES", 134, 140], ["coronavirus", "SPECIES", 141, 152], ["bovine", "SPECIES", 165, 171], ["viral diarrhoea virus", "SPECIES", 172, 193], ["cattle", "SPECIES", 302, 308], ["bovine herpes 1 virus", "SPECIES", 16, 37], ["BoHV-1", "SPECIES", 39, 45], ["bovine respiratory syncytial Virus", "SPECIES", 79, 113], ["BRSV", "SPECIES", 115, 119], ["bovine coronavirus", "SPECIES", 134, 152], ["BoCoV", "SPECIES", 154, 159], ["bovine viral diarrhoea virus", "SPECIES", 165, 193], ["BVDV", "SPECIES", 195, 199], ["cattle", "SPECIES", 302, 308], ["Viruses", "PROBLEM", 0, 7], ["bovine herpes 1 virus", "PROBLEM", 16, 37], ["BoHV", "TEST", 39, 43], ["parainfluenza virus", "PROBLEM", 47, 66], ["PBIV", "TEST", 70, 74], ["bovine respiratory syncytial Virus", "PROBLEM", 79, 113], ["BRSV", "PROBLEM", 115, 119], ["respiratory bovine coronavirus", "PROBLEM", 122, 152], ["bovine viral diarrhoea virus", "PROBLEM", 165, 193], ["BVDV", "PROBLEM", 195, 199], ["stress factors", "PROBLEM", 221, 235], ["respiratory tract infections", "PROBLEM", 270, 298], ["immunosuppression", "TREATMENT", 312, 329], ["damage to the respiratory epithelium", "PROBLEM", 334, 370], ["respiratory syncytial", "ANATOMY", 86, 107], ["respiratory bovine coronavirus", "OBSERVATION", 122, 152], ["respiratory tract", "ANATOMY", 270, 287], ["respiratory epithelium", "ANATOMY", 348, 370]]], ["A primary viral infection can be followed by an opportunistic secondary infection with bacteria like Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, or Trueperella pyogenes [2, 4, 5], but these bacteria could also act as primary pathogen.", [["primary viral infection", "DISEASE", 2, 25], ["infection", "DISEASE", 72, 81], ["Mannheimia haemolytica", "ORGANISM", 101, 123], ["Pasteurella multocida", "ORGANISM", 125, 146], ["Histophilus somni", "ORGANISM", 148, 165], ["Trueperella pyogenes", "ORGANISM", 170, 190], ["Mannheimia haemolytica", "SPECIES", 101, 123], ["Pasteurella multocida", "SPECIES", 125, 146], ["Histophilus somni", "SPECIES", 148, 165], ["Trueperella pyogenes", "SPECIES", 170, 190], ["Mannheimia haemolytica", "SPECIES", 101, 123], ["Pasteurella multocida", "SPECIES", 125, 146], ["Histophilus somni", "SPECIES", 148, 165], ["Trueperella pyogenes", "SPECIES", 170, 190], ["A primary viral infection", "PROBLEM", 0, 25], ["an opportunistic secondary infection", "PROBLEM", 45, 81], ["bacteria", "PROBLEM", 87, 95], ["Mannheimia haemolytica", "PROBLEM", 101, 123], ["Pasteurella multocida", "PROBLEM", 125, 146], ["Histophilus somni", "PROBLEM", 148, 165], ["Trueperella pyogenes", "PROBLEM", 170, 190], ["these bacteria", "PROBLEM", 206, 220], ["primary pathogen", "PROBLEM", 239, 255], ["viral infection", "OBSERVATION", 10, 25], ["infection", "OBSERVATION", 72, 81]]], ["In addition it has become increasingly clear that Mycoplasmas are important contributors to BRD, either as primary pathogens or in co-infection [2, 6\u20139].", [["Mycoplasmas", "CHEMICAL", 50, 61], ["BRD", "DISEASE", 92, 95], ["co-infection", "DISEASE", 131, 143], ["Mycoplasmas", "SIMPLE_CHEMICAL", 50, 61], ["BRD", "SPECIES", 92, 95], ["Mycoplasmas", "PROBLEM", 50, 61], ["BRD", "PROBLEM", 92, 95], ["increasingly", "OBSERVATION_MODIFIER", 26, 38], ["clear", "OBSERVATION", 39, 44], ["Mycoplasmas", "OBSERVATION", 50, 61]]], ["M. bovis is the best known Mycoplasma species causing respiratory disease [4, 7], but also M. dispar and M. bovirhinis have been associated with BRD [2, 9\u201311].", [["respiratory", "ANATOMY", 54, 65], ["respiratory disease", "DISEASE", 54, 73], ["BRD", "DISEASE", 145, 148], ["M. bovis", "ORGANISM", 0, 8], ["Mycoplasma species", "ORGANISM", 27, 45], ["M. dispar", "ORGANISM", 91, 100], ["M. bovirhinis", "ORGANISM", 105, 118], ["M. bovis", "SPECIES", 0, 8], ["M. dispar", "SPECIES", 91, 100], ["M. bovirhinis", "SPECIES", 105, 118], ["M. bovis", "SPECIES", 0, 8], ["M. dispar", "SPECIES", 91, 100], ["M. bovirhinis", "SPECIES", 105, 118], ["Mycoplasma species", "PROBLEM", 27, 45], ["respiratory disease", "PROBLEM", 54, 73], ["BRD", "PROBLEM", 145, 148], ["bovis", "OBSERVATION", 3, 8], ["Mycoplasma species", "OBSERVATION", 27, 45], ["respiratory disease", "OBSERVATION", 54, 73]]], ["M. bovis has not only been identified as a primary or opportunistic pathogen in BRD in beef cattle worldwide, but it has also been implicated in other clinical manifestations in cattle, such as mastitis, otitis, arthritis, and reproductive disorders [7].", [["BRD", "DISEASE", 80, 83], ["mastitis", "DISEASE", 194, 202], ["otitis", "DISEASE", 204, 210], ["arthritis", "DISEASE", 212, 221], ["reproductive disorders", "DISEASE", 227, 249], ["M. bovis", "ORGANISM", 0, 8], ["BRD", "ORGANISM", 80, 83], ["M. bovis", "SPECIES", 0, 8], ["beef", "SPECIES", 87, 91], ["cattle", "SPECIES", 92, 98], ["cattle", "SPECIES", 178, 184], ["M. bovis", "SPECIES", 0, 8], ["BRD", "SPECIES", 80, 83], ["beef", "SPECIES", 87, 91], ["cattle", "SPECIES", 92, 98], ["cattle", "SPECIES", 178, 184], ["opportunistic pathogen", "PROBLEM", 54, 76], ["mastitis", "PROBLEM", 194, 202], ["otitis", "PROBLEM", 204, 210], ["arthritis", "PROBLEM", 212, 221], ["reproductive disorders", "PROBLEM", 227, 249], ["bovis", "OBSERVATION", 3, 8], ["mastitis", "OBSERVATION", 194, 202], ["otitis", "OBSERVATION", 204, 210], ["arthritis", "OBSERVATION", 212, 221]]], ["M. bovirhinis and M. dispar are regularly isolated from the nasal cavity of cattle with respiratory disease and are usually regarded as an opportunistic pathogen in respiratory diseases [7, 12].BackgroundBacteriological, serological and histopathological examinations are important tools to detect particular animal-carriers of Mycoplasma [13], however, these assays are time-consuming, insensitive and can give false positive results.", [["nasal cavity", "ANATOMY", 60, 72], ["respiratory", "ANATOMY", 88, 99], ["respiratory", "ANATOMY", 165, 176], ["respiratory disease", "DISEASE", 88, 107], ["respiratory diseases", "DISEASE", 165, 185], ["M. bovirhinis", "ORGANISM", 0, 13], ["M. dispar", "ORGANISM", 18, 27], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 60, 72], ["cattle", "ORGANISM", 76, 82], ["Mycoplasma", "ORGANISM", 328, 338], ["M. bovirhinis", "SPECIES", 0, 13], ["M. dispar", "SPECIES", 18, 27], ["cattle", "SPECIES", 76, 82], ["M. bovirhinis", "SPECIES", 0, 13], ["M. dispar", "SPECIES", 18, 27], ["cattle", "SPECIES", 76, 82], ["M. dispar", "PROBLEM", 18, 27], ["respiratory disease", "PROBLEM", 88, 107], ["an opportunistic pathogen in respiratory diseases", "PROBLEM", 136, 185], ["histopathological examinations", "TEST", 237, 267], ["Mycoplasma", "PROBLEM", 328, 338], ["these assays", "TEST", 354, 366], ["nasal cavity", "ANATOMY", 60, 72], ["respiratory disease", "OBSERVATION", 88, 107], ["respiratory diseases", "OBSERVATION", 165, 185]]], ["Bronchoalveolar lavage fluid (BALF) from calves with BRD may contain various potential pathogens, but additional antibiotic use in the affected herds can inhibit cultivation and thereby can cause false-negative test results.", [["Bronchoalveolar lavage fluid", "ANATOMY", 0, 28], ["BALF", "ANATOMY", 30, 34], ["BRD", "DISEASE", 53, 56], ["Bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 0, 28], ["BALF", "ORGANISM_SUBSTANCE", 30, 34], ["calves", "ORGANISM", 41, 47], ["calves", "SPECIES", 41, 47], ["calves", "SPECIES", 41, 47], ["BRD", "SPECIES", 53, 56], ["Bronchoalveolar lavage fluid (BALF)", "TEST", 0, 35], ["BRD", "PROBLEM", 53, 56], ["various potential pathogens", "PROBLEM", 69, 96], ["additional antibiotic use", "TREATMENT", 102, 127], ["various", "OBSERVATION_MODIFIER", 69, 76], ["potential", "OBSERVATION_MODIFIER", 77, 86], ["pathogens", "OBSERVATION", 87, 96]]], ["In BRD, differential diagnosis of these pathogens with rapid turnaround time procedure is essential to implement appropriate treatment and intervention measures in a timely manner.", [["BRD", "DISEASE", 3, 6], ["BRD", "PROBLEM", 3, 6], ["these pathogens", "PROBLEM", 34, 49], ["rapid turnaround time procedure", "TREATMENT", 55, 86], ["appropriate treatment", "TREATMENT", 113, 134], ["intervention measures", "TREATMENT", 139, 160]]], ["Rapid detection of these pathogens at the early stage of outbreak can contribute substantially to minimize the spread of infection and increase treatment efficiency.", [["infection", "DISEASE", 121, 130], ["these pathogens", "PROBLEM", 19, 34], ["infection", "PROBLEM", 121, 130], ["increase treatment efficiency", "TREATMENT", 135, 164], ["pathogens", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 121, 130], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["Today quick, highly sensitive and species-specific PCRs are used in the diagnosis of Mycoplasma-associated diseases for M. dispar [14, 15], M. bovis [4, 16] and M. bovirhinis [17] in BALF or nasal swabs.", [["BALF", "ANATOMY", 183, 187], ["nasal swabs", "ANATOMY", 191, 202], ["Mycoplasma-associated diseases", "DISEASE", 85, 115], ["Mycoplasma", "ORGANISM", 85, 95], ["M. dispar", "ORGANISM", 120, 129], ["M. bovis", "ORGANISM", 140, 148], ["M. bovirhinis", "ORGANISM", 161, 174], ["BALF", "CELL", 183, 187], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 191, 202], ["M. dispar", "SPECIES", 120, 129], ["M. bovis", "SPECIES", 140, 148], ["M. bovirhinis", "SPECIES", 161, 174], ["M. dispar", "SPECIES", 120, 129], ["M. bovis", "SPECIES", 140, 148], ["M. bovirhinis", "SPECIES", 161, 174], ["highly sensitive and species", "PROBLEM", 13, 41], ["specific PCRs", "TEST", 42, 55], ["Mycoplasma", "PROBLEM", 85, 95], ["associated diseases", "PROBLEM", 96, 115], ["M. dispar", "TEST", 120, 129], ["M. bovis", "TEST", 140, 148], ["M. bovirhinis", "TEST", 161, 174], ["BALF", "TEST", 183, 187], ["nasal swabs", "TEST", 191, 202], ["Mycoplasma", "OBSERVATION", 85, 95], ["nasal", "ANATOMY", 191, 196]]], ["Combining a 16S Ribosomal DNA PCR with denaturing gradient gel electrophoresis fingerprinting (PCR/DGGE) enabled the simultaneous detection of mixed Mycoplasma populations, however information about the detection limit in clinical samples is limited [18].", [["samples", "ANATOMY", 231, 238], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["16S", "DNA", 12, 15], ["a 16S Ribosomal DNA PCR", "TEST", 10, 33], ["denaturing gradient gel electrophoresis fingerprinting", "TEST", 39, 93], ["PCR/DGGE", "TEST", 95, 103], ["the simultaneous detection", "TEST", 113, 139], ["mixed Mycoplasma populations", "PROBLEM", 143, 171], ["the detection", "TEST", 199, 212], ["mixed", "OBSERVATION_MODIFIER", 143, 148], ["Mycoplasma populations", "OBSERVATION", 149, 171]]], ["Additionally, a DNA microarray assay was developed for the parallel detection of 37 Mycoplasma species [19], in which species-specific probes derived from the 23S rRNA and tuf genes were used for species differentiation.BackgroundMultiplex real-time PCR could be a promising and practical approach to speed up the differential diagnosis from 1 to 2 weeks for traditional culture to 24 h, with limited expenses.", [["DNA", "CELLULAR_COMPONENT", 16, 19], ["23S", "GENE_OR_GENE_PRODUCT", 159, 162], ["rRNA", "CELLULAR_COMPONENT", 163, 167], ["tuf", "GENE_OR_GENE_PRODUCT", 172, 175], ["23S rRNA", "DNA", 159, 167], ["tuf genes", "DNA", 172, 181], ["a DNA microarray assay", "TEST", 14, 36], ["the parallel detection", "TEST", 55, 77], ["Mycoplasma species", "PROBLEM", 84, 102], ["the 23S rRNA", "TEST", 155, 167], ["tuf genes", "TREATMENT", 172, 181], ["species differentiation", "PROBLEM", 196, 219], ["BackgroundMultiplex", "TEST", 220, 239], ["time PCR", "TEST", 245, 253], ["traditional culture", "TEST", 359, 378]]], ["This will make diagnostic testing more accessible for veterinary practitioners and thereby improve BRD diagnosis.", [["diagnostic testing", "TEST", 15, 33]]], ["This report describes the RespoCheck triplex PCR developed by Central Veterinary Institute (CVI, Lelystad, The Netherlands) for detection of three Mycoplasma species.Strains and growth conditions ::: Methods", [["the RespoCheck triplex PCR", "TEST", 22, 48], ["three Mycoplasma species", "PROBLEM", 141, 165], ["Methods", "TREATMENT", 200, 207], ["Mycoplasma species", "OBSERVATION", 147, 165]]]]}